[go: up one dir, main page]

US20190248756A1 - Bcl-3 inhibitors - Google Patents

Bcl-3 inhibitors Download PDF

Info

Publication number
US20190248756A1
US20190248756A1 US16/397,245 US201916397245A US2019248756A1 US 20190248756 A1 US20190248756 A1 US 20190248756A1 US 201916397245 A US201916397245 A US 201916397245A US 2019248756 A1 US2019248756 A1 US 2019248756A1
Authority
US
United States
Prior art keywords
aromatic
hydrogen
alkyl
compound
piperazinyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US16/397,245
Inventor
Andrew David Westwell
Andrea Brancale
Richard William Ernest Clarkson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University College Cardiff Consultants Ltd
Original Assignee
University College Cardiff Consultants Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University College Cardiff Consultants Ltd filed Critical University College Cardiff Consultants Ltd
Priority to US16/397,245 priority Critical patent/US20190248756A1/en
Publication of US20190248756A1 publication Critical patent/US20190248756A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
    • C07C237/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
    • C07C237/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having carbon atoms of carboxamide groups, amino groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings

Definitions

  • Metastasis is the spread of a cancer from an originating tissue or organ to another tissue or organ.
  • the cells which constitute the primary cancerous tumour commonly undergo metaplasia, followed by dysplasia and then anaplasia, resulting in a malignant phenotype.
  • This malignant phenotype allows for intravasation into the circulation, followed by extravasation to a second site for tumourigenesis. After the tumour cells have migrated to another site, they re-penetrate the vessel or walls and continue to multiply, eventually forming another clinically detectable tumour (secondary tumours).
  • metastatic cancers Whilst treatment regimens and therapies for primary tumours are much better understood, with improved efficacy and success rates, and whilst some types of metastatic cancer can be cured with such current treatments, most metastatic cancers show poor response. Treatments for metastatic disease do exist, such as systemic therapy (chemotherapy, biological therapy, targeted therapy, hormonal therapy), local therapy (surgery, radiation therapy), or a combination of these treatments. However, most often the primary goal of these treatments is to control the growth of the cancer or to relieve symptoms caused by same. It is therefore generally considered that most people who die of cancer die of metastatic disease.
  • NF- ⁇ B nuclear factor kappa-light-chain-enhancer of activated B cells
  • NF- ⁇ B is a protein complex that controls the transcription of DNA and is involved in cellular responses to stimuli such as stress, cytokines, free radicals, ultraviolet irradiation, oxidized LDL, and bacterial or viral antigens.
  • stimuli such as stress, cytokines, free radicals, ultraviolet irradiation, oxidized LDL, and bacterial or viral antigens.
  • Members of the NF- ⁇ B family can both induce and repress gene expression through binding to DNA sequences, and regulate numerous genes that control programmed cell death, cell adhesion, proliferation, immunity and inflammation.
  • NF- ⁇ B provides a link between inflammation and cancer progression. Further, NF- ⁇ B is widely used by eukaryotic cells as a regulator of genes that control cell proliferation and cell survival. As such, many different types of human tumours have deregulated NF- ⁇ B: that is, NF- ⁇ B is constitutively active. Deregulated NF- ⁇ B has been documented in many cancers, including solid cancers such as breast, melanoma, lung, colon, pancreatic, oesophageal, and also haematological malignancies.
  • NF- ⁇ B activation was evident in 86% of HER2+/ER ⁇ breast cancers and in 33% of basal like cancers, which are associated with a shortened disease-free interval, poor survival and resistance to cancer therapy.
  • NF- ⁇ B activation in tumour cells, tumour-associated stromal and endothelial cells is thought to play a role in tumour progression and invasion.
  • B-cell Lymphoma 3 (Bcl-3) is a proto-oncogene modulating NF- ⁇ B signaling, which was first identified as a chromosome translocation in B-cell chronic lymphocytic leukaemia.
  • Deregulated Bcl-3 over-expression has been reported in numerous tumours including several leukaemias and lymphomas, such as anaplastic large cell lymphomas (ALCLs), classic Hodgkin lymphomas (cHL) and non-Hodgkin's lymphoma. Additionally, deregulated expression has also been observed in solid tumour cancers, such as breast cancer, nasopharyngeal carcinoma, and hepatocarcinomas.
  • Bcl-3 expression was also observed in normal and tumour tissue, but a correlation between nuclear Bcl-3 and patient survival was observed. Bcl-3 expression has also been found to be increased in breast cancer cell lines and patient breast cancer samples versus non-tumorigenic cell lines and normal adjacent tissue, respectively. Cells overexpressing Bcl-3 also resulted in a significantly higher number of tumours which supports the role for Bcl-3 in breast cancer progression.
  • Bcl-3 specifically promotes the formation of metastasis of ErbB2 breast cancer driven tumours. Although primary tumour growth in the Bcl-3 deficient ErbB2 (MMTV/neu) murine model was not affected, it was shown that the occurrence of developed lung metastasis from a primary breast tumour was significantly reduced by 40%. Moreover, a significant reduction in mitotic index and apoptosis was observed in secondary tumour lesions but not in primary tumours.
  • Bcl-3 may represent a suitable therapeutic target for preventing cancer metastasis and secondary tumour formation.
  • the present application relates to compounds which modulate Bcl-3 activity and may suppress Bcl-3-NF- ⁇ B protein interactions, inhibit NF- ⁇ B signaling and attenuate the cellular characteristics contributing to the metastatic phenotype observed in vivo. Therefore the compounds are suitable for the treatment of cancer, especially for the treatment or prevention of metastatic cancer or secondary tumours.
  • the present application also relates to compounds that modulate Bcl-3 for treatment or prevention of a disease or disorder in which NF- ⁇ B plays a role.
  • R q is phenyl or 1-(4-N—(R N ))piperazinyl, or when A is CR 3 , R 2 is fluorine or chlorine, q is 2 and R q is N-morpholinyl, then at least one of W, R 7 , Y and Z is not hydrogen but W is not OCH 3 ; or when A is CR 3 , R 2 is fluorine or chlorine, q is 2 and R q is N-morpholinyl at least one of R 3 , R 4 , R 5 and R 6 is not hydrogen or halogen.
  • R q is phenyl or 1-(4-N—(R N ))piperazinyl; or when A is CR 3 , R 2 is fluorine or chlorine, q is 2 and R q is N-morpholino, then at least one of R 8 , R 9 , R 10 , and Z is not hydrogen and R 8 is not OCH 3 ; or when A is CR 3 , R 2 is fluorine or chlorine, q is 2 and R q is N-morpholino, then at least one of R 3 , R 4 , R 5 and R 6 is not hydrogen or halogen; and at least three of R 2 , R 3 , R 4 , R 5 and R 6 are hydrogen.
  • a further aspect of the application relates to a compound of Formula (Ia) which has the Formula (Ib).
  • a further aspect of the application relates to a compound of Formula (Ia) which has the Formula (Ic).
  • a further aspect of the application relates to a compound of Formula (Ia) which has the Formula (Id).
  • a further aspect of the application relates to a compound of Formula (Ia) which has the Formula (Ie).
  • a further aspect of the application relates to a compound of Formula (Ia) which has the Formula (If).
  • the application relates to a compound of Formula (I) or Formula (Ia) for use in the treatment of leukaemia or lymphoma.
  • the solid tumour cancer is breast cancer, melanoma, lung cancer, pancreatic cancer, oesophageal cancer, colorectal cancer, nasopharyngeal carcinoma, or hepatocarcinoma.
  • the application relates to a compound of Formula (I) or Formula (Ia) for use in the preparation of an agent for the treatment of cancer.
  • a aspect of the application relates to a compound of Formula (I) or Formula (Ia) for use in the preparation of an agent for the treatment of leukaemia or lymphoma.
  • the application relates to a compound of Formula (I) or Formula (Ia) for use in the preparation of an agent for the treatment of anaplastic large cell lymphomas (ALCLs), classic Hodgkin lymphomas (cHL), non-Hodgkin's lymphoma; or solid tumour cancers.
  • the solid tumour cancer is breast cancer, melanoma, lung cancer, pancreatic cancer, oesophageal cancer, colorectal cancer, nasopharyngeal carcinoma, or hepatocarcinoma.
  • the cancer in another aspect of the application relates to a method for the treatment of cancer, the method comprising administering to a patient in need of such treatment an effective amount of a compound of Formula (I) or Formula (Ia).
  • the cancer is leukaemia or lymphoma.
  • the cancer is anaplastic large cell lymphoma (ALCLs), classic Hodgkin lymphoma (cHL), non-Hodgkin's lymphoma; or solid tumour cancer.
  • the application relates to any of the uses or methods defined above wherein the treatment comprises the treatment or prevention of metastasis in cancers.
  • the application relates to a pharmaceutical composition
  • a pharmaceutical composition comprising a compound of Formula (I) or Formula (Ia) together with a pharmaceutically or veterinarily acceptable excipient or carrier.
  • FIGS. 1 a -1 h are bar graphs showing the results of cell titer blue assays performed on cells treated with various compounds of the application (dark bars (10 ⁇ M), grey bars (1 ⁇ M)) to determine cell viability.
  • FIG. 2 is a graph showing the effect of a number of compounds of the application on cell migration of human breast cancer cell line MDA-MB-436 during a scratch assay.
  • FIG. 3 is a graph showing the effect of compound 12, Reference compound A (Ref. Cmpd A), or control on EGF-induced NF-kB activity.
  • FIG. 4 is a graph showing the effect of compound 12 (Cmpd 12), Reference compound A (Ref. Cmpd A), Reference compound B (Ref. Cmpd B), or control on the disease free survival in a mouse metastasis model.
  • FIG. 5 is a graph which demonstrates the comparative effect of various compounds in human breast cancer MDA-MB-231 xenograft in vivo studies.
  • FIG. 6 is a graph which demonstrates the effect of compound 12 (to inhibit the growth of human breast cancer (MDA-MB-231) at the tumor transplant site.
  • FIG. 7 is a graph which demonstrates the effect of compound 12 to inhibit the growth of human colorectal cell lines (SW480) at the tumor transplant site.
  • FIG. 8 is a graph which demonstrates the effect of compound 12 to inhibit the seeding and early colonization of circulating tumour cells at distal sites.
  • FIG. 9 is a graph which demonstrates the effect of compound 12 to inhibit the colonization and subsequent growth and spread of secondary lesions at distal sites.
  • FIG. 10 is a graph which demonstrates the effect of compound 12 to inhibit the growth of tumour cells at the transplantation site.
  • FIG. 11 is a graph which demonstrates the effect of compound 12 to inhibit the growth of human triple negative breast invasive ductal carcinoma (MDA-MB-436) at the tumor transplant site.
  • the present application provides compounds of Formula (I), Formula (Ia), Formula (Ib), Formula (Ic), Formula (Id), Formula (Ie), and Formula (If), i.e., the compounds of the application.
  • the present application also provides pharmaceutical compositions containing the compounds of the application and various uses of the disclosed compounds.
  • the compounds of the application may be used in treating a disease or disorder in which Bcl-3 plays a role (e.g., cancer).
  • A is CR 3 or N
  • B is CR 7 or N
  • R 2 , R 3 , R 4 , R 5 and R 6 are each, independently, hydrogen, halogen, C 1 -C 6 haloalkyl, NO 2 , NR a R b , OH, O(C 1 -C 6 alkyl), or O(C 1 -C 6 haloalkyl); or R 3 and R 4 together form a C 6 aryl ring, or R 4 and R 5 together form a C 6 aryl ring;
  • R 7 is hydrogen, fluorine, OH, or O(C 1 -C 6 alkyl);
  • R a and R b are each, independently, hydrogen or C 1 -C 6 alkyl
  • W, Y and Z are each, independently hydrogen, fluorine, OH, or O(C 1 -C 6 alkyl);
  • q 2 or 3
  • R q is 1-piperazinyl, 1-(4-N—(R N ))piperazinyl, N-morpholinyl or phenyl;
  • R N is C 1 -C 5 straight chain or C 1 -C 5 branched alkyl
  • R q is phenyl or 1-(4-N—(R N ))piperazinyl, or when A is CR 3 , R 2 is fluorine or chlorine, q is 2 and R q is N-morpholinyl, then at least one of W, R 7 , Y and Z is not hydrogen but W is not OCH 3 ; or when A is CR 3 , R 2 is fluorine or chlorine, q is 2 and R q is N-morpholinyl at least one of R 3 , R 4 , R 5 and R 6 is not hydrogen or halogen.
  • q is 2. In another embodiment, q is 3.
  • A is N. In a further embodiment, A is CR 3 .
  • R q is 1-piperazinyl. In another embodiment, R q is 1-(4-N—(R N ))piperazinyl. In yet another embodiment, R q is N-morpholinyl. In a further embodiment, R q is phenyl.
  • R N is C 1 -C 5 straight chain or C 1 -C 5 branched alkyl. In another embodiment, R N is methyl, ethyl, propyl, isopropyl, n-butyl or n-pentyl. In a preferred embodiment, R N is methyl or ethyl. In a more preferred embodiment, R N is methyl.
  • At least one of R 2 , R 3 , R 4 , R 5 and R 6 is NR a R b .
  • At least one of R 2 , R 3 , R 4 , R 5 and R 6 is C 1 -C 6 haloalkyl.
  • C 1 -C 6 haloalkyl is CF 3 .
  • At least one of R 2 , R 3 , R 4 , R 5 and R 6 is halogen. In a preferred embodiment, at least one of R 2 , R 3 , R 4 , R 5 and R 6 is —Cl or —F.
  • At least one of R 2 , R 3 , R 4 , R 5 and R 6 is —NO 2 .
  • R 2 is fluorine and at least one of R 3 , R 4 , R 5 and R 6 is O(C 1 -C 6 alkyl).
  • R 2 is fluorine and R 4 is O(C 1 -C 6 alkyl). In a preferred embodiment, R 2 is fluorine and R 4 is OCH 3 .
  • At least one of R 3 , R 4 , R 5 and R 6 is OCH 3 .
  • at least one of W, R 7 , Y and Z is not hydrogen.
  • at least one of W, R 7 , Y and Z is O(C 1 -C 6 alkyl).
  • at least one of W, R 7 , Y and Z is OCH 3 .
  • at least one of W, R 7 , Y and Z is halogen.
  • at least one of W, R 7 , Y and Z is fluorine.
  • R 2 is OCH 3 .
  • At least two of R 2 , R 3 , R 4 , R 5 and R 6 are not hydrogen and are not the same.
  • At least three of R 2 , R 3 , R 4 , R 5 and R 6 are not hydrogen and at least two of R 2 , R 3 , R 4 , R 5 and R 6 are not the same.
  • A is CR 3 and one of R 2 , R 3 , R 4 , R 5 and R 6 are not hydrogen. In another embodiment, A is CR 3 and two of R 2 , R 3 , R 4 , R 5 and R 6 are not hydrogen. In yet another embodiment, A is CR 3 and three of R 2 , R 3 , R 4 , R 5 and R 6 are not hydrogen. In a further embodiment, A is CR 3 and four of R 2 , R 3 , R 4 , R 5 and R 6 are not hydrogen.
  • R q is N-morpholinyl, A is CR 3 , and B is CR 7 . In a further embodiment, R q is N-morpholinyl, A is CH, and B is CH. In another embodiment, R q is N-morpholinyl, A is CH, B is CH and q is 2.
  • R q is N-morpholinyl, A is CR 3 , and B is CR 7 . In a further embodiment, R q is N-morpholinyl, A is CH, and B is CH. In another embodiment, R q is N-morpholinyl, A is CH, B is CH and q is 3.
  • R q is 1-piperazinyl, A is CR 3 , and B is CR 7 . In a further embodiment, R q is 1-piperazinyl, A is CH, and B is CH. In another embodiment, R q is 1-piperazinyl, A is CH, B is CH and q is 2.
  • R q is 1-piperazinyl, A is CR 3 , and B is CR 7 . In a further embodiment, R q is 1-piperazinyl, A is CH, and B is CH. In another embodiment, R q is 1-piperazinyl, A is CH, B is CH and q is 3.
  • R q is phenyl, A is CR 3 , and B is CR 7 . In a further embodiment, R q is phenyl, A is CH, and B is CH. In another embodiment, R q is phenyl, A is CH, B is CH and q is 2.
  • R q is phenyl, A is CR 3 , and B is CR 7 . In a further embodiment, R q is phenyl, A is CH, and B is CH. In another embodiment, R q is phenyl, A is CH, B is CH and q is 3.
  • R q is 1-(4-N—(R N ))piperazinyl, A is CR 3 , and B is CR 7 . In a further embodiment, R q is 1-(4-N—(R N ))piperazinyl, A is CH, and B is CH. In another embodiment, R q is 1-(4-N—(R N ))piperazinyl, A is CH, B is CH and q is 2.
  • R q is 1-(4-N—(R N ))piperazinyl, A is CR 3 , and B is CR 7 . In a further embodiment, R q is 1-(4-N—(R N ))piperazinyl, A is CH, and B is CH. In another embodiment, R q is 1-(4-N—(R N ))piperazinyl, A is CH, B is CH and q is 3.
  • R q is N-morpholinyl, A is CR 3 , and B is CR 7 . In a further embodiment, R q is N-morpholinyl, A is CR 3 , B is CR 7 and q is 2. In another embodiment, R q is N-morpholinyl, A is CR 3 , B is CR 7 and q is 3.
  • R q is 1-piperazinyl, A is CR 3 , and B is CR 7 . In a further embodiment, R q is 1-piperazinyl, A is CR 3 , B is CR 7 and q is 2. In another embodiment, R q is 1-piperazinyl, A is CR 3 , B is CR 7 and q is 3.
  • R q is phenyl, A is CR 3 , and B is CR 7 . In a further embodiment, R q is phenyl, A is CR 3 , B is CR 7 and q is 2. In another embodiment, R q is phenyl, A is CR 3 , B is CR 7 and q is 3.
  • R q is 1-(4-N—(R N ))piperazinyl, A is CR 3 , and B is CR 7 .
  • R q is 1-(4-N—(R N ))piperazinyl, A is CR 3 , B is CR 7 and q is 2.
  • R q is 1-(4-N—(R N ))piperazinyl, A is CR 3 , B is CR 7 and q is 3.
  • R q is N-morpholinyl, A is N, and B is CR 7 . In a further embodiment, R q is N-morpholinyl, A is N, B is CR 7 and q is 2. In another embodiment, R q is N-morpholinyl, A is N, B is CR 7 and q is 3.
  • R q is 1-piperazinyl, A is N, and B is CR 7 . In a further embodiment, R q is 1-piperazinyl, A is N, B is CR 7 and q is 2. In another embodiment, R q is 1-piperazinyl, A is N, B is CR 7 and q is 3.
  • R q is phenyl, A is N, and B is CR 7 . In a further embodiment, R q is phenyl, A is N, B is CR 7 and q is 2. In another embodiment, R q is phenyl, A is N, B is CR 7 and q is 3.
  • R q is 1-(4-N—(R N ))piperazinyl, A is N, and B is CR 7 . In a further embodiment, R q is 1-(4-N—(R N ))piperazinyl, A is N, B is CR 7 and q is 2. In another embodiment, R q is 1-(4-N—(R N ))piperazinyl, A is N, B is CR 7 and q is 3.
  • q is 2. In another embodiment, q is 3.
  • A is N. In a further embodiment, A is CR 3 .
  • one of X 1 , X 2 , or X 3 is N. In a further embodiment, none of X 1 , X 2 , or X 3 is N.
  • X 1 is N
  • X 2 is CR 9
  • X 3 is CR 10
  • A is N.
  • X 2 is N
  • X 1 is CR 8
  • X 3 is CR 10
  • A is N.
  • X 3 is N
  • X 1 is CR 8
  • X 2 is CR 9
  • A is N.
  • X 1 is N
  • X 2 is CR 9
  • X 3 is CR 10
  • A is CR 3 .
  • X 2 is N
  • X 1 is CR 8
  • X 3 is CR 10
  • A is CR 3 .
  • X 3 is N
  • X 1 is CR 8
  • X 2 is CR 9
  • A is CR 3 .
  • R q is 1-piperazinyl. In another embodiment, R q is 1-(4-N—(R N ))piperazinyl. In yet another embodiment, R q is N-morpholinyl. In a further embodiment, R q is phenyl.
  • R N is C 1 -C 5 straight chain or C 1 -C 5 branched alkyl. In another embodiment, R N is methyl, ethyl, propyl, isopropyl, n-butyl or n-pentyl. In a preferred embodiment, R N is methyl or ethyl. In a more preferred embodiment, R N is methyl.
  • R 2 , R 3 , R 4 , R 5 and R 6 are each, independently, hydrogen, halogen, C 1 -C 6 haloalkyl, NO 2 , NR a R b , OH, O(C 1 -C 6 alkyl), or O(C 1 -C 6 haloalkyl).
  • R 8 , R 9 , R 10 , and Z are each, independently, hydrogen, flourine, OH, or O(C 1 -C 6 alkyl).
  • R 2 , R 3 , R 4 , R 5 and R 6 are each, independently, hydrogen, halogen, C 1 -C 6 haloalkyl, NO 2 , NR a R b , OH, O(C 1 -C 6 alkyl), or O(C 1 -C 6 haloalkyl).
  • R 2 and R 3 together with the carbon atoms to which they attach form a C 6 aryl ring
  • R 4 , R 5 and R 6 are each, independently, hydrogen, halogen, C 1 -C 6 haloalkyl, NO 2 , NR a R b , OH, O(C 1 -C 6 alkyl), or O(C 1 -C 6 haloalkyl).
  • R 3 and R 4 together with the carbon atoms to which they attach form a C 6 aryl ring
  • R 2 , R 5 and R 6 are each, independently, hydrogen, halogen, C 1 -C 6 haloalkyl, NO 2 , NR a R b , OH, O(C 1 -C 6 alkyl), or O(C 1 -C 6 haloalkyl).
  • R 4 and R 5 together with the carbon atoms to which they attach form a C 6 aryl ring
  • R 2 , R 3 , and R 6 are each, independently, hydrogen, halogen, C 1 -C 6 haloalkyl, NO 2 , NR a R b , OH, O(C 1 -C 6 alkyl), or O(C 1 -C 6 haloalkyl).
  • R 5 and R 6 together with the carbon atoms to which they attach form a C 6 aryl ring
  • R 2 , R 3 , and R 4 are each, independently, hydrogen, halogen, C 1 -C 6 haloalkyl, NO 2 , NR a R b , OH, O(C 1 -C 6 alkyl), or O(C 1 -C 6 haloalkyl).
  • At least one of R 2 , R 3 , R 4 , R 5 and R 6 is NR a R b .
  • At least one of R 2 , R 3 , R 4 , R 5 and R 6 is C 1 -C 6 haloalkyl.
  • C 1 -C 6 haloalkyl is CF 3 .
  • At least one of R 2 , R 3 , R 4 , R 5 and R 6 is halogen. In a preferred embodiment, at least one of R 2 , R 3 , R 4 , R 5 and R 6 is —Cl or —F.
  • At least one of R 2 , R 3 , R 4 , R 5 and R 6 is —NO 2 .
  • R 2 is fluorine and at least one of R 3 , R 4 , R 5 and R 6 is O(C 1 -C 6 alkyl).
  • R 2 is fluorine and R 4 is O(C 1 -C 6 alkyl). In a preferred embodiment, R 2 is fluorine and R 4 is OCH 3 .
  • At least one of R 3 , R 4 , R 5 and R 6 is OCH 3 .
  • at least one of R 8 , R 9 , R 10 , and Z is not hydrogen.
  • at least one of R 8 , R 9 , R 10 , and Z is O(C 1 -C 6 alkyl).
  • at least one of R 8 , R 9 , R 10 , and Z is OCH 3 .
  • at least one of R 8 , R 9 , R 10 , and Z is halogen.
  • at least one of R 8 , R 9 , R 10 , and Z is fluorine.
  • R 2 is OCH 3 .
  • At least two of R 2 , R 3 , R 4 , R 5 and R 6 are not hydrogen and are not the same.
  • At least three of R 2 , R 3 , R 4 , R 5 and R 6 are not hydrogen and at least two of R 2 , R 3 , R 4 , R 5 and R 6 are not the same.
  • A is CR 3 and one of R 2 , R 3 , R 4 , R 5 and R 6 are not hydrogen. In another embodiment, A is CR 3 and two of R 2 , R 3 , R 4 , R 5 and R 6 are not hydrogen. In yet another embodiment, A is CR 3 and three of R 2 , R 3 , R 4 , R 5 and R 6 are not hydrogen. In a further embodiment, A is CR 3 and four of R 2 , R 3 , R 4 , R 5 and R 6 are not hydrogen.
  • R q is N-morpholinyl, A is CR 3 , and X 2 is CR 9 . In a further embodiment, R q is N-morpholinyl, A is CH, and X 2 is CH. In another embodiment, R q is N-morpholinyl, A is CH, X 2 is CH and q is 2.
  • R q is N-morpholinyl, A is CR 3 , and X 2 is CR 9 . In a further embodiment, R q is N-morpholinyl, A is CH, and X 2 is CH. In another embodiment, R q is N-morpholinyl, A is CH, X 2 is CH and q is 3.
  • R q is 1-piperazinyl, A is CR 3 , and X 2 is CR 9 . In a further embodiment, R q is 1-piperazinyl, A is CH, and X 2 is CH. In another embodiment, R q is 1-piperazinyl, A is CH, X 2 is CH and q is 2.
  • R q is 1-piperazinyl, A is CR 3 , and X 2 is CR 9 . In a further embodiment, R q is 1-piperazinyl, A is CH, and X 2 is CH. In another embodiment, R q is 1-piperazinyl, A is CH, X 2 is CH and q is 3.
  • R q is phenyl, A is CR 3 , and X 2 is CR 9 . In a further embodiment, R q is phenyl, A is CH, and X 2 is CH. In another embodiment, R q is phenyl, A is CH, X 2 is CH and q is 2.
  • R q is phenyl, A is CR 3 , and X 2 is CR 9 . In a further embodiment, R q is phenyl, A is CH, and X 2 is CH. In another embodiment, R q is phenyl, A is CH, X 2 is CH and q is 3.
  • R q is 1-(4-N—(R N ))piperazinyl, A is CR 3 , and X 2 is CR 9 .
  • R q is 1-(4-N—(R N ))piperazinyl, A is CH, and X 2 is CH.
  • R q is 1-(4-N—(R N ))piperazinyl, A is CH, X 2 is CH and q is 2.
  • R q is 1-(4-N—(R N ))piperazinyl, A is CR 3 , and X 2 is CR 9 .
  • R q is 1-(4-N—(R N ))piperazinyl, A is CH 2 , and X 2 is CH.
  • R q is 1-(4-N—(R N ))piperazinyl, A is CH, X 2 is CH and q is 3.
  • R q is N-morpholinyl, A is CR 3 , and X 2 is CR 9 .
  • R q is N-morpholinyl, A is CR 3 , X 2 is CR 9 and q is 2.
  • R q is N-morpholinyl, A is CR 3 , X 2 is CR 9 and q is 3.
  • R q is 1-piperazinyl, A is CR 3 , and X 2 is CR 9 .
  • R q is 1-piperazinyl, A is CR 3 , X 2 is CR 9 and q is 2.
  • R q is 1-piperazinyl, A is CR 3 , X 2 is CR 9 and q is 3.
  • R q is phenyl, A is CR 3 , and X 2 is CR 9 . In a further embodiment, R q is phenyl, A is CR 3 , X 2 is CR 9 and q is 2. In another embodiment, R q is phenyl, A is CR 3 , X 2 is CR 9 and q is 3.
  • R q is 1-(4-N—(R N ))piperazinyl, A is CR 3 , and X 2 is CR 9 .
  • R q is 1-(4-N—(R N ))piperazinyl, A is CR 3 , X 2 is CR 9 and q is 2.
  • R q is 1-(4-N—(R N ))piperazinyl, A is CR 3 , X 2 is CR 9 and q is 3.
  • R q is N-morpholinyl, A is N, and X 2 is CR 9 . In a further embodiment, R q is N-morpholinyl, A is N, X 2 is CR 9 and q is 2. In another embodiment, R q is N-morpholinyl, A is N, X 2 is CR 9 and q is 3.
  • R q is 1-piperazinyl, A is N, and X 2 is CR 9 . In a further embodiment, R q is 1-piperazinyl, A is N, X 2 is CR 9 and q is 2. In another embodiment, R q is 1-piperazinyl, A is N, X 2 is CR 9 and q is 3.
  • R q is phenyl, A is N, and X 2 is CR 9 . In a further embodiment, R q is phenyl, A is N, X 2 is CR 9 and q is 2. In another embodiment, R q is phenyl, A is N, X 2 is CR 9 and q is 3.
  • R q is 1-(4-N—(R N ))piperazinyl, A is N, and X 2 is CR 9 .
  • R q is 1-(4-N—(R N ))piperazinyl, A is N, X 2 is CR 9 and q is 2.
  • R q is 1-(4-N—(R N ))piperazinyl, A is N, X 2 is CR 9 and q is 3.
  • a further aspect of the application relates to any compound of Formula (Ia).
  • a further aspect of the application relates to any compound of Formula (Ia), wherein the compound has the Formula (Ib).
  • a further aspect of the application relates to a compound being of Formula (Ib),
  • R N is methyl
  • q is 2. In another embodiment, q is 3.
  • X 2 is CR 9 .
  • At least one of R 8 , R 9 , R 10 and Z is not hydrogen.
  • At least one of R 8 , R 9 , R 10 and Z is O(C 1 -C 6 alkyl).
  • At least one of R 8 , R 9 , R 10 and Z is OCH 3 .
  • At least one of R 8 , R 9 , R 10 and Z is fluorine.
  • At least one of R 2 , R 3 , R 4 , R 5 and R 6 is not hydrogen.
  • At least one of R 2 , R 3 , R 4 , R 5 and R 6 is O(C 1 -C 6 alkyl).
  • At least one of R 2 , R 3 , R 4 , R 5 and R 6 is OCH 3 .
  • At least one of R 2 , R 3 , R 4 , R 5 and R 6 is fluorine.
  • R 12 is hydrogen
  • A is N. In a further embodiment, A is CR 3 .
  • one of X 1 , X 2 , or X 3 is N. In a further embodiment, none of X 1 , X 2 , or X 3 is N.
  • X 1 is N
  • X 2 is CR 9
  • X 3 is CR 10
  • A is N.
  • X 2 is N
  • X 1 is CR 8
  • X 3 is CR 10
  • A is N.
  • X 3 is N
  • X 1 is CR 8
  • X 2 is CR 9
  • A is N.
  • X 1 is N
  • X 2 is CR 9
  • X 3 is CR 10
  • A is CR 3 .
  • X 2 is N
  • X 1 is CR 8
  • X 3 is CR 10
  • A is CR 3 .
  • X 3 is N
  • X 1 is CR 8
  • X 2 is CR 9
  • A is CR 3 .
  • A is CR 3 , and X 2 is CR 9 .
  • A is CH, and X 2 is CH.
  • A is CH, X 2 is CH and q is 2.
  • A is CH, X 2 is CH and q is 3.
  • A is N, and X 2 is CR 9 . In a further embodiment, A is N, X 2 is CR 9 and q is 2. In another embodiment, A is N, X 2 is CR 9 and q is 3.
  • a further aspect of the application relates to any compound of Formula (Ia), wherein the compound has the Formula (Ic).
  • a further aspect of the application relates to a compound being of Formula (Ic),
  • R q is phenyl or 1-(4-N—(R N ))piperazinyl, or when A is CR 3 , R 2 is fluorine or chlorine, q is 2 and R q is N-morpholino, then at least one of R 8 , R 9 , R 10 , and Z is not hydrogen and R 8 is not OCH 3 .
  • R 2 and R 3 together with the carbon atoms to which they attach form a C 6 aryl ring; and R 4 , R 5 and R 6 are each, independently, hydrogen, halogen, C 1 -C 6 haloalkyl, NO 2 , NR a R b , OH, O(C 1 -C 6 alkyl), or O(C 1 -C 6 haloalkyl).
  • R 5 and R 6 together with the carbon atoms to which they attach form a C 6 aryl ring; and R 2 , R 3 and R 4 are each, independently, hydrogen, halogen, C 1 -C 6 haloalkyl, NO 2 , NR a R b , OH, O(C 1 -C 6 alkyl), or O(C 1 -C 6 haloalkyl).
  • X 2 is CR 9 .
  • X 1 is CR 8 . In another embodiment, X 1 is CR 8 and R 8 is hydrogen.
  • X 1 is CR 8 . In another embodiment, X 1 is CR 8 and R 8 is OCH 3 .
  • q is 2. In another embodiment, q is 3.
  • R q is 1-piperazinyl. In one embodiment, R q is 1-(4-N—(R N ))piperazinyl. In one embodiment, R q is N-morpholino. In one embodiment, R q is phenyl.
  • R q is 1-(4-N—(R N ))piperazinyl and R N is methyl, ethyl, propyl, isopropyl, n-butyl or n-pentyl. In one embodiment, R q is 1-(4-N—(R N ))piperazinyl and R N is methyl or ethyl. In one embodiment, R q is 1-(4-N—(R N ))piperazinyl and R N is methyl.
  • At least one of R 8 , R 9 , R 10 , and Z is halogen.
  • At least one of R 8 , R 9 , R 10 , and Z is chlorine or fluorine.
  • R 12 is hydrogen
  • a further aspect of the application relates to a compound being of Formula (Ic),
  • R 3 and R 4 together with the carbon atoms to which they attach form a C 6 aryl ring; and R 2 , R 5 and R 6 are each, independently, hydrogen, halogen, C 1 -C 6 haloalkyl, NO 2 , NR a R b , OH, O(C 1 -C 6 alkyl), or O(C 1 -C 6 haloalkyl).
  • R 4 and R 5 together with the carbon atoms to which they attach form a C 6 aryl ring; and R 2 , R 3 , and R 6 are each, independently, hydrogen, halogen, C 1 -C 6 haloalkyl, NO 2 , NR a R b , OH, O(C 1 -C 6 alkyl), or O(C 1 -C 6 haloalkyl).
  • X 2 is CR 9 .
  • X 1 is CR 8
  • X 2 is CR 9
  • X 3 is CR 10
  • q is 2. In another embodiment, q is 3.
  • R q is 1-piperazinyl. In one embodiment, R q is 1-(4-N—(R N ))piperazinyl. In one embodiment, R q is N-morpholino. In one embodiment, R q is phenyl.
  • R q is 1-(4-N—(R N ))piperazinyl and R N is methyl, ethyl, propyl, isopropyl, n-butyl or n-pentyl. In one embodiment, R q is 1-(4-N—(R N ))piperazinyl and R N is methyl or ethyl. In one embodiment, R q is 1-(4-N—(R N ))piperazinyl and R N is methyl.
  • At least one of R 8 , R 9 , R 10 , and Z is halogen.
  • At least one of R 8 , R 9 , R 10 , and Z is chlorine of fluorine.
  • R 12 is hydrogen
  • R 3 and R 4 together form a C 6 aryl ring.
  • R 2 , R 5 and R 6 are each hydrogen.
  • R 8 , R 9 , R 10 , and Z are each hydrogen.
  • R 3 and R 4 together with the carbon atoms to which they attach form a C 6 aryl ring, and R 2 , R 5 , R 6 , R 8 , R 9 , R 10 , and Z are each hydrogen.
  • R 3 and R 4 together with the carbon atoms to which they attach form a C 6 aryl ring, and R 2 , R 5 , R 6 , R 8 , R 9 , R 10 , and Z are each hydrogen, and q is 2.
  • R 3 and R 4 together with the carbon atoms to which they attach form a C 6 aryl ring, and R 2 , R 5 , R 6 , R 8 , R 9 , R 10 , and Z are each hydrogen, and R q is N-morpholino.
  • a further aspect of the application relates to any compound of Formula (Ic).
  • a further aspect of the application relates to any compound of Formula (Ia), wherein the compound has the Formula (Id).
  • a further aspect of the application relates to a compound being of Formula (Id),
  • R 11 is —NH—(CH 2 ) q —R q .
  • q is 2. In another embodiment, q is 3.
  • R q is 1-piperazinyl. In one embodiment, R q is 1-(4-N—(R N ))piperazinyl. In one embodiment, R q is N-morpholino. In one embodiment, R q is phenyl.
  • R 4 is OCH 3 .
  • A is CR 3 .
  • R 2 , R 3 , R 5 and R 6 are each hydrogen.
  • R 8 , R 10 , and Z are each hydrogen.
  • R 12 is hydrogen
  • a further aspect of the application relates to any compound of Formula (Id).
  • a further aspect of the application relates to any compound of Formula (Ia), wherein the compound has the Formula (Ie).
  • a further aspect of the application relates to a compound being of Formula (Ie),
  • R 11 is —NH—(CH 2 ) q —R q .
  • R q is 1-(4-N—(R N ))piperazinyl.
  • q is 2.
  • R 4 is OCH 3 .
  • R 2 , R 3 , R 5 , R 6 , R 8 , R 9 , and Z are each hydrogen.
  • R 12 is hydrogen
  • a further aspect of the application relates to any compound of Formula (Ie).
  • a further aspect of the application relates to any compound of Formula (Ia), wherein the compound has the Formula (If).
  • a further aspect of the application relates to a compound being of formula (If),
  • A is CR 3 .
  • R 2 , R 3 , R 4 , R 5 , R 6 , R 9 , R 10 and Z are each, independently, hydrogen or fluorine.
  • R 2 is fluorine
  • R 11 is OH or O(C 1 -C 6 alkyl).
  • R 11 is OH or OCH 3 .
  • R 11 is OH.
  • R 12 is hydrogen or methyl.
  • R 12 is hydrogen
  • R 12 is methyl
  • a further aspect of the application relates to any compound of Formula (If).
  • the compound of Formula (I) or Formula (Ia) is selected from a compounds listed in Table 1:
  • alkyl As used herein, “alkyl”, “C 1 , C 2 , C 3 , C 4 , C 5 or C 6 alkyl” or “C 1 -C 6 alkyl” is intended to include C 1 , C 2 , C 3 , C 4 , C 5 or C 6 straight chain (linear) saturated aliphatic hydrocarbon groups and C 3 , C 4 , C 5 or C 6 branched saturated aliphatic hydrocarbon groups.
  • C 1 -C 6 alkyl is intended to include C 1 , C 2 , C 3 , C 4 , C 5 and C 6 alkyl groups.
  • alkyl examples include, moieties having from one to six carbon atoms, such as, but not limited to, methyl, ethyl, n-propyl, i-propyl, n-butyl, s-butyl, t-butyl, n-pentyl, s-pentyl or n-hexyl.
  • a straight chain or branched alkyl has six or fewer carbon atoms (e.g., C 1 -C 6 for straight chain, C 3 -C 6 for branched chain), and in another embodiment, a straight chain or branched alkyl has four or fewer carbon atoms.
  • Heteroalkyl groups are alkyl groups, as defined above, that have an oxygen, nitrogen, sulfur or phosphorous atom replacing one or more hydrocarbon backbone carbon atoms.
  • cycloalkyl As used herein, the term “cycloalkyl”, “C 3 , C 4 , C 5 , C 6 , C 7 or C 8 cycloalkyl” or “C 3 -C 8 cycloalkyl” is intended to include hydrocarbon rings having from three to eight carbon atoms in their ring structure. In one embodiment, a cycloalkyl group has five or six carbons in the ring structure.
  • substituted alkyl refers to alkyl moieties having substituents replacing one or more hydrogen atoms on one or more carbons of the hydrocarbon backbone.
  • substituents can include, for example, alkyl, alkenyl, alkynyl, halogen, hydroxyl, alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, alkylcarbonyl, arylcarbonyl, alkoxycarbonyl, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, alkylthiocarbonyl, alkoxyl, phosphate, phosphonato, phosphinato, amino (including alkylamino, dialkylamino, arylamino, diarylamino and alkylarylamino), acylamino (including alkylcarbonylamino, arylcarbonylamino, carbamoyl
  • Cycloalkyls can be further substituted, e.g., with the substituents described above.
  • An “alkylaryl” or an “aralkyl” moiety is an alkyl substituted with an aryl (e.g., phenylmethyl (benzyl)).
  • lower alkyl includes an alkyl group, as defined above, having from one to six, or in another embodiment from one to four, carbon atoms in its backbone structure.
  • Lower alkenyl and “lower alkynyl” have chain lengths of, for example, two to six or of two to four carbon atoms.
  • alkyl linker is intended to include C 1 , C 2 , C 3 , C 4 , C 5 or C 6 straight chain (linear) saturated aliphatic hydrocarbon groups and C 3 , C 4 , C 5 or C 6 branched saturated aliphatic hydrocarbon groups.
  • C 1 -C 6 alkyl linker is intended to include C 1 , C 2 , C 3 , C 4 , C 5 and C 6 alkyl linker groups.
  • alkyl linker examples include, moieties having from one to six carbon atoms, such as, but not limited to, methyl (—CH 2 —), ethyl (—CH 2 CH 2 —), n-propyl (—CH 2 CH 2 CH 2 —), i-propyl (—CHCH 3 CH 2 —), n-butyl (—CH 2 CH 2 CH 2 CH 2 —), s-butyl (—CHCH 3 CH 2 CH 2 —), i-butyl (—C(CH 3 ) 2 CH 2 —), n-pentyl (—CH 2 CH 2 CH 2 CH 2 CH 2 —), s-pentyl (—CHCH 3 CH 2 CH 2 CH 2 —) or n-hexyl (—CH 2 CH 2 CH 2 CH 2 CH 2 CH 2 —).
  • Alkenyl includes unsaturated aliphatic groups analogous in length and possible substitution to the alkyls described above, but that contain at least one double bond.
  • alkenyl includes straight chain alkenyl groups (e.g., ethenyl, propenyl, butenyl, pentenyl, hexenyl, heptenyl, octenyl, nonenyl, decenyl), branched alkenyl groups, cycloalkenyl (e.g., alicyclic) groups (e.g., cyclopropenyl, cyclopentenyl, cyclohexenyl, cycloheptenyl, cyclooctenyl), alkyl or alkenyl substituted cycloalkenyl groups, and cycloalkyl or cycloalkenyl substituted alkenyl groups.
  • a straight chain or branched alkenyl group has six or fewer carbon atoms in its backbone (e.g., C 2 -C 6 for straight chain, C 3 -C 6 for branched chain).
  • cycloalkenyl groups may have from five to eight carbon atoms in their ring structure, and in one embodiment, cycloalkenyl groups have five or six carbons in the ring structure.
  • C 2 -C 6 includes alkenyl groups containing two to six carbon atoms.
  • C 3 -C 6 includes alkenyl groups containing three to six carbon atoms.
  • Heteroalkenyl includes alkenyl groups, as defined herein, having an oxygen, nitrogen, sulfur or phosphorous atom replacing one or more hydrocarbon backbone carbons.
  • substituted alkenyl refers to alkenyl moieties having substituents replacing one or more hydrogen atoms on one or more hydrocarbon backbone carbon atoms.
  • substituents can include, for example, alkyl, alkenyl, alkynyl, halogen, hydroxyl, alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, alkylcarbonyl, arylcarbonyl, alkoxycarbonyl, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, alkylthiocarbonyl, alkoxyl, phosphate, phosphonato, phosphinato, amino (including alkylamino, dialkylamino, arylamino, diarylamino and alkylarylamino), acylamino (including alkylcarbonylamino, arylcarbonylamino, carbamo
  • Alkynyl includes unsaturated aliphatic groups analogous in length and possible substitution to the alkyls described above, but which contain at least one triple bond.
  • alkynyl includes straight chain alkynyl groups (e.g., ethynyl, propynyl, butynyl, pentynyl, hexynyl, heptynyl, octynyl, nonynyl, decynyl), branched alkynyl groups, and cycloalkyl or cycloalkenyl substituted alkynyl groups.
  • a straight chain or branched alkynyl group has six or fewer carbon atoms in its backbone (e.g., C 2 -C 6 for straight chain, C 3 -C 6 for branched chain).
  • C 2 -C 6 includes alkynyl groups containing two to six carbon atoms.
  • C 3 -C 6 includes alkynyl groups containing three to six carbon atoms.
  • Heteroalkynyl includes alkynyl groups, as defined herein, having an oxygen, nitrogen, sulfur or phosphorous atom replacing one or more hydrocarbon backbone carbons.
  • substituted alkynyl refers to alkynyl moieties having substituents replacing one or more hydrogen atoms on one or more hydrocarbon backbone carbon atoms.
  • substituents can include, for example, alkyl, alkenyl, alkynyl, halogen, hydroxyl, alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, alkylcarbonyl, arylcarbonyl, alkoxycarbonyl, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, alkylthiocarbonyl, alkoxyl, phosphate, phosphonato, phosphinato, amino (including alkylamino, dialkylamino, arylamino, diarylamino and alkylarylamino), acylamino (including alkylcarbonylamino, arylcarbonylamino, carb
  • Aryl includes groups with aromaticity, including “conjugated”, or multicyclic, systems with at least one aromatic ring. Examples include phenyl, benzyl, etc.
  • Heteroaryl groups are aryl groups, as defined above, having from one to four heteroatoms in the ring structure, and may also be referred to as “aryl heterocycles” or “heteroaromatics”.
  • the term “heteroaryl” is intended to include a stable 5-, 6-, or 7-membered monocyclic or 7-, 8-, 9-, 10-, 11- or 12-membered bicyclic aromatic heterocyclic ring which consists of carbon atoms and one or more heteroatoms, e.g., 1 or 1-2 or 1-3 or 1-4 or 1-5 or 1-6 heteroatoms, independently selected from the group consisting of nitrogen, oxygen and sulfur.
  • the nitrogen atom may be substituted or unsubstituted (i.e., N or NR wherein R is H or other substituents, as defined).
  • heteroaryl groups include pyrrole, furan, thiophene, thiazole, isothiazole, imidazole, triazole, tetrazole, pyrazole, oxazole, isoxazole, pyridine, pyrazine, pyridazine, pyrimidine, and the like.
  • aryl and heteroaryl include multicyclic aryl and heteroaryl groups, e.g., tricyclic, bicyclic, e.g., naphthalene, benzoxazole, benzodioxazole, benzothiazole, benzoimidazole, benzothiophene, methylenedioxyphenyl, quinoline, isoquinoline, naphthridine, indole, benzofuran, purine, benzofuran, deazapurine, indolizine.
  • the rings In the case of multicyclic aromatic rings, only one of the rings needs to be aromatic (e.g., 2,3-dihydroindole), although all of the rings may be aromatic (e.g., quinoline).
  • the second ring can also be fused or bridged.
  • the aryl or heteroaryl aromatic ring can be substituted at one or more ring positions with such substituents as described above, for example, alkyl, alkenyl, akynyl, halogen, hydroxyl, alkoxy, alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, alkylcarbonyl, alkylaminocarbonyl, aralkylaminocarbonyl, alkenylaminocarbonyl, alkylcarbonyl, arylcarbonyl, aralkylcarbonyl, alkenylcarbonyl, alkoxycarbonyl, aminocarbonyl, alkylthiocarbonyl, phosphate, phosphonato, phosphinato, amino (including alkylamino, dialkylamino, arylamino, diarylamino and alkylarylamino), acylamino (including alkylcarbonylamino
  • “carbocycle” or “carbocyclic ring” is intended to include any stable monocyclic, bicyclic or tricyclic ring having the specified number of carbons, any of which may be saturated, unsaturated, or aromatic.
  • a C 3 -C 14 carbocycle is intended to include a monocyclic, bicyclic or tricyclic ring having 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13 or 14 carbon atoms.
  • carbocycles include, but are not limited to, cyclopropyl, cyclobutyl, cyclobutenyl, cyclopentyl, cyclopentenyl, cyclohexyl, cycloheptenyl, cycloheptyl, cycloheptenyl, adamantyl, cyclooctyl, cyclooctenyl, cyclooctadienyl, fluorenyl, phenyl, naphthyl, indanyl, adamantyl and tetrahydronaphthyl.
  • Bridged rings are also included in the definition of carbocycle, including, for example, [3.3.0]bicyclooctane, [4.3.0]bicyclononane, [4.4.0]bicyclodecane and [2.2.2]bicyclooctane.
  • a bridged ring occurs when one or more carbon atoms link two non-adjacent carbon atoms.
  • bridge rings are one or two carbon atoms. It is noted that a bridge always converts a monocyclic ring into a tricyclic ring. When a ring is bridged, the substituents recited for the ring may also be present on the bridge. Fused (e.g., naphthyl, tetrahydronaphthyl) and spiro rings are also included.
  • heterocycle includes any ring structure (saturated or partially unsaturated) which contains at least one ring heteroatom (e.g., N, O or S).
  • heterocycles include, but are not limited to, morpholine, pyrrolidine, tetrahydrothiophene, piperidine, piperazine and tetrahydrofuran.
  • heterocyclic groups include, but are not limited to, acridinyl, azocinyl, benzimidazolyl, benzofuranyl, benzothiofuranyl, benzothiophenyl, benzoxazolyl, benzoxazolinyl, benzthiazolyl, benztriazolyl, benztetrazolyl, benzisoxazolyl, benzisothiazolyl, benzimidazolinyl, carbazolyl, 4aH-carbazolyl, carbolinyl, chromanyl, chromenyl, cinnolinyl, decahydroquinolinyl, 2H,6H-1,5,2-dithiazinyl, dihydrofuro[2,3-b]tetrahydrofuran, furanyl, furazanyl, imidazolidinyl, imidazolinyl, imidazolyl, 1H-indazolyl, indol,
  • substituted means that any one or more hydrogen atoms on the designated atom is replaced with a selection from the indicated groups, provided that the designated atom's normal valency is not exceeded, and that the substitution results in a stable compound.
  • a substituent is keto (i.e., ⁇ O)
  • 2 hydrogen atoms on the atom are replaced.
  • Keto substituents are not present on aromatic moieties.
  • Ring double bonds as used herein, are double bonds that are formed between two adjacent ring atoms (e.g., C ⁇ C, C ⁇ N or N ⁇ N).
  • “Stable compound” and “stable structure” are meant to indicate a compound that is sufficiently robust to survive isolation to a useful degree of purity from a reaction mixture, and formulation into an efficacious therapeutic agent.
  • hydroxy or “hydroxyl” includes groups with an —OH or —O—.
  • halo or halogen refers to fluoro, chloro, bromo and iodo.
  • perhalogenated generally refers to a moiety wherein all hydrogen atoms are replaced by halogen atoms.
  • carbonyl or “carboxy” includes compounds and moieties which contain a carbon connected with a double bond to an oxygen atom.
  • moieties containing a carbonyl include, but are not limited to, aldehydes, ketones, carboxylic acids, amides, esters, anhydrides, etc.
  • “Acyl” includes moieties that contain the acyl radical (—C(O)—) or a carbonyl group. “Substituted acyl” includes acyl groups where one or more of the hydrogen atoms are replaced by, for example, alkyl groups, alkynyl groups, halogen, hydroxyl, alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, alkylcarbonyl, arylcarbonyl, alkoxycarbonyl, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, alkylthiocarbonyl, alkoxyl, phosphate, phosphonato, phosphinato, amino (including alkylamino, dialkylamino, arylamino, diarylamino and alkylarylamino), acylamino (including alkylcarbonylamino, arylcarbonylamin
  • Aroyl includes moieties with an aryl or heteroaromatic moiety bound to a carbonyl group. Examples of aroyl groups include phenylcarboxy, naphthyl carboxy, etc.
  • Alkoxyalkyl “alkylaminoalkyl” and “thioalkoxyalkyl” include alkyl groups, as described above, wherein oxygen, nitrogen or sulfur atoms replace one or more hydrocarbon backbone carbon atoms.
  • alkoxy or “alkoxyl” includes substituted and unsubstituted alkyl, alkenyl and alkynyl groups covalently linked to an oxygen atom.
  • alkoxy groups or alkoxyl radicals include, but are not limited to, methoxy, ethoxy, isopropyloxy, propoxy, butoxy and pentoxy groups.
  • substituted alkoxy groups include halogenated alkoxy groups.
  • the alkoxy groups can be substituted with groups such as alkenyl, alkynyl, halogen, hydroxyl, alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, alkylcarbonyl, arylcarbonyl, alkoxycarbonyl, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, alkylthiocarbonyl, alkoxyl, phosphate, phosphonato, phosphinato, amino (including alkylamino, dialkylamino, arylamino, diarylamino, and alkylarylamino), acylamino (including alkylcarbonylamino, arylcarbonylamino, carbamoyl and ureido), amidino, imino, sulfhydryl, alkylthio, arylthio, thiocarboxylate, s
  • ether or “alkoxy” includes compounds or moieties which contain an oxygen bonded to two carbon atoms or heteroatoms.
  • alkoxyalkyl refers to an alkyl, alkenyl, or alkynyl group covalently bonded to an oxygen atom which is covalently bonded to an alkyl group.
  • esters includes compounds or moieties which contain a carbon or a heteroatom bound to an oxygen atom which is bonded to the carbon of a carbonyl group.
  • ester includes alkoxycarboxy groups such as methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, butoxycarbonyl, pentoxycarbonyl, etc.
  • haloalkyl includes compounds or moieties which contain alkyl group substituted with one or more halogen atoms.
  • haloalkyl C 1 , C 2 , C 3 , C 4 , C 5 or C 6 haloalkyl” or “C 1 -C 6 haloalkyl” is intended to include C 1 , C 2 , C 3 , C 4 , C 5 or C 6 straight chain (linear) saturated aliphatic hydrocarbon groups and C 3 , C 4 , C 5 or C 6 branched saturated aliphatic hydrocarbon groups substituted with one or more halogen atoms.
  • haloalkyl groups include, but are not limited to, —CF 3 , —CF 2 CF 3 , and —CF 2 CF 2 CF 3 .
  • amine or “amino” includes moieties where a nitrogen atom is covalently bonded to at least one carbon or heteroatom.
  • Alkylamino includes groups of compounds wherein nitrogen is bound to at least one alkyl group. Examples of alkylamino groups include benzylamino, methylamino, ethylamino, phenethylamino, etc.
  • Dialkylamino includes groups wherein the nitrogen atom is bound to at least two additional alkyl groups. Examples of dialkylamino groups include, but are not limited to, dimethylamino and diethylamino.
  • Arylamino and “diarylamino” include groups wherein the nitrogen is bound to at least one or two aryl groups, respectively.
  • Alkylarylamino refers to an amino group which is bound to at least one alkyl group and at least one aryl group.
  • Alkaminoalkyl refers to an alkyl, alkenyl, or alkynyl group bound to a nitrogen atom which is also bound to an alkyl group.
  • Acylamino includes groups wherein nitrogen is bound to an acyl group. Examples of acylamino include, but are not limited to, alkylcarbonylamino, arylcarbonylamino, carbamoyl and ureido groups.
  • amide or “aminocarboxy” includes compounds or moieties that contain a nitrogen atom that is bound to the carbon of a carbonyl or a thiocarbonyl group.
  • alkaminocarboxy groups that include alkyl, alkenyl or alkynyl groups bound to an amino group which is bound to the carbon of a carbonyl or thiocarbonyl group.
  • arylaminocarboxy groups that include aryl or heteroaryl moieties bound to an amino group that is bound to the carbon of a carbonyl or thiocarbonyl group.
  • alkylaminocarboxy include moieties wherein alkyl, alkenyl, alkynyl and aryl moieties, respectively, are bound to a nitrogen atom which is in turn bound to the carbon of a carbonyl group.
  • Amides can be substituted with substituents such as straight chain alkyl, branched alkyl, cycloalkyl, aryl, heteroaryl or heterocycle. Substituents on amide groups may be further substituted.
  • N-oxides can be converted to N-oxides by treatment with an oxidizing agent (e.g., 3-chloroperoxybenzoic acid (m-CPBA) and/or hydrogen peroxides) to afford other compounds of the present application.
  • an oxidizing agent e.g., 3-chloroperoxybenzoic acid (m-CPBA) and/or hydrogen peroxides
  • m-CPBA 3-chloroperoxybenzoic acid
  • hydrogen peroxides hydrogen peroxides
  • all shown and claimed nitrogen-containing compounds are considered, when allowed by valency and structure, to include both the compound as shown and its N-oxide derivative (which can be designated as N ⁇ O or N + —O ⁇ ).
  • the nitrogens in the compounds of the present application can be converted to N-hydroxy or N-alkoxy compounds.
  • N-hydroxy compounds can be prepared by oxidation of the parent amine by an oxidizing agent such as m-CPBA.
  • nitrogen-containing compounds are also considered, when allowed by valency and structure, to cover both the compound as shown and its N-hydroxy (i.e., N—OH) and N-alkoxy (i.e., N—OR, wherein R is substituted or unsubstituted C 1 -C 6 alkyl, C 1 -C 6 alkenyl, C 1 -C 6 alkynyl, 3-14-membered carbocycle or 3-14-membered heterocycle) derivatives.
  • N—OH N-hydroxy
  • N-alkoxy i.e., N—OR, wherein R is substituted or unsubstituted C 1 -C 6 alkyl, C 1 -C 6 alkenyl, C 1 -C 6 alkynyl, 3-14-membered carbocycle or 3-14-membered heterocycle
  • the structural formula of the compound represents a certain isomer for convenience in some cases, but the present application includes all isomers, such as geometrical isomers, optical isomers based on an asymmetrical carbon, stereoisomers, tautomers, and the like.
  • a crystal polymorphism may be present for the compounds represented by the formula. It is noted that any crystal form, crystal form mixture, or anhydride or hydrate thereof is included in the scope of the present application. Furthermore, so-called metabolite which is produced by degradation of the present compound in vivo is included in the scope of the present application.
  • “Isomerism” means compounds that have identical molecular formulae but differ in the sequence of bonding of their atoms or in the arrangement of their atoms in space. Isomers that differ in the arrangement of their atoms in space are termed “stereoisomers”. Stereoisomers that are not mirror images of one another are termed “diastereoisomers”, and stereoisomers that are non-superimposable mirror images of each other are termed “enantiomers” or sometimes optical isomers. A mixture containing equal amounts of individual enantiomeric forms of opposite chirality is termed a “racemic mixture”.
  • a carbon atom bonded to four nonidentical substituents is termed a “chiral center”.
  • Chiral isomer means a compound with at least one chiral center. Compounds with more than one chiral center may exist either as an individual diastereomer or as a mixture of diastereomers, termed “diastereomeric mixture”. When one chiral center is present, a stereoisomer may be characterized by the absolute configuration (R or S) of that chiral center. Absolute configuration refers to the arrangement in space of the substituents attached to the chiral center. The substituents attached to the chiral center under consideration are ranked in accordance with the Sequence Rule of Cahn, Ingold and Prelog. (Cahn et al., Angew. Chem. Inter. Edit.
  • “Geometric isomer” means the diastereomers that owe their existence to hindered rotation about double bonds. These configurations are differentiated in their names by the prefixes cis and trans, or Z and E, which indicate that the groups are on the same or opposite side of the double bond in the molecule according to the Cahn-Ingold-Prelog rules.
  • atropic isomers are a type of stereoisomer in which the atoms of two isomers are arranged differently in space. Atropic isomers owe their existence to a restricted rotation caused by hindrance of rotation of large groups about a central bond. Such atropic isomers typically exist as a mixture, however as a result of recent advances in chromatography techniques; it has been possible to separate mixtures of two atropic isomers in select cases.
  • Tautomer is one of two or more structural isomers that exist in equilibrium and is readily converted from one isomeric form to another. This conversion results in the formal migration of a hydrogen atom accompanied by a switch of adjacent conjugated double bonds. Tautomers exist as a mixture of a tautomeric set in solution. In solid form, usually one tautomer predominates. In solutions where tautomerization is possible, a chemical equilibrium of the tautomers will be reached. The exact ratio of the tautomers depends on several factors, including temperature, solvent and pH. The concept of tautomers that are interconvertible by tautomerizations is called tautomerism.
  • keto-enol tautomerism a simultaneous shift of electrons and a hydrogen atom occurs.
  • Ring-chain tautomerism arises as a result of the aldehyde group (—CHO) in a sugar chain molecule reacting with one of the hydroxy groups (—OH) in the same molecule to give it a cyclic (ring-shaped) form as exhibited by glucose.
  • tautomeric pairs are: ketone-enol, amide-nitrile, lactam-lactim, amide-imidic acid tautomerism in heterocyclic rings (e.g., in nucleobases such as guanine, thymine and cytosine), amine-enamine and enamine-enamine.
  • crystal polymorphs means crystal structures in which a compound (or a salt or solvate thereof) can crystallize in different crystal packing arrangements, all of which have the same elemental composition. Different crystal forms usually have different X-ray diffraction patterns, infrared spectral, melting points, density hardness, crystal shape, optical and electrical properties, stability and solubility. Recrystallization solvent, rate of crystallization, storage temperature, and other factors may cause one crystal form to dominate. Crystal polymorphs of the compounds can be prepared by crystallization under different conditions.
  • the compounds of the present application can exist in either hydrated or unhydrated (the anhydrous) form or as solvates with other solvent molecules.
  • hydrates include monohydrates, dihydrates, etc.
  • solvates include ethanol solvates, acetone solvates, etc.
  • Solvate means solvent addition forms that contain either stoichiometric or non stoichiometric amounts of solvent. Some compounds have a tendency to trap a fixed molar ratio of solvent molecules in the crystalline solid state, thus forming a solvate. If the solvent is water the solvate formed is a hydrate; and if the solvent is alcohol, the solvate formed is an alcoholate. Hydrates are formed by the combination of one or more molecules of water with one molecule of the substance in which the water retains its molecular state as H 2 O.
  • analog refers to a chemical compound that is structurally similar to another but differs slightly in composition (as in the replacement of one atom by an atom of a different element or in the presence of a particular functional group, or the replacement of one functional group by another functional group).
  • an analog is a compound that is similar or comparable in function and appearance, but not in structure or origin to the reference compound.
  • the term “derivative” refers to compounds that have a common core structure, and are substituted with various groups as described herein.
  • all of the compounds represented by formula I are imidazopyridinyl-aminopyridine derivatives, and have formula I as a common core.
  • bioisostere refers to a compound resulting from the exchange of an atom or of a group of atoms with another, broadly similar, atom or group of atoms.
  • the objective of a bioisosteric replacement is to create a new compound with similar biological properties to the parent compound.
  • the bioisosteric replacement may be physicochemically or topologically based.
  • Examples of carboxylic acid bioisosteres include, but are not limited to, acyl sulfonimides, tetrazoles, sulfonates and phosphonates. See, e.g., Patani and LaVoie, Chem. Rev. 96, 3147-3176, 1996.
  • isotopes include those atoms having the same atomic number but different mass numbers.
  • isotopes of hydrogen include tritium and deuterium
  • isotopes of carbon include C-13 and C-14.
  • these compounds are capable of suppressing Bcl-3-NF- ⁇ B protein interactions, inhibiting NF- ⁇ B signalling and attenuating the cellular characteristics contributing to the metastatic phenotype observed in vivo and therefore the compounds are suitable for the treatment of cancer, especially for the treatment or prevention of metastatic cancer or secondary tumours.
  • references to compounds of Formula (I) or Formula (Ia) includes amorphous and crystalline forms, including all polymorphs, as well as isotopic variants, for example compounds of Formula (I) or Formula (Ia) in which one or more hydrogen atoms is replaced by deuterium, one or more carbon atoms is replaced by 14 C or one or more nitrogen atoms is replaced by 15 N.
  • Compounds of Formula (I) and Formula (Ia) may be prepared by any suitable route.
  • Compounds of Formula (Ia) include the compounds of Formula (Ib), Formula (Ic), Formula (Id), Formula (Ie), and Formula (If).
  • the synthetic processes apply to all compounds of the application.
  • the synthetic processes of the application can tolerate a wide variety of functional groups, therefore various substituted starting materials can be used.
  • the processes generally provide the desired final compound at or near the end of the overall process, although it may be desirable in certain instances to further convert the compound to a pharmaceutically acceptable salt, ester or prodrug thereof.
  • compounds of Formula (I) and Formula (Ia) may be prepared from a compound of general formula (II) and general formula (II′). respectively:
  • R is H or an amine protecting group and q and R q are as defined for Formula (I) and Formula (Ia).
  • the reaction is carried out in the presence of a base, typically a non-nucleophilic base, for example a tertiary amine such as N,N-diisopropylethylamine.
  • a base typically a non-nucleophilic base, for example a tertiary amine such as N,N-diisopropylethylamine.
  • the reaction may be conducted in an organic solvent such as N,N-dimethylformamide and at a temperature of about 15° C. to about 30° C., more typically at about 18 to about 25° C. (room temperature).
  • Amines of general formula (III) are well known and are readily available or may be prepared by literature methods well known to those of skill in the art.
  • R 2 , R 4 , R 5 , and R 6 are as defined for Formula (I) and Formula (Ia) and X is a leaving group, typically a halo group such as chloro.
  • the reaction may be carried out in an organic solvent such as pyridine and at a temperature of about 15 to about 30° C., more typically at about 18 to about 25° C. (room temperature).
  • organic solvent such as pyridine
  • the viability of cells at experimental endpoints for particular assays is determined using the Cell Titre Blue reagent (Promega, Southampton, UK). This reagent measures the cellular metabolic activity using resazurin as an indicator dye. Viable cells, therefore metabolically active, will reduce resazurin into highly fluorescent resofurin. The resulting fluorescence levels are measured and indicate cell viability.
  • Cells are plated at low confluency into 96 well plates in 100 ⁇ l of complete growth media in triplicates and are incubated at 37° C. in 5% CO 2 for the desired test exposure period. For each 100 ⁇ l of media in 96 well plates, 20 ⁇ l Cell Titre Blue reagent is added followed by incubation for an hour at 37° C. in 5% CO 2 . Fluorescence is then measured by setting excitation/emission wavelengths to 560/590 nm on a Fluorostar Optima plate reader (BMG tabtech, Bucks, UK).
  • the migration of cells in the presence of a compound of Formula (I) or Formula (Ia) is determined using a Scratch assay.
  • MDA-MB-231 is a highly metastatic, human basal epithelial cell line isolated from the pleural effusion of an adenocarcinoma.
  • the cells are ‘triple negative’ as they lack estrogen, progesterone and ERBB2 receptor and they strongly over-express EGFR. The expression of receptors in this line has been confirmed by the host laboratory.
  • NF- ⁇ B luciferase assays cells are seeded into clear bottom black 96-well plates (Corning Inc., Lowell, US) in antibiotic free culture media in appropriate density. After about 20-24 hrs, cells are transfected with 10 ng of 3 ⁇ B luciferase plasmid and 10 ng of pcDNA3.1-Lacl plasmid per well. Empty pcDNA3.1 plasmid is also included to normalize the total weight of DNA transfected to 100 ng. For positive and negative controls respectively, 10 ng of pGL3 control or pGL3 basic are transfected in place of 3 ⁇ KB luciferase plasmid. Transfection is carried out using Lipofectamine LTX reagents (Invitrogen, Paisley, UK).
  • the media is aspirated and cells are lyzed using 50 ⁇ l/well of Glo-lysis buffer (Promega, Southampton, UK). The plate is left on a rocker for 20 min to facilitate complete cell lysis. Then, 20 ⁇ l of lysate from each well is removed and transferred into a new clear bottom black well plate for measuring LacZ activity as a transfection efficiency control and is followed by addition of 20 l/well of Beta-Glo substrate (Promega, Southampton, UK) and cultivation at room temperature for at least 20 min.
  • Glo-lysis buffer Promega, Southampton, UK
  • Nude mice are injected i.v. with 200,000 highly metastatic human breast cancer cells expressing luciferase (MDA-MB-231-Luc) then are given a compound of Formula (I) or Formula (Ia) once daily for about 10 days and are monitored for tumours by total body scan using Xenogen-IVIS. Mice with a luciferase signal above background in repeated scans in any part of their torso are scored as having metastatic disease. Total light emission in the abdominal region is quantified at time points up to 49 days post surgery and plotted as mean total light yield.
  • MDA-MB-231-Luc highly metastatic human breast cancer cells expressing luciferase
  • Tumour efficacy of the compounds of the application was determined using murine xenograft models of breast and colorectal cancers, each model demonstrating different aspects of tumour biology. In all experiments, each compound was administered by intraperitoneally at 3.5 mg/kg.
  • Model 1 studied the effect of the compound's ability to inhibit the seeding and early colonization of circulating tumour cells at distal sites, most commonly in the lungs and liver.
  • Human tumour cell lines were injected into the bloodstream of recipient mice, followed by single daily intraperitoneal injections of the compound (3.5 mg/kg in 1% DMSO) for 10 consecutive days. Tumour burden was monitored longitudinally for up to 8 weeks in vivo by live luminescence imaging, and subsequently histology performed on affected organs at the end of the experiment.
  • Model 2 Another model tested the effect of the compound's ability to inhibit the colonization and subsequent growth and spread of secondary lesions at distal sites.
  • Human tumour cell lines were injected into the bloodstream of recipient mice, followed 2 days later by single daily intraperitoneal injections of the compound (3.5 mg/kg in 1% DMSO) for the entire course of the experiment. Tumour burden was monitored longitudinally for up to 8 weeks in vivo by live luminescence imaging, and subsequently histology performed on affected organs at the end of the experiment.
  • Model 4 Another model (Model 4) studied the effect of the compound's ability to inhibit the growth of tumour cells at the transplantation site.
  • Human tumour cell lines were injected subcutaneously into recipient mice, followed 2 days later by single daily intraperitoneal injections of a compound (3.5 mg/kg in 1% DMSO) for the entire course of the experiment. Tumour burden was monitored longitudinally for up to 12 weeks in vivo by palpation and caliper measurements of tumour volume, and subsequently histology performed on tumours at the end of the experiment.
  • the compounds of the present application are Bcl-3 inhibitors and are therefore of use in the treatment of cancer, for example leukaemias and lymphomas, such as anaplastic large cell lymphomas (ALCLs), classic Hodgkin lymphomas (cHL) and non-Hodgkin's lymphoma; and solid tumour cancers, such as breast cancer, melanoma, lung cancer, pancreatic cancer, oesophageal cancer, colorectal cancer, nasopharyngeal carcinoma, ovarian, prostate and hepatocarcinomas.
  • leukaemias and lymphomas such as anaplastic large cell lymphomas (ALCLs), classic Hodgkin lymphomas (cHL) and non-Hodgkin's lymphoma
  • solid tumour cancers such as breast cancer, melanoma, lung cancer, pancreatic cancer, oesophageal cancer, colorectal cancer, nasopharyngeal carcinoma, ovarian, prostate and hepato
  • the present application provides a compound Formula (I) or Formula (Ia) for use in medicine.
  • a compound of Formula (I) or Formula (Ia) for use in medicine for example leukaemias and lymphomas, such as anaplastic large cell lymphomas (ALCLs), classic Hodgkin lymphomas (cHL) and non-Hodgkin's lymphoma; and solid tumour cancers, such as breast cancer, melanoma, lung cancer, pancreatic cancer, oesophageal cancer, colorectal cancer, ovarian cancer, prostate cancer, nasopharyngeal carcinoma, and hepatocarcinomas.
  • leukaemias and lymphomas such as anaplastic large cell lymphomas (ALCLs), classic Hodgkin lymphomas (cHL) and non-Hodgkin's lymphoma
  • solid tumour cancers such as breast cancer, melanoma, lung cancer, pancreatic cancer, oesophageal cancer, colorectal cancer, ovarian cancer, prostate cancer, nasopharyngeal carcinoma, and hepato
  • a compound of Formula (I) or Formula (Ia) in the preparation of an agent for the treatment of cancer, for example leukaemias and lymphomas, such as anaplastic large cell lymphomas (ALCLs), classic Hodgkin lymphomas (cHL) and non-Hodgkin's lymphoma; and solid tumour cancers, such as breast cancer, melanoma, lung cancer, pancreatic cancer, oesophageal cancer, colorectal cancer, ovarian cancer, prostate cancer, nasopharyngeal carcinoma and hepatocarcinomas.
  • leukaemias and lymphomas such as anaplastic large cell lymphomas (ALCLs), classic Hodgkin lymphomas (cHL) and non-Hodgkin's lymphoma
  • solid tumour cancers such as breast cancer, melanoma, lung cancer, pancreatic cancer, oesophageal cancer, colorectal cancer, ovarian cancer, prostate cancer, nasopharyngeal
  • the compounds may be used either in human or in veterinary medicine and the patient may be any mammal but especially a human.
  • the application also provides a method for the treatment of cancer, for example leukaemias and lymphomas, such as anaplastic large cell lymphomas (ALCLs), classic Hodgkin lymphomas (cHL) and non-Hodgkin's lymphoma; and solid tumour cancers, such as breast cancer, melanoma, lung cancer, pancreatic cancer, oesophageal cancer, colorectal cancer, ovarian cancer, prostate cancer, nasopharyngeal carcinoma, and hepatocarcinomas, the method comprising administering to a patient in need of such treatment an effective amount of a compound of Formula (I) or Formula (Ia).
  • ACLs anaplastic large cell lymphomas
  • cHL classic Hodgkin lymphomas
  • non-Hodgkin's lymphoma non-Hodgkin's lymphoma
  • solid tumour cancers such as breast cancer, melanoma, lung cancer, pancreatic cancer, oesophageal cancer, color
  • the compounds are particularly useful for the treatment or prevention of metastasis in cancers.
  • the cancer is breast cancer, more particularly triple negative breast cancer or HER2 enriched breast cancer.
  • the compounds of Formula (I) or Formula (Ia) have been shown to be particularly effective in preventing or treating metastasis in models of these breast cancer subtypes. However this does not preclude its relevance or efficacy in metastatic disease in other tumour types.
  • our experimental evidence in human cancer cell lines indicates that there may also be beneficial therapeutic effects of Bcl-3 suppression on tumour cell viability, as both genetic suppression of Bcl-3 and use of compounds of Formula (I) or Formula (Ia) partially but significantly reduce tumour cell numbers in vitro.
  • the present application provides a compound Formula (I) or Formula (Ia) for use in the preparation of an agent for the treatment of cancer.
  • the present application provides a compound Formula (I) or Formula (Ia) for use in the preparation of an agent for the treatment of leukaemia or lymphoma.
  • the present application provides a compound Formula (I) or Formula (Ia) for use in the treatment or prevention of metastasis in cancers.
  • the compounds of the application will generally be formulated for administration by a desired route.
  • a “subject in need thereof” is a subject having a cell proliferative disorder, or a subject having an increased risk of developing a cell proliferative disorder relative to the population at large.
  • a subject in need thereof can have a precancerous condition.
  • a subject in need thereof has cancer.
  • a “subject” includes a mammal.
  • the mammal can be e.g., any mammal, e.g., a human, primate, bird, mouse, rat, fowl, dog, cat, cow, horse, goat, camel, sheep or a pig.
  • the mammal is a human.
  • contacting a cell refers to a condition in which a compound or other composition of matter is in direct contact with a cell, or is close enough to induce a desired biological effect in a cell.
  • monotherapy refers to the administration of a single active or therapeutic compound to a subject in need thereof.
  • monotherapy will involve administration of a therapeutically effective amount of an active compound.
  • cancer monotherapy with one of the compound of the present application, or a pharmaceutically acceptable salt, prodrug, metabolite, analog or derivative thereof, to a subject in need of treatment of cancer.
  • Monotherapy may be contrasted with combination therapy, in which a combination of multiple active compounds is administered, preferably with each component of the combination present in a therapeutically effective amount.
  • monotherapy with a compound of the present application, or a pharmaceutically acceptable salt, prodrug, metabolite, polymorph or solvate thereof is more effective than combination therapy in inducing a desired biological effect.
  • treating describes the management and care of a patient for the purpose of combating a disease, condition, or disorder and includes the administration of a compound of the present application, or a pharmaceutically acceptable salt, prodrug, metabolite, polymorph or solvate thereof, to alleviate the symptoms or complications of a disease, condition or disorder, or to eliminate the disease, condition or disorder.
  • a compound of the present application can also be used to prevent a disease, condition or disorder.
  • preventing or “prevent” describes reducing or eliminating the onset of the symptoms or complications of the disease, condition or disorder.
  • the term “alleviate” is meant to describe a process by which the severity of a sign or symptom of a disorder is decreased.
  • a sign or symptom can be alleviated without being eliminated.
  • the administration of pharmaceutical compositions of the application leads to the elimination of a sign or symptom, however, elimination is not required.
  • Effective dosages are expected to decrease the severity of a sign or symptom.
  • a sign or symptom of a disorder such as cancer, which can occur in multiple locations, is alleviated if the severity of the cancer is decreased within at least one of multiple locations.
  • severity is meant to describe the potential of cancer to transform from a precancerous, or benign, state into a malignant state.
  • severity is meant to describe a cancer stage, for example, according to the TNM system (accepted by the International Union against Cancer (UICC) and the American Joint Committee on Cancer (AJCC)) or by other art-recognized methods.
  • Cancer stage refers to the extent or severity of the cancer, based on factors such as the location of the primary tumor, tumor size, number of tumors, and lymph node involvement (spread of cancer into lymph nodes).
  • severity is meant to describe the tumor grade by art-recognized methods (see, National Cancer Institute).
  • Tumor grade is a system used to classify cancer cells in terms of how abnormal they look under a microscope and how quickly the tumor is likely to grow and spread. Many factors are considered when determining tumor grade, including the structure and growth pattern of the cells. The specific factors used to determine tumor grade vary with each type of cancer. Severity also describes a histologic grade, also called differentiation, which refers to how much the tumor cells resemble normal cells of the same tissue type (see, National Cancer Institute). Furthermore, severity describes a nuclear grade, which refers to the size and shape of the nucleus in tumor cells and the percentage of tumor cells that are dividing (see, National Cancer Institute).
  • severity describes the degree to which a tumor has secreted growth factors, degraded the extracellular matrix, become vascularized, lost adhesion to juxtaposed tissues, or metastasized. Moreover, severity describes the number of locations to which a primary tumor has metastasized. Finally, severity includes the difficulty of treating tumors of varying types and locations. For example, inoperable tumors, those cancers which have greater access to multiple body systems (hematological and immunological tumors), and those which are the most resistant to traditional treatments are considered most severe.
  • the term “selectively” means tending to occur at a higher frequency in one population than in another population.
  • the compared populations can be cell populations.
  • a compound of the present application, or a pharmaceutically acceptable salt, prodrug, metabolite, polymorph or solvate thereof acts selectively on a cancer or precancerous cell but not on a normal cell.
  • a compound of the present application, or a pharmaceutically acceptable salt, prodrug, metabolite, polymorph or solvate thereof acts selectively to modulate one molecular target (e.g., Bcl-3) but does not significantly modulate another molecular target.
  • a compound of the present application, or a pharmaceutically acceptable salt, prodrug, metabolite, polymorph or solvate thereof can modulate the activity of a molecular target (e.g., a Bcl-3). Modulating refers to stimulating or inhibiting an activity of a molecular target.
  • a compound of the present application, or a pharmaceutically acceptable salt, prodrug, metabolite, polymorph or solvate thereof modulates the activity of a molecular target if it stimulates or inhibits the activity of the molecular target by at least 2-fold relative to the activity of the molecular target under the same conditions but lacking only the presence of said compound.
  • a compound of the present application modulates the activity of a molecular target if it stimulates or inhibits the activity of the molecular target by at least 5-fold, at least 10-fold, at least 20-fold, at least 50-fold, at least 100-fold relative to the activity of the molecular target under the same conditions but lacking only the presence of said compound.
  • the activity of a molecular target may be measured by any reproducible means.
  • the activity of a molecular target may be measured in vitro or in vivo.
  • the activity of a molecular target may be measured in vitro by an enzymatic activity assay or a DNA binding assay, or the activity of a molecular target may be measured in vivo by assaying for expression of a reporter gene.
  • the present application provides a compound Formula (I) or Formula (Ia) for use in combination with one or more additional active agents which are useful in the treatment of cancer.
  • the additional active agent include, but are not limited to, anti-HER2 agents such as trastuzumab and pertuzumab; standard adjuvant therapy regimens such as 5-fluorouracil, doxorubicin, and cyclophosphamide (FAC); 5-fluorouracil, epirubicin, and cyclophosphamide (FEC); and doxorubicin and cyclophosphamide (AC); cyclophosphamide, methotrexate, and 5-fluorouracil (CMF); and docetaxel, doxorubicin, cyclophosphamide (TAC); and anti-angiogenic/antimetastatic agents such as bevacizumab (Avastin).
  • anti-HER2 agents such as trastuzumab and pertuzumab
  • “combination therapy” or “co-therapy” includes the administration of a compound of the present application, or a pharmaceutically acceptable salt, prodrug, metabolite, polymorph or solvate thereof, and at least a second agent as part of a specific treatment regimen intended to provide the beneficial effect from the co-action of these therapeutic agents.
  • the beneficial effect of the combination includes, but is not limited to, pharmacokinetic or pharmacodynamic co-action resulting from the combination of therapeutic agents.
  • Administration of these therapeutic agents in combination typically is carried out over a defined time period (usually minutes, hours, days or weeks depending upon the combination selected).
  • “Combination therapy” may be, but generally is not, intended to encompass the administration of two or more of these therapeutic agents as part of separate monotherapy regimens that incidentally and arbitrarily result in the combinations of the present application.
  • “Combination therapy” is intended to embrace administration of these therapeutic agents in a sequential manner, wherein each therapeutic agent is administered at a different time, as well as administration of these therapeutic agents, or at least two of the therapeutic agents, in a substantially simultaneous manner.
  • Substantially simultaneous administration can be accomplished, for example, by administering to the subject a single capsule having a fixed ratio of each therapeutic agent or in multiple, single capsules for each of the therapeutic agents.
  • Sequential or substantially simultaneous administration of each therapeutic agent can be effected by any appropriate route including, but not limited to, oral routes, intravenous routes, intramuscular routes, and direct absorption through mucous membrane tissues.
  • the therapeutic agents can be administered by the same route or by different routes.
  • a first therapeutic agent of the combination selected may be administered by intravenous injection while the other therapeutic agents of the combination may be administered orally.
  • all therapeutic agents may be administered orally or all therapeutic agents may be administered by intravenous injection.
  • the sequence in which the therapeutic agents are administered is not narrowly critical.
  • Combination therapy also embraces the administration of the therapeutic agents as described above in further combination with other biologically active ingredients and non-drug therapies (e.g., surgery or radiation treatment).
  • the combination therapy further comprises a non-drug treatment
  • the non-drug treatment may be conducted at any suitable time so long as a beneficial effect from the co-action of the combination of the therapeutic agents and non-drug treatment is achieved.
  • the beneficial effect is still achieved when the non-drug treatment is temporally removed from the administration of the therapeutic agents, perhaps by days or even weeks.
  • compositions comprising a compound of each of the formulae described herein in combination with at least one pharmaceutically acceptable excipient or carrier.
  • the carrier or, if more than one be present, each of the carriers, must be acceptable in the sense of being compatible with the other ingredients of the formulation and not deleterious to the recipient.
  • the application relates to a pharmaceutical composition
  • a pharmaceutical composition comprising a compound of Formula (I) or Formula (Ia) together with a pharmaceutically or veterinarily acceptable excipient or carrier.
  • a pharmaceutical composition comprising a compound of Formula (I) or Formula (Ia) together with a pharmaceutically or veterinarily acceptable excipient or carrier.
  • formulated for parenteral administration In one embodiment, formulated for parenteral administration.
  • the present application relates to a process for the preparation of a pharmaceutical composition the process comprising bringing into association the compound of Formula (I) or Formula (Ia) into association with a pharmaceutically or veterinarily acceptable excipient or carrier.
  • a “pharmaceutical composition” is a formulation containing the compounds of the present application in a form suitable for administration to a subject.
  • formulations include those suitable for oral, rectal, nasal, topical (including eye drops, buccal and sublingual), vaginal or parenteral (including subcutaneous, intramuscular, intravenous and intradermal) administration and may be prepared by any methods well known in the art of pharmacy.
  • compositions for parenteral administration.
  • Parenteral formulations will generally be sterile.
  • the composition may be prepared by bringing into association the above defined active agent with the carrier.
  • the formulations are prepared by uniformly and intimately bringing into association the active agent with liquid carriers or finely divided solid carriers or both, and then if necessary shaping the product.
  • the application extends to methods for preparing a pharmaceutical composition comprising bringing a compound of Formula (I) or Formula (Ia) into association with a pharmaceutically or veterinarily acceptable excipient or carrier.
  • the pharmaceutical composition is in bulk or in unit dosage form.
  • the unit dosage form is any of a variety of forms, including, for example, a capsule, an IV bag, a tablet, a single pump on an aerosol inhaler or a vial.
  • the quantity of active ingredient (e.g., a formulation of the disclosed compound or salt, hydrate, solvate or isomer thereof) in a unit dose of composition is an effective amount and is varied according to the particular treatment involved.
  • active ingredient e.g., a formulation of the disclosed compound or salt, hydrate, solvate or isomer thereof
  • the dosage will also depend on the route of administration.
  • routes including oral, pulmonary, rectal, parenteral, transdermal, subcutaneous, intravenous, intramuscular, intraperitoneal, inhalational, buccal, sublingual, intrapleural, intrathecal, intranasal, and the like.
  • Dosage forms for the topical or transdermal administration of a compound of this application include powders, sprays, ointments, pastes, creams, lotions, gels, solutions, patches and inhalants.
  • the active compound is mixed under sterile conditions with a pharmaceutically acceptable carrier, and with any preservatives, buffers or propellants that are required.
  • the phrase “pharmaceutically acceptable” refers to those compounds, materials, compositions, carriers, and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio.
  • “Pharmaceutically acceptable excipient” means an excipient that is useful in preparing a pharmaceutical composition that is generally safe, non-toxic and neither biologically nor otherwise undesirable, and includes excipient that is acceptable for veterinary use as well as human pharmaceutical use.
  • a “pharmaceutically acceptable excipient” as used in the specification and claims includes both one and more than one such excipient.
  • a pharmaceutical composition of the application is formulated to be compatible with its intended route of administration.
  • routes of administration include parenteral, e.g., intravenous, intradermal, subcutaneous, oral (e.g., inhalation), transdermal (topical), and transmucosal administration.
  • Solutions or suspensions used for parenteral, intradermal, or subcutaneous application can include the following components: a sterile diluent such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerine, propylene glycol or other synthetic solvents; antibacterial agents such as benzyl alcohol or methyl parabens; antioxidants such as ascorbic acid or sodium bisulfite; chelating agents such as ethylenediaminetetraacetic acid; buffers such as acetates, citrates or phosphates, and agents for the adjustment of tonicity such as sodium chloride or dextrose.
  • the pH can be adjusted with acids or bases, such as hydrochloric acid or sodium hydroxide.
  • the parenteral preparation can be enclosed in ampoules, disposable syringes or multiple dose vials made of glass or plastic.
  • a compound or pharmaceutical composition of the application can be administered to a subject in many of the well-known methods currently used for chemotherapeutic treatment.
  • a compound of the application may be injected directly into tumors, injected into the blood stream or body cavities or taken orally or applied through the skin with patches.
  • the dose chosen should be sufficient to constitute effective treatment but not as high as to cause unacceptable side effects.
  • the state of the disease condition e.g., cancer, precancer, and the like
  • the health of the patient should preferably be closely monitored during and for a reasonable period after treatment.
  • therapeutically effective amount refers to an amount of a pharmaceutical agent to treat, ameliorate, or prevent an identified disease or condition, or to exhibit a detectable therapeutic or inhibitory effect.
  • the effect can be detected by any assay method known in the art.
  • the precise effective amount for a subject will depend upon the subject's body weight, size, and health; the nature and extent of the condition; and the therapeutic or combination of therapeutics selected for administration.
  • Therapeutically effective amounts for a given situation can be determined by routine experimentation that is within the skill and judgment of the clinician.
  • the disease or condition to be treated is cancer.
  • the disease or condition to be treated is a cell proliferative disorder.
  • the therapeutically effective amount can be estimated initially either in cell culture assays, e.g., of neoplastic cells, or in animal models, usually rats, mice, rabbits, dogs, or pigs.
  • the animal model may also be used to determine the appropriate concentration range and route of administration. Such information can then be used to determine useful doses and routes for administration in humans.
  • Therapeutic/prophylactic efficacy and toxicity may be determined by standard pharmaceutical procedures in cell cultures or experimental animals, e.g., ED 50 (the dose therapeutically effective in 50% of the population) and LD 50 (the dose lethal to 50% of the population).
  • the dose ratio between toxic and therapeutic effects is the therapeutic index, and it can be expressed as the ratio, LD 50 /ED 50 .
  • Pharmaceutical compositions that exhibit large therapeutic indices are preferred. The dosage may vary within this range depending upon the dosage form employed, sensitivity of the patient, and the route of administration.
  • Dosage and administration are adjusted to provide sufficient levels of the active agent(s) or to maintain the desired effect.
  • Factors which may be taken into account include the severity of the disease state, general health of the subject, age, weight, and gender of the subject, diet, time and frequency of administration, drug combination(s), reaction sensitivities, and tolerance/response to therapy.
  • Long-acting pharmaceutical compositions may be administered every 3 to 4 days, every week, or once every two weeks depending on half-life and clearance rate of the particular formulation.
  • compositions containing active compounds of the present application may be manufactured in a manner that is generally known, e.g., by means of conventional mixing, dissolving, granulating, dragee-making, levigating, emulsifying, encapsulating, entrapping, or lyophilizing processes.
  • Pharmaceutical compositions may be formulated in a conventional manner using one or more pharmaceutically acceptable carriers comprising excipients and/or auxiliaries that facilitate processing of the active compounds into preparations that can be used pharmaceutically. Of course, the appropriate formulation is dependent upon the route of administration chosen.
  • compositions suitable for injectable use include sterile aqueous solutions (where water soluble) or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersion.
  • suitable carriers include physiological saline, bacteriostatic water, Cremophor ELTM (BASF, Parsippany, N.J.) or phosphate buffered saline (PBS).
  • the composition must be sterile and should be fluid to the extent that easy syringeability exists. It must be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms such as bacteria and fungi.
  • the carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol, and the like), and suitable mixtures thereof.
  • the proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants.
  • Prevention of the action of microorganisms can be achieved by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, ascorbic acid, thimerosal, and the like.
  • isotonic agents for example, sugars, polyalcohols such as manitol, sorbitol, sodium chloride in the composition.
  • Prolonged absorption of the injectable compositions can be brought about by including in the composition an agent which delays absorption, for example, aluminum monostearate and gelatin.
  • Sterile injectable solutions can be prepared by incorporating the active compound in the required amount in an appropriate solvent with one or a combination of ingredients enumerated above, as required, followed by filtered sterilization.
  • dispersions are prepared by incorporating the active compound into a sterile vehicle that contains a basic dispersion medium and the required other ingredients from those enumerated above.
  • methods of preparation are vacuum drying and freeze-drying that yields a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof.
  • Oral compositions generally include an inert diluent or an edible pharmaceutically acceptable carrier. They can be enclosed in gelatin capsules or compressed into tablets. For the purpose of oral therapeutic administration, the active compound can be incorporated with excipients and used in the form of tablets, troches, or capsules. Oral compositions can also be prepared using a fluid carrier for use as a mouthwash, wherein the compound in the fluid carrier is applied orally and swished and expectorated or swallowed. Pharmaceutically compatible binding agents, and/or adjuvant materials can be included as part of the composition.
  • the tablets, pills, capsules, troches and the like can contain any of the following ingredients, or compounds of a similar nature: a binder such as microcrystalline cellulose, gum tragacanth or gelatin; an excipient such as starch or lactose, a disintegrating agent such as alginic acid, Primogel, or corn starch; a lubricant such as magnesium stearate or Sterotes; a glidant such as colloidal silicon dioxide; a sweetening agent such as sucrose or saccharin; or a flavoring agent such as peppermint, methyl salicylate, or orange flavoring.
  • a binder such as microcrystalline cellulose, gum tragacanth or gelatin
  • an excipient such as starch or lactose, a disintegrating agent such as alginic acid, Primogel, or corn starch
  • a lubricant such as magnesium stearate or Sterotes
  • a glidant such as colloidal silicon dioxide
  • the compounds are delivered in the form of an aerosol spray from pressured container or dispenser, which contains a suitable propellant, e.g., a gas such as carbon dioxide, or a nebulizer.
  • a suitable propellant e.g., a gas such as carbon dioxide, or a nebulizer.
  • Systemic administration can also be by transmucosal or transdermal means.
  • penetrants appropriate to the barrier to be permeated are used in the formulation.
  • penetrants are generally known in the art, and include, for example, for transmucosal administration, detergents, bile salts, and fusidic acid derivatives.
  • Transmucosal administration can be accomplished through the use of nasal sprays or suppositories.
  • the active compounds are formulated into ointments, salves, gels, or creams as generally known in the art.
  • the active compounds can be prepared with pharmaceutically acceptable carriers that will protect the compound against rapid elimination from the body, such as a controlled release formulation, including implants and microencapsulated delivery systems.
  • a controlled release formulation including implants and microencapsulated delivery systems.
  • Biodegradable, biocompatible polymers can be used, such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and polylactic acid. Methods for preparation of such formulations will be apparent to those skilled in the art.
  • the materials can also be obtained commercially from Alza Corporation and Nova Pharmaceuticals, Inc.
  • Liposomal suspensions (including liposomes targeted to infected cells with monoclonal antibodies to viral antigens) can also be used as pharmaceutically acceptable carriers. These can be prepared according to methods known to those skilled in the art, for example, as described in U.S. Pat. No. 4,522,811.
  • Dosage unit form refers to physically discrete units suited as unitary dosages for the subject to be treated; each unit containing a predetermined quantity of active compound calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier.
  • the specification for the dosage unit forms of the application are dictated by and directly dependent on the unique characteristics of the active compound and the particular therapeutic effect to be achieved.
  • the dosages of the pharmaceutical compositions used in accordance with the application vary depending on the agent, the age, weight, and clinical condition of the recipient patient, and the experience and judgment of the clinician or practitioner administering the therapy, among other factors affecting the selected dosage.
  • the dose should be sufficient to result in slowing, and preferably regressing, the growth of the tumors and also preferably causing complete regression of the cancer.
  • Dosages can range from about 0.01 mg/kg per day to about 5000 mg/kg per day. In preferred aspects, dosages can range from about 0.01 mg/kg per day to about 1000 mg/kg per day; so as to maintain the concentration of drug in the plasma at a concentration effective to inhibit Bcl-3.
  • an effective amount of a pharmaceutical agent is that which provides an objectively identifiable improvement as noted by the clinician or other qualified observer. For example, regression of a tumor in a patient may be measured with reference to the diameter of a tumor. Decrease in the diameter of a tumor indicates regression. Regression is also indicated by failure of tumors to reoccur after treatment has stopped.
  • the term “dosage effective manner” refers to amount of an active compound to produce the desired biological effect in a subject or cell.
  • compositions can be included in a container, pack, or dispenser together with instructions for administration.
  • pharmaceutically acceptable salts refer to derivatives of the compounds of the present application wherein the parent compound is modified by making acid or base salts thereof.
  • pharmaceutically acceptable salts include, but are not limited to, mineral or organic acid salts of basic residues such as amines, alkali or organic salts of acidic residues such as carboxylic acids, and the like.
  • the pharmaceutically acceptable salts include the conventional non-toxic salts or the quaternary ammonium salts of the parent compound formed, for example, from non-toxic inorganic or organic acids.
  • pharmaceutically acceptable salts include veterinarily acceptable salts.
  • Salts of the compounds of the present application include salts of organic acids, especially carboxylic acids, including but not limited to acetate, trifluoroacetate, lactate, gluconate, malonate, citrate, tartrate, maleate, malate, pantothenate, adipate, alginate, aspartate, benzoate, butyrate, digluconate, cyclopentanate, glucoheptanate, glycerophosphate, oxalate, heptanoate, hexanoate, fumarate, nicotinate, pamoate, pectinate, 3-phenylpropionate, picrate, pivalate, proprionate, tartrate, lactobionate, pivolate, camphorate, undecanoate and succinate, organic sulfonic acids such as methanesulfonate, ethanesulfonate, 2-hydroxyethane sulfonate, camphorsulfonate, 2-naphthalen
  • pharmaceutically or veterinarily acceptable salts of the compounds of Formula (I) or Formula (Ia) may also include basic addition salts such as sodium, potassium, calcium, aluminium, zinc, magnesium and other metal salts as well as choline, diethanolamine, ethanolamine, ethyl diamine and other well-known basic addition salts.
  • basic addition salts such as sodium, potassium, calcium, aluminium, zinc, magnesium and other metal salts as well as choline, diethanolamine, ethanolamine, ethyl diamine and other well-known basic addition salts.
  • Salts will preferably be pharmaceutically or veterinarily acceptable but other salts may still be valuable as intermediates.
  • the compounds of the present application can also be prepared as esters, for example, pharmaceutically acceptable esters.
  • a carboxylic acid function group in a compound can be converted to its corresponding ester, e.g., a methyl, ethyl or other ester.
  • an alcohol group in a compound can be converted to its corresponding ester, e.g., an acetate, propionate or other ester.
  • the compounds of the present application can also be prepared as prodrugs, for example, pharmaceutically acceptable prodrugs.
  • pro-drug and “prodrug” are used interchangeably herein and refer to any compound which releases an active parent drug in vivo. Since prodrugs are known to enhance numerous desirable qualities of pharmaceuticals (e.g., solubility, bioavailability, manufacturing, etc.), the compounds of the present application can be delivered in prodrug form. Thus, the present application is intended to cover prodrugs of the presently claimed compounds, methods of delivering the same and compositions containing the same. “Prodrugs” are intended to include any covalently bonded carriers that release an active parent drug of the present application in vivo when such prodrug is administered to a subject.
  • Prodrugs in the present application are prepared by modifying functional groups present in the compound in such a way that the modifications are cleaved, either in routine manipulation or in vivo, to the parent compound.
  • Prodrugs include compounds of the present application wherein a hydroxy, amino, sulfhydryl, carboxy or carbonyl group is bonded to any group that may be cleaved in vivo to form a free hydroxyl, free amino, free sulfhydryl, free carboxy or free carbonyl group, respectively.
  • prodrugs include, but are not limited to, esters (e.g., acetate, dialkylaminoacetates, formates, phosphates, sulfates and benzoate derivatives) and carbamates (e.g., N,N-dimethylaminocarbonyl) of hydroxy functional groups, esters (e.g., ethyl esters, morpholinoethanol esters) of carboxyl functional groups, N-acyl derivatives (e.g., N-acetyl) N-Mannich bases, Schiff bases and enaminones of amino functional groups, oximes, acetals, ketals and enol esters of ketone and aldehyde functional groups in compounds of the application, and the like, See Bundegaard, H., Design of Prodrugs , p 1-92, Elesevier, New York-Oxford (1985).
  • esters e.g., acetate, dialkylaminoacetates, formates
  • the compounds, or pharmaceutically acceptable salts, esters or prodrugs thereof are administered orally, nasally, transdermally, pulmonary, inhalationally, buccally, sublingually, intraperintoneally, subcutaneously, intramuscularly, intravenously, rectally, intrapleurally, intrathecally and parenterally.
  • the compound is administered orally.
  • One skilled in the art will recognize the advantages of certain routes of administration.
  • the dosage regimen utilizing the compounds is selected in accordance with a variety of factors including type, species, age, weight, sex and medical condition of the patient; the severity of the condition to be treated; the route of administration; the renal and hepatic function of the patient; and the particular compound or salt thereof employed.
  • An ordinarily skilled physician or veterinarian can readily determine and prescribe the effective amount of the drug required to prevent, counter or arrest the progress of the condition.
  • the compounds described herein, and the pharmaceutically acceptable salts thereof are used in pharmaceutical preparations in combination with a pharmaceutically acceptable carrier or diluent.
  • suitable pharmaceutically acceptable carriers include inert solid fillers or diluents and sterile aqueous or organic solutions.
  • the compounds will be present in such pharmaceutical compositions in amounts sufficient to provide the desired dosage amount in the range described herein.
  • Acid chlorides can be prepared directly from the corresponding carboxylic acid using known synthetic methods, e.g., reaction of the corresponding carboxylic acid in thionyl chloride and catalytic N,N-dimethyl formamide for 8-24 hours at refluxing temperatures.
  • Silica gel plates (Merck Kieselgel 60F 254 ) were used and were developed by the ascending method. After solvent evaporation, compounds were visualized by irradiation with UV light at 254 nm and 366 nm.
  • Compounds 160-206 were prepared of general procedure 1 substituting (IIa) with the appropriate substituted anthranilic acid and substituting (IIb) with the appropriate benzoyl chloride.
  • reaction mixture is diluted with water, washed with ethyl acetate, washed with brine, dried over Mg 2 SO 4 , filtered and evaporated to give a crude compound which is then purified by silica gel column using a mixture of Chloroform:Methanol (9:1) as eluent. The product is collected under reduced pressure to provide the compound shown in Scheme 4.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present application relates to compounds of any one of Formulae I, Ia, Ib, Ic, Id, Ie, and If. Compounds of Formula I have the structure:
Figure US20190248756A1-20190815-C00001
    • wherein A, B, Y, Z, R2, R4, R5, R6, Rq and q are as defined herein. The compounds can be used as inhibitors of Bcl-3 and can be used for the treatment of cancer, particularly metastatic cancer.

Description

    RELATED APPLICATIONS
  • This application is a continuation of U.S. application Ser. No. 15/500,016 filed on Jan. 27, 2017, which claims priority from PCT patent application PCT/IB2015/001807 filed on Jul. 31, 2015, which in turn claims priority from and the benefit of, U.S. Provisional Application No. 62/031,774 filed on Jul. 31, 2014, the contents of which are incorporated herein by reference in their entirety.
    • BACKGROUND
  • Metastasis, or metastatic disease, is the spread of a cancer from an originating tissue or organ to another tissue or organ. The cells which constitute the primary cancerous tumour commonly undergo metaplasia, followed by dysplasia and then anaplasia, resulting in a malignant phenotype. This malignant phenotype allows for intravasation into the circulation, followed by extravasation to a second site for tumourigenesis. After the tumour cells have migrated to another site, they re-penetrate the vessel or walls and continue to multiply, eventually forming another clinically detectable tumour (secondary tumours). Whilst treatment regimens and therapies for primary tumours are much better understood, with improved efficacy and success rates, and whilst some types of metastatic cancer can be cured with such current treatments, most metastatic cancers show poor response. Treatments for metastatic disease do exist, such as systemic therapy (chemotherapy, biological therapy, targeted therapy, hormonal therapy), local therapy (surgery, radiation therapy), or a combination of these treatments. However, most often the primary goal of these treatments is to control the growth of the cancer or to relieve symptoms caused by same. It is therefore generally considered that most people who die of cancer die of metastatic disease.
  • Therefore, improved understanding of cancer progression towards aggressive metastatic forms and tumour cell-specific molecular pathways is necessary to improve and lead to new therapies.
  • NF-κB (nuclear factor kappa-light-chain-enhancer of activated B cells) is a protein complex that controls the transcription of DNA and is involved in cellular responses to stimuli such as stress, cytokines, free radicals, ultraviolet irradiation, oxidized LDL, and bacterial or viral antigens. Members of the NF-κB family can both induce and repress gene expression through binding to DNA sequences, and regulate numerous genes that control programmed cell death, cell adhesion, proliferation, immunity and inflammation.
  • It is known that NF-κB provides a link between inflammation and cancer progression. Further, NF-κB is widely used by eukaryotic cells as a regulator of genes that control cell proliferation and cell survival. As such, many different types of human tumours have deregulated NF-κB: that is, NF-κB is constitutively active. Deregulated NF-κB has been documented in many cancers, including solid cancers such as breast, melanoma, lung, colon, pancreatic, oesophageal, and also haematological malignancies. For example, it has been shown that increased NF-κB activation was evident in 86% of HER2+/ER− breast cancers and in 33% of basal like cancers, which are associated with a shortened disease-free interval, poor survival and resistance to cancer therapy. Moreover, NF-κB activation in tumour cells, tumour-associated stromal and endothelial cells is thought to play a role in tumour progression and invasion.
  • B-cell Lymphoma 3 (Bcl-3) is a proto-oncogene modulating NF-κB signaling, which was first identified as a chromosome translocation in B-cell chronic lymphocytic leukaemia. Deregulated Bcl-3 over-expression has been reported in numerous tumours including several leukaemias and lymphomas, such as anaplastic large cell lymphomas (ALCLs), classic Hodgkin lymphomas (cHL) and non-Hodgkin's lymphoma. Additionally, deregulated expression has also been observed in solid tumour cancers, such as breast cancer, nasopharyngeal carcinoma, and hepatocarcinomas.
  • A role for NF-κB and Bcl-3 in metastatic colorectal cancer has also been shown, where it was observed that NF-κB activation occurs prior to metastatic spread. Notably, Bcl-3 expression was also observed in normal and tumour tissue, but a correlation between nuclear Bcl-3 and patient survival was observed. Bcl-3 expression has also been found to be increased in breast cancer cell lines and patient breast cancer samples versus non-tumorigenic cell lines and normal adjacent tissue, respectively. Cells overexpressing Bcl-3 also resulted in a significantly higher number of tumours which supports the role for Bcl-3 in breast cancer progression.
  • The underlying oncogenic function of Bcl-3 has never been fully elucidated. However, established thinking based on experiments performed on cancer cell lines in vitro is that it has a role in increased cellular proliferation and cell survival. It was previously shown that Bcl-3 specifically promotes the formation of metastasis of ErbB2 breast cancer driven tumours. Although primary tumour growth in the Bcl-3 deficient ErbB2 (MMTV/neu) murine model was not affected, it was shown that the occurrence of developed lung metastasis from a primary breast tumour was significantly reduced by 40%. Moreover, a significant reduction in mitotic index and apoptosis was observed in secondary tumour lesions but not in primary tumours. Furthermore, through gene expression knock down studies, it was shown that deletion of Bcl-3 resulted in an 80% decrease in lung metastases, which was attributed to loss of cell migration but importantly with no effect upon normal mammary function or overall systemic viability. The implication from these observations is that specific targeting of individual NF-κB subunits or their co-activators may be a more beneficial therapeutic strategy than suppressing their upstream regulators which appear to exhibit detrimental systemic toxicity. This therefore suggests Bcl-3 may represent a suitable therapeutic target for preventing cancer metastasis and secondary tumour formation.
  • Thus, there is a need to develop modulators of Bcl-3 for treating or preventing diseases or disorders in which Bcl-3 and/or NF-κB play a role.
    • SUMMARY
  • The present application relates to compounds which modulate Bcl-3 activity and may suppress Bcl-3-NF-κB protein interactions, inhibit NF-κB signaling and attenuate the cellular characteristics contributing to the metastatic phenotype observed in vivo. Therefore the compounds are suitable for the treatment of cancer, especially for the treatment or prevention of metastatic cancer or secondary tumours. The present application also relates to compounds that modulate Bcl-3 for treatment or prevention of a disease or disorder in which NF-κB plays a role.
  • According to a first aspect of the application there is provided a compound of Formula (I):
  • Figure US20190248756A1-20190815-C00002
  • or a pharmaceutically acceptable salt thereof,
  • wherein:
      • A is CR3 or N
      • B is CR7 or N
      • R2, R3, R4, R5 and R6 are each, independently, hydrogen, halogen, C1-C6 haloalkyl, NO2, NRaRb, OH, O(C1-C6 alkyl), or O(C1-C6 haloalkyl); or R3 and R4 together form a C6 aryl ring, or R4 and R5 together form a C6 aryl ring;
      • R7 is hydrogen, fluorine, OH, or O(C1-C6 alkyl);
      • Ra and Rb are each, independently, hydrogen or C1-C6 alkyl;
      • W, Y, and Z are each, independently hydrogen, fluorine, OH, or O(C1-C6 alkyl);
      • q is 2 or 3;
      • Rq is 1-piperazinyl, 1-(4-N—(RN))piperazinyl, N-morpholinyl or phenyl;
      • RN is C1-C5 straight chain or C1-C5 branched alkyl;
  • wherein, when A is CR3 and R2 is fluorine or chlorine, then Rq is phenyl or 1-(4-N—(RN))piperazinyl, or when A is CR3, R2 is fluorine or chlorine, q is 2 and Rq is N-morpholinyl, then at least one of W, R7, Y and Z is not hydrogen but W is not OCH3; or when A is CR3, R2 is fluorine or chlorine, q is 2 and Rq is N-morpholinyl at least one of R3, R4, R5 and R6 is not hydrogen or halogen.
  • According to a second aspect of the application there is provided a compound of Formula (Ia):
  • Figure US20190248756A1-20190815-C00003
  • or a pharmaceutically acceptable salt thereof,
  • wherein:
      • A is CR3 or N;
      • X1 is CR8 or N;
      • X2 is CR9 or N;
      • X3 is CR10 or N;
  • wherein zero or one of X1, X2, or X3 is N;
      • R2, R3, R4, R5 and R6 are each, independently, hydrogen, halogen, C1-C6 haloalkyl, NO2, NRaRb, OH, O(C1-C6 alkyl), S(C1-C6 alkyl), O(C1-C6 haloalkyl), or S(C1-C6 haloalkyl); or R2 and R3 together with the carbon atoms to which they attach form a C6 aryl ring, or R5 and R6 together with the carbon atoms to which they attach form a C6 aryl ring, or R3 and R4 together with the carbon atoms to which they attach form a C6 aryl ring, or R4 and R5 together with the carbon atoms to which they attach form a C6 aryl ring;
      • Ra and Rb are each, independently, hydrogen or C1-C6 alkyl;
      • R8, R9, R10, and Z are each, independently, hydrogen, halogen, OH, or O(C1-C6 alkyl);
      • R11 is OH, O(C1-C6 alkyl), or —NH—(CH2)q—Rq, wherein:
      • q is 2 or 3;
      • Rq is 1-piperazinyl, 1-(4-N—(RN))piperazinyl, N-morpholino or phenyl; and
      • RN is C1-C5 alkyl; and
      • R12 is hydrogen or C1-C6 alkyl;
  • wherein: when A is CR3 and R2 is fluorine or chlorine, then Rq is phenyl or 1-(4-N—(RN))piperazinyl; or when A is CR3, R2 is fluorine or chlorine, q is 2 and Rq is N-morpholino, then at least one of R8, R9, R10, and Z is not hydrogen and R8 is not OCH3; or when A is CR3, R2 is fluorine or chlorine, q is 2 and Rq is N-morpholino, then at least one of R3, R4, R5 and R6 is not hydrogen or halogen; and at least three of R2, R3, R4, R5 and R6 are hydrogen.
  • A further aspect of the application relates to a compound of Formula (Ia) which has the Formula (Ib).
  • A further aspect of the application relates to a compound of Formula (Ia) which has the Formula (Ic).
  • A further aspect of the application relates to a compound of Formula (Ia) which has the Formula (Id).
  • A further aspect of the application relates to a compound of Formula (Ia) which has the Formula (Ie).
  • A further aspect of the application relates to a compound of Formula (Ia) which has the Formula (If).
  • In another aspect of the application relates to a compound of Formula (I) or Formula (Ia) for use in medicine.
  • In another aspect of the application relates to a compound of Formula (I) or Formula (Ia) for use in the treatment of cancer.
  • In another aspect, the application relates to a compound of Formula (I) or Formula (Ia) for use in the treatment of leukaemia or lymphoma.
  • In another aspect of the application relates to a compound of Formula (I) or Formula (Ia) for use in the treatment of anaplastic large cell lymphomas (ALCLs), classic Hodgkin lymphomas (cHL), non-Hodgkin's lymphoma; or solid tumour cancers. In one embodiment, the solid tumour cancer is breast cancer, melanoma, lung cancer, pancreatic cancer, oesophageal cancer, colorectal cancer, nasopharyngeal carcinoma, or hepatocarcinoma.
  • In another aspect, the application relates to a compound of Formula (I) or Formula (Ia) for use in the preparation of an agent for the treatment of cancer.
  • A aspect of the application relates to a compound of Formula (I) or Formula (Ia) for use in the preparation of an agent for the treatment of leukaemia or lymphoma.
  • In another aspect, the application relates to a compound of Formula (I) or Formula (Ia) for use in the preparation of an agent for the treatment of anaplastic large cell lymphomas (ALCLs), classic Hodgkin lymphomas (cHL), non-Hodgkin's lymphoma; or solid tumour cancers. In one embodiment, the solid tumour cancer is breast cancer, melanoma, lung cancer, pancreatic cancer, oesophageal cancer, colorectal cancer, nasopharyngeal carcinoma, or hepatocarcinoma.
  • In another aspect of the application relates to a method for the treatment of cancer, the method comprising administering to a patient in need of such treatment an effective amount of a compound of Formula (I) or Formula (Ia). In one embodiment, the cancer is leukaemia or lymphoma. In another embodiment, the cancer is anaplastic large cell lymphoma (ALCLs), classic Hodgkin lymphoma (cHL), non-Hodgkin's lymphoma; or solid tumour cancer.
  • In another aspect, the application relates to any of the uses or methods defined above wherein the treatment comprises the treatment or prevention of metastasis in cancers.
  • In another aspect of the application relates to any of the uses or methods defined above wherein a compound of Formula (I) or Formula (Ia) is used in combination with one or more additional active agents which are useful in the treatment of cancer.
  • In another aspect, the application relates to a pharmaceutical composition comprising a compound of Formula (I) or Formula (Ia) together with a pharmaceutically or veterinarily acceptable excipient or carrier.
  • Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this application belongs. In the specification, the singular forms also include the plural unless the context clearly dictates otherwise. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present application, suitable methods and materials are described below. All publications, patent applications, patents, and other references mentioned herein are incorporated by reference. The references cited herein are not admitted to be prior art to the application. In the case of conflict, the present specification, including definitions, will control. In addition, the materials, methods, and examples are illustrative only and are not intended to be limiting.
  • Other features and advantages of the application will be apparent from the following detailed description and claims.
    • BRIEF DESCRIPTION OF THE DRAWINGS
  • FIGS. 1a-1h are bar graphs showing the results of cell titer blue assays performed on cells treated with various compounds of the application (dark bars (10 μM), grey bars (1 μM)) to determine cell viability.
  • FIG. 2 is a graph showing the effect of a number of compounds of the application on cell migration of human breast cancer cell line MDA-MB-436 during a scratch assay.
  • FIG. 3 is a graph showing the effect of compound 12, Reference compound A (Ref. Cmpd A), or control on EGF-induced NF-kB activity.
  • FIG. 4 is a graph showing the effect of compound 12 (Cmpd 12), Reference compound A (Ref. Cmpd A), Reference compound B (Ref. Cmpd B), or control on the disease free survival in a mouse metastasis model.
  • FIG. 5 is a graph which demonstrates the comparative effect of various compounds in human breast cancer MDA-MB-231 xenograft in vivo studies.
  • FIG. 6 is a graph which demonstrates the effect of compound 12 (to inhibit the growth of human breast cancer (MDA-MB-231) at the tumor transplant site.
  • FIG. 7 is a graph which demonstrates the effect of compound 12 to inhibit the growth of human colorectal cell lines (SW480) at the tumor transplant site.
  • FIG. 8 is a graph which demonstrates the effect of compound 12 to inhibit the seeding and early colonization of circulating tumour cells at distal sites.
  • FIG. 9 is a graph which demonstrates the effect of compound 12 to inhibit the colonization and subsequent growth and spread of secondary lesions at distal sites.
  • FIG. 10 is a graph which demonstrates the effect of compound 12 to inhibit the growth of tumour cells at the transplantation site.
  • FIG. 11 is a graph which demonstrates the effect of compound 12 to inhibit the growth of human triple negative breast invasive ductal carcinoma (MDA-MB-436) at the tumor transplant site.
    •  DETAILED DESCRIPTION 1. Compounds
  • The present application provides compounds of Formula (I), Formula (Ia), Formula (Ib), Formula (Ic), Formula (Id), Formula (Ie), and Formula (If), i.e., the compounds of the application. The present application also provides pharmaceutical compositions containing the compounds of the application and various uses of the disclosed compounds. The compounds of the application may be used in treating a disease or disorder in which Bcl-3 plays a role (e.g., cancer).
  • The present application provides a compound of Formula (I):
  • Figure US20190248756A1-20190815-C00004
  • wherein:
  • A is CR3 or N
  • B is CR7 or N
  • R2, R3, R4, R5 and R6 are each, independently, hydrogen, halogen, C1-C6 haloalkyl, NO2, NRaRb, OH, O(C1-C6 alkyl), or O(C1-C6 haloalkyl); or R3 and R4 together form a C6 aryl ring, or R4 and R5 together form a C6 aryl ring;
  • R7 is hydrogen, fluorine, OH, or O(C1-C6 alkyl);
  • Ra and Rb are each, independently, hydrogen or C1-C6 alkyl;
  • W, Y and Z are each, independently hydrogen, fluorine, OH, or O(C1-C6 alkyl);
  • q is 2 or 3;
  • Rq is 1-piperazinyl, 1-(4-N—(RN))piperazinyl, N-morpholinyl or phenyl;
  • RN is C1-C5 straight chain or C1-C5 branched alkyl;
  • wherein,
  • when A is CR3 and R2 is fluorine or chlorine, then Rq is phenyl or 1-(4-N—(RN))piperazinyl, or when A is CR3, R2 is fluorine or chlorine, q is 2 and Rq is N-morpholinyl, then at least one of W, R7, Y and Z is not hydrogen but W is not OCH3; or when A is CR3, R2 is fluorine or chlorine, q is 2 and Rq is N-morpholinyl at least one of R3, R4, R5 and R6 is not hydrogen or halogen.
  • In one embodiment, q is 2. In another embodiment, q is 3.
  • In another embodiment, A is N. In a further embodiment, A is CR3.
  • In one embodiment, Rq is 1-piperazinyl. In another embodiment, Rq is 1-(4-N—(RN))piperazinyl. In yet another embodiment, Rq is N-morpholinyl. In a further embodiment, Rq is phenyl.
  • In one embodiment, RN is C1-C5 straight chain or C1-C5 branched alkyl. In another embodiment, RN is methyl, ethyl, propyl, isopropyl, n-butyl or n-pentyl. In a preferred embodiment, RN is methyl or ethyl. In a more preferred embodiment, RN is methyl.
  • In one embodiment, at least one of R2, R3, R4, R5 and R6 is NRaRb.
  • In another embodiment, at least one of R2, R3, R4, R5 and R6 is C1-C6 haloalkyl. In a preferred embodiment, C1-C6 haloalkyl is CF3.
  • In another embodiment, at least one of R2, R3, R4, R5 and R6 is halogen. In a preferred embodiment, at least one of R2, R3, R4, R5 and R6 is —Cl or —F.
  • In another embodiment, at least one of R2, R3, R4, R5 and R6 is —NO2.
  • In yet another embodiment, R2 is fluorine and at least one of R3, R4, R5 and R6 is O(C1-C6 alkyl).
  • In another embodiment, R2 is fluorine and R4 is O(C1-C6 alkyl). In a preferred embodiment, R2 is fluorine and R4 is OCH3.
  • In a further embodiment, at least one of R3, R4, R5 and R6 is OCH3. In another embodiment, at least one of W, R7, Y and Z is not hydrogen. In another embodiment, at least one of W, R7, Y and Z is O(C1-C6 alkyl). In a preferred embodiment, at least one of W, R7, Y and Z is OCH3. In another embodiment, at least one of W, R7, Y and Z is halogen. In a preferred embodiment at least one of W, R7, Y and Z is fluorine.
  • In one embodiment, R2 is OCH3.
  • In another embodiment, at least two of R2, R3, R4, R5 and R6 are not hydrogen and are not the same.
  • In another embodiment, at least three of R2, R3, R4, R5 and R6 are not hydrogen and at least two of R2, R3, R4, R5 and R6 are not the same.
  • In one embodiment, A is CR3 and one of R2, R3, R4, R5 and R6 are not hydrogen. In another embodiment, A is CR3 and two of R2, R3, R4, R5 and R6 are not hydrogen. In yet another embodiment, A is CR3 and three of R2, R3, R4, R5 and R6 are not hydrogen. In a further embodiment, A is CR3 and four of R2, R3, R4, R5 and R6 are not hydrogen.
  • In one embodiment, Rq is N-morpholinyl, A is CR3, and B is CR7. In a further embodiment, Rq is N-morpholinyl, A is CH, and B is CH. In another embodiment, Rq is N-morpholinyl, A is CH, B is CH and q is 2.
  • In one embodiment, Rq is N-morpholinyl, A is CR3, and B is CR7. In a further embodiment, Rq is N-morpholinyl, A is CH, and B is CH. In another embodiment, Rq is N-morpholinyl, A is CH, B is CH and q is 3.
  • In one embodiment, Rq is 1-piperazinyl, A is CR3, and B is CR7. In a further embodiment, Rq is 1-piperazinyl, A is CH, and B is CH. In another embodiment, Rq is 1-piperazinyl, A is CH, B is CH and q is 2.
  • In one embodiment, Rq is 1-piperazinyl, A is CR3, and B is CR7. In a further embodiment, Rq is 1-piperazinyl, A is CH, and B is CH. In another embodiment, Rq is 1-piperazinyl, A is CH, B is CH and q is 3.
  • In one embodiment, Rq is phenyl, A is CR3, and B is CR7. In a further embodiment, Rq is phenyl, A is CH, and B is CH. In another embodiment, Rq is phenyl, A is CH, B is CH and q is 2.
  • In one embodiment, Rq is phenyl, A is CR3, and B is CR7. In a further embodiment, Rq is phenyl, A is CH, and B is CH. In another embodiment, Rq is phenyl, A is CH, B is CH and q is 3.
  • In one embodiment, Rq is 1-(4-N—(RN))piperazinyl, A is CR3, and B is CR7. In a further embodiment, Rq is 1-(4-N—(RN))piperazinyl, A is CH, and B is CH. In another embodiment, Rq is 1-(4-N—(RN))piperazinyl, A is CH, B is CH and q is 2.
  • In one embodiment, Rq is 1-(4-N—(RN))piperazinyl, A is CR3, and B is CR7. In a further embodiment, Rq is 1-(4-N—(RN))piperazinyl, A is CH, and B is CH. In another embodiment, Rq is 1-(4-N—(RN))piperazinyl, A is CH, B is CH and q is 3.
  • In one embodiment, Rq is N-morpholinyl, A is CR3, and B is CR7. In a further embodiment, Rq is N-morpholinyl, A is CR3, B is CR7 and q is 2. In another embodiment, Rq is N-morpholinyl, A is CR3, B is CR7 and q is 3.
  • In one embodiment, Rq is 1-piperazinyl, A is CR3, and B is CR7. In a further embodiment, Rq is 1-piperazinyl, A is CR3, B is CR7 and q is 2. In another embodiment, Rq is 1-piperazinyl, A is CR3, B is CR7 and q is 3.
  • In one embodiment, Rq is phenyl, A is CR3, and B is CR7. In a further embodiment, Rq is phenyl, A is CR3, B is CR7 and q is 2. In another embodiment, Rq is phenyl, A is CR3, B is CR7 and q is 3.
  • In one embodiment, Rq is 1-(4-N—(RN))piperazinyl, A is CR3, and B is CR7. In a further embodiment, Rq is 1-(4-N—(RN))piperazinyl, A is CR3, B is CR7 and q is 2. In another embodiment, Rq is 1-(4-N—(RN))piperazinyl, A is CR3, B is CR7 and q is 3.
  • In one embodiment, Rq is N-morpholinyl, A is N, and B is CR7. In a further embodiment, Rq is N-morpholinyl, A is N, B is CR7 and q is 2. In another embodiment, Rq is N-morpholinyl, A is N, B is CR7 and q is 3.
  • In one embodiment, Rq is 1-piperazinyl, A is N, and B is CR7. In a further embodiment, Rq is 1-piperazinyl, A is N, B is CR7 and q is 2. In another embodiment, Rq is 1-piperazinyl, A is N, B is CR7 and q is 3.
  • In one embodiment, Rq is phenyl, A is N, and B is CR7. In a further embodiment, Rq is phenyl, A is N, B is CR7 and q is 2. In another embodiment, Rq is phenyl, A is N, B is CR7 and q is 3.
  • In one embodiment, Rq is 1-(4-N—(RN))piperazinyl, A is N, and B is CR7. In a further embodiment, Rq is 1-(4-N—(RN))piperazinyl, A is N, B is CR7 and q is 2. In another embodiment, Rq is 1-(4-N—(RN))piperazinyl, A is N, B is CR7 and q is 3.
  • The present application provides a compound of Formula (Ia):
  • Figure US20190248756A1-20190815-C00005
  • or a pharmaceutically acceptable salt thereof,
  • wherein:
      • A is CR3 or N;
      • X1 is CR8 or N;
      • X2 is CR9 or N;
      • X3 is CR10 or N;
      • wherein zero or one of X1, X2, or X3 is N;
      • R2, R3, R4, R5 and R6 are each, independently, hydrogen, halogen, C1-C6 haloalkyl, NO2, NRaRb, OH, O(C1-C6 alkyl), S(C1-C6 alkyl), O(C1-C6 haloalkyl), or S(C1-C6 haloalkyl); or R2 and R3 together with the carbon atoms to which they attach form a C6 aryl ring, or R5 and R6 together with the carbon atoms to which they attach form a C6 aryl ring, or R3 and R4 together with the carbon atoms to which they attach form a C6 aryl ring, or R4 and R5 together with the carbon atoms to which they attach form a C6 aryl ring;
      • Ra and Rb are each, independently, hydrogen or C1-C6 alkyl;
      • R8, R9, R10, and Z are each, independently, hydrogen, halogen, OH, or O(C1-C6 alkyl);
      • R11 is OH, O(C1-C6 alkyl), or —NH—(CH2)q—Rq, wherein:
      • q is 2 or 3;
      • Rq is 1-piperazinyl, 1-(4-N—(RN))piperazinyl, N-morpholino or phenyl; and
      • RN is C1-C5 alkyl; and
      • R12 is hydrogen or C1-C6 alkyl;
      • wherein,
      • when A is CR3 and R2 is fluorine or chlorine, then Rq is phenyl or 1-(4-N—(RN))piperazinyl; or when A is CR3, R2 is fluorine or chlorine, q is 2 and Rq is N-morpholino, then at least one of R8, R9, R10, and Z is not hydrogen and R8 is not OCH3; or when A is CR3, R2 is fluorine or chlorine, q is 2 and Rq is N-morpholino, then at least one of R3, R4, R5 and R6 is not hydrogen or halogen; and at least three of R2, R3, R4, R5 and R6 are hydrogen.
  • In one embodiment, q is 2. In another embodiment, q is 3.
  • In another embodiment, A is N. In a further embodiment, A is CR3.
  • In one embodiment, one of X1, X2, or X3 is N. In a further embodiment, none of X1, X2, or X3 is N.
  • In one embodiment, X1 is N, X2 is CR9, X3 is CR10, and A is N.
  • In one embodiment, X2 is N, X1 is CR8, X3 is CR10, and A is N.
  • In one embodiment, X3 is N, X1 is CR8, X2 is CR9, and A is N.
  • In one embodiment, X1 is N, X2 is CR9, X3 is CR10, and A is CR3.
  • In one embodiment, X2 is N, X1 is CR8, X3 is CR10, and A is CR3.
  • In one embodiment, X3 is N, X1 is CR8, X2 is CR9, and A is CR3.
  • In one embodiment, Rq is 1-piperazinyl. In another embodiment, Rq is 1-(4-N—(RN))piperazinyl. In yet another embodiment, Rq is N-morpholinyl. In a further embodiment, Rq is phenyl.
  • In one embodiment, RN is C1-C5 straight chain or C1-C5 branched alkyl. In another embodiment, RN is methyl, ethyl, propyl, isopropyl, n-butyl or n-pentyl. In a preferred embodiment, RN is methyl or ethyl. In a more preferred embodiment, RN is methyl.
  • In one embodiment, R2, R3, R4, R5 and R6 are each, independently, hydrogen, halogen, C1-C6 haloalkyl, NO2, NRaRb, OH, O(C1-C6 alkyl), or O(C1-C6 haloalkyl).
  • In one embodiment, R8, R9, R10, and Z are each, independently, hydrogen, flourine, OH, or O(C1-C6 alkyl).
  • In one embodiment, R2, R3, R4, R5 and R6 are each, independently, hydrogen, halogen, C1-C6 haloalkyl, NO2, NRaRb, OH, O(C1-C6 alkyl), or O(C1-C6 haloalkyl).
  • In one embodiment, R2 and R3 together with the carbon atoms to which they attach form a C6 aryl ring, and R4, R5 and R6 are each, independently, hydrogen, halogen, C1-C6 haloalkyl, NO2, NRaRb, OH, O(C1-C6 alkyl), or O(C1-C6 haloalkyl).
  • In one embodiment, R3 and R4 together with the carbon atoms to which they attach form a C6 aryl ring, and R2, R5 and R6 are each, independently, hydrogen, halogen, C1-C6 haloalkyl, NO2, NRaRb, OH, O(C1-C6 alkyl), or O(C1-C6 haloalkyl).
  • In one embodiment, R4 and R5 together with the carbon atoms to which they attach form a C6 aryl ring, and R2, R3, and R6 are each, independently, hydrogen, halogen, C1-C6 haloalkyl, NO2, NRaRb, OH, O(C1-C6 alkyl), or O(C1-C6 haloalkyl).
  • In one embodiment, R5 and R6 together with the carbon atoms to which they attach form a C6 aryl ring, and R2, R3, and R4 are each, independently, hydrogen, halogen, C1-C6 haloalkyl, NO2, NRaRb, OH, O(C1-C6 alkyl), or O(C1-C6 haloalkyl).
  • In one embodiment, at least one of R2, R3, R4, R5 and R6 is NRaRb.
  • In another embodiment, at least one of R2, R3, R4, R5 and R6 is C1-C6 haloalkyl. In a preferred embodiment, C1-C6 haloalkyl is CF3.
  • In another embodiment, at least one of R2, R3, R4, R5 and R6 is halogen. In a preferred embodiment, at least one of R2, R3, R4, R5 and R6 is —Cl or —F.
  • In another embodiment, at least one of R2, R3, R4, R5 and R6 is —NO2.
  • In yet another embodiment, R2 is fluorine and at least one of R3, R4, R5 and R6 is O(C1-C6 alkyl).
  • In another embodiment, R2 is fluorine and R4 is O(C1-C6 alkyl). In a preferred embodiment, R2 is fluorine and R4 is OCH3.
  • In a further embodiment, at least one of R3, R4, R5 and R6 is OCH3. In another embodiment, at least one of R8, R9, R10, and Z is not hydrogen. In another embodiment, at least one of R8, R9, R10, and Z is O(C1-C6 alkyl). In a preferred embodiment, at least one of R8, R9, R10, and Z is OCH3. In another embodiment, at least one of R8, R9, R10, and Z is halogen. In a preferred embodiment at least one of R8, R9, R10, and Z is fluorine.
  • In one embodiment, R2 is OCH3.
  • In another embodiment, at least two of R2, R3, R4, R5 and R6 are not hydrogen and are not the same.
  • In another embodiment, at least three of R2, R3, R4, R5 and R6 are not hydrogen and at least two of R2, R3, R4, R5 and R6 are not the same.
  • In one embodiment, A is CR3 and one of R2, R3, R4, R5 and R6 are not hydrogen. In another embodiment, A is CR3 and two of R2, R3, R4, R5 and R6 are not hydrogen. In yet another embodiment, A is CR3 and three of R2, R3, R4, R5 and R6 are not hydrogen. In a further embodiment, A is CR3 and four of R2, R3, R4, R5 and R6 are not hydrogen.
  • In one embodiment, Rq is N-morpholinyl, A is CR3, and X2 is CR9. In a further embodiment, Rq is N-morpholinyl, A is CH, and X2 is CH. In another embodiment, Rq is N-morpholinyl, A is CH, X2 is CH and q is 2.
  • In one embodiment, Rq is N-morpholinyl, A is CR3, and X2 is CR9. In a further embodiment, Rq is N-morpholinyl, A is CH, and X2 is CH. In another embodiment, Rq is N-morpholinyl, A is CH, X2 is CH and q is 3.
  • In one embodiment, Rq is 1-piperazinyl, A is CR3, and X2 is CR9. In a further embodiment, Rq is 1-piperazinyl, A is CH, and X2 is CH. In another embodiment, Rq is 1-piperazinyl, A is CH, X2 is CH and q is 2.
  • In one embodiment, Rq is 1-piperazinyl, A is CR3, and X2 is CR9. In a further embodiment, Rq is 1-piperazinyl, A is CH, and X2 is CH. In another embodiment, Rq is 1-piperazinyl, A is CH, X2 is CH and q is 3.
  • In one embodiment, Rq is phenyl, A is CR3, and X2 is CR9. In a further embodiment, Rq is phenyl, A is CH, and X2 is CH. In another embodiment, Rq is phenyl, A is CH, X2 is CH and q is 2.
  • In one embodiment, Rq is phenyl, A is CR3, and X2 is CR9. In a further embodiment, Rq is phenyl, A is CH, and X2 is CH. In another embodiment, Rq is phenyl, A is CH, X2 is CH and q is 3.
  • In one embodiment, Rq is 1-(4-N—(RN))piperazinyl, A is CR3, and X2 is CR9. In a further embodiment, Rq is 1-(4-N—(RN))piperazinyl, A is CH, and X2 is CH. In another embodiment, Rq is 1-(4-N—(RN))piperazinyl, A is CH, X2 is CH and q is 2.
  • In one embodiment, Rq is 1-(4-N—(RN))piperazinyl, A is CR3, and X2 is CR9. In a further embodiment, Rq is 1-(4-N—(RN))piperazinyl, A is CH2, and X2 is CH. In another embodiment, Rq is 1-(4-N—(RN))piperazinyl, A is CH, X2 is CH and q is 3.
  • In one embodiment, Rq is N-morpholinyl, A is CR3, and X2 is CR9. In a further embodiment, Rq is N-morpholinyl, A is CR3, X2 is CR9 and q is 2. In another embodiment, Rq is N-morpholinyl, A is CR3, X2 is CR9 and q is 3.
  • In one embodiment, Rq is 1-piperazinyl, A is CR3, and X2 is CR9. In a further embodiment, Rq is 1-piperazinyl, A is CR3, X2 is CR9 and q is 2. In another embodiment, Rq is 1-piperazinyl, A is CR3, X2 is CR9 and q is 3.
  • In one embodiment, Rq is phenyl, A is CR3, and X2 is CR9. In a further embodiment, Rq is phenyl, A is CR3, X2 is CR9 and q is 2. In another embodiment, Rq is phenyl, A is CR3, X2 is CR9 and q is 3.
  • In one embodiment, Rq is 1-(4-N—(RN))piperazinyl, A is CR3, and X2 is CR9. In a further embodiment, Rq is 1-(4-N—(RN))piperazinyl, A is CR3, X2 is CR9 and q is 2. In another embodiment, Rq is 1-(4-N—(RN))piperazinyl, A is CR3, X2 is CR9 and q is 3.
  • In one embodiment, Rq is N-morpholinyl, A is N, and X2 is CR9. In a further embodiment, Rq is N-morpholinyl, A is N, X2 is CR9 and q is 2. In another embodiment, Rq is N-morpholinyl, A is N, X2 is CR9 and q is 3.
  • In one embodiment, Rq is 1-piperazinyl, A is N, and X2 is CR9. In a further embodiment, Rq is 1-piperazinyl, A is N, X2 is CR9 and q is 2. In another embodiment, Rq is 1-piperazinyl, A is N, X2 is CR9 and q is 3.
  • In one embodiment, Rq is phenyl, A is N, and X2 is CR9. In a further embodiment, Rq is phenyl, A is N, X2 is CR9 and q is 2. In another embodiment, Rq is phenyl, A is N, X2 is CR9 and q is 3.
  • In one embodiment, Rq is 1-(4-N—(RN))piperazinyl, A is N, and X2 is CR9. In a further embodiment, Rq is 1-(4-N—(RN))piperazinyl, A is N, X2 is CR9 and q is 2. In another embodiment, Rq is 1-(4-N—(RN))piperazinyl, A is N, X2 is CR9 and q is 3.
  • A further aspect of the application relates to any compound of Formula (Ia).
  • A further aspect of the application relates to any compound of Formula (Ia), wherein the compound has the Formula (Ib).
  • A further aspect of the application relates to a compound being of Formula (Ib),
  • Figure US20190248756A1-20190815-C00006
  • or a pharmaceutically acceptable salt thereof,
  • wherein:
      • A is CR3 or N;
      • X1 is CR8 or N;
      • X2 is CR9 or N;
      • X3 is CR10 or N;
      • wherein zero or one of X1, X2, or X3 is N;
      • R2, R3, R4, R5 and R6 are each, independently, hydrogen, halogen, C1-C6 haloalkyl, NO2, NRaRb, OH, O(C1-C6 alkyl), or O(C1-C6 haloalkyl);
      • Ra and Rb are each, independently, hydrogen or C1-C6 alkyl;
      • R8, R9, R10, and Z are each, independently, hydrogen, fluorine, OH, or O(C1-C6 alkyl);
      • q is 2 or 3;
      • RN is C1-C5 alkyl; and
      • R12 is hydrogen or C1-C6 alkyl.
  • In one embodiment, RN is methyl.
  • In one embodiment, q is 2. In another embodiment, q is 3.
  • In one embodiment, X2 is CR9.
  • In one embodiment, at least one of R8, R9, R10 and Z is not hydrogen.
  • In one embodiment, at least one of R8, R9, R10 and Z is O(C1-C6 alkyl).
  • In one embodiment, at least one of R8, R9, R10 and Z is OCH3.
  • In one embodiment, at least one of R8, R9, R10 and Z is fluorine.
  • In one embodiment, at least one of R2, R3, R4, R5 and R6 is not hydrogen.
  • In one embodiment, at least one of R2, R3, R4, R5 and R6 is O(C1-C6 alkyl).
  • In one embodiment, at least one of R2, R3, R4, R5 and R6 is OCH3.
  • In one embodiment, at least one of R2, R3, R4, R5 and R6 is fluorine.
  • In one embodiment, R12 is hydrogen.
  • In one embodiment, A is N. In a further embodiment, A is CR3.
  • In one embodiment, one of X1, X2, or X3 is N. In a further embodiment, none of X1, X2, or X3 is N.
  • In one embodiment, X1 is N, X2 is CR9, X3 is CR10, and A is N.
  • In one embodiment, X2 is N, X1 is CR8, X3 is CR10, and A is N.
  • In one embodiment, X3 is N, X1 is CR8, X2 is CR9, and A is N.
  • In one embodiment, X1 is N, X2 is CR9, X3 is CR10, and A is CR3.
  • In one embodiment, X2 is N, X1 is CR8, X3 is CR10, and A is CR3.
  • In one embodiment, X3 is N, X1 is CR8, X2 is CR9, and A is CR3.
  • In one embodiment, A is CR3, and X2 is CR9. In a further embodiment, A is CH, and X2 is CH. In another embodiment, A is CH, X2 is CH and q is 2. In another embodiment, A is CH, X2 is CH and q is 3.
  • In one embodiment, A is N, and X2 is CR9. In a further embodiment, A is N, X2 is CR9 and q is 2. In another embodiment, A is N, X2 is CR9 and q is 3.
  • A further aspect of the application relates to any compound of Formula (Ia), wherein the compound has the Formula (Ic).
  • A further aspect of the application relates to a compound being of Formula (Ic),
  • Figure US20190248756A1-20190815-C00007
  • or a pharmaceutically acceptable salt thereof,
  • wherein:
      • X1 is CR8 or N;
      • X2 is CR9 or N;
      • X3 is CR10 or N;
      • wherein zero or one of X1, X2, or X3 are N;
      • R2 and R3 together with the carbon atoms to which they attach form a C6 aryl ring, or R5 and R6 together with the carbon atoms to which they attach form a C6 aryl ring, and the remaining of R2, R3, R4, R5 and R6 are each, independently, hydrogen, halogen, C1-C6 haloalkyl, NO2, NRaRb, OH, O(C1-C6 alkyl), or O(C1-C6 haloalkyl);
      • Ra and Rb are each, independently, hydrogen or C1-C6 alkyl;
      • R8, R9, R10, and Z are each, independently, hydrogen, halogen, OH, or O(C1-C6 alkyl);
      • q is 2 or 3;
      • Rq is 1-piperazinyl, 1-(4-N—(RN))piperazinyl, N-morpholino or phenyl;
      • RN is C1-C5 alkyl; and
      • R12 is hydrogen or C1-C6 alkyl;
      • wherein,
  • when A is CR3 and R2 is fluorine or chlorine, then Rq is phenyl or 1-(4-N—(RN))piperazinyl, or when A is CR3, R2 is fluorine or chlorine, q is 2 and Rq is N-morpholino, then at least one of R8, R9, R10, and Z is not hydrogen and R8 is not OCH3.
  • In one embodiment, R2 and R3 together with the carbon atoms to which they attach form a C6 aryl ring; and R4, R5 and R6 are each, independently, hydrogen, halogen, C1-C6 haloalkyl, NO2, NRaRb, OH, O(C1-C6 alkyl), or O(C1-C6 haloalkyl).
  • In one embodiment, R5 and R6 together with the carbon atoms to which they attach form a C6 aryl ring; and R2, R3 and R4 are each, independently, hydrogen, halogen, C1-C6 haloalkyl, NO2, NRaRb, OH, O(C1-C6 alkyl), or O(C1-C6 haloalkyl).
  • In one embodiment, X2 is CR9.
  • In one embodiment, X1 is CR8. In another embodiment, X1 is CR8 and R8 is hydrogen.
  • In one embodiment, X1 is CR8. In another embodiment, X1 is CR8 and R8 is OCH3.
  • In one embodiment, q is 2. In another embodiment, q is 3.
  • In one embodiment, Rq is 1-piperazinyl. In one embodiment, Rq is 1-(4-N—(RN))piperazinyl. In one embodiment, Rq is N-morpholino. In one embodiment, Rq is phenyl.
  • In one embodiment, Rq is 1-(4-N—(RN))piperazinyl and RN is methyl, ethyl, propyl, isopropyl, n-butyl or n-pentyl. In one embodiment, Rq is 1-(4-N—(RN))piperazinyl and RN is methyl or ethyl. In one embodiment, Rq is 1-(4-N—(RN))piperazinyl and RN is methyl.
  • In one embodiment, at least one of R8, R9, R10, and Z is halogen.
  • In one embodiment, at least one of R8, R9, R10, and Z is chlorine or fluorine.
  • In one embodiment, R12 is hydrogen.
  • A further aspect of the application relates to a compound being of Formula (Ic),
  • Figure US20190248756A1-20190815-C00008
  • or a pharmaceutically acceptable salt thereof,
  • wherein:
      • X1 is CR8 or N;
      • X2 is CR9 or N;
      • X3 is CR10 or N;
      • wherein zero or one of X1, X2, or X3 are N;
      • R3 and R4 together with the carbon atoms to which they attach form a C6 aryl ring, or R4 and R5 together with the carbon atoms to which they attach form a C6 aryl ring, and R2, R6 and the remaining of R3 and R5 are each, independently, hydrogen, halogen, C1-C6 haloalkyl, NO2, NRaRb, OH, O(C1-C6 alkyl), or O(C1-C6 haloalkyl);
      • Ra and Rb are each, independently, hydrogen or C1-C6 alkyl;
      • R8, R9, R10, and Z are each, independently, hydrogen, halogen, OH, or O(C1-C6 alkyl);
      • q is 2 or 3;
      • Rq is 1-piperazinyl, 1-(4-N—(RN))piperazinyl, N-morpholino, or phenyl;
      • RN is C1-C5 alkyl; and
      • R12 is hydrogen or C1-C6 alkyl;
      • wherein,
      • when A is CR3 and R2 is fluorine or chlorine, then Rq is phenyl or 1-(4-N—(RN))piperazinyl, or when A is CR3, R2 is fluorine or chlorine, q is 2 and Rq is N-morpholino, then at least one of R8, R9, R10, and Z is not hydrogen and R8 is not OCH3.
  • In one embodiment, R3 and R4 together with the carbon atoms to which they attach form a C6 aryl ring; and R2, R5 and R6 are each, independently, hydrogen, halogen, C1-C6 haloalkyl, NO2, NRaRb, OH, O(C1-C6 alkyl), or O(C1-C6 haloalkyl).
  • In one embodiment, R4 and R5 together with the carbon atoms to which they attach form a C6 aryl ring; and R2, R3, and R6 are each, independently, hydrogen, halogen, C1-C6 haloalkyl, NO2, NRaRb, OH, O(C1-C6 alkyl), or O(C1-C6 haloalkyl).
  • In one embodiment, X2 is CR9.
  • In one embodiment, X1 is CR8, X2 is CR9, and X3 is CR10
  • In one embodiment, q is 2. In another embodiment, q is 3.
  • In one embodiment, Rq is 1-piperazinyl. In one embodiment, Rq is 1-(4-N—(RN))piperazinyl. In one embodiment, Rq is N-morpholino. In one embodiment, Rq is phenyl.
  • In one embodiment, Rq is 1-(4-N—(RN))piperazinyl and RN is methyl, ethyl, propyl, isopropyl, n-butyl or n-pentyl. In one embodiment, Rq is 1-(4-N—(RN))piperazinyl and RN is methyl or ethyl. In one embodiment, Rq is 1-(4-N—(RN))piperazinyl and RN is methyl.
  • In one embodiment, at least one of R8, R9, R10, and Z is halogen.
  • In one embodiment, at least one of R8, R9, R10, and Z is chlorine of fluorine.
  • In one embodiment, R12 is hydrogen.
  • In one embodiment, R3 and R4 together form a C6 aryl ring.
  • In one embodiment, R2, R5 and R6 are each hydrogen.
  • In one embodiment, R8, R9, R10, and Z are each hydrogen.
  • In one embodiment, R3 and R4 together with the carbon atoms to which they attach form a C6 aryl ring, and R2, R5, R6, R8, R9, R10, and Z are each hydrogen.
  • In one embodiment, R3 and R4 together with the carbon atoms to which they attach form a C6 aryl ring, and R2, R5, R6, R8, R9, R10, and Z are each hydrogen, and q is 2.
  • In one embodiment, R3 and R4 together with the carbon atoms to which they attach form a C6 aryl ring, and R2, R5, R6, R8, R9, R10, and Z are each hydrogen, and Rq is N-morpholino.
  • A further aspect of the application relates to any compound of Formula (Ic).
  • A further aspect of the application relates to any compound of Formula (Ia), wherein the compound has the Formula (Id).
  • A further aspect of the application relates to a compound being of Formula (Id),
  • Figure US20190248756A1-20190815-C00009
  • or a pharmaceutically acceptable salt thereof,
  • wherein:
      • A is CR3 or N;
      • R2, R3, R4, R5 and R6 are each, independently, hydrogen, halogen, C1-C6 haloalkyl, NO2, NRaRb, OH, O(C1-C6 alkyl), or O(C1-C6 haloalkyl);
      • Ra and Rb are each, independently, hydrogen or C1-C6 alkyl;
      • R8, R10, and Z are each, independently, hydrogen, fluorine, OH, or O(C1-C6 alkyl);
      • R11 is OH, O(C1-C6 alkyl), or —NH—(CH2)q—Rq, wherein:
      • q is 2 or 3;
      • Rq is 1-piperazinyl, 1-(4-N—(RN))piperazinyl, N-morpholino or phenyl; and
      • RN is C1-C5 alkyl; and
      • R12 is hydrogen or C1-C6 alkyl;
      • wherein:
      • when A is CR3 and R2 is fluorine or chlorine, then Rq is phenyl or 1-(4-N—(RN))piperazinyl; or when A is CR3, R2 is fluorine or chlorine, q is 2 and Rq is N-morpholino, then at least one of R8, R10, and Z is not hydrogen and R8 is not OCH3; or when A is CR3, R2 is fluorine or chlorine, q is 2 and Rq is N-morpholino at least one of R3, R4, R5 and R6 is not hydrogen or halogen; and at least three of R2, R3, R4, R5 and R6 are hydrogen.
  • In one embodiment, R11 is —NH—(CH2)q—Rq.
  • In one embodiment, q is 2. In another embodiment, q is 3.
  • In one embodiment, Rq is 1-piperazinyl. In one embodiment, Rq is 1-(4-N—(RN))piperazinyl. In one embodiment, Rq is N-morpholino. In one embodiment, Rq is phenyl.
  • In one embodiment, R4 is OCH3.
  • In one embodiment, A is CR3.
  • In one embodiment, R2, R3, R5 and R6 are each hydrogen.
  • In one embodiment, R8, R10, and Z are each hydrogen.
  • In one embodiment, R12 is hydrogen.
  • A further aspect of the application relates to any compound of Formula (Id).
  • A further aspect of the application relates to any compound of Formula (Ia), wherein the compound has the Formula (Ie).
  • A further aspect of the application relates to a compound being of Formula (Ie),
  • Figure US20190248756A1-20190815-C00010
  • or a pharmaceutically acceptable salt thereof,
  • wherein:
      • A is CR3 or N;
      • R2, R3, R4, R5 and R6 are each, independently, hydrogen, halogen, C1-C6 haloalkyl, NO2, NRaRb, OH, O(C1-C6 alkyl), or O(C1-C6 haloalkyl);
      • Ra and Rb are each, independently, hydrogen or C1-C6 alkyl;
      • R8, R9, and Z are each, independently, hydrogen, fluorine, OH, or O(C1-C6 alkyl);
      • R11 is OH, O(C1-C6 alkyl), or —NH—(CH2)q—Rq, wherein:
      • q is 2 or 3;
      • Rq is 1-piperazinyl, 1-(4-N—(RN))piperazinyl, N-morpholino or phenyl;
      • RN is C1-C5 alkyl; and
      • R12 is hydrogen or C1-C6 alkyl;
      • wherein:
      • when A is CR3 and R2 is fluorine or chlorine, then Rq is phenyl or 1-(4-N—(RN))piperazinyl; or when A is CR3, R2 is fluorine or chlorine, q is 2 and Rq is N-morpholino, then at least one of R8, R9, and Z is not hydrogen and R8 is not OCH3; or when A is CR3, R2 is fluorine or chlorine, q is 2 and Rq is N-morpholino at least one of R3, R4, R5 and R6 is not hydrogen or halogen; and at least three of R2, R3, R4, R5 and R6 are hydrogen.
  • In one embodiment, R11 is —NH—(CH2)q—Rq.
  • In one embodiment, Rq is 1-(4-N—(RN))piperazinyl.
  • In one embodiment, q is 2.
  • In one embodiment, R4 is OCH3.
  • In one embodiment, R2, R3, R5, R6, R8, R9, and Z are each hydrogen.
  • In one embodiment, R12 is hydrogen.
  • A further aspect of the application relates to any compound of Formula (Ie).
  • A further aspect of the application relates to any compound of Formula (Ia), wherein the compound has the Formula (If).
  • A further aspect of the application relates to a compound being of formula (If),
  • Figure US20190248756A1-20190815-C00011
  • or a pharmaceutically acceptable salt thereof,
  • wherein:
      • A is CR3 or N;
      • R2, R3, R4, R5 and R6 are each, independently, hydrogen, halogen, C1-C6 haloalkyl, NO2, NRaRb, OH, O(C1-C6 alkyl), or O(C1-C6 haloalkyl);
      • Ra and Rb are each, independently, hydrogen or C1-C6 alkyl;
      • R9, R10, and Z are each, independently, hydrogen, fluorine, OH, or O(C1-C6 alkyl);
      • R11 is OH, O(C1-C6 alkyl), or —NH—(CH2)q—Rq,
  • wherein:
      • q is 2 or 3;
      • Rq is 1-piperazinyl, 1-(4-N—(RN))piperazinyl, N-morpholino or phenyl; and
      • RN is C1-C5 alkyl; and
      • R12 is hydrogen or C1-C6 alkyl;
  • wherein,
      • when A is CR3 and R2 is fluorine or chlorine, then Rq is phenyl or 1-(4-N—(RN))piperazinyl; or when A is CR3, R2 is fluorine or chlorine, q is 2 and Rq is N-morpholino, then at least one of R9, R10, and Z is not hydrogen and R8 is not OCH3; or when A is CR3, R2 is fluorine or chlorine, q is 2 and Rq is N-morpholino at least one of R3, R4, R5 and R6 is not hydrogen or halogen; and at least three of R2, R3, R4, R5 and R6 are hydrogen.
  • In one embodiment, A is CR3.
  • In one embodiment, R2, R3, R4, R5, R6, R9, R10 and Z are each, independently, hydrogen or fluorine.
  • In one embodiment, R2 is fluorine.
  • In one embodiment, R11 is OH or O(C1-C6 alkyl).
  • In one embodiment, R11 is OH or OCH3.
  • In one embodiment, R11 is OH.
  • In one embodiment, R12 is hydrogen or methyl.
  • In one embodiment, R12 is hydrogen.
  • In one embodiment, R12 is methyl.
  • A further aspect of the application relates to any compound of Formula (If).
  • A skilled person in the art would understand that any embodiment described within can be combined with any other embodiments.
  • In a further embodiment, the compound of Formula (I) or Formula (Ia) is selected from a compounds listed in Table 1:
  • TABLE 1
    Cmpd Structure Chemical Name
    4
    Figure US20190248756A1-20190815-C00012
         		2-(3-aminobenzamido)-N-(2- morpholinoethyl)benzamide
    5
    Figure US20190248756A1-20190815-C00013
         		2-(4-aminobenzamido)-N-(2- morpholinoethyl)benzamide
    7
    Figure US20190248756A1-20190815-C00014
         		2-(3-chlorobenzamido)-N-(2- morpholinoethyl)benzamide
    8
    Figure US20190248756A1-20190815-C00015
         		2-(4-chlorobenzamido)-N-(2- morpholinoethyl)benzamide
    9
    Figure US20190248756A1-20190815-C00016
         		N-(2-morpholinoethyl)-2-(2- (trifluoromethyl)benzamido) benzamide
    10
    Figure US20190248756A1-20190815-C00017
         		N-(2-morpholinoethyl)-2-(3- (trifluoromethyl)benzamido) benzamide
    11
    Figure US20190248756A1-20190815-C00018
         		N-(2-morpholinoethyl)-2-(4- (trifluoromethyl)benzamido) benzamide
    12
    Figure US20190248756A1-20190815-C00019
         		2-fluoro-4-methoxy-N-(2-((2- morpholinoethyl)carbamoyl) phenyl)benzamide
    13
    Figure US20190248756A1-20190815-C00020
         		2-fluoro-6-(2-fluorobenzamido)- N-(2-morpholinoethyl)benzamide
    14
    Figure US20190248756A1-20190815-C00021
         		4-fluoro-2-(2-fluorobenzamido)- N-(2-morpholinoethyl)benzamide
    15
    Figure US20190248756A1-20190815-C00022
         		2-(2-fluorobenzamido)-4- methoxy-N-(2-morpholinoethyl) benzamide
    17
    Figure US20190248756A1-20190815-C00023
         		2-(3-fluorobenzamido)-3- methoxy-N-(2-morpholinoethyl) benzamide
    18
    Figure US20190248756A1-20190815-C00024
         		2-(4-fluorobenzamido)-3- methoxy-N-(2-morpholinoethyl) benzamide
    19
    Figure US20190248756A1-20190815-C00025
         		2-(2-fluorobenzamido)-4,5- dimethoxy-N-(2-morpholinoethyl) benzamide
    20
    Figure US20190248756A1-20190815-C00026
         		6-(2-fluorobenzamido)-2,3,4- trimethoxy-N-(2-morpholinoethyl) benzamide
    21
    Figure US20190248756A1-20190815-C00027
         		2-fluoro-6-(4-methoxybenzamido)- N-(2-morpholinoethyl)benzamide
    22
    Figure US20190248756A1-20190815-C00028
         		4-fluoro-2-(4-methoxybenzamido)- N-(2-morpholinoethyl)benzamide
    23
    Figure US20190248756A1-20190815-C00029
         		4-methoxy-2-(4- methoxybenzamido)-N-(2- morpholinoethyl)benzamide
    24
    Figure US20190248756A1-20190815-C00030
         		3-methoxy-2-(4- methoxybenzamido)-N-(2- morpholinoethyl)benzamide
    25
    Figure US20190248756A1-20190815-C00031
         		3-methoxy-2-(2- methoxybenzamido)-N-(2- morpholinoethyl)benzamide
    26
    Figure US20190248756A1-20190815-C00032
         		3-methoxy-2-(3- methoxybenzamido)-N-(2- morpholinoethyl)benzamide
    27
    Figure US20190248756A1-20190815-C00033
         		2,3,4-trimethoxy-6-(4- methoxybenzamido)-N-(2- morpholinoethyl)benzamide
    28
    Figure US20190248756A1-20190815-C00034
         		2-fluoro-N-(3-fluoro-2-((2- morpholinoethyl)carbamoyl) phenyl)-4-methoxybenzamide
    29
    Figure US20190248756A1-20190815-C00035
         		2-(2,4-dimethoxybenzamido)-3- methoxy-N-(2-morpholinoethyl) benzamide
    30
    Figure US20190248756A1-20190815-C00036
         		N-(2-((2-morpholinoethyl) carbamoyl)phenyl)-1-naphthamide
    31
    Figure US20190248756A1-20190815-C00037
         		N-(2-((2-morpholinoethyl) carbamoyl)phenyl)-2-naphthamide
    32
    Figure US20190248756A1-20190815-C00038
         		N-(2-((2-morpholinoethyl) carbamoyl)phenyl)nicotinamide
    33
    Figure US20190248756A1-20190815-C00039
         		N-(3,4,5-trimethoxy-2-((2- morpholinoethyl)carbamoyl) phenyl)nicotinamide
    34
    Figure US20190248756A1-20190815-C00040
         		2-fluoro-N-(2-((3- morpholinopropyl)carbamoyl) phenyl)benzamide
    35
    Figure US20190248756A1-20190815-C00041
         		2-(4-methoxybenzamido)-N-(3- morpholinopropyl)benzamide
    36
    Figure US20190248756A1-20190815-C00042
         		N-(2-((3-morpholinopropyl) carbamoyl)phenyl)-1-naphthamide
    37
    Figure US20190248756A1-20190815-C00043
         		N-(2-((3-morpholinopropyl) carbamoyl)phenyl)-2-naphthamide
    38
    Figure US20190248756A1-20190815-C00044
         		2-(4-nitrobenzamido)-N-(2- (piperazin-1-yl)ethyl)benzamide
    39
    Figure US20190248756A1-20190815-C00045
         		2-(4-chlorobenzamido)-N-(2- (piperazin-1-yl)ethyl)benzamide
    40
    Figure US20190248756A1-20190815-C00046
         		N-(2-(piperazin-1-yl)ethyl)-2-(3- (trifluoromethyl)benzamido) benzamide
    41
    Figure US20190248756A1-20190815-C00047
         		N-(2-(piperazin-1-yl)ethyl)-2-(2- (trifluoromethyl)benzamido) benzamide
    42
    Figure US20190248756A1-20190815-C00048
         		2-(4-methoxybenzamido)-N-(2- (piperazin-1-yl)ethyl)benzamide
    43
    Figure US20190248756A1-20190815-C00049
         		3,5-difluoro-N-(2-((2-(piperazin- 1-yl)ethyl)carbamoyl)phenyl) benzamide
    44
    Figure US20190248756A1-20190815-C00050
         		2,6-difluoro-N-(2-((2-(piperazin- 1-yl)ethyl)carbamoyl)phenyl) benzamide
    45
    Figure US20190248756A1-20190815-C00051
         		2,4-difluoro-N-(2-((2-(piperazin- 1-yl)ethyl)carbamoyl)phenyl) benzamide
    46
    Figure US20190248756A1-20190815-C00052
         		2-fluoro-4-methoxy-N-(2-((2- (piperazin-1-yl)ethyl)carbamoyl) phenyl)benzamide
    47
    Figure US20190248756A1-20190815-C00053
         		2-benzamido-N-(2-(4- methylpiperazin-1-yl)ethyl) benzamide
    48
    Figure US20190248756A1-20190815-C00054
         		N-(2-(4-methylpiperazin-1- yl)ethyl)-2-(4-nitrobenzamido) benzamide
    49
    Figure US20190248756A1-20190815-C00055
         		2-fluoro-N-(2-((2-(4- methylpiperazin-1-yl)ethyl) carbamoyl)phenyl)benzamide
    50
    Figure US20190248756A1-20190815-C00056
         		2-(3-fluorobenzamido)-N-(2-(4- methylpiperazin-1-yl)ethyl) benzamide
    51
    Figure US20190248756A1-20190815-C00057
         		2-(3-chlorobenzamido)-N-(2-(4- methylpiperazin-1-yl)ethyl) benzamide
    52
    Figure US20190248756A1-20190815-C00058
         		2-(4-chlorobenzamido)-N-(2-(4- methylpiperazin-1-yl)ethyl) benzamide
    53
    Figure US20190248756A1-20190815-C00059
         		2-methoxy-N-(2-((2-(4- methylpiperazin-1-yl)ethyl) carbamoyl)phenyl)benzamide
    54
    Figure US20190248756A1-20190815-C00060
         		2-(4-methoxybenzamido)-N-(2- (4-methylpiperazin-1-yl)ethyl) benzamide
    55
    Figure US20190248756A1-20190815-C00061
         		2,6-difluoro-N-(2-((2-(4- methylpiperazin-1-yl)ethyl) carbamoyl)phenyl)benzamide
    56
    Figure US20190248756A1-20190815-C00062
         		3,5-difluoro-N-(2-((2-(4- methylpiperazin-1-yl)ethyl) carbamoyl)phenyl)benzamide
    57
    Figure US20190248756A1-20190815-C00063
         		2,4-difluoro-N-(2-((2-(4- methylpiperazin-1-yl)ethyl) carbamoyl)phenyl)benzamide
    58
    Figure US20190248756A1-20190815-C00064
         		2-fluoro-4-methoxy-N-(2-((2-(4- methylpiperazin-1-yl)ethyl) carbamoyl)phenyl)benzamide
    59
    Figure US20190248756A1-20190815-C00065
         		2-(2-fluorobenzamido)-4,5- dimethoxy-N-(2-(4- methylpiperazin-1-yl)ethyl) benzamide
    60
    Figure US20190248756A1-20190815-C00066
         		6-(2-fluorobenzamido)-2,3,4- trimethoxy-N-(2-(4- methylpiperazin-1-yl)ethyl) benzamide
    61
    Figure US20190248756A1-20190815-C00067
         		4,5-dimethoxy-2-(4- methoxybenzamido)-N-(2-(4- methylpiperazin-1-yl)ethyl) benzamide
    62
    Figure US20190248756A1-20190815-C00068
         		2,3,4-trimethoxy-6-(4- methoxybenzamido)-N-(2-(4- methylpiperazin-1-yl)ethyl) benzamide
    63
    Figure US20190248756A1-20190815-C00069
         		N-(2-((2-(4-methylpiperazin-1- yl)ethyl)carbamoyl)phenyl) nicotinamide
    64
    Figure US20190248756A1-20190815-C00070
         		N-(4,5-dimethoxy-2-((2-(4- methylpiperazin-1-yl)ethyl) carbamoyl)phenyl)nicotinamide
    65
    Figure US20190248756A1-20190815-C00071
         		N-(3,4,5-trimethoxy-2-((2-(4- methylpiperazin-1-yl)ethyl) carbamoyl)phenyl)nicotinamide
    66
    Figure US20190248756A1-20190815-C00072
         		2-fluoro-N-(2-((3-(4- methylpiperazin-1-yl)propyl) carbamoyl)phenyl)benzamide
    67
    Figure US20190248756A1-20190815-C00073
         		2-(4-methoxybenzamido)-N-(3- (4-methylpiperazin-1-yl)propyl) benzamide
    68
    Figure US20190248756A1-20190815-C00074
         		N-(2-((3-(4-methylpiperazin-1- yl)propyl)carbamoyl)phenyl)-1- naphthamide
    69
    Figure US20190248756A1-20190815-C00075
         		N-(2-((3-(4-methylpiperazin-1- yl)propyl)carbamoyl)phenyl)-2- naphthamide
    70
    Figure US20190248756A1-20190815-C00076
         		2-nitro-N-(2- (phenethylcarbamoyl)phenyl) benzamide
    71
    Figure US20190248756A1-20190815-C00077
         		2-(3-nitrobenzamido)-N- phenethylbenzamide
    72
    Figure US20190248756A1-20190815-C00078
         		2-(4-nitrobenzamido)-N- phenethylbenzamide
    73
    Figure US20190248756A1-20190815-C00079
         		2-fluoro-N-(2- (phenethylcarbamoyl)phenyl) benzamide
    74
    Figure US20190248756A1-20190815-C00080
         		2-chloro-N-(2- (phenethylcarbamoyl)phenyl) benzamide
    75
    Figure US20190248756A1-20190815-C00081
         		2-(3-chlorobenzamido)-N- phenethylbenzamide
    76
    Figure US20190248756A1-20190815-C00082
         		2-(4-chlorobenzamido)-N- phenethylbenzamide
    77
    Figure US20190248756A1-20190815-C00083
         		N-phenethyl-2-(3- (trifluoromethyl)benzamido) benzamide
    78
    Figure US20190248756A1-20190815-C00084
         		N-phenethyl-2-(4- (trifluoromethyl)benzamido) benzamide
    79
    Figure US20190248756A1-20190815-C00085
         		2-(4-methoxybenzamido)-N- phenethylbenzamide
    80
    Figure US20190248756A1-20190815-C00086
         		2-fluoro-4-methoxy-N-(2- (phenethylcarbamoyl)phenyl) benzamide
    81
    Figure US20190248756A1-20190815-C00087
         		2-fluoro-6-(2-fluorobenzamido)- N-phenethylbenzamide
    82
    Figure US20190248756A1-20190815-C00088
         		4-fluoro-2-(2-fluorobenzamido)- N-phenethylbenzamide
    83
    Figure US20190248756A1-20190815-C00089
         		2-(2-fluorobenzamido)-4- methoxy-N-phenethylbenzamide
    84
    Figure US20190248756A1-20190815-C00090
         		2-(2-fluorobenzamido)-3- methoxy-N-phenethylbenzamide
    85
    Figure US20190248756A1-20190815-C00091
         		2-(3-fluorobenzamido)-3- methoxy-N-phenethylbenzamide
    86
    Figure US20190248756A1-20190815-C00092
         		2-(4-fluorobenzamido)-3- methoxy-N-phenethylbenzamide
    87
    Figure US20190248756A1-20190815-C00093
         		2-fluoro-6-(4- methoxybenzamido)-N- phenethylbenzamide
    88
    Figure US20190248756A1-20190815-C00094
         		4-fluoro-2-(4- methoxybenzamido)-N- phenethylbenzamide
    89
    Figure US20190248756A1-20190815-C00095
         		4-methoxy-2-(4- methoxybenzamido)-N- phenethylbenzamide
    90
    Figure US20190248756A1-20190815-C00096
         		3-methoxy-2-(2- methoxybenzamido)-N- phenethylbenzamide
    91
    Figure US20190248756A1-20190815-C00097
         		3-methoxy-2-(3- methoxybenzamido)-N- phenethylbenzamide
    92
    Figure US20190248756A1-20190815-C00098
         		3-methoxy-2-(4- methoxybenzamido)-N- phenethylbenzamide
    93
    Figure US20190248756A1-20190815-C00099
         		2-(2,4-dimethoxybenzamido)-3- methoxy-N-phenethylbenzamide
    94
    Figure US20190248756A1-20190815-C00100
         		N-(2-(phenethylcarbamoyl) phenyl)nicotinamide
    95
    Figure US20190248756A1-20190815-C00101
         		2-fluoro-N-(2-((3-phenylpropyl) carbamoyl)phenyl)benzamide
    96
    Figure US20190248756A1-20190815-C00102
         		2-(4-methoxybenzamido)-N-(3- phenylpropyl)benzamide
    97
    Figure US20190248756A1-20190815-C00103
         		N-(2-((3-phenylpropyl) carbamoyl)phenyl)-1- naphthamide
    98
    Figure US20190248756A1-20190815-C00104
         		N-(2-((3-phenylpropyl) carbamoyl)phenyl)-2- naphthamide
    99
    Figure US20190248756A1-20190815-C00105
         		3-(4-methoxybenzamido)-N-(2- morpholinoethyl)isonicotinamide
    100
    Figure US20190248756A1-20190815-C00106
         		3-(4-methoxybenzamido)-N- phenethylisonicotinamide
    101
    Figure US20190248756A1-20190815-C00107
         		2-(3-methoxybenzamido)-N-(2- (4-methylpiperazin-1-yl)ethyl) benzamide
    102
    Figure US20190248756A1-20190815-C00108
         		2-(3-chlorobenzamido)-N-(2- (piperazin-1-yl)ethyl)benzamide
    103
    Figure US20190248756A1-20190815-C00109
         		2-chloro-N-(2-((2- morpholinoethyl)carbamoyl) phenyl)benzamide
    104
    Figure US20190248756A1-20190815-C00110
         		2-(2-fluoro-N-methylbenzamido) benzoic acid
    105
    Figure US20190248756A1-20190815-C00111
         		2-(2-fluorobenzamido)nicotinic acid
    106
    Figure US20190248756A1-20190815-C00112
         		2-fluoro-N-methyl-N-(2-((2- morpholinoethyl)carbamoyl) phenyl) benzamide
    107
    Figure US20190248756A1-20190815-C00113
         		2-(4-fluorobenzamido)-N-(2-(4- methylpiperazin-1-yl)ethyl) benzamide
    108
    Figure US20190248756A1-20190815-C00114
         		N-(2-(4-methylpiperazin-1- yl)ethyl)-2-(4-(trifluoromethyl) benzamido)benzamide
    109
    Figure US20190248756A1-20190815-C00115
         		2-fluoro-6-(4- methoxybenzamido)-N-(2-(4- methylpiperazin-1- yl)ethyl)benzamide
    110
    Figure US20190248756A1-20190815-C00116
         		2-fluoro-6-(3- methoxybenzamido)-N-(2-(4- methylpiperazin-1- yl)ethyl)benzamide
    111
    Figure US20190248756A1-20190815-C00117
         		2-fluoro-6-(4- methoxybenzamido)-N-(2- (piperazin-1-yl)ethyl)benzamide
    112
    Figure US20190248756A1-20190815-C00118
         		2-fluoro-6-(3- methoxybenzamido)-N-(2- (piperazin-1-yl)ethyl) benzamide
    113
    Figure US20190248756A1-20190815-C00119
         		4-(4-methoxybenzamido)-N-(2- morpholinoethyl)nicotinamide
    114
    Figure US20190248756A1-20190815-C00120
         		N-(2-(4-methylpiperazin-1- yl)ethyl)-2-(3-(trifluoromethyl) benzamido)benzamide
    115
    Figure US20190248756A1-20190815-C00121
         		2-fluoro-N-(2-((2-(4- methylpiperazin-1- yl)ethyl)carbamoyl)phenyl)-4- (trifluoromethoxyl)benzamide
    116
    Figure US20190248756A1-20190815-C00122
         		4-(4-methoxybenzamido)-N-(2- (4-methylpiperazin-1-yl)ethyl) nicotinamide
    117
    Figure US20190248756A1-20190815-C00123
         		N-(2-(4-methylpiperazin-1- yl)ethyl)-2-(2-(trifluoromethyl) benzamido)benzamide
    118
    Figure US20190248756A1-20190815-C00124
         		N-(2-(piperazin-1-yl)ethyl)-2-(4- (trifluoromethyl)benzamido) benzamide
    119
    Figure US20190248756A1-20190815-C00125
         		N-(2-methoxy-6- (phenethylcarbamoyl)phenyl)-2- naphthamide
    120
    Figure US20190248756A1-20190815-C00126
         		N-(2-methoxy-6-((3- phenylpropyl)carbamoyl)phenyl)- 2-naphthamide
    121
    Figure US20190248756A1-20190815-C00127
         		N-(2-methoxy-6-(3- morpholinopropylcarbamoyl) phenyl)-2-naphthamide
    122
    Figure US20190248756A1-20190815-C00128
         		N-(5-methoxy-2- (phenethylcarbamoyl)phenyl)-2- naphthamide
    123
    Figure US20190248756A1-20190815-C00129
         		N-(2-methoxy-6-((3-(4- methylpiperazin-1- yl)propyl)carbamoyl)phenyl)-2- naphthamide
    124
    Figure US20190248756A1-20190815-C00130
         		2-(2-fluorobenzamido)-3,4,5- trimethoxy-N-(3- phenylpropyl)benzamide
    125
    Figure US20190248756A1-20190815-C00131
         		N-(2-methoxy-6-((3- phenylpropyl)carbamoyl)phenyl)- 1-naphthamide
    126
    Figure US20190248756A1-20190815-C00132
         		4,5-dimethoxy-2-(4- methoxybenzamido)-N-(3- morpholinopropyl)benzamide
    127
    Figure US20190248756A1-20190815-C00133
         		N-(5-methoxy-2-(3- morpholinepropylcarbamoyl) phenyl)-2-naphthamide
    128
    Figure US20190248756A1-20190815-C00134
         		N-(2-methoxy-6-(3- morpholinopropylcarbamoyl) phenyl)-1-naphtamide
    129
    Figure US20190248756A1-20190815-C00135
         		N-(2-((3-phenylpropyl) carbamoyl)phenyl)nicotinamide
    130
    Figure US20190248756A1-20190815-C00136
         		N-(3-fluoro-2-((3- morpholinopropyl)carbamoyl) phenyl) nicotinamide
    131
    Figure US20190248756A1-20190815-C00137
         		3,4,5-trimethoxy-2-(4- methoxybenzamido)-N-(3- morpholinopropyl)benzamide
    132
    Figure US20190248756A1-20190815-C00138
         		N-(2,3,4-trimethoxy-6-((3- morpholinopropyl)carbamoyl) phenyl) nicotinamide
    133
    Figure US20190248756A1-20190815-C00139
         		N-(5-fluoro-2-(3- morpholinopropylcarbamoyl) phenyl)nicotinamide
    134
    Figure US20190248756A1-20190815-C00140
         		N-(2-(3- morpholinopropylcarbamoyl) phenyl)nicotinamide
    135
    Figure US20190248756A1-20190815-C00141
         		N-(3-fluoro-2-((3-(4- methylpiperazin-1- yl)propyl)carbamoyl)phenyl) nicotinamide
    136
    Figure US20190248756A1-20190815-C00142
         		N-(3-fluoro-2-((3- phenylpropyl)carbamoyl)phenyl) nicotinamide
    137
    Figure US20190248756A1-20190815-C00143
         		3,4,5-trimethoxy-2-(4- methoxybenzamido)-N-(3-(4- methylpiperazin-1-yl)propyl) benzamide
    138
    Figure US20190248756A1-20190815-C00144
         		2-(4-methoxybenzamido)-N-(3- morpholinopropyl)benzamide
    139
    Figure US20190248756A1-20190815-C00145
         		N-(4,5-dimethoxy-2-(3- morpholinopropylcarbamoyl) phenyl) nicotinamide
    140
    Figure US20190248756A1-20190815-C00146
         		2-(4-methoxybenzamido)-N-(3- phenylpropyl)benzamide
    141
    Figure US20190248756A1-20190815-C00147
         		2-(2-fluorobenzamido)-4,5- dimethoxy-N-(3- morpholinopropyl)benzamide
    142
    Figure US20190248756A1-20190815-C00148
         		N-(2-methoxy-6-((3- morpholinopropyl)carbamoyl) phenyl) nicotinamide
    143
    Figure US20190248756A1-20190815-C00149
         		2-(methylthio)-N-(2-((3- morpholinopropyl)carbamoyl) phenyl) nicotinamide
    144
    Figure US20190248756A1-20190815-C00150
         		2-(2-fluorobenzamido)-4,5- dimethoxy-N-(3- phenylpropyl)benzamide
    145
    Figure US20190248756A1-20190815-C00151
         		2-(2-fluorobenzamido)-3- methoxy-N-(2-morpholinoethyl) benzamide
    146
    Figure US20190248756A1-20190815-C00152
         		N-(2-morpholinoethyl)-2-(3- nitrobenzamido)benzamide
    147
    Figure US20190248756A1-20190815-C00153
         		N-(2-morpholinoethyl)-2-(2- nitrobenzamido)benzamide
    148
    Figure US20190248756A1-20190815-C00154
         		N-(2-morpholinoethyl)-2-(4- nitrobenzamido)benzamide
  • As used herein, “alkyl”, “C1, C2, C3, C4, C5 or C6 alkyl” or “C1-C6 alkyl” is intended to include C1, C2, C3, C4, C5 or C6 straight chain (linear) saturated aliphatic hydrocarbon groups and C3, C4, C5 or C6 branched saturated aliphatic hydrocarbon groups. For example, C1-C6 alkyl is intended to include C1, C2, C3, C4, C5 and C6 alkyl groups. Examples of alkyl include, moieties having from one to six carbon atoms, such as, but not limited to, methyl, ethyl, n-propyl, i-propyl, n-butyl, s-butyl, t-butyl, n-pentyl, s-pentyl or n-hexyl.
  • In certain embodiments, a straight chain or branched alkyl has six or fewer carbon atoms (e.g., C1-C6 for straight chain, C3-C6 for branched chain), and in another embodiment, a straight chain or branched alkyl has four or fewer carbon atoms.
  • “Heteroalkyl” groups are alkyl groups, as defined above, that have an oxygen, nitrogen, sulfur or phosphorous atom replacing one or more hydrocarbon backbone carbon atoms.
  • As used herein, the term “cycloalkyl”, “C3, C4, C5, C6, C7 or C8 cycloalkyl” or “C3-C8 cycloalkyl” is intended to include hydrocarbon rings having from three to eight carbon atoms in their ring structure. In one embodiment, a cycloalkyl group has five or six carbons in the ring structure.
  • The term “substituted alkyl” refers to alkyl moieties having substituents replacing one or more hydrogen atoms on one or more carbons of the hydrocarbon backbone. Such substituents can include, for example, alkyl, alkenyl, alkynyl, halogen, hydroxyl, alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, alkylcarbonyl, arylcarbonyl, alkoxycarbonyl, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, alkylthiocarbonyl, alkoxyl, phosphate, phosphonato, phosphinato, amino (including alkylamino, dialkylamino, arylamino, diarylamino and alkylarylamino), acylamino (including alkylcarbonylamino, arylcarbonylamino, carbamoyl and ureido), amidino, imino, sulfhydryl, alkylthio, arylthio, thiocarboxylate, sulfates, alkylsulfinyl, sulfonato, sulfamoyl, sulfonamido, nitro, trifluoromethyl, cyano, azido, heterocyclyl, alkylaryl, or an aromatic or heteroaromatic moiety. Cycloalkyls can be further substituted, e.g., with the substituents described above. An “alkylaryl” or an “aralkyl” moiety is an alkyl substituted with an aryl (e.g., phenylmethyl (benzyl)).
  • Unless the number of carbons is otherwise specified, “lower alkyl” includes an alkyl group, as defined above, having from one to six, or in another embodiment from one to four, carbon atoms in its backbone structure. “Lower alkenyl” and “lower alkynyl” have chain lengths of, for example, two to six or of two to four carbon atoms.
  • As used herein, “alkyl linker” is intended to include C1, C2, C3, C4, C5 or C6 straight chain (linear) saturated aliphatic hydrocarbon groups and C3, C4, C5 or C6 branched saturated aliphatic hydrocarbon groups. For example, C1-C6 alkyl linker is intended to include C1, C2, C3, C4, C5 and C6 alkyl linker groups. Examples of alkyl linker include, moieties having from one to six carbon atoms, such as, but not limited to, methyl (—CH2—), ethyl (—CH2CH2—), n-propyl (—CH2CH2CH2—), i-propyl (—CHCH3CH2—), n-butyl (—CH2CH2CH2CH2—), s-butyl (—CHCH3CH2CH2—), i-butyl (—C(CH3)2CH2—), n-pentyl (—CH2CH2CH2CH2CH2—), s-pentyl (—CHCH3CH2CH2CH2—) or n-hexyl (—CH2CH2CH2CH2CH2CH2—).
  • “Alkenyl” includes unsaturated aliphatic groups analogous in length and possible substitution to the alkyls described above, but that contain at least one double bond. For example, the term “alkenyl” includes straight chain alkenyl groups (e.g., ethenyl, propenyl, butenyl, pentenyl, hexenyl, heptenyl, octenyl, nonenyl, decenyl), branched alkenyl groups, cycloalkenyl (e.g., alicyclic) groups (e.g., cyclopropenyl, cyclopentenyl, cyclohexenyl, cycloheptenyl, cyclooctenyl), alkyl or alkenyl substituted cycloalkenyl groups, and cycloalkyl or cycloalkenyl substituted alkenyl groups. In certain embodiments, a straight chain or branched alkenyl group has six or fewer carbon atoms in its backbone (e.g., C2-C6 for straight chain, C3-C6 for branched chain). Likewise, cycloalkenyl groups may have from five to eight carbon atoms in their ring structure, and in one embodiment, cycloalkenyl groups have five or six carbons in the ring structure. The term “C2-C6” includes alkenyl groups containing two to six carbon atoms. The term “C3-C6” includes alkenyl groups containing three to six carbon atoms.
  • “Heteroalkenyl” includes alkenyl groups, as defined herein, having an oxygen, nitrogen, sulfur or phosphorous atom replacing one or more hydrocarbon backbone carbons.
  • The term “substituted alkenyl” refers to alkenyl moieties having substituents replacing one or more hydrogen atoms on one or more hydrocarbon backbone carbon atoms. Such substituents can include, for example, alkyl, alkenyl, alkynyl, halogen, hydroxyl, alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, alkylcarbonyl, arylcarbonyl, alkoxycarbonyl, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, alkylthiocarbonyl, alkoxyl, phosphate, phosphonato, phosphinato, amino (including alkylamino, dialkylamino, arylamino, diarylamino and alkylarylamino), acylamino (including alkylcarbonylamino, arylcarbonylamino, carbamoyl and ureido), amidino, imino, sulfhydryl, alkylthio, arylthio, thiocarboxylate, sulfates, alkylsulfinyl, sulfonato, sulfamoyl, sulfonamido, nitro, trifluoromethyl, cyano, heterocyclyl, alkylaryl, or an aromatic or heteroaromatic moiety.
  • “Alkynyl” includes unsaturated aliphatic groups analogous in length and possible substitution to the alkyls described above, but which contain at least one triple bond. For example, “alkynyl” includes straight chain alkynyl groups (e.g., ethynyl, propynyl, butynyl, pentynyl, hexynyl, heptynyl, octynyl, nonynyl, decynyl), branched alkynyl groups, and cycloalkyl or cycloalkenyl substituted alkynyl groups. In certain embodiments, a straight chain or branched alkynyl group has six or fewer carbon atoms in its backbone (e.g., C2-C6 for straight chain, C3-C6 for branched chain). The term “C2-C6” includes alkynyl groups containing two to six carbon atoms. The term “C3-C6” includes alkynyl groups containing three to six carbon atoms.
  • “Heteroalkynyl” includes alkynyl groups, as defined herein, having an oxygen, nitrogen, sulfur or phosphorous atom replacing one or more hydrocarbon backbone carbons.
  • The term “substituted alkynyl” refers to alkynyl moieties having substituents replacing one or more hydrogen atoms on one or more hydrocarbon backbone carbon atoms. Such substituents can include, for example, alkyl, alkenyl, alkynyl, halogen, hydroxyl, alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, alkylcarbonyl, arylcarbonyl, alkoxycarbonyl, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, alkylthiocarbonyl, alkoxyl, phosphate, phosphonato, phosphinato, amino (including alkylamino, dialkylamino, arylamino, diarylamino and alkylarylamino), acylamino (including alkylcarbonylamino, arylcarbonylamino, carbamoyl and ureido), amidino, imino, sulfhydryl, alkylthio, arylthio, thiocarboxylate, sulfates, alkylsulfinyl, sulfonato, sulfamoyl, sulfonamido, nitro, trifluoromethyl, cyano, azido, heterocyclyl, alkylaryl, or an aromatic or heteroaromatic moiety.
  • “Aryl” includes groups with aromaticity, including “conjugated”, or multicyclic, systems with at least one aromatic ring. Examples include phenyl, benzyl, etc.
  • “Heteroaryl” groups are aryl groups, as defined above, having from one to four heteroatoms in the ring structure, and may also be referred to as “aryl heterocycles” or “heteroaromatics”. As used herein, the term “heteroaryl” is intended to include a stable 5-, 6-, or 7-membered monocyclic or 7-, 8-, 9-, 10-, 11- or 12-membered bicyclic aromatic heterocyclic ring which consists of carbon atoms and one or more heteroatoms, e.g., 1 or 1-2 or 1-3 or 1-4 or 1-5 or 1-6 heteroatoms, independently selected from the group consisting of nitrogen, oxygen and sulfur. The nitrogen atom may be substituted or unsubstituted (i.e., N or NR wherein R is H or other substituents, as defined). The nitrogen and sulfur heteroatoms may optionally be oxidized (i.e., N→O and S(O)p, where p=1 or 2). It is to be noted that total number of S and O atoms in the aromatic heterocycle is not more than 1.
  • Examples of heteroaryl groups include pyrrole, furan, thiophene, thiazole, isothiazole, imidazole, triazole, tetrazole, pyrazole, oxazole, isoxazole, pyridine, pyrazine, pyridazine, pyrimidine, and the like.
  • Furthermore, the terms “aryl” and “heteroaryl” include multicyclic aryl and heteroaryl groups, e.g., tricyclic, bicyclic, e.g., naphthalene, benzoxazole, benzodioxazole, benzothiazole, benzoimidazole, benzothiophene, methylenedioxyphenyl, quinoline, isoquinoline, naphthridine, indole, benzofuran, purine, benzofuran, deazapurine, indolizine.
  • In the case of multicyclic aromatic rings, only one of the rings needs to be aromatic (e.g., 2,3-dihydroindole), although all of the rings may be aromatic (e.g., quinoline). The second ring can also be fused or bridged.
  • The aryl or heteroaryl aromatic ring can be substituted at one or more ring positions with such substituents as described above, for example, alkyl, alkenyl, akynyl, halogen, hydroxyl, alkoxy, alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, alkylcarbonyl, alkylaminocarbonyl, aralkylaminocarbonyl, alkenylaminocarbonyl, alkylcarbonyl, arylcarbonyl, aralkylcarbonyl, alkenylcarbonyl, alkoxycarbonyl, aminocarbonyl, alkylthiocarbonyl, phosphate, phosphonato, phosphinato, amino (including alkylamino, dialkylamino, arylamino, diarylamino and alkylarylamino), acylamino (including alkylcarbonylamino, arylcarbonylamino, carbamoyl and ureido), amidino, imino, sulfhydryl, alkylthio, arylthio, thiocarboxylate, sulfates, alkylsulfinyl, sulfonato, sulfamoyl, sulfonamido, nitro, trifluoromethyl, cyano, azido, heterocyclyl, alkylaryl, or an aromatic or heteroaromatic moiety. Aryl groups can also be fused or bridged with alicyclic or heterocyclic rings, which are not aromatic so as to form a multicyclic system (e.g., tetralin, methylenedioxyphenyl).
  • As used herein, “carbocycle” or “carbocyclic ring” is intended to include any stable monocyclic, bicyclic or tricyclic ring having the specified number of carbons, any of which may be saturated, unsaturated, or aromatic. For example, a C3-C14 carbocycle is intended to include a monocyclic, bicyclic or tricyclic ring having 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13 or 14 carbon atoms. Examples of carbocycles include, but are not limited to, cyclopropyl, cyclobutyl, cyclobutenyl, cyclopentyl, cyclopentenyl, cyclohexyl, cycloheptenyl, cycloheptyl, cycloheptenyl, adamantyl, cyclooctyl, cyclooctenyl, cyclooctadienyl, fluorenyl, phenyl, naphthyl, indanyl, adamantyl and tetrahydronaphthyl. Bridged rings are also included in the definition of carbocycle, including, for example, [3.3.0]bicyclooctane, [4.3.0]bicyclononane, [4.4.0]bicyclodecane and [2.2.2]bicyclooctane. A bridged ring occurs when one or more carbon atoms link two non-adjacent carbon atoms. In one embodiment, bridge rings are one or two carbon atoms. It is noted that a bridge always converts a monocyclic ring into a tricyclic ring. When a ring is bridged, the substituents recited for the ring may also be present on the bridge. Fused (e.g., naphthyl, tetrahydronaphthyl) and spiro rings are also included.
  • As used herein, “heterocycle” includes any ring structure (saturated or partially unsaturated) which contains at least one ring heteroatom (e.g., N, O or S). Examples of heterocycles include, but are not limited to, morpholine, pyrrolidine, tetrahydrothiophene, piperidine, piperazine and tetrahydrofuran.
  • Examples of heterocyclic groups include, but are not limited to, acridinyl, azocinyl, benzimidazolyl, benzofuranyl, benzothiofuranyl, benzothiophenyl, benzoxazolyl, benzoxazolinyl, benzthiazolyl, benztriazolyl, benztetrazolyl, benzisoxazolyl, benzisothiazolyl, benzimidazolinyl, carbazolyl, 4aH-carbazolyl, carbolinyl, chromanyl, chromenyl, cinnolinyl, decahydroquinolinyl, 2H,6H-1,5,2-dithiazinyl, dihydrofuro[2,3-b]tetrahydrofuran, furanyl, furazanyl, imidazolidinyl, imidazolinyl, imidazolyl, 1H-indazolyl, indolenyl, indolinyl, indolizinyl, indolyl, 3H-indolyl, isatinoyl, isobenzofuranyl, isochromanyl, isoindazolyl, isoindolinyl, isoindolyl, isoquinolinyl, isothiazolyl, isoxazolyl, methylenedioxyphenyl, morpholinyl, naphthyridinyl, octahydroisoquinolinyl, oxadiazolyl, 1,2,3-oxadiazolyl, 1,2,4-oxadiazolyl, 1,2,5-oxadiazolyl, 1,3,4-oxadiazolyl, 1,2,4-oxadiazol 5(4H)-one, oxazolidinyl, oxazolyl, oxindolyl, pyrimidinyl, phenanthridinyl, phenanthrolinyl, phenazinyl, phenothiazinyl, phenoxathinyl, phenoxazinyl, phthalazinyl, piperazinyl, piperidinyl, piperidonyl, 4-piperidonyl, piperonyl, pteridinyl, purinyl, pyranyl, pyrazinyl, pyrazolidinyl, pyrazolinyl, pyrazolyl, pyridazinyl, pyridooxazole, pyridoimidazole, pyridothiazole, pyridinyl, pyridyl, pyrimidinyl, pyrrolidinyl, pyrrolinyl, 2H-pyrrolyl, pyrrolyl, quinazolinyl, quinolinyl, 4H-quinolizinyl, quinoxalinyl, quinuclidinyl, tetrahydrofuranyl, tetrahydroisoquinolinyl, tetrahydroquinolinyl, tetrazolyl, 6H-1,2,5-thiadiazinyl, 1,2,3-thiadiazolyl, 1,2,4-thiadiazolyl, 1,2,5-thiadiazolyl, 1,3,4-thiadiazolyl, thianthrenyl, thiazolyl, thienyl, thienothiazolyl, thienooxazolyl, thienoimidazolyl, thiophenyl, triazinyl, 1,2,3-triazolyl, 1,2,4-triazolyl, 1,2,5-triazolyl, 1,3,4-triazolyl and xanthenyl.
  • The term “substituted”, as used herein, means that any one or more hydrogen atoms on the designated atom is replaced with a selection from the indicated groups, provided that the designated atom's normal valency is not exceeded, and that the substitution results in a stable compound. When a substituent is keto (i.e., ═O), then 2 hydrogen atoms on the atom are replaced. Keto substituents are not present on aromatic moieties. Ring double bonds, as used herein, are double bonds that are formed between two adjacent ring atoms (e.g., C═C, C═N or N═N). “Stable compound” and “stable structure” are meant to indicate a compound that is sufficiently robust to survive isolation to a useful degree of purity from a reaction mixture, and formulation into an efficacious therapeutic agent.
  • When a bond to a substituent is shown to cross a bond connecting two atoms in a ring, then such substituent may be bonded to any atom in the ring. When a substituent is listed without indicating the atom via which such substituent is bonded to the rest of the compound of a given formula, then such substituent may be bonded via any atom in such formula. Combinations of substituents and/or variables are permissible, but only if such combinations result in stable compounds.
  • The term “hydroxy” or “hydroxyl” includes groups with an —OH or —O—.
  • As used herein, “halo” or “halogen” refers to fluoro, chloro, bromo and iodo. The term “perhalogenated” generally refers to a moiety wherein all hydrogen atoms are replaced by halogen atoms.
  • The term “carbonyl” or “carboxy” includes compounds and moieties which contain a carbon connected with a double bond to an oxygen atom. Examples of moieties containing a carbonyl include, but are not limited to, aldehydes, ketones, carboxylic acids, amides, esters, anhydrides, etc.
  • “Acyl” includes moieties that contain the acyl radical (—C(O)—) or a carbonyl group. “Substituted acyl” includes acyl groups where one or more of the hydrogen atoms are replaced by, for example, alkyl groups, alkynyl groups, halogen, hydroxyl, alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, alkylcarbonyl, arylcarbonyl, alkoxycarbonyl, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, alkylthiocarbonyl, alkoxyl, phosphate, phosphonato, phosphinato, amino (including alkylamino, dialkylamino, arylamino, diarylamino and alkylarylamino), acylamino (including alkylcarbonylamino, arylcarbonylamino, carbamoyl and ureido), amidino, imino, sulfhydryl, alkylthio, arylthio, thiocarboxylate, sulfates, alkylsulfinyl, sulfonato, sulfamoyl, sulfonamido, nitro, trifluoromethyl, cyano, azido, heterocyclyl, alkylaryl, or an aromatic or heteroaromatic moiety.
  • “Aroyl” includes moieties with an aryl or heteroaromatic moiety bound to a carbonyl group. Examples of aroyl groups include phenylcarboxy, naphthyl carboxy, etc.
  • “Alkoxyalkyl”, “alkylaminoalkyl” and “thioalkoxyalkyl” include alkyl groups, as described above, wherein oxygen, nitrogen or sulfur atoms replace one or more hydrocarbon backbone carbon atoms.
  • The term “alkoxy” or “alkoxyl” includes substituted and unsubstituted alkyl, alkenyl and alkynyl groups covalently linked to an oxygen atom. Examples of alkoxy groups or alkoxyl radicals include, but are not limited to, methoxy, ethoxy, isopropyloxy, propoxy, butoxy and pentoxy groups. Examples of substituted alkoxy groups include halogenated alkoxy groups. The alkoxy groups can be substituted with groups such as alkenyl, alkynyl, halogen, hydroxyl, alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, alkylcarbonyl, arylcarbonyl, alkoxycarbonyl, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, alkylthiocarbonyl, alkoxyl, phosphate, phosphonato, phosphinato, amino (including alkylamino, dialkylamino, arylamino, diarylamino, and alkylarylamino), acylamino (including alkylcarbonylamino, arylcarbonylamino, carbamoyl and ureido), amidino, imino, sulfhydryl, alkylthio, arylthio, thiocarboxylate, sulfates, alkylsulfinyl, sulfonato, sulfamoyl, sulfonamido, nitro, trifluoromethyl, cyano, azido, heterocyclyl, alkylaryl, or an aromatic or heteroaromatic moieties. Examples of halogen substituted alkoxy groups include, but are not limited to, fluoromethoxy, difluoromethoxy, trifluoromethoxy, chloromethoxy, dichloromethoxy and trichloromethoxy.
  • The term “ether” or “alkoxy” includes compounds or moieties which contain an oxygen bonded to two carbon atoms or heteroatoms. For example, the term includes “alkoxyalkyl”, which refers to an alkyl, alkenyl, or alkynyl group covalently bonded to an oxygen atom which is covalently bonded to an alkyl group.
  • The term “ester” includes compounds or moieties which contain a carbon or a heteroatom bound to an oxygen atom which is bonded to the carbon of a carbonyl group. The term “ester” includes alkoxycarboxy groups such as methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, butoxycarbonyl, pentoxycarbonyl, etc.
  • The term “haloalkyl” includes compounds or moieties which contain alkyl group substituted with one or more halogen atoms. As used herein, “haloalkyl”, “C1, C2, C3, C4, C5 or C6 haloalkyl” or “C1-C6 haloalkyl” is intended to include C1, C2, C3, C4, C5 or C6 straight chain (linear) saturated aliphatic hydrocarbon groups and C3, C4, C5 or C6 branched saturated aliphatic hydrocarbon groups substituted with one or more halogen atoms. Examples of haloalkyl groups include, but are not limited to, —CF3, —CF2CF3, and —CF2CF2CF3.
  • As used herein, “amine” or “amino” includes moieties where a nitrogen atom is covalently bonded to at least one carbon or heteroatom. “Alkylamino” includes groups of compounds wherein nitrogen is bound to at least one alkyl group. Examples of alkylamino groups include benzylamino, methylamino, ethylamino, phenethylamino, etc. “Dialkylamino” includes groups wherein the nitrogen atom is bound to at least two additional alkyl groups. Examples of dialkylamino groups include, but are not limited to, dimethylamino and diethylamino. “Arylamino” and “diarylamino” include groups wherein the nitrogen is bound to at least one or two aryl groups, respectively. “Alkylarylamino”, “alkylaminoaryl” or “arylaminoalkyl” refers to an amino group which is bound to at least one alkyl group and at least one aryl group. “Alkaminoalkyl” refers to an alkyl, alkenyl, or alkynyl group bound to a nitrogen atom which is also bound to an alkyl group. “Acylamino” includes groups wherein nitrogen is bound to an acyl group. Examples of acylamino include, but are not limited to, alkylcarbonylamino, arylcarbonylamino, carbamoyl and ureido groups.
  • The term “amide” or “aminocarboxy” includes compounds or moieties that contain a nitrogen atom that is bound to the carbon of a carbonyl or a thiocarbonyl group. The term includes “alkaminocarboxy” groups that include alkyl, alkenyl or alkynyl groups bound to an amino group which is bound to the carbon of a carbonyl or thiocarbonyl group. It also includes “arylaminocarboxy” groups that include aryl or heteroaryl moieties bound to an amino group that is bound to the carbon of a carbonyl or thiocarbonyl group. The terms “alkylaminocarboxy”, “alkenylaminocarboxy”, “alkynylaminocarboxy” and “arylaminocarboxy” include moieties wherein alkyl, alkenyl, alkynyl and aryl moieties, respectively, are bound to a nitrogen atom which is in turn bound to the carbon of a carbonyl group. Amides can be substituted with substituents such as straight chain alkyl, branched alkyl, cycloalkyl, aryl, heteroaryl or heterocycle. Substituents on amide groups may be further substituted.
  • Compounds of the present application that contain nitrogens can be converted to N-oxides by treatment with an oxidizing agent (e.g., 3-chloroperoxybenzoic acid (m-CPBA) and/or hydrogen peroxides) to afford other compounds of the present application. Thus, all shown and claimed nitrogen-containing compounds are considered, when allowed by valency and structure, to include both the compound as shown and its N-oxide derivative (which can be designated as N→O or N+—O−). Furthermore, in other instances, the nitrogens in the compounds of the present application can be converted to N-hydroxy or N-alkoxy compounds. For example, N-hydroxy compounds can be prepared by oxidation of the parent amine by an oxidizing agent such as m-CPBA. All shown and claimed nitrogen-containing compounds are also considered, when allowed by valency and structure, to cover both the compound as shown and its N-hydroxy (i.e., N—OH) and N-alkoxy (i.e., N—OR, wherein R is substituted or unsubstituted C1-C6 alkyl, C1-C6 alkenyl, C1-C6 alkynyl, 3-14-membered carbocycle or 3-14-membered heterocycle) derivatives.
  • In the present specification, the structural formula of the compound represents a certain isomer for convenience in some cases, but the present application includes all isomers, such as geometrical isomers, optical isomers based on an asymmetrical carbon, stereoisomers, tautomers, and the like. In addition, a crystal polymorphism may be present for the compounds represented by the formula. It is noted that any crystal form, crystal form mixture, or anhydride or hydrate thereof is included in the scope of the present application. Furthermore, so-called metabolite which is produced by degradation of the present compound in vivo is included in the scope of the present application.
  • “Isomerism” means compounds that have identical molecular formulae but differ in the sequence of bonding of their atoms or in the arrangement of their atoms in space. Isomers that differ in the arrangement of their atoms in space are termed “stereoisomers”. Stereoisomers that are not mirror images of one another are termed “diastereoisomers”, and stereoisomers that are non-superimposable mirror images of each other are termed “enantiomers” or sometimes optical isomers. A mixture containing equal amounts of individual enantiomeric forms of opposite chirality is termed a “racemic mixture”.
  • A carbon atom bonded to four nonidentical substituents is termed a “chiral center”.
  • “Chiral isomer” means a compound with at least one chiral center. Compounds with more than one chiral center may exist either as an individual diastereomer or as a mixture of diastereomers, termed “diastereomeric mixture”. When one chiral center is present, a stereoisomer may be characterized by the absolute configuration (R or S) of that chiral center. Absolute configuration refers to the arrangement in space of the substituents attached to the chiral center. The substituents attached to the chiral center under consideration are ranked in accordance with the Sequence Rule of Cahn, Ingold and Prelog. (Cahn et al., Angew. Chem. Inter. Edit. 1966, 5, 385; errata 511; Cahn et al., Angew. Chem. 1966, 78, 413; Cahn and Ingold, J. Chem. Soc. 1951 (London), 612; Cahn et al., Experientia 1956, 12, 81; Cahn, J. Chem. Educ. 1964, 41, 116).
  • “Geometric isomer” means the diastereomers that owe their existence to hindered rotation about double bonds. These configurations are differentiated in their names by the prefixes cis and trans, or Z and E, which indicate that the groups are on the same or opposite side of the double bond in the molecule according to the Cahn-Ingold-Prelog rules.
  • Furthermore, the structures and other compounds discussed in this application include all atropic isomers thereof. “Atropic isomers” are a type of stereoisomer in which the atoms of two isomers are arranged differently in space. Atropic isomers owe their existence to a restricted rotation caused by hindrance of rotation of large groups about a central bond. Such atropic isomers typically exist as a mixture, however as a result of recent advances in chromatography techniques; it has been possible to separate mixtures of two atropic isomers in select cases.
  • “Tautomer” is one of two or more structural isomers that exist in equilibrium and is readily converted from one isomeric form to another. This conversion results in the formal migration of a hydrogen atom accompanied by a switch of adjacent conjugated double bonds. Tautomers exist as a mixture of a tautomeric set in solution. In solid form, usually one tautomer predominates. In solutions where tautomerization is possible, a chemical equilibrium of the tautomers will be reached. The exact ratio of the tautomers depends on several factors, including temperature, solvent and pH. The concept of tautomers that are interconvertible by tautomerizations is called tautomerism.
  • Of the various types of tautomerism that are possible, two are commonly observed. In keto-enol tautomerism a simultaneous shift of electrons and a hydrogen atom occurs. Ring-chain tautomerism arises as a result of the aldehyde group (—CHO) in a sugar chain molecule reacting with one of the hydroxy groups (—OH) in the same molecule to give it a cyclic (ring-shaped) form as exhibited by glucose.
  • Common tautomeric pairs are: ketone-enol, amide-nitrile, lactam-lactim, amide-imidic acid tautomerism in heterocyclic rings (e.g., in nucleobases such as guanine, thymine and cytosine), amine-enamine and enamine-enamine.
  • It is to be understood that the compounds of the present application may be depicted as different tautomers. It should also be understood that when compounds have tautomeric forms, all tautomeric forms are intended to be included in the scope of the present application, and the naming of the compounds does not exclude any tautomer form.
  • The term “crystal polymorphs”, “polymorphs” or “crystal forms” means crystal structures in which a compound (or a salt or solvate thereof) can crystallize in different crystal packing arrangements, all of which have the same elemental composition. Different crystal forms usually have different X-ray diffraction patterns, infrared spectral, melting points, density hardness, crystal shape, optical and electrical properties, stability and solubility. Recrystallization solvent, rate of crystallization, storage temperature, and other factors may cause one crystal form to dominate. Crystal polymorphs of the compounds can be prepared by crystallization under different conditions.
  • Additionally, the compounds of the present application, for example, the salts of the compounds, can exist in either hydrated or unhydrated (the anhydrous) form or as solvates with other solvent molecules. Nonlimiting examples of hydrates include monohydrates, dihydrates, etc. Nonlimiting examples of solvates include ethanol solvates, acetone solvates, etc.
  • “Solvate” means solvent addition forms that contain either stoichiometric or non stoichiometric amounts of solvent. Some compounds have a tendency to trap a fixed molar ratio of solvent molecules in the crystalline solid state, thus forming a solvate. If the solvent is water the solvate formed is a hydrate; and if the solvent is alcohol, the solvate formed is an alcoholate. Hydrates are formed by the combination of one or more molecules of water with one molecule of the substance in which the water retains its molecular state as H2O.
  • As used herein, the term “analog” refers to a chemical compound that is structurally similar to another but differs slightly in composition (as in the replacement of one atom by an atom of a different element or in the presence of a particular functional group, or the replacement of one functional group by another functional group). Thus, an analog is a compound that is similar or comparable in function and appearance, but not in structure or origin to the reference compound.
  • As defined herein, the term “derivative” refers to compounds that have a common core structure, and are substituted with various groups as described herein. For example, all of the compounds represented by formula I are imidazopyridinyl-aminopyridine derivatives, and have formula I as a common core.
  • The term “bioisostere” refers to a compound resulting from the exchange of an atom or of a group of atoms with another, broadly similar, atom or group of atoms. The objective of a bioisosteric replacement is to create a new compound with similar biological properties to the parent compound. The bioisosteric replacement may be physicochemically or topologically based. Examples of carboxylic acid bioisosteres include, but are not limited to, acyl sulfonimides, tetrazoles, sulfonates and phosphonates. See, e.g., Patani and LaVoie, Chem. Rev. 96, 3147-3176, 1996.
  • The present application is intended to include all isotopes of atoms occurring in the present compounds. Isotopes include those atoms having the same atomic number but different mass numbers. By way of general example and without limitation, isotopes of hydrogen include tritium and deuterium, and isotopes of carbon include C-13 and C-14.
  • As discussed above, these compounds are capable of suppressing Bcl-3-NF-κB protein interactions, inhibiting NF-κB signalling and attenuating the cellular characteristics contributing to the metastatic phenotype observed in vivo and therefore the compounds are suitable for the treatment of cancer, especially for the treatment or prevention of metastatic cancer or secondary tumours.
  • Throughout the description and claims of this specification, the words “comprise” and “contain” and variations of the words, for example “comprising” and “comprises”, mean “including but not limited to” and do not exclude other moieties, additives, components, integers or steps. Throughout the description and claims of this specification, the singular encompasses the plural unless the context otherwise requires. In particular, where the indefinite article is used, the specification is to be understood as contemplating plurality as well as singularity, unless the context requires otherwise.
  • All references, including any patent or patent application, cited in this specification are hereby incorporated by reference. No admission is made that any reference constitutes prior art. Further, no admission is made that any of the prior art constitutes part of the common general knowledge in the art.
  • Preferred features of each aspect of the application may be as described in connection with any of the other aspects.
  • In the present specification, references to compounds of Formula (I) or Formula (Ia) includes amorphous and crystalline forms, including all polymorphs, as well as isotopic variants, for example compounds of Formula (I) or Formula (Ia) in which one or more hydrogen atoms is replaced by deuterium, one or more carbon atoms is replaced by 14C or one or more nitrogen atoms is replaced by 15N.
    • 2. Synthesis of Compounds of Formula (I) and Formula (Ia)
  • Compounds of Formula (I) and Formula (Ia) may be prepared by any suitable route. Compounds of Formula (Ia) include the compounds of Formula (Ib), Formula (Ic), Formula (Id), Formula (Ie), and Formula (If). The synthetic processes apply to all compounds of the application. The synthetic processes of the application can tolerate a wide variety of functional groups, therefore various substituted starting materials can be used. The processes generally provide the desired final compound at or near the end of the overall process, although it may be desirable in certain instances to further convert the compound to a pharmaceutically acceptable salt, ester or prodrug thereof.
  • Compounds of the present application can be prepared in a variety of ways using commercially available starting materials, compounds known in the literature, or from readily prepared intermediates, by employing standard synthetic methods and procedures either known to those skilled in the art, or which will be apparent to the skilled artisan in light of the teachings herein. Standard synthetic methods and procedures for the preparation of organic molecules and functional group transformations and manipulations can be obtained from the relevant scientific literature or from standard textbooks in the field. Although not limited to any one or several sources, classic texts such as Smith, M. B., March, J., March's Advanced Organic Chemistry: Reactions, Mechanisms, and Structure, 5th edition, John Wiley & Sons: New York, 2001; and Greene, T. W., Wuts, P. G. M., Protective Groups in Organic Synthesis, 3rd edition, John Wiley & Sons: New York, 1999, incorporated by reference herein, are useful and recognized reference textbooks of organic synthesis known to those in the art. The following descriptions of synthetic methods are designed to illustrate, but not to limit, general procedures for the preparation of compounds of the present application.
  • Compounds of the present application can be conveniently prepared by a variety of methods familiar to those skilled in the art. The compounds each of the formulae described herein may be prepared according to the following procedures from commercially available starting materials or starting materials which can be prepared using literature procedures. These procedures show the preparation of representative compounds of this application.
  • All the abbreviations used in this application are found in “Protective Groups in Organic Synthesis” by John Wiley & Sons, Inc, or the MERCK INDEX by MERCK & Co., Inc, or other chemistry books or chemicals catalogs by chemicals vendor such as Aldrich, or according to usage know in the art.
  • For example, compounds of Formula (I) and Formula (Ia) may be prepared from a compound of general formula (II) and general formula (II′). respectively:
  • Figure US20190248756A1-20190815-C00155
  • wherein A, B, W, Y, Z, R2, R4, R5, and R6 are as defined for Formula (I);
    wherein A, Z, X1, X2, X3, R2, R4, R5, and R6 are as defined for Formula (Ia);
    by reaction with a compound of general formula (III):
  • Figure US20190248756A1-20190815-C00156
  • wherein R is H or an amine protecting group and q and Rq are as defined for Formula (I) and Formula (Ia).
  • The reaction is carried out in the presence of a base, typically a non-nucleophilic base, for example a tertiary amine such as N,N-diisopropylethylamine. The reaction may be conducted in an organic solvent such as N,N-dimethylformamide and at a temperature of about 15° C. to about 30° C., more typically at about 18 to about 25° C. (room temperature).
  • Amines of general formula (III) are well known and are readily available or may be prepared by literature methods well known to those of skill in the art.
  • Compounds of general formula (II) and general formula (II′) may be prepared from compounds of general formula (IIa) or general formula (IIa′), respectively:
  • Figure US20190248756A1-20190815-C00157
  • wherein B, W, Y, and Z are as defined for Formula (I);
    by reaction with compounds of general formula (IIb):
  • Figure US20190248756A1-20190815-C00158
  • wherein A, R2, R4, R5, and R6 are as defined for Formula (I) and Formula (Ia) and X is a leaving group, typically a halo group such as chloro.
  • The reaction may be carried out in an organic solvent such as pyridine and at a temperature of about 15 to about 30° C., more typically at about 18 to about 25° C. (room temperature).
  • Compounds of general formulae (IIa), (IIa′), and (IIb) are well known and are readily available or may be prepared by literature methods well known to those of skill in the art.
  • An example of a general procedure for the synthesis of a compound of general formula (II) is described below in Scheme A.
  • Figure US20190248756A1-20190815-C00159
  • An example of a general procedure for the synthesis of a compound of Formula (I) is described below in Scheme B.
  • Figure US20190248756A1-20190815-C00160
    • 3. Biological Assays Cell Titre Blue Viability Cell Based Assay
  • The viability of cells at experimental endpoints for particular assays is determined using the Cell Titre Blue reagent (Promega, Southampton, UK). This reagent measures the cellular metabolic activity using resazurin as an indicator dye. Viable cells, therefore metabolically active, will reduce resazurin into highly fluorescent resofurin. The resulting fluorescence levels are measured and indicate cell viability.
  • Cells are plated at low confluency into 96 well plates in 100 μl of complete growth media in triplicates and are incubated at 37° C. in 5% CO2 for the desired test exposure period. For each 100 μl of media in 96 well plates, 20 μl Cell Titre Blue reagent is added followed by incubation for an hour at 37° C. in 5% CO2. Fluorescence is then measured by setting excitation/emission wavelengths to 560/590 nm on a Fluorostar Optima plate reader (BMG tabtech, Bucks, UK).
    • Cell Count
  • To establish cell viability over time period of three days, respective cells are seeded at low confluency into 96 well plates in 100 μl of complete growth media in triplicates and are incubated at 37° C. in 5% CO2. After 24 hrs, cells from triplicate wells are detached for the first time point using 0.25% Trypsin/EDTA (Invitrogen) and resuspended in complete growth media and individually counted. The same is done for each cell line at 48 hrs and 72 hrs post-seeding.
    • Determination of the Migration of Cells in Scratch Assay
  • The migration of cells in the presence of a compound of Formula (I) or Formula (Ia) is determined using a Scratch assay.
  • For the Scratch Assay, 1 micromolar solutions of the compounds are prepared. In six well plates, the complete growth media of the seeded cells (density 11*10E−6 in 20 mL) is removed and replaced by 3 mL of a fresh one containing compounds of Formula (I) or Formula (Ia). Media is used as a negative compound.
  • After a 24 h incubation period at 5% CO2 and 37° C., the media is removed and a scratch is performed in each well. 1 mL of fresh complete growth media is used to wash the well. After its removal, 3 mL of a solution containing a compound of Formula (I) or Formula (Ia) is added in each well in triplicate. Pictures of the wells are then taken. After 24 h, pictures of the wells are again taken. The comparison between the two images provides a measure of the migration of the cells.
    • Determination of NF-kB Activity in Cells
  • MDA-MB-231 is a highly metastatic, human basal epithelial cell line isolated from the pleural effusion of an adenocarcinoma. The cells are ‘triple negative’ as they lack estrogen, progesterone and ERBB2 receptor and they strongly over-express EGFR. The expression of receptors in this line has been confirmed by the host laboratory.
  • For NF-κB luciferase assays, cells are seeded into clear bottom black 96-well plates (Corning Inc., Lowell, US) in antibiotic free culture media in appropriate density. After about 20-24 hrs, cells are transfected with 10 ng of 3×κB luciferase plasmid and 10 ng of pcDNA3.1-Lacl plasmid per well. Empty pcDNA3.1 plasmid is also included to normalize the total weight of DNA transfected to 100 ng. For positive and negative controls respectively, 10 ng of pGL3 control or pGL3 basic are transfected in place of 3×KB luciferase plasmid. Transfection is carried out using Lipofectamine LTX reagents (Invitrogen, Paisley, UK).
  • After 48 hrs post-transfection with luciferase reporter plasmid, the media is aspirated and cells are lyzed using 50 μl/well of Glo-lysis buffer (Promega, Southampton, UK). The plate is left on a rocker for 20 min to facilitate complete cell lysis. Then, 20 μl of lysate from each well is removed and transferred into a new clear bottom black well plate for measuring LacZ activity as a transfection efficiency control and is followed by addition of 20 l/well of Beta-Glo substrate (Promega, Southampton, UK) and cultivation at room temperature for at least 20 min. Subsequently, 30 l/well of Bright-Glo luciferase substrate (Promega, Southampton, UK) is added to the original plate and is assayed immediately for luminescence activity. The luminescence produced from either reaction is read using a Fluorostar Optima plate reader (BMG tabtech, Bucks, UK). The resulting luciferase activity is then normalized against lacZ activity obtained from Beta-glo measurement and is displayed as relative light units (R.t.U).
    • In Vivo Metastasis Mouse Models
  • Nude mice are injected i.v. with 200,000 highly metastatic human breast cancer cells expressing luciferase (MDA-MB-231-Luc) then are given a compound of Formula (I) or Formula (Ia) once daily for about 10 days and are monitored for tumours by total body scan using Xenogen-IVIS. Mice with a luciferase signal above background in repeated scans in any part of their torso are scored as having metastatic disease. Total light emission in the abdominal region is quantified at time points up to 49 days post surgery and plotted as mean total light yield.
  • Tumour efficacy of the compounds of the application was determined using murine xenograft models of breast and colorectal cancers, each model demonstrating different aspects of tumour biology. In all experiments, each compound was administered by intraperitoneally at 3.5 mg/kg.
  • One model (Model 1) studied the effect of the compound's ability to inhibit the seeding and early colonization of circulating tumour cells at distal sites, most commonly in the lungs and liver. Human tumour cell lines were injected into the bloodstream of recipient mice, followed by single daily intraperitoneal injections of the compound (3.5 mg/kg in 1% DMSO) for 10 consecutive days. Tumour burden was monitored longitudinally for up to 8 weeks in vivo by live luminescence imaging, and subsequently histology performed on affected organs at the end of the experiment.
  • Another model (Model 2) tested the effect of the compound's ability to inhibit the colonization and subsequent growth and spread of secondary lesions at distal sites. Human tumour cell lines were injected into the bloodstream of recipient mice, followed 2 days later by single daily intraperitoneal injections of the compound (3.5 mg/kg in 1% DMSO) for the entire course of the experiment. Tumour burden was monitored longitudinally for up to 8 weeks in vivo by live luminescence imaging, and subsequently histology performed on affected organs at the end of the experiment.
  • Another model (Model 4) studied the effect of the compound's ability to inhibit the growth of tumour cells at the transplantation site. Human tumour cell lines were injected subcutaneously into recipient mice, followed 2 days later by single daily intraperitoneal injections of a compound (3.5 mg/kg in 1% DMSO) for the entire course of the experiment. Tumour burden was monitored longitudinally for up to 12 weeks in vivo by palpation and caliper measurements of tumour volume, and subsequently histology performed on tumours at the end of the experiment.
    • 4. Methods of Treatment
  • As discussed above, the compounds of the present application are Bcl-3 inhibitors and are therefore of use in the treatment of cancer, for example leukaemias and lymphomas, such as anaplastic large cell lymphomas (ALCLs), classic Hodgkin lymphomas (cHL) and non-Hodgkin's lymphoma; and solid tumour cancers, such as breast cancer, melanoma, lung cancer, pancreatic cancer, oesophageal cancer, colorectal cancer, nasopharyngeal carcinoma, ovarian, prostate and hepatocarcinomas.
  • In another aspect, the present application provides a compound Formula (I) or Formula (Ia) for use in medicine.
  • Therefore, in a further aspect of the application there is provided a compound of Formula (I) or Formula (Ia) for use in medicine. In particular, there is provided a compound of Formula (I) or Formula (Ia) for use in the treatment of cancer, for example leukaemias and lymphomas, such as anaplastic large cell lymphomas (ALCLs), classic Hodgkin lymphomas (cHL) and non-Hodgkin's lymphoma; and solid tumour cancers, such as breast cancer, melanoma, lung cancer, pancreatic cancer, oesophageal cancer, colorectal cancer, ovarian cancer, prostate cancer, nasopharyngeal carcinoma, and hepatocarcinomas.
  • In a further aspect of the application, there is provided the use of a compound of Formula (I) or Formula (Ia) in the preparation of an agent for the treatment of cancer, for example leukaemias and lymphomas, such as anaplastic large cell lymphomas (ALCLs), classic Hodgkin lymphomas (cHL) and non-Hodgkin's lymphoma; and solid tumour cancers, such as breast cancer, melanoma, lung cancer, pancreatic cancer, oesophageal cancer, colorectal cancer, ovarian cancer, prostate cancer, nasopharyngeal carcinoma and hepatocarcinomas.
  • The compounds may be used either in human or in veterinary medicine and the patient may be any mammal but especially a human.
  • The application also provides a method for the treatment of cancer, for example leukaemias and lymphomas, such as anaplastic large cell lymphomas (ALCLs), classic Hodgkin lymphomas (cHL) and non-Hodgkin's lymphoma; and solid tumour cancers, such as breast cancer, melanoma, lung cancer, pancreatic cancer, oesophageal cancer, colorectal cancer, ovarian cancer, prostate cancer, nasopharyngeal carcinoma, and hepatocarcinomas, the method comprising administering to a patient in need of such treatment an effective amount of a compound of Formula (I) or Formula (Ia).
  • The compounds are particularly useful for the treatment or prevention of metastasis in cancers.
  • Suitably, the cancer is breast cancer, more particularly triple negative breast cancer or HER2 enriched breast cancer. The compounds of Formula (I) or Formula (Ia) have been shown to be particularly effective in preventing or treating metastasis in models of these breast cancer subtypes. However this does not preclude its relevance or efficacy in metastatic disease in other tumour types. Moreover, our experimental evidence in human cancer cell lines indicates that there may also be beneficial therapeutic effects of Bcl-3 suppression on tumour cell viability, as both genetic suppression of Bcl-3 and use of compounds of Formula (I) or Formula (Ia) partially but significantly reduce tumour cell numbers in vitro.
  • In yet another aspect, the present application provides a compound Formula (I) or Formula (Ia) for use in the preparation of an agent for the treatment of cancer.
  • In a further aspect, the present application provides a compound Formula (I) or Formula (Ia) for use in the preparation of an agent for the treatment of leukaemia or lymphoma.
  • In another aspect, the present application provides a compound Formula (I) or Formula (Ia) for use in the treatment or prevention of metastasis in cancers.
  • The compounds of the application will generally be formulated for administration by a desired route.
  • As used herein, a “subject in need thereof” is a subject having a cell proliferative disorder, or a subject having an increased risk of developing a cell proliferative disorder relative to the population at large. A subject in need thereof can have a precancerous condition. Preferably, a subject in need thereof has cancer. A “subject” includes a mammal. The mammal can be e.g., any mammal, e.g., a human, primate, bird, mouse, rat, fowl, dog, cat, cow, horse, goat, camel, sheep or a pig. Preferably, the mammal is a human.
  • As used herein, “contacting a cell” refers to a condition in which a compound or other composition of matter is in direct contact with a cell, or is close enough to induce a desired biological effect in a cell.
  • As used herein, “monotherapy” refers to the administration of a single active or therapeutic compound to a subject in need thereof. Preferably, monotherapy will involve administration of a therapeutically effective amount of an active compound. For example, cancer monotherapy with one of the compound of the present application, or a pharmaceutically acceptable salt, prodrug, metabolite, analog or derivative thereof, to a subject in need of treatment of cancer. Monotherapy may be contrasted with combination therapy, in which a combination of multiple active compounds is administered, preferably with each component of the combination present in a therapeutically effective amount. In one aspect, monotherapy with a compound of the present application, or a pharmaceutically acceptable salt, prodrug, metabolite, polymorph or solvate thereof, is more effective than combination therapy in inducing a desired biological effect.
  • As used herein, “treating” or “treat” describes the management and care of a patient for the purpose of combating a disease, condition, or disorder and includes the administration of a compound of the present application, or a pharmaceutically acceptable salt, prodrug, metabolite, polymorph or solvate thereof, to alleviate the symptoms or complications of a disease, condition or disorder, or to eliminate the disease, condition or disorder.
  • A compound of the present application, or a pharmaceutically acceptable salt, prodrug, metabolite, polymorph or solvate thereof, can also be used to prevent a disease, condition or disorder. As used herein, “preventing” or “prevent” describes reducing or eliminating the onset of the symptoms or complications of the disease, condition or disorder.
  • As used herein, the term “alleviate” is meant to describe a process by which the severity of a sign or symptom of a disorder is decreased. Importantly, a sign or symptom can be alleviated without being eliminated. In a preferred embodiment, the administration of pharmaceutical compositions of the application leads to the elimination of a sign or symptom, however, elimination is not required. Effective dosages are expected to decrease the severity of a sign or symptom. For instance, a sign or symptom of a disorder such as cancer, which can occur in multiple locations, is alleviated if the severity of the cancer is decreased within at least one of multiple locations.
  • As used herein, the term “severity” is meant to describe the potential of cancer to transform from a precancerous, or benign, state into a malignant state. Alternatively, or in addition, severity is meant to describe a cancer stage, for example, according to the TNM system (accepted by the International Union Against Cancer (UICC) and the American Joint Committee on Cancer (AJCC)) or by other art-recognized methods. Cancer stage refers to the extent or severity of the cancer, based on factors such as the location of the primary tumor, tumor size, number of tumors, and lymph node involvement (spread of cancer into lymph nodes). Alternatively, or in addition, severity is meant to describe the tumor grade by art-recognized methods (see, National Cancer Institute). Tumor grade is a system used to classify cancer cells in terms of how abnormal they look under a microscope and how quickly the tumor is likely to grow and spread. Many factors are considered when determining tumor grade, including the structure and growth pattern of the cells. The specific factors used to determine tumor grade vary with each type of cancer. Severity also describes a histologic grade, also called differentiation, which refers to how much the tumor cells resemble normal cells of the same tissue type (see, National Cancer Institute). Furthermore, severity describes a nuclear grade, which refers to the size and shape of the nucleus in tumor cells and the percentage of tumor cells that are dividing (see, National Cancer Institute).
  • In another aspect of the application, severity describes the degree to which a tumor has secreted growth factors, degraded the extracellular matrix, become vascularized, lost adhesion to juxtaposed tissues, or metastasized. Moreover, severity describes the number of locations to which a primary tumor has metastasized. Finally, severity includes the difficulty of treating tumors of varying types and locations. For example, inoperable tumors, those cancers which have greater access to multiple body systems (hematological and immunological tumors), and those which are the most resistant to traditional treatments are considered most severe. In these situations, prolonging the life expectancy of the subject and/or reducing pain, decreasing the proportion of cancerous cells or restricting cells to one system, and improving cancer stage/tumor grade/histological grade/nuclear grade are considered alleviating a sign or symptom of the cancer.
  • As used herein, the term “selectively” means tending to occur at a higher frequency in one population than in another population. The compared populations can be cell populations. Preferably, a compound of the present application, or a pharmaceutically acceptable salt, prodrug, metabolite, polymorph or solvate thereof, acts selectively on a cancer or precancerous cell but not on a normal cell. Preferably, a compound of the present application, or a pharmaceutically acceptable salt, prodrug, metabolite, polymorph or solvate thereof, acts selectively to modulate one molecular target (e.g., Bcl-3) but does not significantly modulate another molecular target.
  • A compound of the present application, or a pharmaceutically acceptable salt, prodrug, metabolite, polymorph or solvate thereof, can modulate the activity of a molecular target (e.g., a Bcl-3). Modulating refers to stimulating or inhibiting an activity of a molecular target. Preferably, a compound of the present application, or a pharmaceutically acceptable salt, prodrug, metabolite, polymorph or solvate thereof, modulates the activity of a molecular target if it stimulates or inhibits the activity of the molecular target by at least 2-fold relative to the activity of the molecular target under the same conditions but lacking only the presence of said compound. More preferably, a compound of the present application, or a pharmaceutically acceptable salt, prodrug, metabolite, polymorph or solvate thereof, modulates the activity of a molecular target if it stimulates or inhibits the activity of the molecular target by at least 5-fold, at least 10-fold, at least 20-fold, at least 50-fold, at least 100-fold relative to the activity of the molecular target under the same conditions but lacking only the presence of said compound. The activity of a molecular target may be measured by any reproducible means. The activity of a molecular target may be measured in vitro or in vivo. For example, the activity of a molecular target may be measured in vitro by an enzymatic activity assay or a DNA binding assay, or the activity of a molecular target may be measured in vivo by assaying for expression of a reporter gene.
  • In another aspect, the present application provides a compound Formula (I) or Formula (Ia) for use in combination with one or more additional active agents which are useful in the treatment of cancer. The additional active agent include, but are not limited to, anti-HER2 agents such as trastuzumab and pertuzumab; standard adjuvant therapy regimens such as 5-fluorouracil, doxorubicin, and cyclophosphamide (FAC); 5-fluorouracil, epirubicin, and cyclophosphamide (FEC); and doxorubicin and cyclophosphamide (AC); cyclophosphamide, methotrexate, and 5-fluorouracil (CMF); and docetaxel, doxorubicin, cyclophosphamide (TAC); and anti-angiogenic/antimetastatic agents such as bevacizumab (Avastin).
  • As used herein, “combination therapy” or “co-therapy” includes the administration of a compound of the present application, or a pharmaceutically acceptable salt, prodrug, metabolite, polymorph or solvate thereof, and at least a second agent as part of a specific treatment regimen intended to provide the beneficial effect from the co-action of these therapeutic agents. The beneficial effect of the combination includes, but is not limited to, pharmacokinetic or pharmacodynamic co-action resulting from the combination of therapeutic agents. Administration of these therapeutic agents in combination typically is carried out over a defined time period (usually minutes, hours, days or weeks depending upon the combination selected). “Combination therapy” may be, but generally is not, intended to encompass the administration of two or more of these therapeutic agents as part of separate monotherapy regimens that incidentally and arbitrarily result in the combinations of the present application.
  • “Combination therapy” is intended to embrace administration of these therapeutic agents in a sequential manner, wherein each therapeutic agent is administered at a different time, as well as administration of these therapeutic agents, or at least two of the therapeutic agents, in a substantially simultaneous manner. Substantially simultaneous administration can be accomplished, for example, by administering to the subject a single capsule having a fixed ratio of each therapeutic agent or in multiple, single capsules for each of the therapeutic agents. Sequential or substantially simultaneous administration of each therapeutic agent can be effected by any appropriate route including, but not limited to, oral routes, intravenous routes, intramuscular routes, and direct absorption through mucous membrane tissues. The therapeutic agents can be administered by the same route or by different routes. For example, a first therapeutic agent of the combination selected may be administered by intravenous injection while the other therapeutic agents of the combination may be administered orally. Alternatively, for example, all therapeutic agents may be administered orally or all therapeutic agents may be administered by intravenous injection. The sequence in which the therapeutic agents are administered is not narrowly critical.
  • “Combination therapy” also embraces the administration of the therapeutic agents as described above in further combination with other biologically active ingredients and non-drug therapies (e.g., surgery or radiation treatment). Where the combination therapy further comprises a non-drug treatment, the non-drug treatment may be conducted at any suitable time so long as a beneficial effect from the co-action of the combination of the therapeutic agents and non-drug treatment is achieved. For example, in appropriate cases, the beneficial effect is still achieved when the non-drug treatment is temporally removed from the administration of the therapeutic agents, perhaps by days or even weeks.
    • 5. Pharmaceutical Compositions
  • The present application also provides pharmaceutical compositions comprising a compound of each of the formulae described herein in combination with at least one pharmaceutically acceptable excipient or carrier. The carrier, or, if more than one be present, each of the carriers, must be acceptable in the sense of being compatible with the other ingredients of the formulation and not deleterious to the recipient.
  • In one aspect, the application relates to a pharmaceutical composition comprising a compound of Formula (I) or Formula (Ia) together with a pharmaceutically or veterinarily acceptable excipient or carrier. In one embodiment, formulated for parenteral administration.
  • In another aspect, the present application relates to a process for the preparation of a pharmaceutical composition the process comprising bringing into association the compound of Formula (I) or Formula (Ia) into association with a pharmaceutically or veterinarily acceptable excipient or carrier.
  • A “pharmaceutical composition” is a formulation containing the compounds of the present application in a form suitable for administration to a subject.
  • The formulations include those suitable for oral, rectal, nasal, topical (including eye drops, buccal and sublingual), vaginal or parenteral (including subcutaneous, intramuscular, intravenous and intradermal) administration and may be prepared by any methods well known in the art of pharmacy.
  • The route of administration will depend upon the condition to be treated but preferred compositions are formulated for parenteral administration. Parenteral formulations will generally be sterile.
  • The composition may be prepared by bringing into association the above defined active agent with the carrier. In general, the formulations are prepared by uniformly and intimately bringing into association the active agent with liquid carriers or finely divided solid carriers or both, and then if necessary shaping the product. The application extends to methods for preparing a pharmaceutical composition comprising bringing a compound of Formula (I) or Formula (Ia) into association with a pharmaceutically or veterinarily acceptable excipient or carrier.
  • In one embodiment, the pharmaceutical composition is in bulk or in unit dosage form. The unit dosage form is any of a variety of forms, including, for example, a capsule, an IV bag, a tablet, a single pump on an aerosol inhaler or a vial. The quantity of active ingredient (e.g., a formulation of the disclosed compound or salt, hydrate, solvate or isomer thereof) in a unit dose of composition is an effective amount and is varied according to the particular treatment involved. One skilled in the art will appreciate that it is sometimes necessary to make routine variations to the dosage depending on the age and condition of the patient. The dosage will also depend on the route of administration. A variety of routes are contemplated, including oral, pulmonary, rectal, parenteral, transdermal, subcutaneous, intravenous, intramuscular, intraperitoneal, inhalational, buccal, sublingual, intrapleural, intrathecal, intranasal, and the like. Dosage forms for the topical or transdermal administration of a compound of this application include powders, sprays, ointments, pastes, creams, lotions, gels, solutions, patches and inhalants. In one embodiment, the active compound is mixed under sterile conditions with a pharmaceutically acceptable carrier, and with any preservatives, buffers or propellants that are required.
  • As used herein, the phrase “pharmaceutically acceptable” refers to those compounds, materials, compositions, carriers, and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio.
  • “Pharmaceutically acceptable excipient” means an excipient that is useful in preparing a pharmaceutical composition that is generally safe, non-toxic and neither biologically nor otherwise undesirable, and includes excipient that is acceptable for veterinary use as well as human pharmaceutical use. A “pharmaceutically acceptable excipient” as used in the specification and claims includes both one and more than one such excipient.
  • A pharmaceutical composition of the application is formulated to be compatible with its intended route of administration. Examples of routes of administration include parenteral, e.g., intravenous, intradermal, subcutaneous, oral (e.g., inhalation), transdermal (topical), and transmucosal administration. Solutions or suspensions used for parenteral, intradermal, or subcutaneous application can include the following components: a sterile diluent such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerine, propylene glycol or other synthetic solvents; antibacterial agents such as benzyl alcohol or methyl parabens; antioxidants such as ascorbic acid or sodium bisulfite; chelating agents such as ethylenediaminetetraacetic acid; buffers such as acetates, citrates or phosphates, and agents for the adjustment of tonicity such as sodium chloride or dextrose. The pH can be adjusted with acids or bases, such as hydrochloric acid or sodium hydroxide. The parenteral preparation can be enclosed in ampoules, disposable syringes or multiple dose vials made of glass or plastic.
  • A compound or pharmaceutical composition of the application can be administered to a subject in many of the well-known methods currently used for chemotherapeutic treatment. For example, for treatment of cancers, a compound of the application may be injected directly into tumors, injected into the blood stream or body cavities or taken orally or applied through the skin with patches. The dose chosen should be sufficient to constitute effective treatment but not as high as to cause unacceptable side effects. The state of the disease condition (e.g., cancer, precancer, and the like) and the health of the patient should preferably be closely monitored during and for a reasonable period after treatment.
  • The term “therapeutically effective amount”, as used herein, refers to an amount of a pharmaceutical agent to treat, ameliorate, or prevent an identified disease or condition, or to exhibit a detectable therapeutic or inhibitory effect. The effect can be detected by any assay method known in the art. The precise effective amount for a subject will depend upon the subject's body weight, size, and health; the nature and extent of the condition; and the therapeutic or combination of therapeutics selected for administration. Therapeutically effective amounts for a given situation can be determined by routine experimentation that is within the skill and judgment of the clinician. In a preferred aspect, the disease or condition to be treated is cancer. In another aspect, the disease or condition to be treated is a cell proliferative disorder.
  • For any compound, the therapeutically effective amount can be estimated initially either in cell culture assays, e.g., of neoplastic cells, or in animal models, usually rats, mice, rabbits, dogs, or pigs. The animal model may also be used to determine the appropriate concentration range and route of administration. Such information can then be used to determine useful doses and routes for administration in humans. Therapeutic/prophylactic efficacy and toxicity may be determined by standard pharmaceutical procedures in cell cultures or experimental animals, e.g., ED50 (the dose therapeutically effective in 50% of the population) and LD50 (the dose lethal to 50% of the population). The dose ratio between toxic and therapeutic effects is the therapeutic index, and it can be expressed as the ratio, LD50/ED50. Pharmaceutical compositions that exhibit large therapeutic indices are preferred. The dosage may vary within this range depending upon the dosage form employed, sensitivity of the patient, and the route of administration.
  • Dosage and administration are adjusted to provide sufficient levels of the active agent(s) or to maintain the desired effect. Factors which may be taken into account include the severity of the disease state, general health of the subject, age, weight, and gender of the subject, diet, time and frequency of administration, drug combination(s), reaction sensitivities, and tolerance/response to therapy. Long-acting pharmaceutical compositions may be administered every 3 to 4 days, every week, or once every two weeks depending on half-life and clearance rate of the particular formulation.
  • The pharmaceutical compositions containing active compounds of the present application may be manufactured in a manner that is generally known, e.g., by means of conventional mixing, dissolving, granulating, dragee-making, levigating, emulsifying, encapsulating, entrapping, or lyophilizing processes. Pharmaceutical compositions may be formulated in a conventional manner using one or more pharmaceutically acceptable carriers comprising excipients and/or auxiliaries that facilitate processing of the active compounds into preparations that can be used pharmaceutically. Of course, the appropriate formulation is dependent upon the route of administration chosen.
  • Pharmaceutical compositions suitable for injectable use include sterile aqueous solutions (where water soluble) or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersion. For intravenous administration, suitable carriers include physiological saline, bacteriostatic water, Cremophor EL™ (BASF, Parsippany, N.J.) or phosphate buffered saline (PBS). In all cases, the composition must be sterile and should be fluid to the extent that easy syringeability exists. It must be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms such as bacteria and fungi. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol, and the like), and suitable mixtures thereof. The proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants. Prevention of the action of microorganisms can be achieved by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, ascorbic acid, thimerosal, and the like. In many cases, it will be preferable to include isotonic agents, for example, sugars, polyalcohols such as manitol, sorbitol, sodium chloride in the composition. Prolonged absorption of the injectable compositions can be brought about by including in the composition an agent which delays absorption, for example, aluminum monostearate and gelatin.
  • Sterile injectable solutions can be prepared by incorporating the active compound in the required amount in an appropriate solvent with one or a combination of ingredients enumerated above, as required, followed by filtered sterilization. Generally, dispersions are prepared by incorporating the active compound into a sterile vehicle that contains a basic dispersion medium and the required other ingredients from those enumerated above. In the case of sterile powders for the preparation of sterile injectable solutions, methods of preparation are vacuum drying and freeze-drying that yields a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof.
  • Oral compositions generally include an inert diluent or an edible pharmaceutically acceptable carrier. They can be enclosed in gelatin capsules or compressed into tablets. For the purpose of oral therapeutic administration, the active compound can be incorporated with excipients and used in the form of tablets, troches, or capsules. Oral compositions can also be prepared using a fluid carrier for use as a mouthwash, wherein the compound in the fluid carrier is applied orally and swished and expectorated or swallowed. Pharmaceutically compatible binding agents, and/or adjuvant materials can be included as part of the composition. The tablets, pills, capsules, troches and the like can contain any of the following ingredients, or compounds of a similar nature: a binder such as microcrystalline cellulose, gum tragacanth or gelatin; an excipient such as starch or lactose, a disintegrating agent such as alginic acid, Primogel, or corn starch; a lubricant such as magnesium stearate or Sterotes; a glidant such as colloidal silicon dioxide; a sweetening agent such as sucrose or saccharin; or a flavoring agent such as peppermint, methyl salicylate, or orange flavoring.
  • For administration by inhalation, the compounds are delivered in the form of an aerosol spray from pressured container or dispenser, which contains a suitable propellant, e.g., a gas such as carbon dioxide, or a nebulizer.
  • Systemic administration can also be by transmucosal or transdermal means. For transmucosal or transdermal administration, penetrants appropriate to the barrier to be permeated are used in the formulation. Such penetrants are generally known in the art, and include, for example, for transmucosal administration, detergents, bile salts, and fusidic acid derivatives. Transmucosal administration can be accomplished through the use of nasal sprays or suppositories. For transdermal administration, the active compounds are formulated into ointments, salves, gels, or creams as generally known in the art.
  • The active compounds can be prepared with pharmaceutically acceptable carriers that will protect the compound against rapid elimination from the body, such as a controlled release formulation, including implants and microencapsulated delivery systems. Biodegradable, biocompatible polymers can be used, such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and polylactic acid. Methods for preparation of such formulations will be apparent to those skilled in the art. The materials can also be obtained commercially from Alza Corporation and Nova Pharmaceuticals, Inc. Liposomal suspensions (including liposomes targeted to infected cells with monoclonal antibodies to viral antigens) can also be used as pharmaceutically acceptable carriers. These can be prepared according to methods known to those skilled in the art, for example, as described in U.S. Pat. No. 4,522,811.
  • It is especially advantageous to formulate oral or parenteral compositions in dosage unit form for ease of administration and uniformity of dosage. Dosage unit form as used herein refers to physically discrete units suited as unitary dosages for the subject to be treated; each unit containing a predetermined quantity of active compound calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier. The specification for the dosage unit forms of the application are dictated by and directly dependent on the unique characteristics of the active compound and the particular therapeutic effect to be achieved.
  • In therapeutic applications, the dosages of the pharmaceutical compositions used in accordance with the application vary depending on the agent, the age, weight, and clinical condition of the recipient patient, and the experience and judgment of the clinician or practitioner administering the therapy, among other factors affecting the selected dosage. Generally, the dose should be sufficient to result in slowing, and preferably regressing, the growth of the tumors and also preferably causing complete regression of the cancer. Dosages can range from about 0.01 mg/kg per day to about 5000 mg/kg per day. In preferred aspects, dosages can range from about 0.01 mg/kg per day to about 1000 mg/kg per day; so as to maintain the concentration of drug in the plasma at a concentration effective to inhibit Bcl-3. The precise amount of a compound of Formula (I) or Formula (Ia) which is therapeutically effective, and the route by which such compound is best administered, is readily determined by one of ordinary skill in the art by comparing the blood level of the agent to the concentration required to have a therapeutic effect.
  • An effective amount of a pharmaceutical agent is that which provides an objectively identifiable improvement as noted by the clinician or other qualified observer. For example, regression of a tumor in a patient may be measured with reference to the diameter of a tumor. Decrease in the diameter of a tumor indicates regression. Regression is also indicated by failure of tumors to reoccur after treatment has stopped. As used herein, the term “dosage effective manner” refers to amount of an active compound to produce the desired biological effect in a subject or cell.
  • The pharmaceutical compositions can be included in a container, pack, or dispenser together with instructions for administration.
  • The compounds of the present application are capable of further forming salts. All of these forms are also contemplated within the scope of the claimed application.
  • As used herein, “pharmaceutically acceptable salts” refer to derivatives of the compounds of the present application wherein the parent compound is modified by making acid or base salts thereof. Examples of pharmaceutically acceptable salts include, but are not limited to, mineral or organic acid salts of basic residues such as amines, alkali or organic salts of acidic residues such as carboxylic acids, and the like. The pharmaceutically acceptable salts include the conventional non-toxic salts or the quaternary ammonium salts of the parent compound formed, for example, from non-toxic inorganic or organic acids. In certain embodiments pharmaceutically acceptable salts include veterinarily acceptable salts.
  • Salts of the compounds of the present application include salts of organic acids, especially carboxylic acids, including but not limited to acetate, trifluoroacetate, lactate, gluconate, malonate, citrate, tartrate, maleate, malate, pantothenate, adipate, alginate, aspartate, benzoate, butyrate, digluconate, cyclopentanate, glucoheptanate, glycerophosphate, oxalate, heptanoate, hexanoate, fumarate, nicotinate, pamoate, pectinate, 3-phenylpropionate, picrate, pivalate, proprionate, tartrate, lactobionate, pivolate, camphorate, undecanoate and succinate, organic sulfonic acids such as methanesulfonate, ethanesulfonate, 2-hydroxyethane sulfonate, camphorsulfonate, 2-naphthalenesulfonate, benzenesulfonate, p-chlorobenzenesulfonate and p-toluenesulfonate; and inorganic acids such as hydrochloride, hydrobromide, hydroiodide, sulfate, bisulfate, hemisulfate, thiocyanate, persulfate, phosphoric and sulfonic acids.
  • Where appropriate, pharmaceutically or veterinarily acceptable salts of the compounds of Formula (I) or Formula (Ia) may also include basic addition salts such as sodium, potassium, calcium, aluminium, zinc, magnesium and other metal salts as well as choline, diethanolamine, ethanolamine, ethyl diamine and other well-known basic addition salts.
  • Salts will preferably be pharmaceutically or veterinarily acceptable but other salts may still be valuable as intermediates.
  • It should be understood that all references to pharmaceutically acceptable salts include solvent addition forms (solvates) or crystal forms (polymorphs) as defined herein, of the same salt.
  • The compounds of the present application can also be prepared as esters, for example, pharmaceutically acceptable esters. For example, a carboxylic acid function group in a compound can be converted to its corresponding ester, e.g., a methyl, ethyl or other ester. Also, an alcohol group in a compound can be converted to its corresponding ester, e.g., an acetate, propionate or other ester.
  • The compounds of the present application can also be prepared as prodrugs, for example, pharmaceutically acceptable prodrugs. The terms “pro-drug” and “prodrug” are used interchangeably herein and refer to any compound which releases an active parent drug in vivo. Since prodrugs are known to enhance numerous desirable qualities of pharmaceuticals (e.g., solubility, bioavailability, manufacturing, etc.), the compounds of the present application can be delivered in prodrug form. Thus, the present application is intended to cover prodrugs of the presently claimed compounds, methods of delivering the same and compositions containing the same. “Prodrugs” are intended to include any covalently bonded carriers that release an active parent drug of the present application in vivo when such prodrug is administered to a subject. Prodrugs in the present application are prepared by modifying functional groups present in the compound in such a way that the modifications are cleaved, either in routine manipulation or in vivo, to the parent compound. Prodrugs include compounds of the present application wherein a hydroxy, amino, sulfhydryl, carboxy or carbonyl group is bonded to any group that may be cleaved in vivo to form a free hydroxyl, free amino, free sulfhydryl, free carboxy or free carbonyl group, respectively.
  • Examples of prodrugs include, but are not limited to, esters (e.g., acetate, dialkylaminoacetates, formates, phosphates, sulfates and benzoate derivatives) and carbamates (e.g., N,N-dimethylaminocarbonyl) of hydroxy functional groups, esters (e.g., ethyl esters, morpholinoethanol esters) of carboxyl functional groups, N-acyl derivatives (e.g., N-acetyl) N-Mannich bases, Schiff bases and enaminones of amino functional groups, oximes, acetals, ketals and enol esters of ketone and aldehyde functional groups in compounds of the application, and the like, See Bundegaard, H., Design of Prodrugs, p 1-92, Elesevier, New York-Oxford (1985).
  • The compounds, or pharmaceutically acceptable salts, esters or prodrugs thereof, are administered orally, nasally, transdermally, pulmonary, inhalationally, buccally, sublingually, intraperintoneally, subcutaneously, intramuscularly, intravenously, rectally, intrapleurally, intrathecally and parenterally. In one embodiment, the compound is administered orally. One skilled in the art will recognize the advantages of certain routes of administration.
  • The dosage regimen utilizing the compounds is selected in accordance with a variety of factors including type, species, age, weight, sex and medical condition of the patient; the severity of the condition to be treated; the route of administration; the renal and hepatic function of the patient; and the particular compound or salt thereof employed. An ordinarily skilled physician or veterinarian can readily determine and prescribe the effective amount of the drug required to prevent, counter or arrest the progress of the condition.
  • Techniques for formulation and administration of the disclosed compounds of the application can be found in Remington: the Science and Practice of Pharmacy, 19th edition, Mack Publishing Co., Easton, Pa. (1995). In an embodiment, the compounds described herein, and the pharmaceutically acceptable salts thereof, are used in pharmaceutical preparations in combination with a pharmaceutically acceptable carrier or diluent. Suitable pharmaceutically acceptable carriers include inert solid fillers or diluents and sterile aqueous or organic solutions. The compounds will be present in such pharmaceutical compositions in amounts sufficient to provide the desired dosage amount in the range described herein.
  • All percentages and ratios used herein, unless otherwise indicated, are by weight. Other features and advantages of the present application will become apparent from the different examples. The provided examples illustrate different components and methodology useful in practicing the present application. Generally speaking, the application extends to any novel one, or any novel combination, of the features disclosed in this specification (including the accompanying claims and drawings). The examples do not limit the claimed application. Thus, features, integers, characteristics, compounds or chemical moieties described in conjunction with a particular aspect, embodiment or example of the application are to be understood to be applicable to any other aspect, embodiment or example described herein, unless incompatible therewith. Based on the present disclosure the skilled artisan can identify and employ other components and methodology useful for practicing the present application. Moreover, unless stated otherwise, any feature disclosed herein may be replaced by an alternative feature serving the same or a similar purpose.
  • The Application will now be described by way of example only with reference to the Examples below:
    • 6. Examples
  • All the chemicals, reagents and solvents were purchased from SIGMA Aldrich or Alpha Aesar without further purification or purified by standard techniques. Acid chlorides can be prepared directly from the corresponding carboxylic acid using known synthetic methods, e.g., reaction of the corresponding carboxylic acid in thionyl chloride and catalytic N,N-dimethyl formamide for 8-24 hours at refluxing temperatures. Silica gel plates (Merck Kieselgel 60F254) were used and were developed by the ascending method. After solvent evaporation, compounds were visualized by irradiation with UV light at 254 nm and 366 nm. Purification was performed by silica gel chromatography using silica gel 40-60 μm from Merck and the appropriate eluent mixture. Melting points were determined using Griffin Melting Point Apparatus. 1H-NMR, 13C-NMR, 19F-NMR spectra were recorded using a Bruker AVANCE (500 MHz and 75 MHz) spectrometer auto-calibrated to the deuterated solvent reference peak (used the applied solvent simultaneously as internal standard).
  • Chemical shifts (δ) are given in ppm (parts per million) relative to tetramethylsilane (used as internal standard, δ=0 ppm) together with the relative assignment, the coupling constant (J(H-H)/Hz) and the multiplicity: singlet (s), doublet (d), triplet (t), quartet (q), multiplet (m), broad multiplet (bm). MestReNova version: 6.0.2-5475 software program was used for the assignment of peaks and for the calculation of the coupling constant. Mass spectrometry was carried out in Electrospray mode on a Bruker MicroTOF instrument.
    • General Procedure 1:
  • The compounds of general formula (II) can be prepared according to the synthetic scheme shown in Scheme 1.
  • Figure US20190248756A1-20190815-C00161
  • To a suspension containing 1 equivalent of anthranilic acid (IIa) in the minimum amount of pyridine is added 2.2 equivalents of the appropriate benzoyl-chloride (IIb). The reaction mixture is stirred at room temperature over a period between about 2 hours and 12 hours. The reaction is monitored by TLC and is stopped after the complete disappearance of the anthranilic acid (IIa). The reaction is poured into a 10% aqueous solution of sodium carbonate. The formed precipitate is collected by filtration under reduced pressure as a powder and washed three times with n-hexane in order to obtain the title compound (II).
  • Compounds 160-206 were prepared of general procedure 1 substituting (IIa) with the appropriate substituted anthranilic acid and substituting (IIb) with the appropriate benzoyl chloride.
    • Example 1 Synthesis of 2-(2-chlorophenyl)-4H-benzo[d][1,3]oxazin-4-one (160)
  • Figure US20190248756A1-20190815-C00162
  • Compound 160 was obtained as a white powder in 89% yield. 1H-NMR (CDCl3): δ 7.57 (td, J=7.6, 1.3 Hz, 1H), 7.62-7.74 (m, 3H), 7.76 (d, J=7.8 Hz, 1H), 7.95 (dd, J=7.7, 1.5 Hz, 1H), 7.98-8.04 (m, 1H), 8.22 (dd, J=1.2, 7.9 Hz, 1H) ppm. 13C-NMR (CDCl3): δ 116.82 (C,C-aromatic), 127.11 (CH,C-aromatic), 127.49 (CH,C-aromatic), 128.05 (CH,C-aromatic), 129.38 (CH,C-aromatic), 130.20 (C,C-aromatic), 130.64 (CH,C-aromatic), 131.67 (C,C-aromatic), 131.76 (CH,C-aromatic), 132.85 (CH,C-aromatic), 137.05 (CH,C-aromatic), 145.80 (C,C-aromatic), 155.78 (C,C-aromatic), 158.72 (C,C-aromatic) ppm.
    • Example 2 Synthesis of 2-(3-chlorophenyl)-4H-benzo[d][1,3]oxazin-4-one (161)
  • Figure US20190248756A1-20190815-C00163
  • Compound 161 was obtained as a white powder in 39% yield. 1H-NMR (CDCl3): δ 7.63-7.67 (m, 2H), 7.74-7.79 (m, 2H), 7.96-8.01 (m, 1H), 8.14-8.17 (m, 3H) ppm. 13C-NMR (CDCl3): δ 117.10 (C, C-aromatic), 126.42 (CH, C-aromatic), 127.05 (CH, C-aromatic), 127.20 (CH, C-aromatic), 128.11 (CH, C-aromatic), 128.96 (CH, C-aromatic), 131.06 (CH, C-aromatic), 132.23 (C, C-aromatic), 132.42 (CH, C-aromatic), 136.94 (CH, C-aromatic), 145.97 (C, C-aromatic), 155.33 (C, C-aromatic), 158.68 (C, C-aromatic), 159.1 (C, C-aromatic) ppm.
    • Example 3 Synthesis of 2-(4-chlorophenyl)-4H-benzo[d][1,3]oxazin-4-one (162)
  • Figure US20190248756A1-20190815-C00164
  • Compound 162 was obtained as a white powder in 45% yield. 1H-NMR (CDCl3): δ 7.54 (m, 3H), 7.71 (d, J=5 Hz, 1H), 7.86 (m, 1H), 8.28 (m, 3H) ppm. 13C-NMR (CDCl3): δ 116.8 (C, C-aromatic), 124.1 (CH, C-aromatic), 126.5 (CH, C-aromatic), 127.9 (C, C-aromatic), 128.9 (CH, C-aromatic), 128.2 (CH, C-aromatic), 129.1 (CH, C-aromatic), 135.2 (CH, C-aromatic), 136.6 (C, C-aromatic), 146.1 (C, C-aromatic), 156.2 (C, C-aromatic), 159.4 (C, C-aromatic) ppm.
    • Example 4 Synthesis of 2-(2-nitrophenyl)-4H-benzo[d][1,3]oxazin-4-one (163)
  • Figure US20190248756A1-20190815-C00165
  • Compound 163 was obtained as a white powder in 71% yield. 1H-NMR (CDCl3): δ 7.65-7.61 (m, 1H). 7.72-7.69 (m, 1H), 7.70-7.78 (m, 2H), 7.84-7.93 (m, 1H), 8.01-8.04 (m, 1H), 8.08 (dd, J=1.0, 8.1 Hz, 1H), 8.29 (dd, J=1.2, 7.9 Hz, 1H) ppm. 13C-NMR (CDCl3): δ 116.68 (C, C-aromatic), 124.57 (CH, C-aromatic), 124.98 (C, C-aromatic), 127.04 (CH, C-aromatic), 128.22 (CH, C-aromatic), 129.61 (CH, C-aromatic), 131.16 (CH, C-aromatic), 132.97 (CH, C-aromatic), 133.60 (CH, C-aromatic), 137.26 (CH, C-aromatic), 145.58 (C, C-aromatic), 148.15 (C, C-aromatic), 154.50 (C, C-aromatic), 158.20 (C, C-aromatic) ppm.
    • Example 5 Synthesis of 2-(3-nitrophenyl)-4H-benzo[d][1,3]oxazin-4-one (164)
  • Figure US20190248756A1-20190815-C00166
  • Compound 164 was obtained as a white powder in 61% yield. 1H-NMR (CDCl3): δ 7.62 (s, 1H), 7.77 (m, 2H), 7.96-7.89 (m, 1H), 8.30 (d, J=1.2 Hz, 1H), 8.51-8.44 (m, 1H), 8.70-8.56 (m, 1H), 9.22 (s, 1H) ppm. 13C-NMR (CDCl3): δ 117.11 (C, C-aromatic), 123.39 (CH, C-aromatic), 126.88 (CH, C-aromatic), 128.87 (CH, C-aromatic), 129.17 (CH, C-aromatic), 129.98 (CH, C-aromatic), 132.19 (CH, C-aromatic), 131.65 (C, C-aromatic), 133.68 (CH, C-aromatic), 136.95 (CH, C-aromatic), 145.99 (C, C-aromatic), 158.36 (C, C-aromatic), 167.99 (C, C-aromatic), 173.58 (C, C-aromatic) ppm.
    • Example 6 Synthesis of 2-(4-nitrophenyl)-4H-benzo[d][1,3]oxazin-4-one (165)
  • Figure US20190248756A1-20190815-C00167
  • Compound 165 was obtained as a white powder in 95% yield. 1H-NMR (CDCl3): δ 7.69 (t, J=7.6 Hz, 2H), 7.79 (d, J=8.1 Hz, 2H), 8.00 (t, J=7.8 Hz, 2H), 8.19 (t, J=7.8 Hz, 2H) ppm. 13C-NMR (CDCl3): δ 117.20 (C, C-aromatic), 124.08 (CH, C-aromatic), 127.24 (CH, C-aromatic), 128.13 (CH, C-aromatic), 129.13 (CH, C-aromatic), 129.37 (CH, C-aromatic), 135.81 (C, C-aromatic), 136.98 (CH, C-aromatic), 145.77 (C, C-aromatic), 149.62 (C, C-aromatic), 154.74 (C, C-aromatic), 158.43 (C, C-aromatic) ppm.
    • Example 7 Synthesis of 2-(4-methoxyphenyl)-4H-benzo[d][1,3]oxazin-4-one (166)
  • Figure US20190248756A1-20190815-C00168
  • Compound 166 was obtained as a white powder in 95.31% yield. 1H-NMR (CDCl3): δ 3.92 (s, 7H), 7.01-7.05 (m, 4H), 7.47-7.53 (m, 2H), 7.67 (d, J=8.0 Hz, 2H), 7.80-7.85 (m, 2H), 8.25 (dd, J=1.3, 7.9 Hz, 2H), 8.27-8.31 (m, 4H) ppm. 13C-NMR (CDCl3): δ 55.57 (CH3, C-aliphatic), 114.16 (CH, C-aromatic), 116.73 (C, C-aromatic), 122.56 (C, C-aromatic), 126.93 (CH, C-aromatic), 127.72 (CH, C-aromatic), 128.57 (CH, C-aromatic), 130.30 (CH, C-aromatic), 132.85 (CH, C-aromatic), 136.52 (CH, C-aromatic), 147.37 (C, C-aromatic), 157.14 (C, C-aromatic), 159.82 (C, C-aromatic), 163.29 (C, C-aromatic) ppm.
    • Example 8 Synthesis of 2-(2-fluorophenyl)-4H-benzo[d][1,3]oxazin-4-one (167)
  • Figure US20190248756A1-20190815-C00169
  • Compound 167 was obtained as a yellow powder in 89.4% yield. 1H-NMR (500 MHz, CDCl3): δ 7.29 (2H, s), 7.59 (2H, s), 7.76 (1H, s), 7.88 (1H, s), 8.16 (1H, s), 8.29 (1H, d, J=7.88 Hz) ppm. 13C-NMR (CDCl3): δ 117.02 (C, C-aromatic), 117.20 (CH, C-aromatic), 117.38 (CH, C-aromatic), 119.10 (C, C-aromatic), 124.33 (CH, C-aromatic), 127.46 (CH, C-aromatic), 128.60 (CH, C-aromatic), 128.80 (CH, C-aromatic), 131.16 (CH, C-aromatic), 133.99 (CH, C-aromatic), 134.06 (CH, C-aromatic), 136.65 (CH, C-aromatic), 146.71 (C, C-aromatic), 159.24 (C, C-aromatic), 160.37 (C, C-aromatic), 162.44 (C, C-aromatic) ppm. 19F-NMR (CDCl3): δ −105.99 ppm.
    • Example 9 Synthesis of 2-(2-fluoro-4-methoxyphenyl)-4H-benzo[d][1,3]oxazin-4-one (168)
  • Figure US20190248756A1-20190815-C00170
  • Compound 168 was obtained as a white powder in 25% yield. 1H-NMR (CDCl3): δ 6.76 (dd, J=2.4, 12.9 Hz, 1H), 6.84 (dd, J=2.4, 8.9 Hz, 1H), 7.52-7.56 (m, 1H), 7.71 (d, J=8.1 Hz, 1H), 7.82-7.88 (m, 1H), 8.13 (t, J=8.7 Hz, 1H), 8.26 (dd, J=1.2, 7.9 Hz, 1H) ppm. 13C-NMR (CDCl3): δ 55.87 (CH3, C-aliphatic), 102.66 (CH, C-aromatic), 110.68 (C, C-aromatic), 116.82 (C, C-aromatic), 127.19 (CH,C-aromatic), 128.21 (CH, C-aromatic), 128.52 (CH, C-aromatic), 132.17 (CH,C-aromatic), 132.19 (CH,C-aromatic), 136.51 (CH, C-aromatic), 147.08 (C, C-aromatic), 159.41 (C, C-aromatic), 161.80 (C, C-aromatic), 163.87 (C, C-aromatic), 164.34 (C, C-aromatic) ppm.
    • Example 10 Synthesis of 5-fluoro-2-(4-methoxyphenyl)-4H-benzo[d][1,3]oxazin-4-one (169)
  • Figure US20190248756A1-20190815-C00171
  • Compound 169 was obtained as a white powder in 56% yield. 1H-NMR (CDCl3): δ 3.93 (s, 3H), 7.00-7.05 (m, 2H), 7.14-7.21 (m, 1H), 7.48 (d, J=8.1 Hz, 1H), 7.72-7.78 (m, 1H), 8.25-8.32 (m, 2H) ppm. 13C-NMR (CDCl3): δ 55.57 (CH3, C-aliphatic), 114.14 (CH, C-aromatic), 114.66 (CH, C-aromatic), 122.02 (C, C-aromatic), 122.79 (CH, C-aromatic), 130.53 (CH, C-aromatic), 132.85 (CH, C-aromatic), 134.99 (C, C-aromatic), 137.18 (CH, C-aromatic), 149.21 (C, C-aromatic), 160.89 (C, C-aromatic), 163.02 (C, C-aromatic), 163.6 (C, C-aromatic) ppm. 19F-NMR (CDCl3): δ −106.84 ppm.
    • Example 11 Synthesis of 7-methoxy-2-(4-methoxyphenyl)-4H-benzo[d][1,3]oxazin-4-one (170)
  • Figure US20190248756A1-20190815-C00172
  • Compound 170 was obtained as a white powder in 90% yield. 1H-NMR (CDCl3): δ 3.92 (s, 3H), 3.97 (s, 3H), 6.99-7.05 (m, 3H), 7.08 (d, J=2.4 Hz, 1H), 8.12-8.16 (m, 1H), 8.25-8.30 (m, 2H) ppm. 13C-NMR (CDCl3): δ 55.61 (CH3, C-aliphatic), 55.88 (CH3, C-aliphatic), 108.57 (CH, C-aromatic), 109.56 (C, C-aromatic), 114.14 (CH, C-aromatic), 116.91 (CH, C-aromatic), 122.63 (C, C-aromatic), 130.31 (CH, C-aromatic), 132.85 (CH, C-aromatic), 149.82 (C, C-aromatic), 155.00 (C, C-aromatic), 159.47 (C, C-aromatic), 163.30 (C, C-aromatic), 166.29 (C, C-aromatic) ppm.
    • Example 12 Synthesis of 5-fluoro-2-(2-fluorophenyl)-4H-benzo[d][1,3]oxazin-4-one (171)
  • Figure US20190248756A1-20190815-C00173
  • Compound 171 was obtained as a beige powder in 26% yield. 1H-NMR (CDCl3): δ 7.23-7.35 (m, 3H), 7.55-7.62 (m, 2H), 7.79-7.83 (m, 1H), 8.10-8.15 (m, 1H) ppm. 13C-NMR (CDCl3): δ 115.72 (CH, C-aromatic), 117.35 (CH, C-aromatic), 123.35 (CH, C-aromatic), 123.38 (CH, C-aromatic), 124.37 (C, C-aromatic), 124.40 (CH, C-aromatic), 131.20 (CH, C-aromatic), 134.36 (CH, C-aromatic), 134.44 (CH, C-aromatic), 137.32 (CH, C-aromatic), 137.40 (CH, C-aromatic), 148.42 (C, C-aromatic), 154.69 (CH, C-aromatic), 160.47 (CH, C-aromatic), 162.55 (C, C-aromatic), 162.89 (C, C-aromatic) ppm.
    • Example 13 Synthesis of 5-fluoro-2-(2-fluoro-4-methoxyphenyl)-4H-benzo[d][1,3]oxazin-4-one (172)
  • Figure US20190248756A1-20190815-C00174
  • Compound 172 was obtained as a white powder in 31% yield. 1H-NMR (CDCl3): δ 3.92 (s, 3H), 6.76 (dd, J=2.4, 12.9 Hz, 1H), 6.82-6.85 (m, 1H), 7.21 (t, J=8.7 Hz, 1H), 7.51 (t, J=7.5 Hz, 1H), 7.72-7.80 (m, 1H), 8.13 (t, J=8.7 Hz, 1H) ppm. 13C-NMR (CDCl3): δ 55.94 (CH3, C-aliphatic), 102.82 (CH, C-aromatic), 110.76 (CH, C-aromatic), 115.10 (C, C-aromatic), 123.08 (CH, C-aromatic), 132.27 (CH, C-aromatic), 137.18 (CH, C-aromatic), 137.26 (CH, C-aromatic), 148.84 (C, C-aromatic), 153.80 (C, C-aromatic), 160.78 (C, C-aromatic), 161.05 (C, C-aromatic), 161.97 (C, C-aromatic), 162.91 (C, C-aromatic) ppm. 19F-NMR (CDCl3): δ −104.71, −106.43 ppm.
    • Example 14 Synthesis of 2-(2-fluoro-4-methoxyphenyl)-7-methoxy-4H-benzo[d][1,3]oxazin-4-one (173)
  • Figure US20190248756A1-20190815-C00175
  • Compound 173 was obtained as a white powder in 17% yield. 1H-NMR (CDCl3): δ 3.91 (s, 3H), 3.97 (s, 3H), 6.76 (dd, J=2.2, 12.9 Hz, 1H), 6.84 (dd, J=2.2, 8.9 Hz, 1H), 7.03-7.13 (m, 2H), 8.07-8.18 (m, 2H) ppm. 13C-NMR (126 MHz, CDCl3): δ 55.92 (CH3, C-aliphatic), 102.88 (CH, C-aromatic), 106.3 (C, C-aromatic), 108.82 (CH, C-aromatic), 110.5 (C, C-aromatic), 110.63 (CH, C-aromatic), 117.49 (CH, C-aromatic), 130.16 (CH, C-aromatic), 132.19 (CH, C-aromatic), 154.9 (C, C-aromatic), 156.3 (C, C-aromatic), 159.4 (C, C-aromatic), 160.6 (C, C-aromatic), 162.1 (C, C-aromatic), 167.1 (C, C-aromatic) ppm. 19F-NMR (471 MHz, CDCl3): δ −110.94 ppm.
    • Example 15 Synthesis of 2-(2-fluorophenyl)-7-methoxy-4H-benzo[d][1,3]oxazin-4-one (174)
  • Figure US20190248756A1-20190815-C00176
  • Compound 174 was obtained as a beige powder in 54% yield. 1H-NMR (CDCl3): δ 3.98 (s, 3H), 7.12 (dd, J=2.5, 8.8 Hz, 1H), 7.16 (d, J=2.4 Hz, 1H), 7.26 (dd, J=8.4, 11.1 Hz, 1H), 7.32 (t, J=7.6 Hz, 1H), 7.55-7.61 (m, 1H), 8.10-8.15 (m, 2H) ppm. 13C-NMR (CDCl3): δ 55.98 (CH3, C-aliphatic), 106.3 (C, C-aroamtic), 109.15 (CH, C-aroamtic), 117.37 (CH, C-aroamtic), 117.94 (CH, C-aroamtic), 118.6 (C, C-aromatic), 124.32 (CH, C-aroamtic), 130.23 (CH, C-aroamtic), 131.14 (CH, C-aroamtic), 133.97 (CH, C-aroamtic), 154.9 (C, C-aromatic), 156.3 (C, C-aromatic), 159.1 (C, C-aromatic), 159.8 (C, C-aromatic), 167.6 (C, C-aromatic) ppm.
    • Example 16 Synthesis of 2-(4-methoxyphenyl)-4H-pyrido[3,4-d][1,3]oxazin-4-one (175)
  • Figure US20190248756A1-20190815-C00177
  • Compound 175 was obtained as a white powder in 75% yield. 1H-NMR (CDCl3): δ 3.93 (s, 3H), 7.02-7.08 (m, 2H), 8.00 (dd, J=0.7, 5.1 Hz, 1H), 8.21-8.35 (m, 2H), 8.76 (d, J=5.1 Hz, 1H), 9.11 (s, 1H) ppm. 13C-NMR (126 MHz, CDCl3): δ 55.60 (CH3, C-aromatic), 114.14 (CH, C-aromatic), 114.36 (CH, C-aromatic), 119.96 (C, C-aromatic), 121.81 (C, C-aromatic), 122.33 (CH, C-aromatic), 130.61 (C, C-aromatic), 132.86 (C, C-aromatic), 147.82 (CH, C-aromatic), 150.24 (CH, C-aromatic), 158.06 (C, C-aromatic), 158.95 (C, C-aromatic), 163.84 (C, C-aromatic) ppm.
    • Example 17 Synthesis of 7-fluoro-2-(4-methoxyphenyl)-4H-benzo[d][1,3]oxazin-4-one (176)
  • Figure US20190248756A1-20190815-C00178
  • Compound 176 was obtained as a white powder in 93% yield. 1H-NMR (CDCl3): δ 3.92 (s, 3H), 7.01-7.04 (m, 2H), 7.16-7.20 (m, 1H), 7.32 (dd, J=2.4, 9.4 Hz, 1H), 8.23-8.26 (m, 1H), 8.26-8.29 (m, 2H) ppm. 13C-NMR (126 MHz, CDCl3): δ 55.56 (CH3, C-aromatic), 112.83 (CH, C-aromatic), 113.01 (CH, C-aromatic), 114.24 (CH, C-aromatic), 116.04 (C, C-aromatic), 116.23 (CH, C-aromatic), 122.12 (CH, C-aromatic), 130.54 (C, C-aromatic), 131.35 (C, C-aromatic), 158.35 (C, C-aromatic), 158.88 (C, C-aromatic), 163.61 (C, C-aromatic), 168.84 (C, C-aromatic) ppm.
    • Example 18 Synthesis of 7-fluoro-2-(2-fluorophenyl)-4H-benzo[d][1,3]oxazin-4-one (177)
  • Figure US20190248756A1-20190815-C00179
  • Compound 177 was obtained as a white powder in 94% yield. 1H-NMR (CDCl3): δ 7.23-7.27 (m, 1H), 7.31-7.37 (m, 2H), 7.42 (dd, J=1.24, 9.1 Hz, 1H), 7.57-7.63 (m, 1H), 8.11-8.16 (m, 1H), 8.31 (dd, J=5.9, 8.8 Hz, 1H) ppm. 13C-NMR (126 MHz, CDCl3): δ 113.50 (CH, C-aromatic), 113.61 (C, C-aromatic), 117.30 (CH, C-aromatic), 117.47 (CH, C-aromatic), 124.41 (CH, C-aromatic), 131.40 (CH, C-aromatic), 134.41 (CH, C-aromatic), 134.48 (CH, C-aromatic), 149.03 (C, C-aromatic), 158.29 (C, C-aromatic), 160.48 (C, C-aromatic), 162.56 (C, C-aromatic), 166.63 (C, C-aromatic), 168.87 (C, C-aromatic) ppm. 19F-NMR (CDCl3): δ −104.11, −112.36 ppm.
    • Example 19 Synthesis of 2-(2-(trifluoromethyl)phenyl)-4H-benzo[d][1,31]oxazin-4-one (178)
  • Figure US20190248756A1-20190815-C00180
  • Compound 178 was obtained as a white powder in 53% yield. 1H-NMR (CDCl3): δ 7.65-7.60 (m, 1H), 7.69-7.75 (m, 3H), 7.85-7.89 (m, 2H), 7.95-7.99 (m, 1H), 8.31 (dd, J=1.4, 7.9 Hz, 1H) ppm. 13C NMR (126 MHz, CDCl3): 116.91 (C, C-aromatic), 122.04 (C, C-aromatic), 127.46 (CH, C-aromatic), 128.69 (CH, C-aromatic), 129.12 (CH, C-aromatic), 129.21 (CH, C-aromatic), 130.09 (C, C-aromatic), 131.08 (CH, C-aromatic), 131.28 (CH, C-aromatic), 131.89 (CH, C-aromatic), 136.72 (CH, C-aromatic), 146.32 (C, C-aromatic), 156.80 (C, C-aromatic), 158.66 (C, C-aromatic) ppm. 19F-NMR: δ −58.79 ppm.
    • Example 20 Synthesis of 2-(3-(trifluoromethyl)phenyl)-4H-benzo[d][1,31]oxazin-4-one (179)
  • Figure US20190248756A1-20190815-C00181
  • Compound 179 was obtained as a white powder in 41% yield. 1H-NMR (CDCl3): δ 7.60 (t, J=7.6 Hz, 1H), 7.69 (t, J=7.8 Hz, 1H), 7.76 (d, J=8.1 Hz, 1H), 7.84-7.93 (m, 2H), 8.30 (d, J=7.9 Hz, 1H), 8.53 (d, J=7.9 Hz, 1H), 8.63 (s, 1H) ppm. 13C NMR (126 MHz, CDCl3): δ117.12 (C, C-aromatic), 125.29 (CH, C-aromatic), 127.44 (CH, C-aromatic), 128.82 (CH, C-aromatic), 129.80 (CH, C-aromatic), 131.23 (CH, C-aromatic), 131.34 (C, C-aromatic), 133.68 (CH, C-aromatic), 136.78 (CH, C-aromatic), (CH, C-aromatic), 146.57 (C, C-aromatic), 155.60 (C, C-aromatic), 155.92 (C, C-aromatic), 159.05 (C, C-aromatic) ppm. 19F-NMR: δ −62.75 ppm.
    • Example 21 Synthesis of 2-(4-(trifluoromethyl)phenyl)-4H-benzo[d][1,3]oxazin-4-one (180)
  • Figure US20190248756A1-20190815-C00182
  • Compound 180 was obtained as a white powder in 73% yield. 1H-NMR (CDCl3): δ 7.58-7.62 (m, 1H), 7.74-7.87 (m, 3H), 7.88-7.92 (m, 1H), 8.30 (dd, J=1.4, 7.9 Hz, 1H), 8.47 (d, J=8.2 Hz, 2H). 13C-NMR (126 MHz, CDCl3): δ 117.11 (C, C-aromatic), 125.47 (CH, C-aromatic), 127.64 (CH, C-aromatic), 128.65 (CH, C-aromatic), 128.77 (CH, C-aromatic), 128.95 (CH, C-aromatic), 136.64 (CH, C-aromatic), 133.43 (C, C-aromatic), 133.83 (C, C-aromatic), 134.14 (C, C-aromatic), 134.41 (C, C-aromatic), 146.58 (C, C-aromatic), 158.95 (C, C-aromatic) ppm. 19F-NMR:−63.59 ppm.
    • Example 22 Synthesis of 2-(4-methoxyphenyl)-4H-pyrido[2,3-d][1,3]oxazin-4-one (181)
  • Figure US20190248756A1-20190815-C00183
  • Compound 181 was obtained as a white powder in 43% yield. 1H-NMR (CDCl3): δ 3.93 (s, 3H), 7.05 (d, J=8.9 Hz, 2H), 7.29 (s, 1H), 8.40 (d, J=8.9 Hz, 2H), 8.56 (dd, J=1.9, 7.8 Hz, 1H), 9.01 (dd, J=4.6, 1.9 Hz, 1H) ppm. 13C-NMR (126 MHz, CDCl3): δ 55.59 (CH3, C-aromatic), 112.45 (C, C-aromatic), 114.34 (CH, C-aromatic), 121.68 (C, C-aromatic), 123.02 (CH, C-aromatic), 131.20 (CH, C-aromatic), 137.83 (CH, C-aromatic), 157.53 (CH, C-aromatic), 158.22 (C, C-aromatic), 159.64 (C, C-aromatic), 164.17 (C, C-aromatic) ppm.
    • Example 23 Synthesis of 2-(4-methoxyphenyl)-4H-pyrido[4,3-d][1,3]oxazin-4-one (182)
  • Figure US20190248756A1-20190815-C00184
  • Compound 182 was obtained as a white powder in 76% yield. 1H-NMR (CDCl3): δ 3.94 (s, 3H), 6.97-7.10 (m, 2H), 7.29 (s, 1H), 8.28-8.43 (m, 2H), 8.93 (d, J=5.6 Hz, 1H), 9.43 (d, J=0.6 Hz, 1H) ppm. 13C-NMR (126 MHz, CDCl3): δ 55.65 (CH3, C-aromatic), 112.55 (C, C-aromatic), 114.41 (CH, C-aromatic), 120.14 (C, C-aromatic), 121.62 (CH, C-aromatic), 131.19 (CH, C-aromatic), 151.59 (CH, C-aromatic), 153.22 (CH, C-aromatic), 156.12 (C, C-aromatic), 158.15 (C, C-aromatic), 164.30 (C, C-aromatic) ppm.
    • Example 24 Synthesis of 2-(naphthalen-1-yl)-4H-benzo[d][1,3]oxazin-4-one (183)
  • Figure US20190248756A1-20190815-C00185
  • Compound 183 was obtained as a white powder in 89% yield. 1H-NMR (CDCl3): δ 7.58-7.64 (m, 3H), 7.68-7.72 (m, 1H), 7.84 (dd, J=0.6, 8.1 Hz, 1H), 7.89-7.94 (m, 1H), 7.97 (t, J=6.3 Hz, 1H), 8.09 (d, J=8.2 Hz, 1H), 8.32-8.38 (m, 2H), 9.17 (dd, J=4.9, 8.3 Hz, 1H) ppm. 13C-NMR (126 MHz, CDCl3): δ 117.03 (C, C-aromatic), 124.82 (CH, C-aromatic), 125.79 (CH, C-aromatic), 126.42 (CH, C-aromatic), 126.79 (C, C-aromatic), 127.44 (CH, C-aromatic), 127.88 (CH, C-aromatic), 128.57 (CH, C-aromatic), 128.63 (CH, C-aromatic), 128.85 (CH, C-aromatic), 130.04 (CH, C-aromatic), 130.78 (C, C-aromatic), 133.19 (CH, C-aromatic), 134.09 (C, C-aromatic), 136.31 (CH, C-aromatic), 146.85 (C, C-aromatic), 157.71 (C, C-aromatic), 159.77 (C, C-aromatic) ppm.
    • Example 25 Synthesis of 2-(naphthalen-2-yl)-4H-benzo[d][1,3]oxazin-4-one (184)
  • Figure US20190248756A1-20190815-C00186
  • Compound 184 was obtained as a white powder in 91% yield. 1H-NMR (CDCl3): δ 7.60 (dd, J=1.2, 7.6 Hz, 3H), 7.77 (dd, J=0.5, 8.1 Hz, 1H), 7.88 (ddd, J=1.5, 7.3, 8.2, Hz, 1H), 7.93 (d, J=8.0 Hz, 1H), 7.98 (d, J=8.7 Hz, 1H), 8.03 (d, J=7.9 Hz, 1H), 8.30 (dd, J=1.1, 7.9 Hz, 1H), 8.40 (dd, J=1.7, 8.7 Hz, 1H), 8.88 (s, 1H) ppm. 13C-NMR (126 MHz, CDCl3): δ 117.09 (C, C-aromatic), 124.18 (CH, C-aromatic), 126.89 (CH, C-aromatic), 127.29 (C, C-aromatic), 127.45 (C, C-aromatic), 127.83 (CH, C-aromatic), 128.28 (CH, C-aromatic), 128.33 (CH, C-aromatic), 128.58 (CH, C-aromatic), 128.67 (CH, C-aromatic), 129.39 (CH, C-aromatic), 129.55 (CH, C-aromatic), 132.80 (C, C-aromatic), 135.37 (CH, C-aromatic), 136.61 (CH, C-aromatic), 147.13 (C, C-aromatic), 157.24 (C, C-aromatic), 159.68 (C, C-aromatic) ppm.
    • Example 26 Synthesis of 2-(2-fluorophenyl)-4H-pyrido[2,3-d][1,3]oxazin-4-one (185)×
  • Figure US20190248756A1-20190815-C00187
  • Compound 185 was obtained as a white powder in 27.52% yield. 1H-NMR (CDCl3): δ 7.23-7.28 (m, 1H), 7.31-7.37 (m, 1H), 7.56 (dd, J=4.7, 4.7 Hz, 1H), 7.59-7.66 (m, 1H), 8.31 (td, J=1.8, 7.7 Hz, 1H), 8.61 (dd, J=2.0, 7.8 Hz, 1H), 9.07 (dd, J=2.0, 4.7 Hz, 1H) ppm. 13C-NMR (126 MHz, CDCl3): δ 112.89 (C, C-aromatic), 117.39 (CH, C-aromatic), 117.57 (CH, C-aromatic), 124.06 (CH, C-aromatic), 124.43 (CH, C-aromatic), 131.79 (CH, C-aromatic), 135.07 (CH, C-aromatic), 135.15 (C, C-aromatic), 137.90 (CH, C-aromatic), 157.53 (C, C-aromatic), 157.66 (CH, C-aromatic), 159.11 (C, C-aromatic), 160.78 (C, C-aromatic), 162.87 (C, C-aromatic) ppm. 19F-NMR: δ −107.15 ppm.
    • Example 27 Synthesis of 5-fluoro-2-(2-methoxyphenyl)-4H-benzo[d][1,3]oxazin-4-one (186)
  • Figure US20190248756A1-20190815-C00188
  • Compound 186 was obtained as a white powder in 98% yield. 13C-NMR (126 MHz, CDCl3): δ 56.13 (CH3, C-aliphatic), 112.22 (CH, C-aromatic), 115.15 (CH, C-aromatic, J=26.25 MHz), 120.09 (CH, C-aromatic), 120.61 (C, C-aromatic), 123.11 (CH, C-aromatic), 123.15 (CH, C-aromatic), 131.39 (CH, C-aromatic), 133.54 (CH, C-aromatic), 137.08 (CH, C-aromatic), 148.87 (C, C-aromatic), 155.35 (C, C-aromatic), 158.71 (C, C-aromatic), 158.80 (C, C-aromatic), 160.76 (C, C-aromatic), 162.89 (C, C-aromatic) ppm. 19F-NMR: δ −106.66 ppm.
    • Example 28 Synthesis of 5-fluoro-2-(3-methoxyphenyl)-4H-benzo[d][1,3]oxazin-4-one (187)
  • Figure US20190248756A1-20190815-C00189
  • Compound 187 was obtained as a white powder in 94% yield. 1H-NMR (CDCl3): δ 3.94 (s, 3H), 7.16 (ddd, J=0.9, 2.6, 8.2 Hz, 1H), 7.21 (ddd, J=0.9, 8.4, 9.5 Hz, 1H), 7.44 (t, J=8.0 Hz, 1H), 7.53 (d, J=8.1 Hz, 1H), 7.77-7.81 (m, 1H), 7.82 (dt, J=2.8, 5.4 Hz, 1H), 7.92 (ddd, J=1.0, 1.4, 7.8 Hz, 1H) ppm. 13C-NMR (126 MHz, CDCl3): δ 55.59 (CH3, C-aliphatic), 112.75 (CH, C-aromatic), 115.11 (CH, C-aromatic), 119.71 (CH, C-aromatic), 121.06 (CH, C-aromatic), 123.12 (CH, C-aromatic), 129.83 (CH, C-aromatic), 131.09 (CH, C-aromatic), 137.18 (C, C-aromatic), 137.26 (CH, C-aromatic), 148.77 (C, C-aromatic), 155.22 (C, C-aromatic), 157.75 (C, C-aromatic), 159.93 (C, C-aromatic), 160.87 (C, C-aromatic), 163.00 (C, C-aromatic) ppm. 19F-NMR: δ −106.52 ppm.
    • Example 29 Synthesis of 2-(2-fluoro-4-(trifluoromethoxy)phenyl)-4H-benzo[d][1,3]oxazin-4-one (188)
  • Figure US20190248756A1-20190815-C00190
  • Compound 188 was obtained as a white powder in 95% yield. 1H-NMR (CDCl3): δ 7.11-7.21 (m, 2H), 7.58-7.63 (m, 1H), 7.75 (d, J=8.1 Hz, 1H), 7.86-7.92 (m, 1H), 8.24 (t, J=8.5 Hz, 1H), 8.29 (dd, J=7.9, 1.2 Hz, 1H) ppm. 13C-NMR (126 MHz, CDCl3): δ 109.97 (CH, C-aromatic), 116.14 (CH, C-aromatic), 117.03 (C, C-aromatic), 119.00 (C, C-aromatic), 117.2 (C, C-aromatic), 127.51 (CH, C-aromatic), 128.68 (CH, C-aromatic), 129.01 (CH, C-aromatic), 132.47 (CH, C-aromatic), 136.72 (CH, C-aromatic), 146.27 (C, C-aromatic), 152.46 (C, C-aromatic), 158.85 (C, C-aromatic), 160.68 (C, C-aromatic) ppm. 19F-NMR: δ −57.99, −103.77 ppm.
    • Example 30 Synthesis of 6,7-dimethoxy-2-(4-methoxyphenyl)-4H-benzo[d][1,3]oxazin-4-one (189)
  • Figure US20190248756A1-20190815-C00191
  • Compound 189 was obtained as a white powder in 72% yield. 1H-NMR (CDCl3): δ 3.83 (s, 3H), 3.93 (s, 3H), 3.96 (s, 3H), 6.89-6.97 (m, 2H), 7.01 (s, 1H), 7.19 (s, 1H), 7.48 (s, 1H), 8.14-8.18 (m, 1H) ppm. 13C-NMR (126 MHz, CDCl3): δ 55.51 (—CH3, C-aliphatic), 56.44 (—CH3, C-aliphatic), 56.50 (—CH3, C-aliphatic), 107.71 (CH, C-aromatic), 107.85 (CH, C-aromatic), 107.56 (CH, C-aromatic), 109.26 (C, C-aromatic), 114.15 (CH, C-aromatic), 122.80 (C, C-aromatic), 129.93 (CH, C-aromatic), 132.85 (CH, C-aromatic), 143.76 (C, C-aromatic), 149.37 (C, C-aromatic), 156.49 (C, C-aromatic) 156.72 (C, C-aromatic), 159.74 (C, C-aromatic), 163.05 (C, C-aromatic) ppm.
    • Example 31 Synthesis of 6,7,8-trimethoxy-2-(4-methoxyphenyl)-4H-benzo[d][1,3]oxazin-4-one (190)
  • Figure US20190248756A1-20190815-C00192
  • Compound 190 was obtained as a white powder in 79% yield. 1H-NMR (CDCl3): δ 3.92 (s, 3H), 3.99 (s, 3H), 4.09 (s, 3H), 4.18 (s, 3H), 6.96-7.06 (m, 2H), 7.45 (s, 1H), 8.09-8.15 (m, 1H), 8.26-8.33 (m, 2H) ppm. 13C-NMR (126 MHz, CDCl3): δ 55.51 (CH3, C-aliphatic), 56.40 (CH3, C-aliphatic), 61.51 (CH3, C-aliphatic), 62.71 (CH3, C-aliphatic), 104.02 (CH, C-aromatic), 112.06 (C, C-aromatic), 114.11 (CH, C-aromatic), 122.83 (C, C-aromatic), 129.99 (CH, C-aromatic), 136.92 (C, C-aromatic), 147.64 (C, C-aromatic), 149.45 (C, C-aromatic), 152.99 (C, C-aromatic), 155.26 (C, C-aromatic), 159.76 (C, C-aromatic), 163.05 (C, C-aromatic) ppm.
    • Example 32 Synthesis of 8-methoxy-2-(naphthalene-2-yl)-4H-benzo[d][1,3]oxazin-4-one (191)
  • Figure US20190248756A1-20190815-C00193
  • Compound 191 was obtained as a white powder in 89% yield. 1H-NMR (CDCl3): δ 4.11 (s, 3H), 7.34-7.39 (m, 1H), 7.51 (t, J=7.9 Hz, 1H), 7.57-7.69 (m, 2H), 7.87-7.94 (m, 2H), 7.97 (d, J=8.2 Hz, 1H), 8.03 (d, J=7.9 Hz, 1H), 8.44 (dd, J=1.7, 8.7 Hz, 1H), 8.89 (s, 1H) ppm. 13C-NMR (126 MHz, CDCl3): δ 56.64 (CH3, C-aliphatic), 117.31 (CH, C-aromatic), 118.03 (C, C-aromatic), 119.91 (CH, C-aromatic), 124.36 (CH, C-aromatic), 126.85 (CH, C-aromatic), 127.46 (CH, C-aromatic), 127.83 (CH, C-aromatic), 128.3 (CH, C-aromatic), 128.54 (C, C-aromatic), 128.7 (CH, C-aromatic), 129.42 (CH, C-aromatic), 129.57 (CH, C-aromatic) 132.76 (C, C-aromatic), 135.35 (C, C-aromatic), 137.09 (C, C-aromatic), 154.37 (C, C-aromatic), 156.65 (C, C-aromatic), 159.63 (C, C-aromatic) ppm.
    • Example 33 Synthesis of 7-methoxy-2-(naphthalene-2-yl)-4H-benzo[d][1,3]oxazin-4-one (192)
  • Figure US20190248756A1-20190815-C00194
  • Compound 192 was obtained as a white powder in 87% yield. 1H-NMR (CDCl3): δ 4.01 (s, 3H), 7.10 (dt, J=4.6, 9.3 Hz, 1H), 7.54-7.65 (m, 1H), 7.68-7.73 (m, 1H), 7.93 (d, J=8.0 Hz, 1H), 7.96-8.02 (m, 1H), 8.04 (dd, J=8.0, 11.2 Hz, 1H), 8.19-8.26 (m, 1H), 8.39 (dd, J=1.7, 8.7 Hz, 1H), 8.81 (s, 1H), 8.87 (s, 1H) ppm. 13C-NMR (126 MHz, CDCl3): δ 55.96 (CH3, C-aliphatic), 108.96 (CH, C-aromatic), 109.86 (C, C-aromatic), 117.43 (CH, C-aromatic), 124.16 (CH, C-aromatic), 126.91 (CH, C-aromatic), 127.84 (CH, C-aromatic), 127.96 (C, C-aromatic), 128.36 (CH, C-aromatic), 128.59 (CH, C-aromatic), 129.41 (CH, C-aromatic), 129.62 (CH, C-aromatic), 130.33 (CH, C-aromatic), 132.85 (C, C-aromatic), 135.36 (C, C-aromatic), 149.57 (C, C-aromatic), 158.08 (C, C-aromatic), 159.39 (C, C-aromatic), 166.37 (C, C-aromatic) ppm.
    • Example 34 Synthesis of 2-(2-fluorophenyl)-6,7,8-trimethoxy-4H-benzo[d][1,3]oxazin-4-one (193)
  • Figure US20190248756A1-20190815-C00195
  • Compound 193 was obtained as a white powder in 79% yield. 1H-NMR (CDCl3): δ 4.01 (3H, s), 4.09 (3H, s), 4.21 (3H, s), 7.22-7.26 (1H, m), 7.30-7.32 (1H, m), 7.48 (1H, s), 7.54-7.56 (1H, m), 8.15-8.18 (1H, m) ppm. 13C-NMR (126 MHz, CDCl3): δ 56.47 (CH3, C-aliphatic), 61.55 (CH3, C-aliphatic), 62.77 (CH3, C-aliphatic), 103.89 (CH, C-aromatic), 112.39 (C, C-aromatic), 117.26 (CH, C-aromatic), 124.24 (CH, C-aromatic), 130.87 (CH, C-aromatic), 133.65 (CH, C-aromatic), 136.08 (C, C-aromatic), 148.06 (C, C-aromatic), 149.33 (C, C-aromatic), 152.28 (C, C-aromatic), 153.77 (C, C-aromatic), 159.25 (C, C-aromatic), 160.44 (C, C-aromatic), 162.51 (C, C-aromatic) ppm.
    • Example 35 Synthesis of 8-methoxy-(2-naphthalen-1-yl)-4H-benzo[d][1,3]oxazin-4-one (194)
  • Figure US20190248756A1-20190815-C00196
  • Compound 194 was obtained as a yellow powder in 82% yield. 1H-NMR (CDCl3): δ 4.09 (s, 3H), 7.38 (dd, J=1.1, 8.2 Hz, 1H), 7.55 (t, J=8.0 Hz, 1H), 7.57-7.63 (m, 2H), 7.68-7.76 (m, 1H), 7.87-7.96 (m, 2H), 8.06 (d, J=8.2 Hz, 1H), 8.35 (dd, J=1.2, 7.3 Hz, 1H), 9.20 (t, J=9.8 Hz, 1H) ppm. 13C-NMR (126 MHz, CDCl3): δ 56.59 (CH3, C-aliphatic), 117.26 (CH, C-aromatic), 117.97 (C, C-aromatic), 119.62 (CH, C-aromatic), 124.76 (CH, C-aromatic), 125.70 (CH, C-aromatic), 126.34 (CH, C-aromatic), 127.28 (C, C-aromatic), 128.03 (CH, C-aromatic), 128.79 (CH, C-aromatic), 128.95 (CH, C-aromatic), 130.00 (CH, C-aromatic), 130.97 (C, C-aromatic), 133.06 (CH, C-aromatic), 135.54 (C, C-aromatic), 136.89 (C, C-aromatic), 154.65 (C, C-aromatic), 156.95 (C, C-aromatic), 159.76 (C, C-aromatic) ppm.
    • Example 36 Synthesis of 6,7-dimethoxy-2-(4-methoxyphenyl)-4H-benzo[d][1,3]oxazin-4-one (195)
  • Figure US20190248756A1-20190815-C00197
  • Compound 195 was obtained as a white powder in 91% yield. 1H-NMR (CDCl3): δ 3.83 (s, 3H), 3.93 (s, 3H), 3.96 (s, 3H), 6.87-6.95 (m, 2H), 7.01 (s, 1H), 7.48 (s, 1H), 8.13-8.21 (m, 2H) ppm. 13C-NMR (126 MHz, CDCl3): δ 55.51 (CH3, C-aliphatic), 56.44 (CH3, C-aliphatic), 56.50 (CH3, C-aliphatic), 107.71 (CH, C-aromatic), 107.85 (CH, C-aromatic), 107.56 (CH, C-aromatic), 109.26 (C, C-aromatic), 114.15 (CH, C-aromatic), 122.80 (C, C-aromatic), 129.93 (CH, C-aromatic), 132.85 (CH, C-aromatic), 143.76 (C, C-aromatic), 149.37 (C, C-aromatic), 156.49 (C, C-aromatic) 156.72 (C, C-aromatic), 159.74 (C, C-aromatic), 163.05 (C, C-aromatic) ppm.
    • Example 37 Synthesis of 6,7,8-trimethoxy-2-(4-methoxyphenyl)4H-benzo[d][1,3]oxazin-4-one (196)
  • Figure US20190248756A1-20190815-C00198
  • Compound 196 was obtained as a white powder in 85% yield. 1H-NMR (CDCl3): δ 3.83 (s, 3H), 3.90 (s, 3H), 3.99 (s, 3H), 4.09 (s, 3H), 6.99-6.84 (m, 2H), 7.19 (s, 1H), 8.27-8.14 (m, 2H) ppm. 13C-NMR (126 MHz, CDCl3): δ 55.51 (CH3, C-aliphatic), 56.40 (CH3, C-aliphatic), 61.51 (—CH3, C-aliphatic), 62.71 (CH3, C-aliphatic), 104.02 (CH, C-aromatic), 112.06 (C, C-aromatic), 114.11 (CH, C-aromatic), 122.83 (C, C-aromatic), 129.99 (CH, C-aromatic), 136.92 (C, C-aromatic), 147.64 (C, C-aromatic), 149.45 (C, C-aromatic), 152.99 (C, C-aromatic), 155.26 (C, C-aromatic), 159.76 (C, C-aromatic), 163.05 (C, C-aromatic) ppm.
    • Example 38 Synthesis of 2-(pyridin-3-yl)-4H-benzo[d][1,3]oxazin-4-one (197)
  • Figure US20190248756A1-20190815-C00199
  • Compound 197 was obtained as a white powder in 81% yield. 1H-NMR (CDCl3): δ 7.49 (ddd, J=0.8, 4.8, 8.0 Hz, 1H), 7.60 (td, J=1.1, 7.9 Hz, 1H), 7.76 (dd, J=0.6, 8.1 Hz, 1H), 7.90 (ddd, J=1.5, 7.4, 8.1 Hz, 1H), 8.30 (dd, J=1.3, 7.9 Hz, 1H), 8.46-8.63 (m, 1H), 8.83 (dd, J=1.7, 4.8 Hz, 1H), 9.55 (dd, J=0.7, 2.2 Hz, 1H) ppm. 13C-NMR (126 MHz, CDCl3): δ 117.20 (C, C-aromatic), 123.48 (C, C-aromatic), 126.42 (CH, C-aromatic), 127.42 (C, C-aromatic), 128.78 (CH, C-aromatic), 128.86 (CH, C-aromatic), 135.49 (CH, C-aromatic), 136.81 (CH, C-aromatic), 146.52 (C, C-aromatic), 149.73 (C, C-aromatic), 152.99 (C, C-aromatic), 155.60 (C, C-aromatic), 158.98 (C, C-aromatic) ppm.
    • Example 39 Synthesis of 5-fluoro-2-(pyridin-3-yl)-4H-benzo[d][1,3]oxazin-4-one (198)
  • Figure US20190248756A1-20190815-C00200
  • Compound 198 was obtained as a white powder in 62% yield. 1H-NMR (CDCl3): δ 7.22-7.29 (m, 2H), 7.50 (ddd, J=0.7, 4.8, 8.0 Hz, 1H), 7.57 (d, J=8.1 Hz, 1H), 7.85 (td, J=5.5, 8.2 Hz, 1H), 8.36-8.65 (m, 1H), 8.84 (dd, J=1.7, 4.8 Hz, 1H), 9.45-9.52 (m, 1H) ppm. 13C-NMR (126 MHz, CDCl3): δ 115.75-115.92 (CH, C-aromatic), 123.30 (CH, C-aromatic), 123.33 (CH, C-aromatic), 125.97 (C, C-aromatic), 135.62 (CH, C-aromatic), 137.51-137.59 (CH, C-aromatic), 148.21 (C, C-aromatic), 149.86 (CH, C-aromatic), 153.30 (CH, C-aromatic), 154.46 (C, C-aromatic), 156.36 (C, C-aromatic), 160.87 (C, C-aromatic), 163.01 (C, C-aromatic) ppm. 19F-NMR: δ −105.84 ppm.
    • Example 40 Synthesis of 6,7,8-trimethoxy-2-(pyridin-3-yl)-4H-benzo[d][1,3]oxazin-4-one (199)
  • Figure US20190248756A1-20190815-C00201
  • Compound 199 was obtained as a white powder in 75% yield. 1H-NMR (CDCl3): δ 4.02 (s, 3H), 4.10 (s, 3H), 4.20 (s, 3H), 7.29 (s, 1H), 7.37-7.59 (m, 1H), 8.50-8.65 (m, 1H), 8.81 (dd, J=1.7, 4.8 Hz, 1H), 9.55 (dd, J=0.7, 2.2 Hz, 1H) ppm. 13C-NMR (126 MHz, CDCl3): δ 56.49 (CH3, C-aromatic), 61.56 (CH3, C-aromatic), 62.87 (CH3, C-aromatic), 104.24 (CH, C-aromatic), 112.54 (C, C-aromatic), 123.45 (CH, C-aromatic), 126.60 (C, C-aromatic), 135.14 (CH, C-aromatic), 135.95 (C, C-aromatic), 148.21 (C, C-aromatic), 148.52 (C, C-aromatic), 149.47 (CH, C-aromatic), 149.62 (C, C-aromatic), 152.68 (CH, C-aromatic), 153.88 (C, C-aromatic), 158.94 (C, C-aromatic) ppm.
    • Example 41 Synthesis of 7-fluoro-2-(pyridin-3-yl)-4H-benzo[d][1,3]oxazin-4-one (200)
  • Figure US20190248756A1-20190815-C00202
  • Compound 200 was obtained as a white powder in 58% yield. 1H-NMR (CDCl3): δ 7.27-7.35 (m, 1H), 7.42 (dd, J=2.4, 9.1 Hz, 1H), 7.50 (ddd, J=0.7, 4.8, 8.0 Hz, 1H), 8.31 (dd, J=5.9, 8.7 Hz, 1H), 8.55-8.60 (m, 1H), 8.85 (dd, J=1.7, 4.8 Hz, 1H), 9.54 (d, J=1.5 Hz, 1H) ppm. 13C-NMR (126 MHz, CDCl3): δ 113.57 (CH, C-aromatic), 113.73 (C, C-aromatic), 117.27 (CH, C-aromatic), 123.52 (CH, C-aromatic), 126.07 (C, C-aromatic), 131.59 (CH, C-aromatic), 135.66 (CH, C-aromatic), 149.88 (CH, C-aromatic), 153.34 (CH, C-aromatic), 156.73 (C, C-aromatic), 158.00 (C, C-aromatic), 166.86 (C, C-aromatic), 168.91 (C, C-aromatic) ppm. 19F-NMR: δ −98.26 ppm.
    • Example 42 Synthesis of 6,7-dimethoxy-2-(pyridin-3-yl)-4H-benzo[d][1,3]oxazin-4-one (201)
  • Figure US20190248756A1-20190815-C00203
  • Compound 201 was obtained as a white powder in 58% yield. 1H-NMR (CDCl3): δ 4.04 (s, 3H), 4.08 (s, 3H), 7.04 (bs, 1H), 7.37-7.64 (m, 1H), 7.55 (d, J=56.3 Hz, 1H), 8.31-8.61 (m, 1H), 8.81 (dd, J=1.7, 4.8, Hz, 1H), 9.52 (d, J=1.6 Hz, 1H) ppm. 13C-NMR (126 MHz, CDCl3): δ 56.52 (CH3, C-aliphatic), 56.60 (CH3, C-aliphatic), 107.72 (CH, C-aromatic), 108.26 (CH, C-aromatic), 109.84 (C, C-aromatic), 123.45 (CH, C-aromatic), 126.60 (C, C-aromatic), 135.12 (CH, C-aromatic), 142.88 (C, C-aromatic), 149.46 (CH, C-aromatic), 150.15 (C, C-aromatic), 152.66 (CH, C-aromatic), 154.81 (C, C-aromatic), 156.63 (C, C-aromatic), 158.96 (C, C-aromatic) ppm.
    • Example 43 Synthesis of 2-(2-fluorophenyl)-6,7-dimethoxy-4H-benzo[d][1,3]oxazin-4-one (202)
  • Figure US20190248756A1-20190815-C00204
  • Compound 202 was obtained as a white powder in 78% yield. 1H-NMR (CDCl3): δ 3.95 (s, 3H), 3.97 (s, 3H), 7.08 (s, 1H), 7.11-7.25 (m, 2H), 7.39-7.49 (m, 1H), 7.49-7.56 (m, 1H), 8.04 (td, J=1.8, 7.7 Hz, 1H) ppm. 13C-NMR (126 MHz, CDCl3): δ 56.50 (CH3, C-aliphatic), 56.59 (CH3, C-aliphatic), 107.54 (CH, C-aromatic), 108.38 (CH, C-aromatic), 109.66 (C, C-aromatic), 117.16 (CH, C-aromatic), 124.32 (CH, C-aromatic), 130.91 (CH, C-aromatic), 133.65 (CH, C-aromatic), 143.04 (C, C-aromatic), 150.08 (C, C-aromatic), 154.10 (C, C-aromatic), 156.49 (C, C-aromatic), 159.18 (C, C-aromatic), 160.23 (C, C-aromatic), 162.29 (C, C-aromatic) ppm. 19F-NMR: δ −109.78 ppm.
    • Example 44 Synthesis of 8-methoxy-2-(pyridin-3-yl)-4H-benzo[d][1,3]oxazin-4-one (202)
  • Figure US20190248756A1-20190815-C00205
  • Compound 202 was obtained as a white powder in 72% yield. 1H-NMR (CDCl3): δ 3.99 (s, 3H), 7.19 (s, 1H), 7.35-7.43 (m, 1H), 7.44 (t, J=8.0 Hz, 1H), 7.78 (dd, J=1.2, 7.9 Hz, 1H), 8.43-8.64 (m, 1H), 8.72 (dd, J=1.7, 4.8 Hz, 1H), 9.46 (dd, J=0.7, 2.2 Hz, 1H) ppm. 13C-NMR (126 MHz, CDCl3): δ 56.66 (CH3, C-aliphatic), 117.65 (CH, C-aromatic), 118.19 (C, C-aromatic), 119.97 (CH, C-aromatic), 123.43 (CH, C-aromatic), 126.53 (C, C-aromatic), 129.31 (CH, C-aromatic), 135.60 (CH, C-aromatic), 136.46 (C, C-aromatic), 149.69 (CH, C-aromatic), 152.92 (CH, C-aromatic), 154.50 (C, C-aromatic), 158.89 (CH, C-aromatic) ppm.
    • Example 45 Synthesis of 5,6,7-trimethoxy-2-(4-methoxyphenyl)-4H-benzo[d][1,3]oxazin-4-one (203)
  • Figure US20190248756A1-20190815-C00206
  • Compound 203 was obtained as a white solid in 93% yield. 1H-NMR (CDCl3): δ 3.92 (s, 3H), 3.99 (s, 3H), 4.1 (s, 3H), 4.19 (s, 3H), 7.1 (d, J=9.05 Hz, 2H), 7.45 (s, 1H), 8.28 (d, J=8.9 Hz, 2H) ppm. 13C-NMR (126 MHz, CDCl3): δ 55.52 (CH3, C-aliphatic), 56.40 (CH3, C-aliphatic), 61.53 (CH3, C-aliphatic), 62, 73 (CH3, C-aliphatic), 103.99 (CH, C-aromatic), 112.04 (C, C-aromatic), 114.10 (CH, C-aromatic), 122.79 (C, C-aromatic), 129.98 (CH, C-aromatic), 136.92 (C, C-aromatic), 147.61 (C, C-aromatic), 149.42 (C, C-aromatic), 152.97 (C, C-aromatic), 155.24 (C, C-aromatic), 159.77 (C, C-aromatic), 163.04 (C, C-aromatic) ppm.
    • Example 46 Synthesis of 2-(2-fluorophenyl)-5,6,7-trimethoxy-4H-benzo[d][1,3]oxazin-4-one (204)
  • Figure US20190248756A1-20190815-C00207
  • Compound 204 was obtained as a white solid in 68.66% yield. 1H-NMR (CDCl3): δ 4.00 (s, 3H), 4.09 (s, 3H), 4.20 (s, 3H), 7.21-7.25 (m, 1H), 7.3 (td, J=1.2, 7.5 Hz, 1H), 7.47 (s, 1H), 7.52-7.57 (m, 2H), 8.16 (td, J=1.65, 7.7 Hz, 1H) ppm. 13C-NMR (126 MHz, CDCl3): δ 56.46 (CH3, C-aliphatic), 61.56 (CH3, C-aliphatic), 62.78 (CH3, C-aliphatic), 103.86 (CH, C-aromatic), 112.36 (C, C-aromatic), 117.26 (CH, C-aromatic), 119.13 (C, C-aromatic), 124.25 (CH, C-aromatic), 130.86 (CH, C-aromatic), 133.66 (CH, C-aromatic), 136.06 (C, C-aromatic), 148.03 (C, C-aromatic), 149.31 (C, C-aromatic), 153.74 (C, C-aromatic), 159.25 (C, C-aromatic), 160.41 (C, C-aromatic), 162.49 (C, C-aromatic) ppm.
    • Example 47 Synthesis of 5,6,7-trimethoxy-2-(pyridin-3-yl)-4H-benzo[d][1,3]oxazin-4-one (205)
  • Figure US20190248756A1-20190815-C00208
  • Compound 205 was obtained as a white solid in 50% yield. 1H-NMR (CDCl3): δ 4.01 (s, 3H), 4.09 (s, 3H), 4.19 (s, 3H), 7.47 (s, 1H), 7.49 (dd, J=0.8, 7.55 Hz, 1H), 8.58 (dt, J=1.9, 8.1 Hz, 1H), 8.80 (dd, J=1.7, 4.75 Hz, 1H), 9.54 (d, J=1.95 Hz, 1H) ppm. 13C-NMR (126 MHz, CDCl3): δ 56.49 (CH3, C-aliphatic), 61.57 (CH3, C-aliphatic), 62.89 (CH3, C-aliphatic), 104.22 (CH, C-aromatic), 112.52 (C, C-aromatic), 123.58 (CH, C-aromatic), 126.72 (C, C-aromatic), 135.39 (CH, C-aromatic), 135.90 (C, C-aromatic), 148.02 (C, C-aromatic), 149.17 (CH, C-aromatic), 149.61 (C, C-aromatic), 152.35 (CH, C-aromatic), 153.23 (C, C-aromatic), 153.89 (C, C-aromatic), 158.89 (C, C-aromatic) ppm.
    • Example 48 Synthesis of 2-(2-(methylthio)pyridin-3-yl)-4H-benzo[d][1,3]oxazin-4-one (206)
  • Figure US20190248756A1-20190815-C00209
  • Compound 206 was obtained as a white solid in 85% yield. 1H-NMR (CDCl3): δ 2.62 (s, 3H), 7.18 (dd, J=4.7, 7.9 Hz, 1H), 7.49-7.66 (m, 1H), 7.83 (dd, J=0.7, 8.1 Hz, 1H), 7.86-7.93 (m, 1H), 8.28 (dd, J=1.1, 7.9 Hz, 1H), 8.42 (dd, J=1.8, 7.9 Hz, 1H), 8.64 (dd, J=1.8, 4.7 Hz, 1H) ppm. 13C-NMR (126 MHz, CDCl3): δ 14.73 (CH3, C-aliphatic), 116.89 (C, C-aromatic), 118.22 (CH, C-aromatic), 123.64 (C, C-aromatic), 127.32 (CH, C-aromatic), 128.66 (CH, C-aromatic), 128.87 (CH, C-aromatic), 136.72 (CH, C-aromatic), 137.23 (C, C-aromatic), 146.20 (CH, C-aromatic), 151.14, 154.78 (C, C-aromatic), 159.32 (C, C-aromatic), 161.86 (C, C-aromatic) ppm.
    • General Procedure 2:
  • The compounds of the application with the general formula below can be prepared according to the synthetic scheme shown in Scheme 2.
  • Figure US20190248756A1-20190815-C00210
  • To a solution of compound (II) or (II′) (1 equivalent) in N,N-dimethyl-formamide (DMF) is added 2 equivalents of N,N-diisopropylethylamine (DIPEA) and 2.2 equivalent of 2-morpholinoethanamine (IIIa). The reaction mixture is stirred at about 15° C. to about 28° C. for about 12 hours to about 24 hours. The reaction mixture is diluted with water, washed with ethyl acetate, washed with brine, dried over Mg2SO4, filtered and evaporated to give a crude compound which is then purified by silica gel column using a mixture of Chloroform:Methanol (9:1) as eluent. The product is collected under reduced pressure to provide the compound with the general formula shown in Scheme 2.
  • Compounds 4, 5, 7-15, 17-33, 99, 103, 113, 145-148 were prepared according to General Procedure 2 substituting (II) or (II′) with the appropriate substituted compound.
    • Example 49 Synthesis of 2-(3-aminobenzamido)-N-(2-morpholinoethyl)benzamide (4)
  • Figure US20190248756A1-20190815-C00211
  • Compound 4 was obtained as a white powder in 47% yield. 1H-NMR (CDCl3): δ 2.55 (s, 4H), 2.66 (t, J=5.9 Hz, 2H), 3.58 (dd, J=5.4, 11.1 Hz, 2H), 3.74-3.78 (m, 4H), 3.87 (s, 2H), 6.87 (dd, J=1.6, 7.9 Hz, 1H), 7.01 (s, 1H), 7.13-7.19 (m, 1H), 7.30-7.33 (m, 1H), 7.37-7.39 (m, 1H), 7.42 (d, J=7.7 Hz, 1H), 7.55 (dd, J=7.9, 16.7 Hz, 2H), 8.91-8.78 (m, 1H), 12.08 (s, 1H) ppm. 13C-NMR (126 MHz, CDCl3): δ 35.93 (CH2, C-aromatic), 53.27 (CH2, C-aromatic), 56.54 (CH2, C-aromatic), 66.94 (CH2, C-aromatic), 114.10 (CH, C-aromatic), 117.07 (CH, C-aromatic), 118.35 (CH, C-aromatic), 121.73 (CH, C-aromatic), 122.82 (CH, C-aromatic), 126.53 (CH, C-aromatic), 129.70 (CH, C-aromatic), 132.72 (CH, C-aromatic), 135.75 (C, C-aromatic), 136.51 (C, C-aromatic), 140.09 (C, C-aromatic), 146.80 (C, C-aromatic), 165.67 (C, C-aromatic), 169.18 (C, C-aromatic) ppm. MS(ESI)+: 369 [M+H]+. m.p.: (from ethanol/water) 126-128° C.
    • Example 50 Synthesis of 2-(4-aminobenzamido)-N-(2-morpholinoethyl)benzamide (5)
  • Figure US20190248756A1-20190815-C00212
  • Compound 5 was obtained as a light brown powder in 42% yield. 1H-NMR (CDCl3): δ 2.54 (s, 4H), 2.65 (t, J=5.9 Hz, 2H), 3.51 (s, 4H), 3.55-3.61 (m, 1H), 3.73-3.78 (m, 1H), 4.05 (s, 2H), 6.75 (d, J=8.6 Hz, 2H), 7.03 (s, 1H), 7.12 (t, J=7.6 Hz, 1H), 7.53 (dd, J=7.8, 13.5 Hz, 2H), 7.90 (d, J=8.5 Hz, 2H), 8.81 (d, J=8.3 Hz, 1H), 11.99 (s, 1H) ppm. 13C-NMR (CDCl3): δ 35.98 (CH2, C-aliphatic), 53.27 (CH2, C-aliphatic), 56.53 (CH2, C-aliphatic), 66.97 (CH2, C-aliphatic), 114.32 (CH, C-aromatic), 120.28 (C, C-aromatic), 121.61 (CH, C-aromatic), 122.35 (CH, C-aromatic), 124.42 (C, C-aromatic), 126.49 (CH, C-aromatic), 129.33 (CH, C-aromatic), 132.66 (CH, C-aromatic), 140.46 (C, C-aromatic), 149.92 (C, C-aromatic), 165.42 (C, C-aromatic), 169.31 (C, C-aromatic) ppm. MS(ESI)+: 369.2 [M+H]+. m.p.: (from ethanol/water) 101-105° C.
    • Example 51 Synthesis of 2-(3-chlorobenzamido)-N-(2-morpholinoethyl)benzamide (7)
  • Figure US20190248756A1-20190815-C00213
  • Compound 7 was obtained as a white powder in 10% yield. 1H-NMR (CDCl3): δ 2.55 (s, 4H), 2.66 (t, J=5.9 Hz, 2H), 3.59 (dd, J=5.5, 11.1 Hz, 2H), 3.73-3.81 (m, 4H), 7.03 (s, 1H), 7.14-7-19 (m, 1H), 7.47 (t, J=7.8 Hz, 1H), 7.52-7.56 (m, 2H), 7.57-7.60 (m, 1H), 7.90-7.95 (m, 1H), 8.07 (t, J=1.8 Hz, 1H), 8.82 (dd, J=0.7, 8.4 Hz, 1H), 12.35 (s, 1H) ppm. 13C-NMR (CDCl3): δ 36.03 (CH2, C-aliphatic), 53.29 (CH2, C-aliphatic), 56.55 (CH2, C-aliphatic), 67.6 (CH2, C-aliphatic), 120.25 (C, C-aromatic), 121.57 (CH, C-aromatic), 123.15 (CH, C-aromatic), 125.09 (CH, C-aromatic), 1226.64 (CH, C-aromatic), 128.09 (CH, C-aromatic), 128.41 (CH, C-aromatic), 130.05 (CH, C-aromatic), 131.84 (CH, C-aromatic), 132.77 (C, C-aromatic), 135.00 (C, C-aromatic), 136.74 (C, C-aromatic), 139.85 (C, C-aromatic), 164.16 (C, C-aromatic), 169.06 (C, C-aromatic) ppm. MS(ESI)+: 388.2, 389.2 [M+H]+. m.p.: (from ethanol) 107-109° C.
    • Example 52 Synthesis of 2-(4-chlorobenzamido)-N-(2-morpholinoethyl)benzamide (8)
  • Figure US20190248756A1-20190815-C00214
  • Compound 8 was obtained as a white powder in 40% yield. 1H-NMR (CDCl3): δ 2.54 (s, 4H), 2.66 (t, J=5.9 Hz, 2H), 3.58 (dd, J=5.5, 11.1 Hz, 2H), 3.73-3.81 (m, 4H), 7.03 (s, 1H), 7.16-7.21 (m, 1H), 7.49-7.52 (m, 2H), 7.53-7.61 (m, 2H), 7.94-8.10 (m, 2H), 8.83 (d, J=8.4 Hz, 1H), 12.35 (s, 1H) ppm. 13C-NMR (CDCl3): δ 35.97 (CH2, C-aliphatic), 53.26 (CH2, C-aliphatic), 56.43 (CH2, C-aliphatic), 67.00 (CH2, C-aliphatic), 120.14 (C, C-aromatic), 121.60 (CH, C-aromatic), 123.05 (CH, C-aromatic), 126.51 (CH, C-aromatic), 128.87 (CH, C-aromatic), 129.03 (CH, C-aromatic), 132.89 (CH, C-aromatic), 133.31 (C, C-aromatic), 138.11 (C, C-aromatic), 140.07 (C, C-aromatic), 164.47 (C, C-aromatic), 169.12 (C, C-aromatic) ppm. MS(ESI)+: 388.1, 389.2 [M+H]+. m.p.: (from ethanol/water) 93-95° C.
    • Example 53 Synthesis of N-(2-morpholinoethyl)-2-(2-(trifluoromethyl)benzamido) benzamide
  • Figure US20190248756A1-20190815-C00215
  • Compound 9 was obtained as a white powder in 59% yield. 1H-NMR (CDCl3): δ 2.50-2.55 (m, 4H), 2.60 (dd, J=10.2, 16.1 Hz, 2H), 3.50 (dd, J=5.6, 11.1 Hz, 2H), 3.69-3.80 (m, 4H), 6.94 (s, 1H), 7.11-7.24 (m, 1H), 7.52 (dd, J=1.4, 7.9 Hz, 1H), 7.56-7.62 (m, 2H), 7.66 (t, J=7.4 Hz, 1H), 7.70 (t, J=7.4 Hz, 1H), 7.77 (d, J=7.8 Hz, 1H), 8.80 (d, J=8.3 Hz, 1H), δ 11.59 (s, 1H) ppm. 13C NMR (126 MHz, CDCl3): 35.90 (CH2, C-aliphatic), 53.27 (CH2, C-aliphatic), 56.48 (CH2, C-aliphatic), 66.98 (CH2, C-aliphatic), 120.69 (C, C-aromatic), 121.82 (CH, C-aromatic), 123.46 (CH, C-aromatic), 124.64 (C, C-aromatic), 126.74 (CH, C-aromatic), 126.78 (C, C-aromatic), 127.80 (CH, C-aromatic), 128.15 (CH, C-aromatic), 130.01 (CH, C-aromatic), 132.17 (CH, C-aromatic), 132.79 (CH, C-aromatic), 139.46 (C, C-aromatic), 166.14 (C, C-aromatic), 168.71 (C, C-aromatic) ppm. 19F-NMR: δ −58.944 ppm. MS(ESI)+: 422.3 [M+H]+. m.p.: 90-92° C.
    • Example 54 Synthesis of N-(2-morpholinoethyl)-2-(3-(trifluoromethyl)benzamido) benzamide
  • Figure US20190248756A1-20190815-C00216
  • Compound 10 was obtained as a white powder in 63% yield. 1H-NMR (CDCl3): δ 2.53-2.57 (m, 4H), 2.64-2.68 (m, 2H), 3.50-3.63 (m, 2H), 3.74-3.82 (m, 4H), 7.02 (s, 1H), 7.16-7.26 (m, 1H), 7.54-7.62 (m, 2H), 7.67 (d, J=7.8 Hz, 1H), 7.82 (d, J=7.8 Hz, 1H), 8.22 (d, J=7.9 Hz, 1H), 8.38 (s, 1H), 8.85 (dd, J=0.9, 8.4 Hz, 1H), 12.51 (s, 1H) ppm. 13C NMR (126 MHz, CDCl3): 36.00 (CH2, C-aliphatic), 53. 29 (CH2, C-aliphatic), 56.46 (CH2, C-aliphatic), 67.00 (CH2, C-aliphatic), 120.18 (C, C-aromatic), 121.67 (CH, C-aromatic), 123.24 (C, C-aromatic), 125.04 (CH, C-aromatic), 125.07 (CH, C-aromatic), 126.47 (CH, C-aromatic), 128.30, 128.33 (CH, C-aromatic), 129.34 (CH, C-aromatic), 130.09 (CH, C-aromatic), 132.25 (C, C-aromatic), 132.92 (CH, C-aromatic), 135.85 (C, C-aromatic), 139.98 (C, C-aromatic), 164.04 (C, C-aromatic), 169.05 (C, C-aromatic) ppm. 19F-NMR: δ −62.90. ppm. MS(ESI)+: 422.1 [M+H]+.
    • Example 55 Synthesis of N-(2-morpholinoethyl)-2-(4-(trifluoromethyl)benzamido) benzamide CF3
  • Figure US20190248756A1-20190815-C00217
  • Compound 11 was obtained as a white powder in 22% yield. 1H-NMR (CDCl3): δ 2.56 (s, 4H), 2.67 (t, J=5.9 Hz, 2H), 3.50-3.60 (m, 2H), 3.71-3.79 (m, 4H), 7.09 (s, 1H), 7.14-7.21 (m, 1H), 7.55-7.62 (m, 2H), 7.80 (d, J=8.2 Hz, 2H), 8.18 (d, J=8.1 Hz, 2H), 8.86 (dd, J=0.8, 8.4 Hz, 1H), 12.53 (s, 1H) ppm. 13C NMR (126 MHz, CDCl3): δ35.98 (CH2, C-aliphatic), 53.28 (CH2, C-aliphatic), 56.46 (CH2, C-aliphatic), 66.96 (CH2, C-aliphatic), 120.18 (C, C-aromatic), 121.62 (CH, C-aromatic), 123.28 (CH, C-aromatic), 125.82 (CH, C-aromatic), 126.51 (CH, C-aromatic), 127.87 (CH, C-aromatic), 132.95 (CH, C-aromatic), 137.85 (C, C-aromatic), 138.22 (C, C-aromatic), 139.99 (C, C-aromatic), 163.66 (C, C-aromatic), 168.94 (C, C-aromatic) ppm. 19F-NMR: δ −63.08 ppm. MS(ESI)+: 422.1 [M+H]+. m.p.: 99-101° C.
    • Example 56 Synthesis of 2-fluoro-4-methoxy-N-(2-((2-morpholinoethyl)carbamoyl)phenyl) benzamide (12)
  • Figure US20190248756A1-20190815-C00218
  • Compound 12 was obtained as a light brown powder in 57% yield. 1H-NMR (CDCl3): δ 2.54 (s, 4H), 2.64 (t, J=5.9 Hz, 2H), 3.58 (dd, J=5.4, 11.1 Hz, 2H), 3.73-3.78 (m, 4H), 3.88 (s, 3H), 6.71 (dd, J=2.4, 13.3 Hz, 1H), 6.79-6.84 (m, 1H), 6.90 (s, 1H), 7.12-7.21 (m, 1H), 7.49-7.58 (m, 2H), 8.06 (t, J=8.9 Hz, 1H), 8.74 (d, J=8.4 Hz, 1H), 11.69 (d, J=8.5 Hz, 1H) ppm. 13C-NMR (CDCl3): δ 35.90 (CH2, C-aliphatic), 53.28 (CH2, C-aliphatic), 55.83 (CH3, C-aliphatic), 56.65 (CH2, C-aliphatic), 66.89 (CH2, C-aliphatic), 101.87 (C, C-aromatic), 110.68 (CH, C-aromatic), 114.79 (C, C-aromatic), 122.07 (C, C-aromatic), 122.64 (CH, C-aromatic), 123.19 (CH, C-aromatic), 126.62 (CH, C-aromatic), 132.29 (CH, C-aromatic), 132.90 (CH, C-aromatic), 139.19 (C, C-aromatic), 160.60 (C, C-aromatic), 162.08 (C, C-aromatic), 162.59 (C, C-aromatic), 163.67 (C, C-aromatic), 163.76 (C, C-aromatic), 168.72 (C, C-aromatic) ppm. 19F-NMR (CDCl3): δ −109.25 ppm. MS(ESI)+: 402.2 [M+H]+. m.p.: (from ethanol) 115-117° C.
    • Example 57 Synthesis of 2-fluoro-6-(2-fluorobenzamido)-N-(2-morpholinoethyl) benzamide
  • Figure US20190248756A1-20190815-C00219
  • Compound 13 was obtained as a white powder in 23% yield. 1H-NMR (CDCl3): δ 2.53 (s, 4H), 2.62 (t, J=6.0 Hz, 2H), 3.59 (dd, J=5.0, 10.6 Hz, 2H), 3.72-3.81 (m, 4H), 6.93 (dd, J=8.3, 11.8 Hz, 1H), 7.22 (dd, J=8.4, 11.2 Hz, 1H), 7.30-7.33 (m, 1H), 7.40-7.56 (m, 3H), 8.05 (td, J=7.7, 1.8 Hz, 1H), 8.61 (d, J=8.5 Hz, 1H), 12.08 (d, J=6.4 Hz, 1H) ppm. 13C-NMR (CDCl3): δ 36.19 (CH2, C-aliphatic), 53.14 (CH2, C-aliphatic), 56.05 (CH2, C-aliphatic), 67.00 (CH2, C-aliphatic), 110.30 (C, C-aromatic), 110.85 (CH, C-aromatic), 116.59 (CH, C-aromatic), 118.35 (CH, C-aromatic), 124.65 (C, C-aromatic), 131.53 (CH, C-aromatic), 132.59 (CH, C-aromatic), 132.68 (CH, C-aromatic), 133.46 (CH, C-aromatic), 133.53 (CH, C-aromatic), 140.89 (C, C-aromatic), 159.55 (C, C-aromatic), 161.42 (C, C-aromatic), 162.45 (C, C-aromatic), 164.64 (C, C-aromatic) ppm. MS(ESI)+: 390.2 [M+H]+. 19F-NMR (CDCl3): δ −112.34, −113.94 ppm. m.p.: 88-90° C.
    • Example 58 Synthesis of 4-fluoro-2-(2-fluorobenzamido)-N-(2-morpholinoethyl) benzamide (14)
  • Figure US20190248756A1-20190815-C00220
  • Compound 14 was obtained as a white powder in 47% yield. 1H-NMR (CDCl3): δ 2.53 (s, 4H), 2.57-2.71 (m, 2H), 3.56 (dd, J=5.5, 11.1 Hz, 2H), 3.69-3.85 (m, 4H), 6.79-6.86 (m, 2H), 7.16-7.22 (m, 1H), 7.25-7.31 (m, 1H), 7.45-7.58 (m, 2H), 7.98-8.06 (m, 1H), 8.65 (dd, J=2.6, 11.9 Hz, 1H), 12.11 (d, J=6.7 Hz, 1H) ppm. 13C-NMR (126 MHz, CDCl3): δ 35.97 (CH2, C-aromatic), 53.28 (CH2, C-aromatic), 56.53 (CH2, C-aromatic), 66.97 (CH2, C-aromatic), 110.19 (CH, C-aromatic), 110.37 (CH, C-aromatic), 116.50 (CH, C-aromatic), 117.53 (C, C-aromatic), 122.04 (C, C-aromatic), 124.73 (CH, C-aromatic), 128.42 (CH, C-aromatic), 131.57 (CH, C-aromatic), 133.69 (CH, C-aromatic), 159.33 (C, C-aromatic), 161.35 (C, C-aromatic), 163.72 (C, C-aromatic), 165.71 (C, C-aromatic), 168.01 (C, C-aromatic) ppm. 19F-NMR: δ −104.11, −112.36 ppm. MS(ESI)+: 390.2 [M+H]+. m.p.: 104-106° C.
    • Example 59 Synthesis of 2-(2-fluorobenzamido)-4-methoxy-N-(2-morpholinoethyl) benzamide (15)
  • Figure US20190248756A1-20190815-C00221
  • Compound 15 was obtained as a white powder in 36% yield. 1H-NMR (CDCl3): δ 2.53 (s, 4H), 2.63 (t, J=5.9 Hz, 2H), 3.54 (dd, J=5.4, 11.1 Hz, 2H), 3.73-3.78 (m, 4H), 3.94 (s, 3H), 6.71 (dd, J=2.6, 8.7 Hz, 1H), 6.80 (s, 1H), 7.22 (dd, J=8.4, 10.5 Hz, 1H), 7.29-7.32 (m, 1H), 7.45 (d, J=8.8 Hz, 1H), 7.48-7.53 (m, 1H), 7.95-8.04 (m, 1H), 8.55 (d, J=2.6 Hz, 1H), δ 12.33 (d, J=5.3 Hz, 1H) ppm. 13C-NMR (CDCl3): δ 35.83 (CH2, C-aliphatic), 53.27 (CH2, C-aliphatic), 55.58 (CH3, C-aliphatic), 56.61 (CH2, C-aliphatic), 67.00 (CH2, C-aliphatic), 106.06 (CH, C-aromatic), 110.35 (CH, C-aromatic), 116.62 (C, C-aromatic), 124.60 (CH, C-aromatic), 127.87 (CH, C-aromatic), 131.29 (CH, C-aromatic), 133.31 (CH, C-aromatic), 141.66 (CH, C-aromatic) ppm. 19F-NMR: δ −112.57 ppm. MS(ESI)+: 402.2 [M+H]+. m.p.: (from ethanol/water) 114-116° C.
    • Example 60 Synthesis of 2-(3-fluorobenzamido)-3-methoxy-N-(2-morpholinoethyl) benzamide (17)
  • Figure US20190248756A1-20190815-C00222
  • Compound 17 was obtained as a white powder in 88% yield. 1H-NMR (CDCl3): δ 2.42-2.50 (m, 4H), 2.52-2.56 (m, 2H), 3.45-3.49 (m, 2H), 3.67-3.69 (m, 4H), 3.91 (s, 3H), 6.77-6.81 (m, 1H), 7.11-7.15 (m, 2H), 7.25-7.27 (m, 1H), 7.30-7.32 (m, 1H), 7.46-7.50 (m, 1H), 7.68-7.70 (m, 1H), 7.755 (d, J=7.55 Hz, 1H), 9.157 (d, J=7.42, 1H) ppm. 13C-NMR (126 MHz, CDCl3): δ 36.00 (CH2, C-aliphatic), 53.26 (CH2, C-aliphatic), 56.24 (CH3, C-aliphatic), 56.67 (CH2, C-aliphatic), 66.92 (CH2, C-aliphatic), 113.6 (CH, C-aromatic), 114.02 (CH, C-aromatic), 115.06 (CH, C-aromatic), 118.99 (CH, C-aromatic), 120.10 (CH, C-aromatic), 123.14 (CH, C-aromatic), 124.83 (C, C-aromatic), 126.96 (CH, C-aromatic), 130.34 (C, C-aromatic), 137.11 (C, C-aromatic), 154.17 (C, C-aromatic), 163.0 (C, C-aromatic), 168.38 (C, C-aromatic), 170.30 (C, C-aromatic) ppm. 19F-NMR: −111.75 ppm. MS(ESI)+: 402.2 [M+H]+. m.p.: 128-131° C.
    • Example 61 Synthesis of 2-(4-fluorobenzamido)-3-methoxy-N-(2-morpholinoethyl) benzamide (18)
  • Figure US20190248756A1-20190815-C00223
  • Compound 18 was obtained as a white powder in 30% yield. 1H-NMR (CDCl3): δ 2.45 (t, J=4.36 Hz, 4H), 2.537 (dd, 4.18, 7.84 Hz, 2H), 3.45-3.49 (m, 2H), 3.687 (t, J=4.63 Hz, 4H), 3.913 (s, 3H), 6.79-6.80 (m, 1H), 7.10-7.19 (m, 3H), 7.291 (q, J=4.88 Hz, 2H), 7.98-8.02 (m, 2H), 9.101 (s, 1H) ppm. 13C-NMR (CDCl3): 36.04 (CH2, C-aliphatic), 53.27 (CH2, C-aliphatic), 56.23 (CH3, C-aliphatic), 56.71 (CH2, C-aliphatic), 66.91 (CH2, C-aliphatic), 114.02 (CH, C-aromatic), 115.59 (CH, C-aromatic), 115.77 (CH, C-aromatic), 119.13 (CH, C-aromatic), 126.83 (CH, C-aromatic), 130.03 (CH, C-aromatic), 130.10 (CH, C-aromatic), 130.49 (C, C-aromatic), 131.78 (C, C-aromatic), 154.23 (C, C-aromatic), 164.05 (C, C-aromatic), 164.92 (C, C-aromatic), 166.06 (C, C-aromatic), 168.42 (C, C-aromatic) ppm. 19F-NMR (CDCl3CDCl3): −107.695 ppm. MS(ESI)+: 402.2 [M+H]+. m.p.: 148-151° C.
    • Example 62 Synthesis of 2-(2-fluorobenzamido)-4,5-dimethoxy-N-(2-morpholinoethyl) benzamide (19)
  • Figure US20190248756A1-20190815-C00224
  • Compound 19 was obtained as a white solid in 16% yield. 1H-NMR (500 MHz, CDCl3): δ 12.08 (d, J=5, 1H, ArNHCO), 8.58 (s, 1H, CONHCH2), 8.04 (dt, J=7.65, 1.75, 1H, H), 7.53-7.48 (m, 1H), 7.29 (td, J=7.4, 1.15, 1H), 7.21 (dd, J=11.35, 0.9, 1H), 7.00 (s, 1H), 6.93 (s, 1H), 4.02 (s, 3H, OCH3), 3.95 (s, 3H, OCH3), 3.75 (t, J=4.25, 4H), 3.56 (q, J=5.8, 2H, NHCH2CH2), 2.66 (t, J=5.8, 2H, NHCH2CH2), 2.56 (s, 4H). 13C-NMR (126 MHz, CDCl3) δ 168.39 (ArC═O), 162.32 (ArC═O), 161.36 (ArC), 159.37 (ArC), 152.11 (ArC), 144.50 (ArC), 134.91 (ArC), 133.31 (d, JC-F=8.82, ArCH), 131.30 (d, JC-F=1.26, ArCH), 124.63 (d, JC-F=15, ArCH), 116.53 (d, JC-F=23.94, ArCH), 112.87 (ArC), 109.52 (ArCH), 105.68 (ArCH), 66.94 (CH2), 56.63 (CH2), 56.45 (CH3), 56.16 (CH3), 53.23 (CH2), 35.72 (CH2). MS (ESI): 432.2 [M+1]. m.p. (from ethanol/water): 136° C.
    • Example 63 Synthesis of 6-(2-fluorobenzamido)-2,3,4-trimethoxy-N-(2-morpholinoethyl) benzamide (20)
  • Figure US20190248756A1-20190815-C00225
  • Compound 20 was obtained as a white solid in 41% yield. 1H-NMR (500 MHz, CDCl3): δ 8.68 (d, J=13.2, ArNHCO), 8.16 (t, J=7.9, 1H, CONHCH2), 7.56 (q, J=7.05, 1H), 7.32 (t, J=7.45, 1H), 7.23 (dd, J=11.9, 8.15, 1H), 7.00 (d, J=0.85, 1H), 6.94 (s, 1H), 3.94 (s, 3H, OCH3), 3.93 (s, 3H, OCH3), 3.92 (s, 3H, OCH3), 3.59 (t, J=4, 4H), 3.5 (q, J=5.55, 2H, NHCH2CH2), 2.49 (t, J=5.9, NHCH2CH2), 2.37 (s, 4H). 13C-NMR (126 MHz, CDCl3) δ 167.47 (ArC═O), 159.88 (ArC═O), 152.25 (ArC), 148.66 (ArC), 144.18 (ArC), 134.03 (d, JC-F=10.08, ArCH), 132.27 (ArCH), 128.56 (ArC), 124.95 (d, JC-F=2.52, ArCH), 121.17 (ArC), 116.38 (d, JC-F=23.94, ArCH), 106.83, 66.69 (CH2), 61.16 (CH3), 61.02 (CH3), 56.96 (CH2), 56.29 (CH3), 53.25 (CH2), 36.03 (CH2). MS (ESI): 462.20 [M+1]. m.p. (from ethanol/water): 141° C.
    • Example 64 Synthesis of 2-fluoro-6-(4-methoxybenzamido)-N-(2-morpholinoethyl) benzamide (21)
  • Figure US20190248756A1-20190815-C00226
  • Compound 21 was obtained as a white powder in 51% yield. 1H-NMR (CDCl3): δ 2.54 (s, 4H), 2.64 (t, J=6.0 Hz, 2H), 3.61 (dd, J=4.8, 10.5 Hz, 2H), 3.79-3.72 (m, 4H), 3.90 (s, 3H), 6.80-6.88 (m, 1H), 7.07-6.96 (m, 2H), 7.40-7.48 (m, 1H), 7.62 (d, J=11.8 Hz, 1H), 8.10-7.94 (m, 2H), 8.69 (d, J=8.5 Hz, 1H), 12.54 (s, 1H) ppm. 13C-NMR (CDCl3CDCl3): δ 36.24 (CH2, C-aliphatic), 53.14 (CH2, C-aliphatic), 55.46 (CH3, C-aliphatic), 55.98 (CH2, C-aliphatic), 67.02 (CH2, C-aliphatic), 109.89 (CH, C-aromatic), 110.09 (CH, C-aromatic), 113.99 (CH, C-aromatic), 117.38 (CH, C-aromatic), 117.40 (C, C-aromatic), 127.07 (CH, C-aromatic), 129.40 (CH, C-aromatic), 132.95 (C, C-aromatic), 133.04 (C, C-aromatic), 142.26 (C, C-aromatic), 160.02 (C, C-aromatic), 161.97 (C, C-aromatic), 162.59 (C, C-aromatic), 165.24 (C, C-aromatic) ppm. 19F-NMR: δ −111.56 ppm. MS(ESI)+: 402 [M+H]+. m.p.: (from ethanol/water) 82-84° C.
    • Example 65 Synthesis of 4-fluoro-2-(4-methoxybenzamido)-N-(2-morpholinoethyl) benzamide (22)
  • Figure US20190248756A1-20190815-C00227
  • Compound 22 was obtained as a white powder in 23% yield. 1H-NMR (CDCl3): δ 2.55 (s, 4H), 2.66 (t, J=6.0 Hz, 2H), 3.57 (dd, J=5.6, 11.0 Hz, 2H), 3.74-3.78 (m, 4H), 3.90 (s, 3H), 6.79-6.81 (m, 1H), 6.96 (s, 1H), 7.00-7.06 (m, 2H), 7.51 (dd, J=6.0, 8.7 Hz, 1H), 8.01-8.05 (m, 2H), 8.66-8.71 (m, 1H), 12.42 (s, 1H) ppm. 13C-NMR (126 MHz, CDCl3): δ 35.49 (CH2, C-aromatic), 41.09 (CH2, C-aromatic), 55.46 (CH3, C-aromatic), 108.69 (CH, C-aromatic), 109.58 (CH, C-aromatic), 114.06 (CH, C-aromatic), 126.81 (C, C-aromatic), 128.77 (CH, C-aromatic), 129.39 (CH, C-aromatic), 138.47 (C, C-aromatic), 142.54 (C, C-aromatic), 162.73 (C, C-aromatic), 165.29 (C, C-aromatic), 165.99 (C, C-aromatic), 168.60, 168.60 (C, C-aromatic) ppm. 19F-NMR: δ −104.27 ppm. MS(ESI)+: 402 [M+H]+. m.p.: (from ethanol/water) 114-116° C.
    • Example 66 Synthesis of 4-methoxy-2-(4-methoxybenzamido)-N-(2-morpholinoethyl) benzamide (23)
  • Figure US20190248756A1-20190815-C00228
  • Compound 23 was obtained as a white powder in 27% yield. 1H-NMR (CDCl3): δ 2.60 (s, 4H), 2.70 (s, 2H), 3.59 (d, J=5.2 Hz, 2H), 3.80 (s, 4H), 3.90 (s, 3H), 3.93 (s, 3H), 6.68 (dd, J=2.6, 8.8 Hz, 1H), 6.93-7.07 (m, 3H), 7.50 (d, J=8.9 Hz, 1H), 7.94-8.10 (m, 2H), 8.60 (d, J=2.6 Hz, 1H), 12.66 (s, 1H) ppm. 13C-NMR (CDCl3): δ 35.85 (CH2, C-aliphatic), 53.27 (CH2, C-aliphatic), 55.45 (CH3, C-aliphatic), 55.57 (CH3, C-aliphatic), 56.58 (CH2, C-aliphatic), 66.99 (CH2, C-aliphatic), 104.84 (CH, C-aromatic), 109.97 (CH, C-aromatic), 111.90 (C, C-aromatic), 114.00 (CH, C-aromatic), 127.25 (C, C-aromatic), 127.83 (CH, C-aromatic), 129.32 (CH, C-aromatic), 142.85 (C, C-aromatic), 162.51 (C, C-aromatic), 163.01 (C, C-aromatic), 165.45 (C, C-aromatic), 169.10 (C, C-aromatic) ppm. MS(ESI)+:414.2 [M+H]+. m.p.: (from ethanol/water) 86-88° C.
    • Example 67 Synthesis of 3-methoxy-2-(4-methoxybenzamido)-N-(2-morpholinoethyl) benzamide (24)
  • Figure US20190248756A1-20190815-C00229
  • Compound 24 was obtained as a white powder in 41% yield. 1H-NMR (CDCl3): δ 2.43 (s, 4H), 2.51 (t, J=6.0 Hz, 2H), 3.47 (dd, J=5.7, 11.4 Hz, 2H), 3.69-3.65 (m, 4H), 3.89 (s, 3H), 3.90 (s, 3H), 6.87 (s, 1H), 6.97-7.00 (m, 2H), 7.08 (d, J=7.9 Hz, 1H), 7.16 (dd, J=1.1, 7.8 Hz, 1H), 7.24-7.31 (m, 1H), 7.92-7.97 (m, 2H), 8.89 (s, 1H) ppm. 13C-NMR (126 MHz, CDCl3): δ 35.99 (CH2, C-aromatic), 53.24 (CH2, C-aromatic), 55.49 (CH3, C-aromatic), 56.21 (CH3, C-aromatic), 56.78 (CH2, C-aromatic), 66.88 (CH2, C-aromatic), 113.70 (CH, C-aromatic), 113.85 (CH, C-aromatic), 119.42 (CH, C-aromatic), 124.97 (C, C-aromatic), 126.49 (C, C-aromatic), 126.71 (CH, C-aromatic), 129.57 (CH, C-aromatic), 132.25 (C, C-aromatic), 154.07 (C, C-aromatic), 162.61 (C, C-aromatic), 165.76 (C, C-aromatic), 168.45 (C, C-aromatic) ppm. MS(ESI)+: 414 [M+H]+. m.p.: (from ethanol/water) 133-135° C.
    • Example 68 Synthesis of 3-methoxy-2-(2-methoxybenzamido)-N-(2-morpholinoethyl) benzamide (25)
  • Figure US20190248756A1-20190815-C00230
  • Compound 25 was obtained as a white powder in 41% yield. 1H-NMR (CDCl3): 2.34 (d, J=14.65 Hz, 4H), 2.46 (t, J=6.06 Hz, 2H), 3.48 (q, J=5.71 Hz, 2H), 3.58 (t, J=4.41 Hz, 4H), 3.90 (s, 3H), 4.07 (s, 3H), 6.87-6.89 (m, 1H), 7.04-7.13 (m, 3H), 7.23 (dd, J=0.78 Hz, 7.58 Hz, 1H), 7.30-7.31 (m, 1H), 7.50-7.54 (m, 1H), 8.263 (dd, J=1.48, 7.73 Hz, 1H), 9.89 (d, J=0.39 Hz, 1H) ppm. 13C-NMR (CDCl3): 36.12 (CH2, C-aliphatic), 53.25 (CH2, C-aliphatic), 56.20 (CH3, C-aliphatic), 56.97 (CH2, C-aliphatic), 66.83 (CH2, C-aliphatic), 111.67 (CH, C-aromatic), 112.82 (CH, C-aromatic), 120.23 (CH, C-aromatic), 121.35 (CH, C-aromatic), 121.35 (C, C-aromatic), 123.56 (C, C-aromatic), 127.06 (CH, C-aromatic), 132.69 (CH, C-aromatic), 133.40 (CH, C-aromatic), 134.77 (C, C-aromatic), 153.73 (C, C-aromatic), 157.91 (C, C-aromatic), 164.56 (C, C-aromatic), 168.28 (C, C-aromatic) ppm. MS(ESI)+: 414.2 [M+H]+. m.p.: 105-107° C.
    • Example 69 Synthesis of 3-methoxy-2-(3-methoxybenzamido)-N-(2-morpholinoethyl) benzamide (26)
  • Figure US20190248756A1-20190815-C00231
  • Compound 26 was obtained as a white powder in 37% yield. 1H-NMR (CDCl3): δ 2.42 (t, J=4.21 Hz, 4H), 2.51 (t, J=6.02 Hz, 2H), 3.47 (q, J=5.69 Hz, 2H), 3.66 (t, J=4.62 Hz, 4H), 3.88 (s, 3H), 3.90 (s, 3H), 6.80 (s, 1H), 7.08-7.12 (m, 2H), 7.159 (dd, J=1.26, 7.77 Hz, 1H), 7.28-7.31 (m, 1H), 7.39-7.42 (m, 1H), 7.53-7.55 (m, 2H), 8.92 (s, 1H) ppm. 13C-NMR (CDCl3): 36.04 (CH2, C-aliphatic), 53.27 (CH2, C-aliphatic), 55.47 (CH3, C-aliphatic), 56.21 (CH3, C-aliphatic), 56.78 (CH2, C-aliphatic), 66.89 (CH2, C-aliphatic), 112.81 (CH, C-aromatic), 113.75 (CH, C-aromatic), 118.26 (CH, C-aromatic), 119.38 (CH. C-aromatic), 119.58 (CH, C-aromatic), 124.75 (C, C-aromatic), 126.87 (CH, C-aromatic), 126.69 (CH, C-v), 132.35 (C, C-aromatic), 135.69 (C, C-aromatic), 154.12 (C, C-aromatic), 159.89 (C, C-aromatic), 165.96 (C, C-aromatic), 168.32 (C, C-aromatic) ppm. MS(ESI)+: 414.2 [M+H]+. m.p.: 110-113° C.
    • Example 70 Synthesis of 2,3,4-trimethoxy-6-(4-methoxybenzamido)-N-(2-morpholino ethyl)benzamide (27)
  • Figure US20190248756A1-20190815-C00232
  • Compound 27 was obtained as a white solid in 18% yield. 1H-NMR (500 MHz, CDCl3): δ 8.49 (s, 1H, ArNHCO), 7.95 (d, J=8.2, 2H), 7.04 (s, 1H, CONHCH2), 6.99 (d, J=7.3, 2H), 6.93 (s, 1H), 3.94 (s, 3H, OCH3), 3.92 (s, 3H, OCH3), 3.90 (s, 3H, OCH3), 3.89 (s, 3H, OCH3), 3.63 (t, J=4.2), 3.45 (q, J=5.45, 2H, NHCH2CH2), 2.47 (t, J=6.4, 2H, NHCH2CH2), 2.38 (s, 4H). 13C-NMR (126 MHz, CDCl3) δ 167.86 (ArC═O), 166.76 (ArC═O), 162.75 (ArC), 151.94 (ArC), 149.10 (ArC), 144.44 (ArC), 129.47 (ArCH), 127.94 (ArC), 126.13 (ArC), 122.44 (ArC), 113.93 (ArCH), 106.55 (ArCH), 66.73 (CH2), 61.11 (CH3), 61.00 (CH3), 56.92 (CH2), 56.30 (CH3), 55.51 (CH3) 53.23 (CH2), 36.04 (CH2). MS (ESI): 474.2 [M+1]. m.p. (from ethanol/water): 143° C.
    • Example 71 Synthesis of 2-fluoro-N-(3-fluoro-2-((2-morpholinoethyl)carbamoyl)phenyl)-4-methoxybenzamide (28)
  • Figure US20190248756A1-20190815-C00233
  • Compound 28 was obtained as a white powder in 40% yield. 1H-NMR (CDCl3): δ 2.53 (s, 4H), 2.62 (t, J=6.0 Hz, 2H), 3.60 (dd, J=0.6, 5.21 Hz, 2H), 3.73-3.77 (m, 4H), 3.88 (d, J=6.1 Hz, 3H), 6.71 (dd, J=2.3, 13.3 Hz, 1H), 6.83 (dd, J=2.3, 8.8 Hz, 1H), 6.91 (dd, J=8.6, 11.3 Hz, 1H), 7.38 (s, 1H), 7.46 (dd, J=8.3, 15.0 Hz, 1H), 8.04 (t, J=8.9 Hz, 1H), 8.56 (d, J=8.5 Hz, 1H), 11.89 (d, J=7.8 Hz, 1H) ppm. 13C-NMR (CDCl3): δ 36.19 (CH2, C-aliphatic), 53.14 (CH2, C-aliphatic), 55.84 (CH3, C-aliphatic), 56.08 (CH2, C-aliphatic), 67.00 (CH2, C-aliphatic), 101.79 (CH, C-aromatic), 102.00 (CH, C-aromatic), 110.47 (CH, C-aromatic), 110.67 (CH, C-aromatic), 110.73 (CH, C-aromatic), 110.76 (CH, C-aromatic), 118.43 (CH, C-aromatic), 132.44 (CH, C-aromatic), 132.53 (CH, C-aromatic), 132.87 (CH, C-aromatic), 132.90 (CH, C-aromatic), 140.98 (C, C-aromatic), 158.96 (C, C-aromatic), 160.52 (C, C-aromatic), 161.51 (C, C-aromatic), 162.09 (C, C-aromatic), 162.39 (C, C-aromatic), 163.65 (C, C-aromatic), 164.83 (C, C-aromatic) ppm. 19F-NMR: δ −109.44, −112.34 ppm. MS(ESI)+: 420 [M+H]+. m.p.: 105-107° C.
    • Example 72 Synthesis of 2-(2,4-dimethoxybenzamido)-3-methoxy-N-(2-morpholinoethyl) benzamide (29)
  • Figure US20190248756A1-20190815-C00234
  • Compound 29 was obtained as a white powder in 41% yield. 1H-NMR (CDCl3): δ 2.345 (t, J=4.39 Hz, 4H), 2.454 (t, J=6.14 Hz, 2H), 3.476 (q, J=5.72 Hz, 2H), 3.596 (t, J=4.63 Hz, 4H), 3.892 (d, J=3.17 Hz, 6H), 4.043 (s, 3H), 6.561 (d, J=2.30 Hz, 1H), 6.635 (dd, J=2.32, 8.78 Hz, 1H), 6.933 (s, 1H), 7.035 (dd, J=1.44, 8.11 Hz, 1H), 7.23-7.30 (m, 2H), 8.22 (d, J=8.76 Hz, 1H), 9.72 (s, 1H) ppm. 13C-NMR (125 MHz, CDCl3): δ 36.13 (CH2, C-aliphatic), 53.26 (CH2, C-aliphatic), 55.60 (CH3, C-aliphatic), 56.15 (CH3, C-aliphatic), 56.19 (CH3, C-aliphatic), 56.99 (CH2, C-aliphatic), 66.85 (CH2, C-aliphatic), 98.74 (CH, C-aromatic), 105.51 (CH, C-aromatic), 112.73 (CH, C-aromatic), 114.33 (C, C-aromatic), 120.30 (CH, C-aromatic), 123.69 (C, C-aromatic), 126.95 (CH, C-aromatic), 134.37 (CH, C-aromatic), 134.93 (C, C-aromatic), 153.74 (C, C-aromatic), 159.29 (C, C-aromatic), 163.96 (C, C-aromatic), 164.51 (C, C-aromatic), 168.31 (C, C-aromatic) ppm. MS(ESI)+: 444.2 [M+H]+. m.p.: 103-106° C.
    • Example 73 Synthesis of N-(2-((2-morpholinoethyl)carbamoyl)phenyl)-1-naphthamide (30)
  • Figure US20190248756A1-20190815-C00235
  • Compound 30 was obtained as a white powder in 41% yield. 1H-NMR (CDCl3): δ 2.44 (s, 4H), 2.52 (t, J=5.8 Hz, 2H), 3.41 (dd, J=5.5, 1.1 Hz, 2H), 3.59-3.72 (m, 4H), 7.11 (td, J=1.1, 7.8 Hz, 1H), 7.44-7.58 (m, 6H), 7.80 (dd, J=4.8, 11.9 Hz, 2H), 7.89 (d, J=8.3 Hz, 1H), 8.47 (d, J=8.3 Hz, 1H), 8.84 (d, J=8.0 Hz, 1H), 11.72 (s, 1H) ppm. 13C-NMR (CDCl3): δ 35.90 (CH2, C-aliphatic), 53.27 (CH2, C-aliphatic), 56. 54 (CH2, C-aliphatic), 66.95 (CH2, C-aliphatic), 120.75 (CH, C-aromatic), 121.76 (C, C-aromatic), 123.12 (CH, C-aromatic), 124.97 (CH, C-aromatic), 125.53 (CH, C-aromatic), 125.67 (CH, C-aromatic), 126.38 (CH, C-aromatic), 126.55 (CH, C-aromatic), 127.12 (CH, C-aromatic), 128.34 (C, C-aromatic), 130.49 (CH, C-aromatic), 131.21 (CH, C-aromatic), 132.70 (C, C-aromatic), 133.95 (CH, C-aromatic), 134.45 (C, C-aromatic), 140.00 (C, C-aromatic), 167.68 (C, C-aromatic), 168.95 (C, C-aromatic) ppm. MS(ESI)+: 404.2 [M+H]+. m.p.: (from DCM/n-hexane) 93-95° C.
    • Example 74 Synthesis of N-(2-((2-morpholinoethyl)carbamoyl)phenyl)-2-naphthamide (31)
  • Figure US20190248756A1-20190815-C00236
  • Compound 31 was obtained as a white powder in 28% yield. 1H-NMR (CDCl3): δ 2.57 (s, 4H), 2.68 (t, J=5.8 Hz, 2H), 3.41-3.63 (m, 2H), 3.71-3.85 (m, 4H), 7.04 (s, 1H), 7.19 (t, J=7.1 Hz, 1H), 7.60 (m, 5H), 7.92 (d, J=7.7 Hz, 1H), 7.99 (d, J=8.6 Hz, 1H), 8.05 (d, J=7.6 Hz, 1H), 8.12 (dd, J=1.7, 8.6 Hz, 1H), 8.61 (s, 1H), 8.90 (d, J=8.2 Hz, 1H), 12.41 (s, 1H) ppm. 13C-NMR (CDCl3): δ 35.98 (CH2, C-aliphatic), 53.30 (CH2, C-aliphatic), 56.61 (CH2, C-aliphatic), 66.92 (CH2, C-aliphatic), 120.47 (C, C-aromatic), 121.79 (CH, C-aromatic), 122.91 (CH, C-aromatic), 123.69 (CH, C-aromatic), 126.53 (CH, C-aromatic), 126.64 (CH, C-aromatic), 127.72 (CH, C-aromatic), 127.79 (CH, C-aromatic), 128.42 (CH, C-aromatic), 128.61 (CH, C-aromatic), 129.39 (CH, C-aromatic), 132.17 (C, C-aromatic), 132.64 (CH, C-aromatic), 132.79 (C, C-aromatic), 134.98 (C, C-aromatic), 140.23 (C, C-aromatic), 165.52 (C, C-aromatic), 169.19 (C, C-aromatic) ppm. MS(ESI)+: 404.2 [M+H]+. m.p.: (from DCM/n-hexane) 105-107° C.
    • Example 75 Synthesis of N-(2-((2-morpholinoethyl)carbamoyl)phenyl)nicotinamide (32)
  • Figure US20190248756A1-20190815-C00237
  • Compound 32 was obtained as a white solid in 48% yield. 1H-NMR (500 MHz, CDCl3): δ 12.53 (s, 1H, ArNHCO), 9.32 (d, J=1.5, 1H, CONHCH2), 8.84 (dd, J=9.1, 1H), 8.80 (dd, J=5.5, 1, 1H), 8.33 (dt, J=8.2, 1H), 7.61-7.56 (m, 2H), 7.47 (td, J=4.5, 0.5, 1H), 7.2 (td, J=8, 1.5, 1H), 7.14 (s, 1H), 3.78 (t, J=4.5, 4H), 3.60 (q, J=4.5, 2H, NHCH2CH2), 2.68 (t, J=6, 2H, NHCH2CH2), 2.57 (s, 4H). 13C-NMR (126 MHz, CDCl3) δ 169.07 (ArC═O), 163.73 (ArC═O), 152.46 (ArCH), 149.13 (ArCH), 139.94 (ArC), 134.91 (ArCH), 132.94 (ArCH), 130.52 (ArC), 126.56 (ArCH), 123.46 (ArCH), 13.30 (ArCH), 121.64 (ArCH), 120.03 (ArC), 66.84 (CH2), 56.60 (CH2), 53.29 (CH2), 35.92 (CH2). MS (ESI): 355.2. m.p. (from ethanol/water): 85° C.
    • Example 76 Synthesis of N-(3,4,5-trimethoxy-2-((2-morpholinoethyl)carbamoyl)phenyl) nicotinamide (33)
  • Figure US20190248756A1-20190815-C00238
  • Compound 33 was obtained as a white solid. 1H-NMR (500 MHz, CDCl3) δ 9.22 (s, 1H, ArNHCO), 9.09, (s, 1H, CONHCH2), 8.79 (d, J=4.1), 8.28 (dt, J=7.95, 1.8, 1H), 7.45 (dd, J=7.65, 5.1, 1H), 6.98 (s, 1H), 6.9 (s, 1H), 3.94 (d, J=1.9, 6H, OCH3), 3.93 (s, 3H, OCH3), 3.70-3.66 (m, 4H), 3.51-3.45 (m, 2H, NHCH2CH2), 2.56 (t, J=5.6, 2H, NHCH2CH2), 2.48 (s, 4H). 13C-NMR (126 MHz, CDCl3) δ 167.95 (ArC═O), 164.96 (ArC═O), 152.68 (ArCH), 152.04 (ArC), 149.26 (ArC), 148.90 (ArCH), 144.72 (ArC), 135.38 (ArCH), 129.81 (ArC), 123.52 (ArCH), 122.48 (ArC), 106.10 (ArCH), 66.58 (CH2), 61.06 (CH3), 61.00 (CH3), 56.87 (CH2), 56.38 (CH3), 53.22 (CH2), 35.86 (CH2). MS (ESI): 445.2 [M+1]. m.p. (from ethanol/water): 155° C.
    • Example 77 Synthesis of 3-(4-methoxybenzamido)-N-(2-morpholinoethyl)isonicotinamide (99)
  • Figure US20190248756A1-20190815-C00239
  • Compound 99 was obtained as a white powder in 43% yield. 1H-NMR (CDCl3): δ 2.55 (s, 4H), 2.67 (t, J=5.9 Hz, 2H), 3.59 (s, 2H), 3.75-3.79 (m, 4H), 3.91 (s, 3H), 7.02-7.05 (m, 2H), 7.21 (s, 1H), 7.34 (d, J=5.0 Hz, 1H), 8.01-8.04 (m, 2H), 8.46 (d, J=5.1 Hz, 1H), 10.12 (s, 1H), 11.80 (s, 1H) ppm. 13C-NMR (126 MHz, CDCl3): δ 36.01 (CH2, C-aromatic), 53.26 (CH2, C-aromatic), 55.50 (CH3, C-aromatic), 56.27 (CH2, C-aromatic), 66.95 (CH2, C-aromatic), 114.08 (CH, C-aromatic), 119.25 (CH, C-aromatic), 125.67 (C, C-aromatic), 126.31 (C, C-aromatic), 129.48 (CH, C-aromatic), 135.65 (C, C-aromatic), 143.85 (CH, C-aromatic), 144.61 (CH, C-aromatic), 162.81 (C, C-aromatic), 164.94 (C, C-aromatic), 167.32 (C, C-aromatic) ppm. MS(ESI)+: 395.1 [M+H]+. m.p.: 90-92° C.
    • Example 78 Synthesis of 2-chloro-N-(2-((2-morpholinoethyl)carbamoyl)phenyl)benzamide (103)
  • Figure US20190248756A1-20190815-C00240
  • Compound 103 was obtained as a yellow powder in 80% yield. 1H-NMR (CDCl3): δ 2.54 (s, 4H), 2.63 (t, J=5.7 Hz, 2H), 3.52 (dd, J=5.4, 11.0 Hz, 2H), 3.76 (d, J=4.1 Hz, 4H), 6.99 (d, J=18.7 Hz, 1H), 7.20 (t, J=7.6 Hz, 1H), 7.30-7.39 (m, 2H), 7.48 (dd, J=1.2, 7.8 Hz, 1H), 7.54 (d, J=7.7 Hz, 1H), 7.58 (t, J=7.8 Hz, 1H), 7.68 (dd, J=2.0, 7.2 Hz, 1H), 8.83 (d, J=8.3 Hz, 1H), 11.65 (s, 1H) ppm. 13C-NMR (126 MHz, CDCl3): δ 30.74 (CH2, C-aliphatic), 35.74 (CH2, C-aliphatic), 53.18 (CH2, C-aliphatic), 66.13 (CH2, C-aliphatic), 120.49 (CH, C-aromatic), 123.37 (CH, C-aromatic), 127.63 (CH, C-aromatic), 128.09 (CH, C-aromatic), 128.89 (CH, C-aromatic), 129.77 (C, C-aromatic), 130.17 (CH, C-aromatic), 131.73 (CH, C-aromatic), 132.02 (CH, C-aromatic), 136.24 (C, C-aromatic), 138.45 (C, C-aromatic), 162.27 (C, C-aromatic), 164.30 (C, C-aromatic), 168.06 (C, C-aromatic) ppm. MS(ESI)+: 388.1, 389.1 [M+H]+. m.p.: (from ethanol/water) 133-137° C.
    • Example 79 Synthesis of 2-fluoro-N-methyl-N-(2-((2-morpholinoethyl)carbamoyl)phenyl) benzamide (106)
  • Figure US20190248756A1-20190815-C00241
  • Compound 106 was obtained as an oil in 18% yield. 1H-NMR (500 MHz, CDCl3): δ 2.24 (d, J=12.3 Hz, 3H), 2.32-2.77 (m, 10H), 3.48 (dd, J=5.4, 11.2 Hz, 2H), 6.95-7.17 (m, 1H), 7.40-7.62 (m, 2H), 7.70 (d, J=8.2 Hz, 2H), 8.09 (d, J=8.1 Hz, 2H), 8.76 (d, J=8.4 Hz, 1H), 12.46 (s, 1H) ppm. 13C-NMR (126 MHz, CDCl3): δ 35.84 (CH3, C-aliphatic), 102.05 (CH, C-aromatic), 102.28 (CH, C-aromatic), 110.55 (CH, C-aromatic), 110.76 (CH, C-aromatic), 118.61 (CH, C-aromatic), 132.21 (CH, C-aromatic), 132.78 (CH, C-aromatic), 132.98 (CH, C-aromatic), 158.95 (C, C-aromatic), 160.53 (C, C-aromatic), 161.49 (C, C-aromatic), 162.06 (C, C-aromatic), 163.68 (C, C-aromatic), 164.82 (C, C-aromatic) ppm.
    • Example 80 Synthesis of 4-(4-methoxybenzamido)-N-(2-morpholinoethyl)nicotinamide (113)
  • Figure US20190248756A1-20190815-C00242
  • Compound 113 was obtained as a white powder in 55% yield. 1H-NMR (500 MHz, CDCl3): δ 2.46 (d, J=4.2 Hz, 4H), 2.58 (t, J=5.9 Hz, 2H), 3.51 (dd, J=5.3, 11.1 Hz, 2H), 3.62-3.70 (m, 4H), 3.81 (s, 3H), 6.88-6.99 (m, 2H), 7.04 (s, 1H), 7.19 (s, 1H), 7.94 (dd, J=2.4, 9.4 Hz, 2H), 8.54 (d, J=5.8 Hz, 1H), 8.63-8.73 (m, 1H), 12.36 (s, 1H) ppm. 13C-NMR (126 MHz, CDCl3): δ 35.93 (CH2, C-aliphatic), 53.28 (CH2, C-aliphatic), 55.49 (CH3, C-aliphatic), 56.30 (CH2, C-aliphatic), 66.95 (CH2, C-aliphatic), 114.16 (CH, C-aromatic), 114.46 (CH, C-aromatic), 126.25 (C, C-aromatic), 129.59 (CH, C-aromatic), 147.22 (C, C-aromatic), 147.94 (CH, C-aromatic), 153.46 (CH, C-aromatic), 163.06 (C, C-aromatic), 165.50 (C, C-aromatic), 165.62 (C, C-aromatic), 167.69 (C, C-aromatic) ppm. MS (ESI)+: 385.2 [M+H]+. m.p. (from ethanol/water): 105-107° C.
    • Example 81 Synthesis of 2-(2-fluorobenzamido)-3-methoxy-N-(2-morpholinoethyl)benzamide (145)
  • Figure US20190248756A1-20190815-C00243
  • Compound 145 was obtained as a white powder in 31% yield. 1H-NMR (CDCl3): δ 2.37-2.40 (m, 4H), 2.50-2.52 (m, 2H), 3.48-3.51 (m, 2H), 3.62-3.65 (m, 4H), 3.91 (s, 3H), 6.77-6.79 (m, 1H), 7.08-7.09 (m, 1H), 7.19-7.23 (m, 2H), 7.30-7.33 (m, 2H), 7.52-7.57 (m, 1H), 8.14-8.17 (m, 1H), 8.97-8.99 (m, 1H) ppm. 13C-NMR (126 MHz, CDCl3): δ 36.07 (CH2, C-aliphatic), 53.28 (CH2, C-aliphatic), 56.20 (CH3, C-aliphatic), 56.90 (CH2, C-aliphatic), 66.87 (CH2, C-aliphatic), 113.26 (CH, C-aromatic), 116.33 (CH, C-aromatic), 119.79 (CH—C-aromatic), 123.60 (C, C-aromatic), 124.76 (CH, C-aromatic), 127.26 (CH, C-aromatic), 132.26 (CH, C-aromatic), 133.77 (CH, C-aromatic), 134.19 (CH, C-aromatic), 138.90 (C, C-aromatic), 153.82 (C, C-aromatic), 159.93 (C, C-aromatic), 161.91 (C, C-aromatic), 168.07 (C, C-aromatic) ppm. 19F-NMR: δ −112.47 ppm. MS(ESI)+: 402.2 [M+H]+. m.p.: 105-107° C.
    • Example 82 Synthesis of N-(2-morpholinoethyl)-2-(3-nitrobenzamido)benzamide (146)
  • Figure US20190248756A1-20190815-C00244
  • Compound 146 was obtained as a white powder in 51% yield. 1H-NMR (CDCl3): δ 2.60 (s, 4H), 2.71 (s, 2H), 3.61 (d, J=5.2 Hz, 2H), 3.80 (s, 4H), 7.24 (t, J=7.2 Hz, 2H), 7.61 (t, J=7.4 Hz, 2H), 8.24 (d, J=8.8 Hz, 2H), 8.39 (d, J=8.7 Hz, 2H), 8.86 (d, J=8.1 Hz, 1H), 12.71 (s, 1H) ppm. 13C-NMR (126 MHz, CDCl3): δ 36.58 (CH2, C-aliphatic), 53.20 (CH2, C-aliphatic), 56.93 (CH2, C-aliphatic), 66.17 (CH2, C-aliphatic), 120.64 (C, C-aromatic), 120.92 (CH, C-aromatic), 123.39 (CH, C-aromatic), 126.88 (CH, C-aromatic), 127.58 (CH, C-aromatic), 128.15 (CH, C-aromatic), 128.43 (CH, C-aromatic), 132.21 (CH, C-aromatic), 138.76 (CH, C-aromatic), 140.10 (C, C-aromatic), 149.41 (C, C-aromatic), 162.69 (C, C-aromatic), 168.38 (C, C-aromatic), 173.58 (C, C-aromatic) ppm. MS(ESI)+: 399.2 [M+H]+. m.p.: 147-149° C.
    • Example 83 Synthesis of N-(2-morpholinoethyl)-2-(2-nitrobenzamido)benzamide (147)
  • Figure US20190248756A1-20190815-C00245
  • Compound 147 was obtained as a white powder in 43% yield. 1H-NMR (CDCl3): δ 2.39 (t, J=4.7 Hz, 4H), 2.46 (t, J=6.8 Hz, 2H), 2.46 (t, J=6.8 Hz, H), 3.37 (q, J=6.5 Hz, 2H), 3.53 (t, J=4.6 Hz, 4H), 7.20-7.27 (m, 1H), 7.59 (t, J=8.2 Hz, 1H), 7.82 (m, 3H), 7.91 (t, J=15.2 Hz, 1H), 8.13 (d, J=8.3, 1H) ppm. 13C-NMR (126 MHz, CDCl3): δ 36.48 (CH2, C-aliphatic), 53.19 (CH2, C-aliphatic), 56.95 (CH2, C-aliphatic), 66.14 (CH2, C-aliphatic), 120.89 (CH, C-aromatic), 121.76 (C, C-aromatic), 123.67 (CH, C-aromatic), 124.57 (CH, C-aromatic), 128.11 (CH, C-aromatic), 128.38 (CH, C-aromatic), 131.68 (CH, C-aromatic), 131.58 (CH, C-aromatic), 132.02 (C, C-aromatic), 134.11 (CH, C-aromatic), 138.23 (C, C-aromatic), 147.02 (C, C-aromatic), 163.35 (C, C-aromatic), 168.01 (C, C-aromatic) ppm. MS(ESI)+: 399.19 [M+H]+. m.p.: 138-140° C.
    • Example 84 Synthesis of N-(2-morpholinoethyl)-2-(4-nitrobenzamido)benzamide (148)
  • Figure US20190248756A1-20190815-C00246
  • Compound 148 was obtained as a white powder in 51% yield. 1H-NMR (CDCl3): δ 2.44 (m, 6H), 3.44 (q, J=6.5 Hz, 2H), 3.54 (t, J=4.6 Hz, 4H), 7.20-7.27 (m, 1H,), 7.57-7.60 (m, 1H), 7.85 (dd, J=1.5, 8.0 Hz, 1H), 8.16 (d, J=8.9 Hz, 2H), 8.44 (d, J=8.9 Hz, 2H), 8.59 (d, J=8.4 Hz, 1H), 8.83 (s, 1H), 12.70 (s, 1H) ppm. 13C-NMR (126 MHz, CDCl3): δ 36.58 (CH2, C-aliphatic), 53.20 (CH2, C-aliphatic), 56.93 (CH2, C-aliphatic), 66.17 (CH2, C-aliphatic), 120.64 (CH, C-aromatic), 120.92 (C, C-aromatic), 123.47 (CH, C-aromatic), 124.13 (CH, C-aromatic), 128.15 (CH, C-aromatic), 128.43 (CH, C-aromatic), 132.21 (CH, C-aromatic), 138.76 (C, C-aromatic), 140.10 (C, C-aromatic), 149.41 (C, C-aromatic), 162.69 (C, C-aromatic), 168.38 (CH, C-aromatic) ppm. MS(ESI)+: 399.2 [M+H]+. m.p.: 147-149° C.
    • General Procedure 3:
  • The compounds of the application with the general formula shown below can be prepared according to the synthetic scheme in Scheme 3.
  • Figure US20190248756A1-20190815-C00247
  • To a solution of compound (II) or (II′) (1 equivalent) in N,N-dimethyl-formamide (DMF) is added 2 equivalents of N,N-diisopropylethylamine (DIPEA) and 2.2 equivalent of 3-morpholinopropylamine (XVa). The reaction mixture is stirred at about 15° C. to about 28° C. for about 6 hours to about 24 hours. The reaction mixture is diluted with water, washed with ethyl acetate, washed with brine, dried over Mg2SO4, filtered and evaporated to give a crude compound which is then purified by silica gel column using a mixture of Chloroform:Methanol (9:1) as eluent. The product is collected under reduced pressure to provide the compound with the general formula shown in Scheme 3.
  • Compounds 34-37, 126-128, 130-134, 138, 139, and 141-143 were prepared according to General Procedure 3 substituting (II) or (II′) with the appropriate substituted compound.
    • Example 85 Synthesis of 2-fluoro-N-(2-((3-morpholinopropyl)carbamoyl)phenyl) benzamide (34)
  • Figure US20190248756A1-20190815-C00248
  • Compound 34 was obtained as a white precipitate in 25% yield. 1H-NMR (500 MHz, CDCl3): δ 1.82 (2H, m), 2.57 (6H, m), 3.59 (2H, td, J=4.89, 5.91 Hz), 3.72 (4H, d, J=0.49 Hz), 7.20 (2H, m), 7.29 (1H, m), 7.55 (3H, m), 8.06 (1H, td, J=1.85, 7.71 Hz), 8.45 (1H, m), 8.80 (1H, dd), 12.01 (1H, m) ppm. 19F-NMR (CDCl3): δ −112.48 ppm. MS (ESI)+: 386.2 [M+H]+. Melting point: 76-79° C.
    • Example 86 Synthesis of 2-(4-methoxybenzamido)-N-(3-morpholinopropyl)benzamide (35)
  • Figure US20190248756A1-20190815-C00249
  • Compound 35 was obtained as a white powder in 64% yield. 1H-NMR (500 MHz, CDCl3): δ 1.85 (2H, m), 2.54 (4H, m), 2.63 (2H, dd, J=3.88, 7.36 Hz), 3.61 (2H, m), 3.74 (4H, t, J=4.29 Hz), 3.90 (3H, s), 7.02 (2H, m), 7.13 (1H, td, J=0.98, 7.59 Hz), 7.55 (1H, m), 7.62 (1H, dd, J=1.03, 7.80 Hz), 8.05 (2H, m), 8.60 (1H, m), 8.84 (1H, dd, J=1.00, 8.44 Hz), 12.32 (1H, s) ppm. 13C-NMR (126 MHz, CDCl3): δ 23.41 (CH2, C-aliphatic), 40.97 (CH2, C-aliphatic), 53.82 (CH2, C-aliphatic), 55.42 (CH3, C-aliphatic), 58.95 (CH2, C-aliphatic), 66.79 (CH2, C-aliphatic), 113.95 (CH, C-aromatic), 120.23 (C, C-aromatic), 121.52 (CH, C-aromatic), 122.30 (CH, C-aromatic), 126.77 (CH, C-aromatic), 127.34 (C, C-aromatic), 129.33 (CH, C-aromatic), 132.62 (CH, C-aromatic), 140.41 (C, C-aromatic), 162.46 (C, C-aromatic), 165.19 (C, C-aromatic), 169.28 (C, C-aromatic) ppm. MS (ESI)+: 398.2 [M+H]+. Melting point (from DCM/n-hexane): 112-114° C.
    • Example 87 Synthesis of N-(2-((3-morpholinopropyl)carbamoyl)phenyl)-1-naphthamide (36)
  • Figure US20190248756A1-20190815-C00250
  • Compound 36 was obtained as a white powder in 74% yield. 1H-NMR (500 MHz, CDCl3): δ 1.77 (2H, m), 2.56 (3H, s), 2.58 (3H, s), 3.52 (2H, dd, J=5.7, 10.9 Hz), 3.74 (4H, s), 7.20 (1H, td, J=1.05, 7.62 Hz), 7.55-7.75 (5H, m), 7.91 (2H, m), 7.98 (1H, d, J=8.33 Hz), 8.57 (2H, m), 8.95 (1H, m), 12.03 (1H, s) ppm. 13C-NMR (126 MHz, CDCl3): δ 23.38 (CH2, C-aliphatic), 40.62 (CH2, C-aliphatic), 53.72 (CH2, C-aliphatic), 58.68 (CH2, C-aliphatic), 66.65 (CH2, C-aliphatic), 120.72 (C, C-aromatic), 121.64 (CH, C-aromatic), 122.86 (CH, C-aromatic), 125.00 (CH, C-aromatic), 125.56 (CH, C-aromatic), 125.70 (CH, C-aromatic), 126.35 (CH, C-aromatic), 126.88 (CH, C-aromatic), 127.08 (CH, C-aromatic), 128.32 (CH, C-aromatic), 130.52 (C, C-aromatic), 131.15 (CH, C-aromatic), 132.63 (CH, C-aromatic), 133.95 (C, C-aromatic), 134.51 (C, C-aromatic), 140.08 (C, C-aromatic), 167.90 (C, C═O), 168.91 (C, C═O) ppm. MS (ESI)+: 418.2 [M+H]+. Melting point (from DCM/n-hexane): 110-112° C.
    • Example 88 Synthesis of N-(2-((3-morpholinopropyl)carbamoyl)phenyl)-2-naphthamide (37)
  • Figure US20190248756A1-20190815-C00251
  • Compound 37 was obtained as a white powder in 53% yield. 1H-NMR (500 MHz, CDCl3): δ 1.85 (2H, m), 2.56 (4H, m), 2.64 (2H, m), 3.63 (2H, m), 3.74 (4H, m), 7.18 (1H, dd), 7.59 (3H, m), 7.65 (1H, m), 7.92 (1H, d, J=7.79 Hz), 7.99 (1H, s), 8.05 (1H, m), 8.14 (1H, m), 8.63 (2H, m), 8.90 (1H, d, J=8.43 Hz), 12.58 (1H, s) ppm. 13C-NMR (126 MHz, CDCl3): δ 23.44 (CH2, C-aliphatic), 40.91 (CH2, C-aliphatic), 53.80 (CH2, C-aliphatic), 58.88 (CH2, C-aliphatic), 66.76 (CH2, C-aliphatic), 120.57 (C, C-aromatic), 121.70 (CH, C-aromatic), 122.64 (CH, C-aromatic), 123.72 (CH, C-aromatic), 126.60 (CH, C-aromatic), 126.83 (CH, C-aromatic), 127.70 (CH, C-aromatic), 128.43 (CH, C-aromatic), 128.59 (CH, C-aromatic), 129.40 (CH, C-aromatic), 132.23 (C, C-aromatic), 132.66 (CH, C-aromatic), 132.82 (C, C-aromatic), 134.96 (C, C-aromatic), 140.24 (C, C-aromatic), 165.69 (C, C═O), 169.22 (C, C═O) ppm. MS (ESI)+: 418.2 [M+H]+. Melting point (from DCM/n-hexane): 103-105° C.
    • Example 89 Synthesis of N-(2-methoxy-6-(3-morpholinopropylcarbamoyl)phenyl)-2-naphthamide (121)
  • Figure US20190248756A1-20190815-C00252
  • Compound 121 was obtained as a white powder in 38% yield. 1H-NMR (500 MHz, CDCl3): δ 1.51-1.78 (m, 3H), 2.32 (s, 3H), 2.39 (t, J=6.0 Hz, 2H), 3.38 (dd, J=5.6, 11.3 Hz, 2H), 3.50-3.53 (m, 4H), 3.84 (s, 3H), 7.05 (dd, J=8.0, 15.8 Hz, 2H), 7.21 (s, 1H), 7.46-7.53 (m, 2H), 7.81-7.93 (5H, m), 8.45 (1H, s), 9.46 (1H, s) ppm. 13C-NMR (126 MHz, CDCl3): δ 24.30 (—CH2, C-aliphatic), 40.19 (CH2, C-aliphatic), 53.67 (CH2, C-aliphatic), 56.27 (CH3, C-aliphatic), 58.18 (CH2, C-aliphatic), 66.89 (—CH2, C-aliphatic), 114.09 (CH, C-aromatic), 119.02 (CH, C-aromatic), 124.20 (CH, C-aromatic), 125.59 (C, C-aromatic), 126.56 (CH, C-aromatic), 126.72 (CH, C-aromatic), 127.75 (CH, C-aromatic), 127.82 (CH, C-aromatic), 128.49 (CH, C-aromatic), 128.51 (CH, C-aromatic), 129.21 (CH, C-aromatic) 131.57 (C, C-aromatic), 131.68 (C, C-aromatic), 132.70 (C, C-aromatic), 135.01 (C, C-aromatic), 154.44 (C, C-aromatic), 166.10 (C, C-aromatic), 168.45 (C, C-aromatic) ppm. MS (ESI)+: 448.2 [M+H]+. Melting point (from methanol/water) 140-142° C.
    • Example 90 Synthesis of 4,5-dimethoxy-2-(4-methoxybenzamido)-N-(3-morpholinopropyl)benzamide (126)
  • Figure US20190248756A1-20190815-C00253
  • Compound 126 was obtained as a white powder in 39% yield. 1H-NMR (500 MHz, CDCl3): δ 1.73 (dt, J=6.0, 12.0 Hz, 3H), 2.27 (s, 3H), 2.35 (bs, 6H), 2.51-2.56 (m, 3H), 3.47 (dd, J=5.8, 11.2 Hz, 2H), 3.95 (s, 3H), 7.15 (d, J=8.3 Hz, 1H), 7.20 (dd, J=1.2, 7.8 Hz, 1H), 7.24-7.34 (m, 1H), 7.54-7.63 (m, 2H), 7.91 (d, J=7.9 Hz, 1H), 7.95 (d, J=8.6 Hz, 1H), 8.00 (d, J=7.9 Hz, 1H), 8.06 (dd, J=1.8, 8.6 Hz, 1H), 8.26 (s, 1H), 8.55 (s, 1H), 9.77 (s, 1H) ppm. 13C-NMR (126 MHz, CDCl3): δ 24.22 (CH2, C-aliphatic), 40.38 (CH2, C-aliphatic), 53.84 (CH2, C-aliphatic), 55.44 (CH3, C-aliphatic), 56.07 (CH3, C-aliphatic), 57.60 (CH3, C-aliphatic), 58.42 (CH2, C-aliphatic), 66.77 (CH2, C-aromatic), 104.91 (CH, C-aromatic), 111.78 (CH, C-aromatic), 113.99 (CH, C-aromatic), 127.30 (C, C-aromatic), 129.23 (CH, C-aromatic), 136.58 (C, C-aromatic), 143.99 (C, C-aromatic), 153.04 (C, C-aromatic), 162.45 (C, C-aromatic), 165.19 (C, C-aromatic), 165.55 (C, C-aromatic), 169.09 (C, C-aromatic) ppm. MS (ESI)+: 448.2 [M+H]+. Melting point (from acetone/n-hexane) 102-104° C.
    • Example 91 Synthesis of N-(5-methoxy-2-(3-morpholinepropylcarbamoyl)phenyl)-2-naphthamide (127)
  • Figure US20190248756A1-20190815-C00254
  • Compound 127 was obtained as a white powder in 44% yield. 1H-NMR (500 MHz, CDCl3): δ 1.74 (dt, J=5.9, 11.6, 2H), 2.46 (s, 4H), 2.55-2.50 (m, 2H), 3.55 (dd, J=5.9, 10.9 Hz, 2H), 3.61-3.73 (m, 4H), 3.87 (3H, s), 6.60 (dd, J=2.6, 8.8 Hz, 1H), 7.41-7.53 (m, 1H), 7.82 (d, J=7.9 Hz, 2H), 7.89 (d, J=8.6 Hz, 1H), 7.96 (d, J=7.8 Hz, 2H), 8.05 (dd, J=1.8, 8.6 Hz, 2H), 8.39 (s, 1H), 8.49-8.62 (m, 1H), 12.87-12.94 (m, 1H) ppm. 13C-NMR (126 MHz, CDCl3): δ 23.52 (CH2, C-aliphatic), 41.02 (CH2, C-aliphatic), 53.91 (CH2, C-aliphatic), 55.59 (CH3, C-aliphatic), 59.16 (CH2, C-aliphatic), 66.94 (CH2, C-aliphatic), 105.16 (CH, C-aromatic), 109.86 (CH, C-aromatic), 112.44 (C, C-aromatic), 123.66 (CH, C-aromatic), 126.60 (CH, C-aromatic), 127.71 (CH, C-aromatic), 127.78 (CH, C-aromatic), 128.15 (CH, C-aromatic), 128.54 (CH, C-aromatic), 128.63 (CH, C-aromatic), 129.46 (CH, C-aromatic), 132.21 (C, C-aromatic), 132.83 (C, C-aromatic), 134.98 (C, C-aromatic), 142.61 (C, C-aromatic), 162.93 (C, C-aromatic), 165.94 (C, C-aromatic), 169.10 (C, C-aromatic) ppm. Melting point (from ethanol/water) 131-133° C.
    • Example 92 Synthesis of N-(2-methoxy-6-(3-morpholinopropylcarbamoyl)phenyl)-1-naphthamide (128)
  • Figure US20190248756A1-20190815-C00255
  • Compound 128 was obtained as a white powder in 24% yield. 1H-NMR (500 MHz, CDCl3): δ 1.68-1.93 (m, 2H), 2.45 (s, 4H), 2.52 (t, J=6.0 Hz, 2H), 3.53 (dd, J=5.8, 11.6 Hz, 2H), 3.63 (s, 4H), 3.95 (s, 3H), 7.01-7.24 (m, 2H), 7.48-7.61 (m, 3H), 7.85 (s, 1H), 7.89-7.94 (m, 2H), 7.98 (d, J=8.2 Hz, 1H), 8.59 (d, J=7.3 Hz, 2H), 11.58 (s, 1H) ppm. 13C-NMR (126 MHz, CDCl3): δ 24.59 (CH2, C-aliphatic), 39.98 (CH2, C-aliphatic), 53.61 (CH2, C-aliphatic), 56.18 (CH3, C-aliphatic), 57.96 (CH2, C-aliphatic), 66.85 (CH2, C-aliphatic), 113.55 (CH, C-aromatic), 119.17 (CH, C-aromatic), 124.86 (CH, C-aromatic), 125.78 (CH, C-aromatic), 125.96 (CH, C-aromatic), 126.38 (CH, C-aromatic), 126.93 (CH, C-aromatic), 127.16 (CH, C-aromatic), 127.20 (C, C-aromatic), 128.28 (CH, C-aromatic), 130.55 (C, C-aromatic), 131.09 (CH, C-aromatic), 133.09 (C, C-aromatic), 133.17 (C, C-aromatic), 133.80 (C, C-aromatic), 133.95 (C, C-aromatic), 154.22 (C, C-aromatic), 168.37 (C, C-aromatic) ppm. Melting point (from ethanol/water) 130-132° C.
    • Example 93 Synthesis of N-(3-fluoro-2-((3-morpholinopropyl)carbamoyl)phenyl) nicotinamide (130)
  • Figure US20190248756A1-20190815-C00256
  • Compound 130 was obtained as a white powder in 79% yield. 1H-NMR (500 MHz, CDCl3): δ 1.75 (dt, J=5.8, 11.6 Hz, 2H), 2.46 (s, 4H), 2.52-2.56 (m, 2H), 3.52 (dd, J=5.9, 10.6 Hz, 2H), 3.64 (t, J=4.5 Hz, 4H), 7.10 (td, J=1.1, 7.8 Hz, 1H), 7.37 (ddd, J=0.7, 4.8, 7.9 Hz, 1H), 7.47-7.51 (m, 1H), 7.54-7.58 (m, 1H), 8.25 (ddd, J=1.7, 2.2, 8.0 Hz, 1H), 8.67 (s, 1H), 8.70 (dd, J=1.6, 4.8 Hz, 1H), 8.76 (dd, J=1.0, 8.4 Hz, 1H), 9.24 (d, J=1.8 Hz, 1H), 12.62 (s, 1H) ppm. 13C-NMR (126 MHz, CDCl3): δ 30.41 (CH2, C-aliphatic), 33.58 (CH2, C-aliphatic), 39.82 (CH2, C-aliphatic), 57.62 (CH2, C-aliphatic), 60.10 (CH2, C-aliphatic), 124.46 (CH, C-aromatic), 128.52 (CH, C-aromatic), 128.73 (CH, C-aromatic), 130.07 (C,C-aromatic), 130.47 (CH, C-aromatic), 132.85 (CH, C-aromatic), 134.86 (CH, C-aromatic), 139.73 (C, C-aromatic), 141.21 (C, C-aromatic), 149.20 (CH, C-aromatic), 152.48 (CH, C-aromatic), 163.75 (C, C-aromatic), 169.01 (C, C-aromatic) ppm. 19F-NMR (CDCl3): δ −110.50 ppm. Melting point (from acetone/n-hexane) 120-122° C.
    • Example 94 Synthesis of 3,4,5-trimethoxy-2-(4-methoxybenzamido)-N-(3-morpholinopropyl)benzamide (131)
  • Figure US20190248756A1-20190815-C00257
  • Compound 131 was obtained as a white powder in 63% yield. 1H-NMR (500 MHz, CDCl3): δ 1.58 (dt, J=6.6, 13.2 Hz, 2H), 2.29 (dd, J=9.5, 16.2 Hz, 4H), 3.33 (dd, J=6.4, 12.1 Hz, 2H), 3.41-3.64 (m, 4H), 3.81 (s, 3H), 3.82 (s, 3H), 3.83 (s, 3H), 3.85 (s, 3H), 6.75-6.88 (m, 2H), 6.89-6.98 (m, 4H), 7.67-7.89 (m, 4H), 8.47 (s, 2H) ppm. 13C-NMR (126 MHz, CDCl3): δ 25.36 (CH2, C-aliphatic), 39.23 (CH2, C-aliphatic), 53.59 (CH2, C-aliphatic), 55.50 (CH3, C-aliphatic), 56.58 (CH3, C-aliphatic), 57.18 (CH3, C-aliphatic), 61.01 (CH3, C-aliphatic), 61.07 (CH2, C-aliphatic), 66.94 (CH2, C-aliphatic), 106.66 (CH, C-aromatic), 113.96 (CH, C-aromatic), 122.67 (C, C-aromatic), 126.22 (C, C-aromatic), 128.41 (C, C-aromatic), 129.49 (CH, C-aromatic), 144.66 (C, C-aromatic), 149.46 (C, C-aromatic), 152.01 (C, C-aromatic), 162.75 (C, C-aromatic), 166.96 (C, C-aromatic), 167.99 (C, C-aromatic) ppm. MS(ESI)+: 458.2 [M+H]+ Melting point (from acetone/n-hexane) 121-123° C.
    • Example 95 Synthesis of N-(2,3,4-trimethoxy-6-((3-morpholinopropyl)carbamoyl)phenyl) nicotinamide (132)
  • Figure US20190248756A1-20190815-C00258
  • Compound 132 was obtained as a white powder in 23% yield. 1H-NMR (500 MHz, CDCl3): δ 1.70-1.76 (m, 2H), 2.43 (s, 2H), 2.48 (t, J=5.5 Hz, 2H), 3.42-3.52 (m, 8H), 3.66 (t, J=4.4 Hz, 3H), 3.94 (s, 3H), 3.96 (s, 3H), 6.85 (s, 1H), 7.45 (dd, J=4.8, 7.9 Hz, 1H), 7.52 (d, J=26.4 Hz, 1H), 8.22-8.29 (m, 1H), 8.80 (dd, J=4.8, 1.5 Hz, 1H), 9.25-9.13 (m, 2H) ppm. 13C-NMR (126 MHz, CDCl3): δ 24.82 (CH2, C-aliphatic), 39.85 (CH2, C-aliphatic), 53.69 (CH2, C-aliphatic), 56. (CH3, C-aliphatic), 57.73 (CH2, C-aliphatic), 60.99 (CH3, C-aliphatic), 61.02 (CH3, C-aliphatic), 66.93 (CH3, C-aliphatic), 106.38 (CH, C-aromatic), 123.03 (C, C-aromatic), 123.50 (CH, C-aromatic), 126.44 (C, C-aromatic), 130.09 (C, C-aromatic), 135.28 (CH, C-aromatic), 144.86 (C, C-aromatic), 148.95 (CH, C-aromatic), 149.11 (C, C-aromatic), 151.64 (C, C-aromatic), 152.63 (CH, C-aromatic), 164.99 (C, C-aromatic), 168.06 (C, C-aromatic) ppm. MS(ESI)+: 458.2 [M+H]+. Melting point (from acetone/n-hexane) 120-122° C.
    • Example 96 Synthesis of N-(5-fluoro-2-(3-morpholinopropylcarbamoyl)phenyl)nicotinamide (133)
  • Figure US20190248756A1-20190815-C00259
  • Compound 133 was obtained as a white powder in 57% yield. 1H-NMR (500 MHz, CDCl3): δ 1.72-1.88 (m, 2H), 2.36-2.47 (m, 2H), 2.53 (bs, 4H), 3.52 (dd, J=5.8, 10.6 Hz, 2H), 3.65 (s, 4H), 6.79 (ddd, J=2.6, 7.4, 8.8 Hz, 1H), 7.37 (s, 1H), 7.55 (dd, J=6.2, 8.5 Hz, 1H), 8.19-8.30 (m, 1H), 8.61 (dd, J=2.6, 11.6 Hz, 1H), 8.64 (d, J=14.1 Hz, 1H), 8.71 (dd, J=1.5, 4.8 Hz, 1H), 9.23 (d, J=1.8 Hz, 1H), 12.89 (s, 1H) ppm. 13C-NMR (126 MHz, CDCl3): δ 23.15 (CH2, C-aliphatic), 41.20 (CH2, C-aliphatic), 53.84 (CH2, C-aliphatic), 59.11 (CH2, C-aliphatic), 66.86 (CH2, C-aliphatic), 108.76 (CH, C-aromatic), 109.97 (CH, C-aromatic), 116.08 (C, C-aromatic), 123.51 (CH, C-aromatic), 128.62 (CH, C-aromatic), 130.18 (C, C-aromatic), 134.91 (CH, C-aromatic), 142.23 (C, C-aromatic), 149.23 (CH, C-aromatic), 152.65 (CH, C-aromatic), 163.95 (C, C-aromatic), 165.97 (C, C-aromatic), 168.42 (C, C-aromatic) ppm. 19F-NMR (CDCl3): δ −103.82 ppm. Melting point (from dichloromethane/n-hexane) 127-129° C.
    • Example 97 Synthesis of N-(2-(3-morpholinopropylcarbamol)phenyl)nicotinamide (134)
  • Figure US20190248756A1-20190815-C00260
  • Compound 134 was obtained as a white powder in 79% yield. 1H-NMR (500 MHz, CDCl3): δ 1.72-1.77 (m, 2H), 2.43-2.46 (m, 4H), 2.54 (t, J=5.9 Hz, 2H), 3.52 (td, J=4.5, 6 Hz, 2H), 3.64 (t, J=4.5 Hz, 4H), 7.10 (td, J=1.5, 7.75 Hz, 1H), 7.38 (ddd, J=1, 5, 8 Hz, 1H), 7.47-7.51 (m, 1H), 7.55 (dd, J=1.5, 8 Hz, 1H), 8.24-8.26 (m, 1H), 8.67 (s, 1H), 8.70 (dd, J=1.5, 4.5 Hz, 1H), 8.76 (dd, J=1.2, 8.5 Hz, 1H), 9.24 (dd, J=1.1, 2.25 MHz, 1H), 12.62 (bs, H) ppm. 13C-NMR (126 MHz, CDCl3): δ 23.30 (CH2, C-aliphatic), 41.02 (CH2, C-aliphatic), 53.88 (CH2, C-aliphatic), 59.09 (CH2, C-aliphatic), 66.89 (CH2, C-aliphatic), 120.23 (C, C-aromatic), 121.55 (CH, C-aromatic), 123.03 (CH, C-aromatic), 123.49 (CH, C-aromatic), 126.86 (CH, C-aromatic), 130.50 (C, C-aromatic), 132.82 (CH, C-aromatic), 134.90 (CH, C-aromatic), 139.75 (C, C-aromatic), 149.19 (CH, C-aromatic), 152.41 (CH, C-aromatic), 163.69 (C, C-aromatic), 168.96 (C, C-aromatic) ppm. Melting point (from ethanol) 99-101° C.
    • Example 98 Synthesis of 2-(4-methoxybenzamido)-N-(3-morpholinopropyl)benzamide (138)
  • Figure US20190248756A1-20190815-C00261
  • Compound 138 was obtained as a white powder in 67% yield. 1H-NMR (500 MHz, CDCl3): δ 1.74 (dt, J=5.9, 11.6 Hz, 2H), 2.45 (s, 4H), 2.53 (d, J=5.5 Hz, 2H), 3.52 (dd, J=5.8, 10.7 Hz, 2H), 3.63 (t, J=4.4 Hz, 4H), 3.80 (s, 3H), 6.83-6.96 (m, 2H), 7.04 (td, J=1.2, 7.8 Hz, 1H), 7.42-7.48 (m, 1H), 7.51 (dd, J=1.3, 7.9 Hz, 1H), 7.99-7.79 (m, 2H), 8.55 (s, 1H), 8.75 (dd, J=1.0, 8.4 Hz, 1H), 12.23 (s, 1H) ppm. 13C-NMR (126 MHz, CDCl3): δ 23.37 (CH2, C-aliphatic), 41.15 (CH2, C-aliphatic), 53.87 (CH2, C-aliphatic), 55.44 (CH3, C-aliphatic), 59.12 (CH2, C-aliphatic), 66.89 (CH2, C-aliphatic), 113.95 (CH, C-aromatic), 120.35 (C, C-aromatic), 121.53 (CH, C-aromatic), 122.30 (CH, C-aromatic), 126.77 (CH, C-aromatic), 127.33 (C, C-aromatic), 129.34 (CH, C-aromatic), 132.64 (CH, C-aromatic), 140.40 (C, C-aromatic), 162.46 (C, C-aromatic), 165.20 (C, C-aromatic), 169.26 (C, C-aromatic) ppm. Melting point (from dichloromethane) 108-110° C.
    • Example 99 Synthesis of N-(4,5-dimethoxy-2-(3-morpholinopropylcarbamoyl)phenyl) nicotinamide (139)
  • Figure US20190248756A1-20190815-C00262
  • Compound 139 was obtained as a white powder in 74% yield. 1H-NMR (500 MHz, CDCl3): δ 1.81 (d, J=16.7 Hz, 2H), 1.83-1.91 (m, 2H), 2.53 (s, 3H), 2.58 (dd, J=11.0, 17.1 Hz, 2H), 3.60 (dd, J=5.6, 11.4 Hz, 2H), 3.73 (d, J=4.0 Hz, 3H), 3.95 (s, 3H), 4.04 (d, J=7.5 Hz, 2H), 7.10 (s, 1H), 7.47-7.64 (m, 1H), 7.98 (s, 1H), 8.24-8.43 (m, 1H), 8.63 (d, J=22.8 Hz, 1H), 8.79 (dd, J=1.4, 4.8 Hz, 1H), 9.32 (d, J=1.8 Hz, 1H), 12.85 (s, 1H) ppm. 13C-NMR (126 MHz, CDCl3): δ 24.17 (CH2, C-aliphatic), 40.30 (CH2, C-aliphatic), 53.82 (CH2, C-aliphatic), 56.12 (CH3, C-aliphatic), 57.56 (CH3, C-aliphatic), 58.34 (CH2, C-aliphatic), 66.74 (CH2, C-aliphatic), 104.93 (CH, C-aromatic), 111.67 (CH, C-aromatic), 111.77 (C, C-aromatic), 123.49 (CH, C-aromatic), 130.57 (C, C-aromatic), 134.78 (CH, C-aromatic), 136.03 (C, C-aromatic), 144.47 (C, C-aromatic), 149.14 (CH, C-aromatic), 152.37 (CH, C-aromatic), 153.09 (C, C-aromatic), 163.66 (C, C-aromatic), 168.95 (C, C-aromatic) ppm. Melting point (from ethyl acetate/n-hexane) 69-71° C.
    • Example 100 Synthesis of 2-(2-fluorobenzamido)-4,5-dimethoxy-N-(3-morpholinopropyl) benzamide (141)
  • Figure US20190248756A1-20190815-C00263
  • Compound 141 was obtained as a white powder. 1H-NMR (500 MHz, CDCl3): δ 1.71 (dd, J=26.1, 31.9 Hz, 2H). 2.43 (s, 3H), 2.46 (bs, 4H), 3.47 (dt, J=15.4, 30.9 Hz, 2H), 3.51-3.71 (m, 3H), 3.85 (s, 3H), 3.93 (s, 3H), 6.98 (s, 1H), 7.12 (ddd, J=0.9, 8.3, 11.2 Hz, 2H), 7.42 (dddd, J=1.8, 5.1, 7.1, 8.3 Hz, 1H), 7.67 (s, 1H), 7.95 (td, J=1.8, 7.7 Hz, 1H), 8.47 (s, 1H), 12.01 (s, 1H) ppm. 13C-NMR (126 MHz, CDCl3): δ 24.30 (CH2, C-aliphatic), 40.11 (CH2, C-aliphatic), 53.76 (CH2, C-aliphatic), 56.09 (CH3, C-aliphatic), 57.34 (CH3, C-aliphatic), 58.24 (CH2, C-aliphatic), 66.72 (CH2, C-aliphatic), 105.82 (CH, C-aromatic), 111.34 (CH, C-aromatic), 116.50 (CH, C-aromatic), 116.69 (CH, C-aromatic), 124.59 (CH, C-aromatic), 124.62 (CH, C-aromatic), 131.26 (CH, C-aromatic), 133.28 (C, C-aromatic), 135.04 (C, C-aromatic), 144.51 (C, C-aromatic), 152.48 (C, C-aromatic), 159.03 (C, C-aromatic), 161.27 (C, C-aromatic), 162.99 (C, C-aromatic), 168.55 (C, C-aromatic) ppm. 19F-NMR (CDCl3): δ −112.59 ppm. Melting point 75-77° C.
    • Example 101 Synthesis of N-(2-methoxy-6-((3-morpholinopropyl)carbamoyl)phenyl) nicotinamide (142)
  • Figure US20190248756A1-20190815-C00264
  • Compound 142 was obtained as a white powder in 51% yield. 1H-NMR (500 MHz, CDCl3): δ 1.70 (dd, J=5.9, 11.9 Hz, 2H), 2.44 (s, 3H), 2.47 (d, J=18.6 Hz, 4H), 3.24-3.42 (m, 2H), 3.65 (bs, 4H), 3.84 (s, 3H), 7.04 (bs, 2H), 7.32-7.47 (m, 1H), 8.03 (s, 1H), 8.12-8.24 (m, 1H), 8.69 (dd, J=1.6, 4.8 Hz, 1H), 9.14 (d, J=1.7 Hz, 1H), 9.55 (s, 1H) ppm. 13C-NMR (126 MHz, CDCl3): δ 23.91 (CH2, C-aliphatic), 40.17 (CH2, C-aliphatic), 53.61 (CH2, C-aliphatic), 56.26 (CH3, C-aliphatic), 58.20 (CH2, C-aliphatic), 66.67 (CH2, C-aliphatic), 114.31 (CH, C-aromatic), 118.90 (CH, C-aromatic), 123.42 (CH, C-aromatic), 125.38 (C, C-aromatic), 126.68 (CH, C-aromatic), 130.14 (C, C-aromatic), 130.89 (C, C-aromatic), 135.36 (CH, C-aromatic), 149.19 (CH, C-aromatic), 152.47 (CH, C-aromatic), 154.33 (C, C-aromatic), 163.94 (C, C-aromatic), 168.40 (C, C-aromatic) ppm. Melting point (from ethanol) 125-127° C.
    • Example 102 Synthesis of 2-(methylthio)-N-(2-((3-morpholinopropyl)carbamoyl)phenyl) nicotinamide (143)
  • Figure US20190248756A1-20190815-C00265
  • Compound 143 was obtained as a white powder in 68% yield. 1H-NMR (500 MHz, CDCl3): δ 1.73 (dt, J=5.9, 11.4 Hz, 2H), 2.46 (s, 3H), 2.48 (s, 4H), 2.51-2.55 (m, 2H), 3.47 (dd, J=5.8, 10.7 Hz, 2H), 3.64 (d, J=4.1 Hz, 4H), 7.02 (dd, J=12.0, 16.9 Hz, 1H), 7.04-7.14 (m, 1H), 7.43-7.52 (m, 1H), 7.52 (d, J=7.8 Hz, 1H), 7.89 (dd, J=1.7, 7.7 Hz, 1H), 8.49 (dd, J=1.7, 4.8 Hz, 1H), 8.61 (s, 1H), 8.71 (dd, J=0.9, 8.4 Hz, 1H), 12.11 (s, 1H) ppm. 13C-NMR (126 MHz, CDCl3): δ 13.91 (CH3, C-aliphatic), 23.25 (CH2, C-aliphatic), 40.96 (CH2, C-aliphatic), 53.79 (CH2, C-aliphatic), 58.96 (CH2, C-aliphatic), 66.76 (CH2, C-aliphatic), 118.49 (CH, C-aromatic), 120.47 (C, C-aromatic), 121.76 (CH, C-aromatic), 123.02 (CH, C-aromatic), 126.79 (CH, C-aromatic), 129.04 (C, C-aromatic), 132.71 (CH, C-aromatic), 134.84 (CH, C-aromatic), 139.75 (C, C-aromatic), 150.69 (CH, C-aromatic), 160.57 (C, C-aromatic), 165.19 (C, C-aromatic), 169.02 (C, C-aromatic) ppm. Melting point 128-130° C.
    • General Procedure 4:
  • The compounds of the application with the general formula below can be prepared according to the synthetic scheme shown in Scheme 4.
  • Figure US20190248756A1-20190815-C00266
  • To a solution of compound (II) or (II′) (1 equivalent) in N,N-dimethyl-formamide (DMF) is added 2 equivalents of N,N-diisopropylethylamine (DIPEA) and 2.2 equivalent of 2-(4-methylpiperazin-1-yl)ethanamine (Va). The reaction mixture is stirred at about 15° C. to about 28° C. for about 6 hours to about 24 hours. The reaction mixture is diluted with water, washed with ethyl acetate, washed with brine, dried over Mg2SO4, filtered and evaporated to give a crude compound which is then purified by silica gel column using a mixture of Chloroform:Methanol (9:1) as eluent. The product is collected under reduced pressure to provide the compound shown in Scheme 4.
  • Compounds 38-46, 102, 111, 112, and 118 were prepared according to General Procedure 4 substituting (II) or (II′) with the appropriate substituted compound.
    • Example 103 Synthesis of 2-(4-nitrobenzamido)-N-(2-(piperazin-1-yl)ethyl)benzamide (38)
  • Figure US20190248756A1-20190815-C00267
  • Compound 38 was obtained as a yellow solid in 13% yield. 1H-NMR (500 MHz, CDCl3): δ 12.73 (s, 1H, ArNHCO), 8.85 (d, J=8.25, 1H, CONHCH2), 8.39 (d, J=9, 2H), 8.24 (d, J=9, 2H), 7.6 (q, J=7.5, 2H), 7.22 (t, J=6.75, 1H), 7.2 (s, 1H), 3.58 (q, J=5.25, 2H, NHCH2 CH 2), 3.00 (t, J=4.7, 4H), 2.67 (t, J=6.05, 2H, NHCH2 CH 2), 2.6 (s, 5H). 13C-NMR (126 MHz, CDCl3): δ 169.02 (ArC═O), 163.29 (ArC═O), 149.76 (ArC), 140.50 (ArC), 139.85 (ArC), 133.06 (ArCH). 128.61 (ArCH), 126.61 (ArCH), 123.99 (ArCH), 123.57 (ArCH), 121.54 (ArCH), 119.80 (ArC), 56.33 (CH2), 53.35 (CH2), 45.71 (CH2), 36.07 (CH2). MS (ESI): 398.2 [M+1]. m.p. (from ethanol/water): 98° C.
    • Example 104 Synthesis of 2-(4-chlorobenzamido)-N-(2-(piperazin-1-yl)ethyl)benzamide (39)
  • Figure US20190248756A1-20190815-C00268
  • Compound 39 was obtained as a yellow solid in 63% yield. 1H-NMR (500 MHz, CDCl3): δ 12.38 (s, 1H, ArNHCO), 8.78 (d, J=8.4, 1H, CONHCH2), 7.98 (d, J=8.4, 2H), 7.56-7.50 (m, 2H), 7.47 (d, J=8.4, 2H′), 7.26-7.24 (m, 1H), 7.13 (t, J=7.35, 1H), 3.54 (q, J=5.8, 2H, NHCH 2CH2), 2.91 (t, J=4.2, 4H), 2.61 (t, J=5.75, 2H, NHCH2CH 2), 2.56-2.41 (m, 5H). 13C-NMR (126 MHz, CDCl3): δ 169.10 (ArC═O), 164.47 (ArC═O), 139.96 (ArC), 138.06 (ArC), 133.29 (ArC), 132.73 (ArCH), 129.00 (ArCH), 128.85 (ArCH), 126.71 (ArCH), 123.04 (ArCH), 121.44 (ArCH), q20.18 (ArC), 56.58 (CH2), 53.91 (CH2), 45.96 (CH2), 36.13 (CH2). MS (ESI): 387.2 [M+1]. m.p. (from ethanol/water): 60° C.
    • Example 105 Synthesis of N-(2-(piperazin-1-yl)ethyl)-2-(3-(trifluoromethyl)benzamido) benzamide (40)
  • Figure US20190248756A1-20190815-C00269
  • Compound 40 was obtained as a white powder in 36% yield. 1H-NMR (CDCl3): δ 1.70 (s, 1H), 2.52 (s, 4H), 2.64 (s, 2H), 2.94 (s, 4H), 3.57 (d, J=4.7 Hz, 2H), 7.14-7.22 (m, 2H), 7.58 (dd, J=7.4, 13.1 Hz, 2H), 7.67 (t, J=7.5 Hz, 1H), 7.82 (d, J=7.5 Hz, 1H), 8.22 (d, J=7.7 Hz, 1H), 8.38 (s, 1H), 8.84 (d, J=8.1 Hz, 1H), 12.56 (s, 1H) ppm. 13C-NMR (CDCl3): δ 36.08 (CH2, C-aliphatic), 46.12 (CH2, C-aliphatic), 54.01 (CH2, C-aliphatic), 56.44 (CH2, C-aliphatic), 120.22 (C, C-aromatic), 121.61 (CH, C-aromatic), 123.22 (CH, C-aromatic), 125.07 (CH, C-aromatic), 125.10 (CH, C-aromatic), 126.52 (CH, C-aromatic), 128.27 (CH, C-aromatic), 128.30 (CH, C-aromatic), 129.33 (CH, C-aromatic), 130.08 (CH, C-aromatic), 131.51 (C, C-aromatic), 132.85 (CH, C-aromatic), 135.88 (C, C-aromatic), 139.99 (C, C-aromatic), 164.04 (C, C-aromatic), 169.00 (C, C-aromatic) ppm. 19F-NMR (CDCl3): δ −62.90 ppm. MS(ESI)+: 421.2 [M+H]+. m.p.: (from ethanol/H2O) 67-70° C.
    • Example 106 Synthesis of N-(2-(piperazin-1-yl)ethyl)-2-(2-(trifluoromethyl)benzamido) benzamide (41)
  • Figure US20190248756A1-20190815-C00270
  • Compound 41 was obtained as a white powder in 21% yield. 1H-NMR (CDCl3): δ 1.76 (s, 1H), 2.50 (s, 4H), 2.59 (dd, J=10.4, 16.3 Hz, 2H), 2.94 (t, J=4.8 Hz, 4H), 3.48 (dd, J=5.7, 10.9 Hz, 2H), 7.03 (s, 1H), 7.20 (td, J=1.1, 7.8 Hz, 1H), 7.52 (dt, J=5.7, 11.3 Hz, 1H), 7.58 (td, J=2.9, 8.1 Hz, 2H), 7.66 (t, J=7.2 Hz, 1H), 7.71 (d, J=7.5 Hz, 1H), 7.77 (d, J=7.8 Hz, 1H), 8.80 (d, J=8.3 Hz, 1H), 11.65 (s, 1H) ppm. 13C-NMR (CDCl3): δ 35.99 (CH2, C-aliphatic), 46.05 (CH2, C-aliphatic), 53.91 (CH2, C-aliphatic), 56.47 (CH2, C-aliphatic), 120.46 (C, C-aromatic), 121.76 (CH, C-aromatic), 123.45 (CH, C-aromatic), 126.49 (CH, C-aromatic), 126.73 (CH, C-aromatic), 126.77 (CH, C-aromatic), 128.15 (CH, C-aromatic), 129.99 (CH, C-aromatic), 132.17 (CH, C-aromatic), 132.73 (C, C-aromatic), 136.35 (C, C-aromatic) 139.48 (C, C-aromatic), 166.12 (C, C-aromatic), 168.67 (C, C-aromatic) ppm. 19F-NMR (CDCl3): δ −58.94 ppm. MS(ESI)+: 421.2 [M+H]+.
    • Example 107 Synthesis of 2-(4-methoxybenzamido)-N-(2-(piperazin-1-yl)ethyl)benzamide (42)
  • Figure US20190248756A1-20190815-C00271
  • Compound 42 was obtained as a yellow solid in 23% yield. 1H-NMR (500 MHz, CDCl3): δ 12.19 (s, 1H, ArNHCO), 8.83 (d, J=8.05, 1H, CONHCH2), 8.03 (d, J=8.05, 2H), 7.58-7.49 (m, 2H), 7.16-7.07 (m, 2H), 7.01 (d, J=6.9, 2H), 3.89 (s, 3H, OCH3), 3.56 (q, J=4.55, 2H, NHCH2CH 2), 2.99-2.91 (m, 4H), 2.63 (t, J=5.7, 2H, NHCH2CH 2), 2.60-2.48 (m, 5H). 13C-NMR (126 MHz, CDCl3): δ 169.20 (ArC═O), 165.18 (ArC═O), 162.47 (ArC), 140.33 (ArC), 132.68 (ArCH), 129.31 (ArCH), 127.23 (ArC), 126.57 (ArCH), 122.60 (ArCH), 121.53 (ArCH), 120.25 (ArC), 113.96 (ArCH), 56.46 (CH2), 55.45 (CH3), 53.67 (CH2), 45.93 (CH2), 36.10 (CH2). MS (ESI): 383.2 [M+1]. m.p. (from ethanol/water): 91° C.
    • Example 108 Synthesis of 3,5-difluoro-N-(2-((2-(piperazin-1-yl)ethyl)carbamoyl)phenyl) benzamide (43)
  • Figure US20190248756A1-20190815-C00272
  • Compound 43 was obtained as a yellow solid in 17% yield. 1H-NMR (500 MHz, CDCl3): δ 12.5 (s, 1H, ArNHCO), 8.78 (d, J=7.9, 1H, CONHCH2), 7.61-7.52 (m, 4H), 7.18 (q, J=7.3, 2H), 7.00 (t, J=9.8, 1H), 3.57 (q, J=4.15, 2H, NHCH 2CH2), 2.95 (t, J=4.55, 4H), 2.64 (t, J=5.3, 2H, NHCH2CH 2), 2.59-2.44 (m, 5H). 13C-NMR (126 MHz, CDCl3): δ 168.96 (ArC═O), 163.03 (ArC═O), 139.79 (ArC), 138.47 (ArC), 132.90 (ArCH), 126.59 (ArCH), 123.39 (ArCH), 121.57 (ArCH), 120.09 (ArC), 110.75 (d, JC-F=6.3, ArCH), 110.59 (d, JC-F=6.3, ArCH), 107.16 (t, JC-F=26.46, 25.2, ArCH), 56.47 (CH2), 53.57 (CH2), 45.82 (CH2), 36.06 (CH2). MS (ESI): 389.2 [M+1]. m.p. (from ethanol/water): 68° C.
    • Example 109 Synthesis of 2,6-difluoro-N-(2-((2-(piperazin-1-yl)ethyl)carbamoyl)phenyl) benzamide (44)
  • Figure US20190248756A1-20190815-C00273
  • Compound 44 was obtained as a white solid in 33.5% yield. 1H-NMR (500 MHz, CDCl3): δ 11.81 (s, 1H, ArNHCO), 8.81 (d, J=7.25, 1H, CONHCH2), 7.57-7.50 (m, 2H), 7.39 (q, J=7.25, 1H), 7.18-7.12 (m, 2H), 7.0 (t, J=7.25, 2H), 3.49 (q, J=5.2, 2H, NHCH 2CH2), 2.94-2.88 (m, 4H), 2.59 (t, J=5.2, 2H, NHCH2CH 2), 2.47 (s, 4H), 1.96 (s, 1H). 13C-NMR (126 MHz, CDCl3): δ 168.63 (ArC═O), 160.97 (d, JC-F=7.56, ArC), 158.93 (t, J=7.56, ArC), 139.15 (ArC), 132.64 (ArCH), 131.78 (t, JC-F=10.08, 10.08, ArCH), 126.58 (ArCH), 123.57 (ArCH), 121.75 (ArCH), 120.69 (ArC), 112.24 (d, JC-F=5.04, ArCH), 112.07 (d, JC-F=3.78, ArCH), 56.52 (CH2), 54.12 (CH2), 46.16 (CH2), 36.04 (CH2). MS (ESI): 389.2 [M+1]. m.p. (from ethanol/water): 79° C.
    • Example 110 Synthesis of 2,4-difluoro-N-(2-((2-(piperazin-1-yl)ethyl)carbamoyl)phenyl) benzamide (45)
  • Figure US20190248756A1-20190815-C00274
  • Compound 45 was obtained as a white solid in 12% yield. 1H-NMR (500 MHz, CDCl3): δ 11.86 (d, J=6.5, 1H, ArNHCO), 8.7 (d, J=8.5, 1H, CONHCH2), 8.07 (q, J=6.9, 1H), 7.54-7.47 (m, 2H), 7.16-7.09 (m, 2H), 6.99 (t, J=7.95, 1H.), 6.92 (t, J=9.8, 1H), 3.51 (q, J=5.35, 2H, NHCH 2CH2), 2.9 (t, J=4.75, 4H), 2.58 (t, 5.85, 2H, NHCH2CH 2), 2.49 (s, 4H), 1.25 (s, 1H). 13C-NMR (126 MHz, CDCl3): δ 168.68 (ArC═O), 161.29 (ArC═O), 138.99 (ArC), 133.35 (d, JC-F=10.08, ArCH), 132.45 (ArCH), 126.68 (ArCH), 123.54 (ArCH), 121.77 (ArC), 112.26 (d, JC-F=21.42, ArCH), 104.70 (t, JC-F=26.46, ArCH), 56.42 (CH2), 52.01 (CH2), 44.86 (CH2), 36.11 (CH2). MS (ESI): 389.2 [M+1]. m.p. (from ethanol/water): 84° C.
    • Example 111 Synthesis of 2-fluoro-4-methoxy-N-(2-((2-(piperazin-1-yl)ethyl)carbamoyl) phenyl)benzamide (46)
  • Figure US20190248756A1-20190815-C00275
  • Compound 46 was obtained as a yellow powder in 23% yield. 1H-NMR (500 MHz, CDCl3): δ 2.48 (4H, s), 2.54 (2H, m), 2.90 (4H, t, J=4.82 Hz), 3.47 (2H, m), 3.79 (3H, s), 6.62 (1H, dd, J=2.42, 13.31 Hz), 6.76 (1H, dd, J=2.44, 13.30 Hz), 7.07 (1H, td, J=1.08, 7.59 Hz), 7.43 (3H, m), 7.96 (1H, t, J=8.90 Hz), 8.64 (1H, dd, J=0.70, 8.46 Hz), 11.59 (1H, m) ppm. m.p. (from DCM/n-hexane): 107-109° C.
    • Example 112 Synthesis of 2-(3-chlorobenzamido)-N-(2-(piperazin-1-yl)ethyl)benzamide (102)
  • Figure US20190248756A1-20190815-C00276
  • Compound 102 was obtained as a yellow solid in 63% yield. 1H-NMR (500 MHz, CDCl3): δ 2.41-2.56 (m, 5H), 2.61 (t, J=5.75 Hz, 2H), 2.91 (t, J=4.2 Hz, 4H), 3.54 (q, J=5.8 Hz, 2H), 7.13 (t, J=7.35 Hz, 1H), 7.24-7.28 (m, 1H), 7.47 (d, J=8. 4 Hz, 2H), 7.50-7.56 (m, 2H), 7.98 (d, J=8.4 Hz, 2H), 8.78 (d, J=8.4 Hz, 1H), 12.38 (s, 1H) ppm. 13C-NMR (126 MHz, CDCl3): δ 36.13 (CH2, C-aliphatic), 45.96 (CH2, C-aliphatic), 53.91 (CH2, C-aliphatic), 56.58 (CH2, C-aliphatic), 120.18 (C, C-aromatic), 121.44 (CH, C-aromatic), 123.04 (CH, C-aromatic), 126.71 (CH, C-aromatic), 128.85 (CH, C-aromatic), 129.00 (CH, C-aromatic), 132.73 (CH, C-aromatic), 133.29 (C, C-aromatic), 138.06 (C, C-aromatic), 139.96 (C, C-aromatic), 164.47 (C, C-aromatic), 169.10 (C, C-aromatic) ppm. MS (ESI)+: 387.2 [M+H]+. m.p. (from ethanol/water): 59-61° C.
    • Example 113 Synthesis of 2-fluoro-6-(4-methoxybenzamido)-N-(2-(piperazin-1-yl)ethyl)benzamide (111)
  • Figure US20190248756A1-20190815-C00277
  • Compound 111 was obtained as a white powder in 34% yield. 1H-NMR (500 MHz, CDCl3): 2.25 (d, J=14.7 Hz, 4H), 2.58 (dd, J=21.6, 15.7 Hz, 8H), 3.49 (s, 3H), 7.05 (s, 1H), 7.09 (dd, J=16.9, 9.5 Hz, 1H), 7.52-7.44 (m, 2H), 7.58 (t, J=7.8 Hz, 1H), 7.73 (d, J=7.8 Hz, 1H), 8.13 (d, J=7.8 Hz, 1H), 8.29 (s, 1H), 8.75 (d, J=8.4 Hz, 1H), 12.46 (s, 1H) ppm. 13C-NMR (CDCl3): δ 36.37 (CH2, C-aliphatic), 46.13 (CH2, C-aliphatic), 53.98 (CH2, C-aliphatic), 55.47 (CH3, C-aliphatic), 56.03 (CH2, C-aliphatic), 109.92 (CH, C-aromatic), 113.99 (CH, C-aromatic), 117.33 (CH, C-aromatic), 127.07 (C, C-aromatic), 129.40 (CH, C-aromatic), 132.89 (CH, C-aromatic), 132.98, 141.87 (C, C-aromatic), 159.62 (C, C-aromatic), 161.79 (C, C-aromatic), 162.57 (C, C-aromatic), 165.27 (C, C-aromatic) ppm. 19F-NMR (CDCl3): δ −111.78 ppm. MS(ESI)+: 401.2 [M+H]+. Melting point: (from Ethanol/water) 96-98° C.
    • Example 114 Synthesis of 2-fluoro-6-(3-methoxybenzamido)-N-(2-(piperazin-1-yl)ethyl) benzamide (112
  • Figure US20190248756A1-20190815-C00278
  • Compound 112 was obtained as a white powder in 45% yield. 1H-NMR (CDCl3): δ 1.30 (s, 1H), 2.04 (d, J=32.0 Hz, 1H), 2.52 (s, 3H), 2.61 (dd, J=10.8, 16.8 Hz, 2H), 2.95 (t, J=4.4 Hz, 4H), 3.59 (d, J=5.2 Hz, 2H), 3.91 (s, 3H), 6.90 (dd, J=8.5, 11.7 Hz, 1H), 7.09-7.14 (m, 1H), 7.41-7.52 (m, 2H), 7.60-7.70 (m, 3H), 8.70 (d, J=8.4 Hz, 1H), 12.67 (s, 1H) ppm. 13C-NMR (CDCl3): δ 36.35 (—CH2, C-aliphatic), 45.85 (—CH2, C-aliphatic), 53.48 (—CH2, C-aliphatic), 55.46 (—CH3, C-aliphatic), 55.97 (—CH2, C-aliphatic), 108.99 (C, C-aromatic), 110.26 (CH, C-aromatic), 110.46 (CH, C-aromatic), 112.50 (CH, C-aromatic), 117.42 (CH, C-aromatic), 118.51 (CH, C-aromatic), 119.26 (CH, C-aromatic), 129.84 (CH, C-aromatic), 132.97 (C, C-aromatic), 136.24 (C, C-aromatic), 141.88 (C, C-aromatic), 159.94 (C, C-aromatic), 161.79 (C, C-aromatic), 165.55 (C, C-aromatic) ppm. 19F-NMR (CDCl3): δ −111.66 ppm. MS(ESI)+: 401.2 [M+H]+. Melting point: (from Ethanol/water) 83-85° C.
    • Example 115 Synthesis of N-(2-(piperazin-1-yl)ethyl)-2-(4-(trifluoromethyl)benzamido) benzamide (118)
  • Figure US20190248756A1-20190815-C00279
  • Compound 118 was obtained as a white powder in 18% yield. 1H-NMR (CDCl3): δ 1.67 (s, 2H), 2.42-2.57 (m, 4H), 2.59-2.72 (m, 2H), 2.95 (t, J=4.8 Hz, 3H), 3.55 (dt, J=12.7, 25.5 Hz, 2H), 7.00-7.19 (m, 1H), 7.13 (s, 1H), 7.49-7.64 (m, 2H), 7.80 (d, J=8.2 Hz, 2H), 8.10-8.18 (m, 2H), 8.86 (dt, J=3.3, 6.5 Hz, 1H), 12.50 (d, J=62.6 Hz, 1H) ppm. 13C-NMR (CDCl3): δ 36.07 (CH2, C-aliphatic), 46.07 (CH2, C-aliphatic), 53.92 (CH2, C-aliphatic), 56.41 (CH2, C-aliphatic), 120.46 (C, C-aromatic), 121.58 (CH, C-aromatic), 123.26 (CH, C-aromatic), 125.82 (CH, C-aromatic), 126.54 (CH, C-aromatic), 127.87 (CH, C-aromatic), 132.89 (CH, C-aromatic), 138.60 (C, C-aromatic), 140.01 (C, C-aromatic), 164.70 (C, C-aromatic), 166.14 (C, C-aromatic), 168.65 (C, C-aromatic) ppm. 19F-NMR (CDCl3): δ −62.98 ppm. MS(ESI)+: 421.2 [M+H]+.
    • General Procedure 5:
  • The compounds of the application with the general formula shown below can be prepared according to the synthetic scheme shown in Scheme 5.
  • Figure US20190248756A1-20190815-C00280
  • To a solution of compound (II) or (II′) (1 equivalent) in N,N-dimethyl-formamide (DMF) is added 2 equivalents of N,N-diisopropylethylamine (DIPEA) and 2.2 equivalent of 2-(4-methylpiperazin-1-yl)ethanamine (VIa). The reaction mixture is stirred at about 15° C. to about 28° C. for about 6 hours to about 24 hours. The reaction mixture is diluted with water, washed with ethyl acetate, washed with brine, dried over Mg2SO4, filtered and evaporated to give a crude compound which is then purified by silica gel column using a mixture of Chloroform:Methanol (9:1) as eluent. The product is collected under reduced pressure to provide the compound with the general formula shown in Scheme 5.
  • Compounds 47-65, 101, 107-110, and 114-117 were prepared according to General Procedure 5 substituting (II) or (II′) with the appropriate substituted compound.
    • Example 116 Synthesis of 2-benzamido-N-(2-(4-methylpiperazin-1-yl)ethyl)benzamide (47)
  • Figure US20190248756A1-20190815-C00281
  • Compound 47 was obtained as a white powder in 88% yield. 1H-NMR (500 MHz, CDCl3): δ 12.28 (s, 1H, ArNHCO), 8.86 (dd, J=8.5, 0.8 1H, CONHCH2), 8.07 (dd, J=8.2, 1.3, 2H), 7.58-7.51 (m, 5H), 7.16 (td, J=7.6, 0.9, 1H), 7.07 (s, 1H), 3.57 (q, J=5.45, 2H, NHCH2CH2), 2.66 (t, J=5.45, 2H, NHCH2CH2), 2.64-2.38 (m, 8H), 2.34 (s, 3H, CH3). 13C-NMR (126 MHz, CDCl3): δ 169.11 (ArC═O), 165.57 (ArC═O), 140.17 (ArC), 134.92 (ArC), 132.69 (ArCH), 131.78 (ArCH), 128.75 (ArCH), 127.41 (ArCH), 126.56 (ArCH), 122.84 (ArCH), 121.62 (ArCH), 120.42 (ArC), 55.90 (CH2), 55.10 (CH2), 52.66 (CH2), 45.92 (CH3), 36.27 (CH2). MS (ESI): 367.2 [M+1]. m.p. (from ethanol/water): 80° C.
    • Example 117 Synthesis of N-(2-(4-methylpiperazin-1-yl)ethyl)-2-(4-nitrobenzamido) benzamide (48)
  • Figure US20190248756A1-20190815-C00282
  • Compound 48 was obtained as a white solid in 85% yield. 1H-NMR (500 MHz, CDCl3): δ 12.73 (s, 1H, ArNHCO), 8.85 (dd, J=8.45, 0.9, 1H, CONHCH2), 8.37 (d, J=8.95, 2H), 8.23 (d, J=8.9, 2H), 7.61-7.55 (m, 2H), 7.21 (td, J=7.35, 1.15, 1H), 7.18 (s, 1H), 3.57 (q, J=5.35, 2H, NHCH 2CH2), 2.67 (t, J=5.9, 2H, NHCH2CH 2), 2.65-2.42 (m, 8H), 2.34 (s, 3H, CH3). 13C-NMR (126 MHz, CDCl3): δ 168.98 (C═O), 163.27 (ArC═O), 149.77 (ArC), 140.51 (ArC), 139.87 (ArC), 132.97 (ArCH), 128.59 (ArCH), 126.61 (ArCH), 123.96 (ArCH), 123.51 (ArCH), 121.51, 119.99 (ArC), 55.79 (CH2), 55.11 (CH2), 52.68 (CH2), 45.94 (CH3), 36.27 (CH2). MS (ESI): 412.2 [M+1]. m.p. (from ethanol/water): 122° C.
    • Example 118 Synthesis of 2-fluoro-N-(2-((2-(4-methylpiperazin-1-yl)ethyl)carbamoyl) phenyl)benzamide (49)
  • Figure US20190248756A1-20190815-C00283
  • Compound 49 was obtained as a white solid in 25% yield. 1H-NMR (500 MHz, CDCl3): δ 11.83 (d, J=6.5, 1H, ArNHCO), 8.73 (d, J=8.1, 1H, CONHCH2), 8.03 (td, J=7.7, 1.85, 1H), 7.52-7.45 (m, 3H), 7.26 (td, J=7.55, 1, 1H), 7.18 (dd, J=8.3, 0.9, 1H), 7.13 (td, J=7.65, 1.05, 1H), 7.0 (s, 1H), 3.51 (q, J=4.5, 2H, NHCH 2CH2), 2.60 (t, J=6.1, 2H, NHCH2CH 2), 2.58-2.33 (m, 8H), 2.29 (s, 3H, CH3). 13C-NMR (126 MHz, CDCl3): δ 168.61 (ArC), 162.28 (d, JC-F=2.52, ArC), 161.33 (ArC═O), 159.3 (ArC), 139.05 (ArC), 133.32 (d, JC-F=8.82, ArC), 132.21 (ArCH), 131.46 (ArCH), 126.68 (ArCH), 124.59 (ArCH), 123.34 (ArCH), 122.80 (ArCH), 122.37 (ArCH), 121.96 (ArC), 116.52 (d, JC-F=23.94, ArC), 55.99 (CH2), 55.11 (CH2), 52.70 (CH2), 45.94 (CH3), 36.31 (CH2). MS (ESI): 385.2 [M+1]. m.p. (from ethanol/water): 116° C.
    • Example 119 Synthesis of 2-(3-fluorobenzamido)-N-(2-(4-methylpiperazin-1-yl)ethyl) benzamide (50)
  • Figure US20190248756A1-20190815-C00284
  • Compound 50 was obtained as a white solid in 67% yield. 1H-NMR (500 MHz, CDCl3): δ 12.40 s, 1H, ArNHCO), 8.83 (d, J=9.75, 1H, CONHCH2), 7.83 (d, J=4.98, 1H), 7.78 (d, J=9.95, 1H), 7.60-7.54 (m, 2H), 7.53-7.48 (m, 1H), 7.26 (td, J=4.99, 1H), 7.18 (t, J=9.41, 1H), 7.12 (s, 1H), 3.57 (q, J=4.98, 2H, NHCH 2CH2), 2.67 (t, J=5, 2H, NHCH2CH 2), 2.65-2.37 (m, 8H), 2.35 (s, 3H, CH3). 13C-NMR (126 MHz, CDCl3): δ 169.04 (ArC═O), 164.24 (ArC═O), 163.94 (ArC), 161.97 (ArC), 139.97 (ArC), 137.33 (ArC), 132.81 (ArCH), 130.41 (d, JC-F=7.56, ArCH), 126.60 (ArCH), 123.12 (ArCH), 122.73 (d, JC-F=2.52, ArCH), 121.58 (ArCH), 120.23 (ArC), 118.82 (d, JC-F=21.42, ArCH), 115.92 (d, JC-F=22.68, ArCH), 55.86 (CH2), 55.03 (CH2), 52.59 (CH2), 45.88 (CH3), 36.23 (CH2). MS (ESI): 385.2 [M+1]. m.p. (from ethanol/water): 81° C.
    • Example 120 Synthesis of 2-(3-chlorobenzamido)-N-(2-(4-methylpiperazin-1-yl)ethyl) benzamide (51)
  • Figure US20190248756A1-20190815-C00285
  • Compound 51 was obtained as a white solid in 7% yield. 1H-NMR (500 MHz, CDCl3): δ 12.39 (s, ArNHCO), 8.83 (d, J=8.1, 1H, CONHCH2), 8.01 (d, J=8.1, 2H), 7.59-7.53 (m, 2H), 7.49 (d, J=8.1, 2H), 7.18 (t, J=7.55, 1H), 7.13 (s, 1H), 3.57 (q, J=5, NHCH2CH 2), 2.68 (t, J=5.6, 2H, NHCH 2CH2), 2.66-2.40 (m, 8H), 2.35 (s, 3H, CH3). 13C-NMR (126 MHz, CDCl3): δ 169.10 (ArC═O), 164.46 (ArC═O), 140.08 (ArC), 138.09 (ArC), 133.33 (ArC), 132.83 (ArCH), 129.02 (ArCH), 128.87 (ArCH), 126.61 (ArCH), 123.04 (ArCH), 121.53 (ArCH), 120.13 (ArC), 55.84 (CH2), 55.00 (CH2), 52.54 (CH2), 45.85 (CH3), 36.21 (CH2). MS (ESI): 401.2 [M+1]. m.p. (from ethanol/water): 104° C.
    • Example 121 Synthesis of 2-(4-chlorobenzamido)-N-(2-(4-methylpiperazin-1-yl)ethyl) benzamide (52)
  • Figure US20190248756A1-20190815-C00286
  • Compound 52 was obtained as a white solid in 6% yield. 1H-NMR (500 MHz, CDCl3): δ 12.56 (s, 1H, ArNHCO), 9.32 (d, J=5.02, 1H, CONHCH2), 8.84 (d, J=10.03, 1H), 8.79 (dd, J=5, 0.0065, 1H), 8.33 (dt, J=10.00, 4.99, 1H), 7.62-7.55 (m, 2H), 7.47 (dd, J=9.9, 4.9, 1H), 7.20 (t, J=9.95, 1H), 7.17 (s, 1H), 3.57 (t, J=5.02, 2H, NHCH2CH 2), 2.68 (t, J=5.27, 2H, NHCH2CH 2), 2.66-2.42 (m, 8H), 2.35 (s, 3H, CH3). 13C-NMR (126 MHz, CDCl3): δ 169.08 (ArC═O), 164.46 (ArC═O), 140.06 (ArC), 138.08 (ArC), 133.32 (ArC), 132.80 (ArCH), 129.01 (ArCH), 128.87 (ArCH), 126.59 (ArCH), 123.03 (ArCH), 121.52 (ArCH), 120.15 (ArC), 55.82 (CH2), 55.09 (CH2), 52.65 (CH2), 45.94 (CH3), 36.25 (CH2). MS (ESI): 401.2 [M+1]. m.p. (from ethanol/water): 99° C.
    • Example 122 Synthesis of 2-methoxy-N-(2-((2-(4-methylpiperazin-1-yl)ethyl)carbamoyl) phenyl)benzamide (53)
  • Figure US20190248756A1-20190815-C00287
  • Compound 53 was obtained as a yellow solid in 78% yield. 1H-NMR (500 MHz, CDCl3): δ 11.76 (s, 1H, ArNHCO), 8.71 (d, 1H, NHCH2CH2), 8.22 (dd, J=8, 1.5, 1H), 7.54-7.44 (m, 3H), 7.14 (t, J=8, 1H), 7.10 (t, J=8, 1, 1H), 7.03 (d, J=8, 1H), 6.73 (s, 1H), 3.55 (q, J=5.5, 2H, NHCH2CH 2), 2.61 (t, J=6, 2H, NHCH2CH 2), 2.59-2.36 (m, 8H), 2.31 (s, 3H, CH3). 13C-NMR (126 MHz, CDCl3): δ 168.71 (ArC═O), 164.21 (ArC═O), 157.75 (ArC), 138.41 (ArC), 133.07 (ArCH), 132.28 (ArCH), 131.63 (ArCH), 126.64 (ArCH), 124.45 (ArC), 123.18 (ArCH), 123.11 (ArCH), 122.51 (ArC) 120.92 (ArCH), 11.38 (ArCH), 56.23 (CH2), 55.69 (CH3), 55.04 (CH2), 52.69 (CH2), 45.88 (CH3), 36.25 (CH2). MS (ESI): 397.2 [M+1]. m.p. (from ethanol/water): 111° C.
    • Example 123 Synthesis of 2-(4-methoxybenzamido)-N-(2-(4-methylpiperazin-1-yl)ethyl) benzamide (54)
  • Figure US20190248756A1-20190815-C00288
  • Compound 54 was obtained as a white solid in 76% yield. 1H-NMR (500 MHz, CDCl3): δ 12.18 (s, 1H, ArNHCO), 8.80 (d, J=10, 1H, CONHCH2), 8.1 (d, J=8.45, 2H), 7.54-7.48 (m, 2H), 7.15 (s, 1H), 7.09 (t, J=6, 1H), 7.0 (d, J=9, 2H), 3.90 (s, 3H, OCH3), 3.54 (q, J=5.1, 2H, NHCH 2CH2), 2.63 (t, J=6, 2H, NHCH2CH 2), 2.61-2.34 (m, 8H), 2.30 (s, 3H, CH3). 13C-NMR (126 MHz, CDCl3): δ 169.21 (ArC═O), 165.18 (ArC═O), 162.49 (ArC), 140.30 (ArC), 132.58 (ArCH), 129.30 (ArCH), 127.25 (ArC), 126.63 (ArCH), 122.56 (ArCH), 121.46 (ArCH), 120.27 (ArC), 113.96 (ArCH), 56.00 (CH2), 55.42 (CH3), 55.08 (CH2), 52.70 (CH2), 45.92 (CH3), 36.33 (CH2). MS (ESI): 397.2 [M+1]. m.p. (from ethanol/water): 114° C.
    • Example 124 Synthesis of 2,6-difluoro-N-(2-((2-(4-methylpiperazin-1-yl)ethyl)carbamoyl) phenyl)benzamide (55)
  • Figure US20190248756A1-20190815-C00289
  • Compound 55 was obtained as a white solid in 54% yield. 1H-NMR (500 MHz, CDCl3): δ 11.8 (s, ArNHCO), 8.81 (d, J=8.05, 1H, CONHCH2), 7.57-7.52 (m, 2H), 7.40 (q, J=6.5, 1H), 7.18 (t, J=7.5, 1H), 7.08 (s, 1H), 6.99 (t, J=8, 2H), 3.50 (q, J=6, 2H, NHCH 2CH2), 2.62 (t, J=6.5, 2H, NHCH2CH 2), 2.60-2.38 (m, 8H), 2.32 (s, 3H, CH3). 13C-NMR (126 MHz, CDCl3): δ168.64 (ArC═O), 161.69 (d, JC-F=7.56, ArC), 158.95 (t, JC-F=12.6, 7.56, ArC), 156.44 (ArC), 149.33 (ArC), 143.33 (ArC), 129.91 (ArCH), 122.76 (ArC), 114.13 (ArC), 55.92 (CH2), 55.08 (CH2), 52.66 (CH2), 50.59 (CH2), 56.43 (CH3), 36.23 (CH2). MS (ESI): 314.1 [M+1]. m.p. (from ethanol/water): 81° C.
    • Example 125 Synthesis of 3,5-difluoro-N-(2-((2-(4-methylpiperazin-1-yl)ethyl)carbamoyl) phenyl)benzamide (56)
  • Figure US20190248756A1-20190815-C00290
  • Compound 56 was obtained as a white solid in 65% yield. 1H-NMR (500 MHz, CDCl3): δ 12.51 (s, 1H, ArNHCO), 8.8 (d, J=8.1, 1H, CONHCH2), 7.59 (d, J=7.85, 3H), 7.55 (d, J=7.80, 1H, H6), 7.19 (td, J=7.2, 0.9, 1H), 7.11 (s, 1H), 7.00 (tt, J=8.65, 2.1, 1H), 3.57 (q, J=5.4, 2H, NHCH 2CH2), 2.66 (t, J=5.85, 2H, NHCH2CH 2), 2.64-2.37 (m, 8H), 2.33 (s, 3H, CH3). 13C-NMR (126 MHz, CDCl3): δ 168.92 (ArC═O), 164.08 (d, JC-F=12.6, ArC), 163.11 (ArC═O), 162.54 (d, JC-F=11.34, ArC), 139.84 (ArC), 132.85 (ArCH), 126.54 (ArCH), 123.33 (ArCH), 121.57 (ArCH), 120.13 (ArC), 110.75 (d, JC-F=7.56, ArCH), 110.59 (d, JC-F=7.56, ArCH), 107.12 (t, JC-F=25.2, ArCH), 55.85 (CH2), 55.13 (CH2), 55.70 (CH2), 45.96 (CH3), 36.25 (CH2). MS (ESI): 403.2 [M+1]. m.p. (from ethanol/water): 111° C.
    • Example 126 Synthesis of 2,4-difluoro-N-(2-((2-(4-methylpiperazin-1-yl)ethyl)carbamoyl) phenyl)benzamide (57)
  • Figure US20190248756A1-20190815-C00291
  • Compound 57 was obtained as a yellow solid in 85% yield. 1H-NMR (500 MHz, CDCl3): δ 11.89 (s, 1H, ArNHCO), 8.75 (d, J=8.3, 1H, CONHCH2), 8.11 (q, J=8.85, 1H), 7.55 (t, J=8.05, 1H), 7.51 (dd, J=7.8, 1.25, 1H), 7.2 (td, J=7.6, 1, 1H), 7.02 (t, J=8.2, 1H), 6.97-6.92 (m, 2H), 3.54 (q, J=5.45, 2H, NHCH 2CH2), 2.64 (t, J=6.1, 2H, NHCH2CH 2), 2.61-2.36 (m, 8H), 2.32 (s, 3H, CH3). 13C-NMR (126 MHz, CDCl3): δ 168.59 (ArC═O), 165.88 (ArC═O), 163.85 (ArC), 161.93 (ArC), 161.32 (ArC), 139.10 (ArC), 133.31 (dd, J=3.78, ArCH), 132.35 (ArCH), 126.59 (ArCH), 123.44 (ArCH), 122.46 (ArCH), 121.83 (ArC), 112.17 (dd, JC-F=2.52, 18.9, ArCH), 104.67 (t, JC-F=27.72, 25.2, ArCH), 55.92 (CH2), 55.16 (CH2), 52.73 (CH2), 45.98 (CH3), 36.25 (CH2). MS (ESI): 403.2 [M+1]. m.p. (from ethanol/water): 121-122° C. Acc. Mass (CI, M+1) C21H26FN4O2, calc.: 385.2034; found: 385.2036.
    • Example 127 Synthesis of 2-fluoro-4-methoxy-N-(2-((2-(4-methylpiperazin-1-yl)ethyl) carbamoyl)phenyl)benzamide (58)
  • Figure US20190248756A1-20190815-C00292
  • Compound 58 was obtained as a yellow powder in 30% yield. 1H-NMR (500 MHz, CDCl3): δ 1.36 (1H, d, J=2.37 Hz), 2.29 (3H, s), 2.56 (8H, m), 3.48 (3H, s), 3.79 (3H, s), 6.62 (1H, dd, J=2.44, 13.30 Hz), 6.74 (1H, t, J=4.44 Hz), 6.8 (1H, s) 7.07 (1H, m), 7.44 (2H, m), 7.97 (1H, d, J=8.91 Hz), 8.64 (1H, dd, J=0.99, 8.76 Hz), 11.60 (1H, d, J=7.7 Hz) ppm. 13C-NMR (126 MHz, CDCl3): δ 36.14 (CH2, C-aliphatic), 45.36 (CH3, C-aliphatic), 52.02 (CH2, C-aliphatic), 54.56 (CH2, C-aliphatic), 55.82 (CH3, C-aliphatic), 56.16 (CH2, C-aliphatic), 101.87 (CH, C-aromatic), 110.70 (CH, C-aliphatic), 122.06 (C, C-aromatic), 122.62 (CH, C-aromatic), 123.71 (CH, C-aromatic), 126.71 (CH, C-aromatic), 132.26 (CH, C-aromatic), 132.89 (CH, C-aromatic), 139.18 (C, C-aromatic), 160.3 (C, C-aliphatic), 162.5 (C, C-aliphatic) 168.78 (C, C-aliphatic), 178.0 (C, C═O), 179.7 (C, C═O) ppm. 19F-NMR (CDCl3): δ −109.26 ppm. MS (ESI)+: 415.2 [M+H]+. m.p.: 110-112° C.
    • Example 128 Synthesis of 2-(2-fluorobenzamido)-4,5-dimethoxy-N-(2-(4-methylpiperazin-1-yl)ethyl)benzamide (59)
  • Figure US20190248756A1-20190815-C00293
  • Compound 59 was obtained as a white solid in 89% yield. 1H-NMR (500 MHz, CDCl3): δ 12.12 (d, J=5.5, 1H, ArNHCO), 8.49 (s, 1H, CONHCH2), 7.95 (t, J=6.65, 1H), 7.43 (q, J=6.35, 1H′), 7.20 (t, J=6.95, 1H), 7.18-7.09 (m, 2H), 6.99 (s, 1H), 3.93 (s, 3H, C5OCH 3), 3.84 (s, 3H, C4OCH 3), 3.44 (q, J=5.45, 2H, NHCH 2CH2), 2.54 (t, J=5.51, 2H, NHCH2CH 2), 2.52-2.24 (m, 8H), 2.21 (s, 3H). 13C-NMR (126 MHz, CDCl3): δ 168.32 (ArC═O), 162.25 (ArC═O), 161.25 (ArC), 159.25 (ArC), 151.81 (ArC), 144.37 (ArC), 134.75 (ArC), 133.24 (d, JC-F=8.82, ArCH), 131.12 (d, JC-F=1.26, ArCH), 124.57 (d, JC-F=2.52, ArCH), 116.52 (d, JC-F=22.68, ArCH), 112.82 (ArC), 109.48 (ArCH), 105.43 (ArCH), 56.21 (CH3), 56.04 (CH3), 55.99 (CH2), 55.14 (CH2), 52.57 (CH2), 45.95 (CH3), 36.09 (CH2). MS (ESI): 445.2 [M+1]. m.p. (from ethanol/water): 60° C.
    • Example 129 Synthesis of 6-(2-fluorobenzamido)-2,3,4-trimethoxy-N-(2-(4-methyl piperazin-1-yl)ethyl)benzamide (60)
  • Figure US20190248756A1-20190815-C00294
  • Compound 60 was obtained as a white solid in 51.4% yield. 1H-NMR (500 MHz, CDCl3): δ 8.71 (d, J=13.65, 1H, ArNHCO), 8.16 (t, J=6.85, 1H), 7.57 (q, J=5.7, 1H), 7.32 (t, J=6.85, 1H), 7.23 (dd, J=11.2, 8.55, 1H), 6.99 (s, 1H), 6.92 (s, 1H, CONHCH2), 3.94 (s, 3H, OCH3), 3.93 (s, 3H, OCH3), 3.92 (s, 3H, OCH3), 3.49 (q, J=5.1, NHCH 2CH2), 2.58-2.48 (m, 2H, NHCH2CH 2), 2.48-2.33 (m, 8H), 2.29 (s, 3H, N—CH 3). 13C-NMR (126 MHz, CDCl3): δ 167.41 (ArC═O), 163.09 (ArC═O), 161.87 (ArC), 159.89 (ArC), 152.16 (ArC), 148.75 (ArC), 144.19 (ArC), 133.33 (d, JC-F=8.82, ArCH), 132.28 (ArCH), 128.47 (ArC), 124.90 (d, JC-F=3.78, ArCH), 121.35 (ArC), 116.36 (d, JC-F=25.2, ArCH), 106.74 (ArCH), 61.11 (CH3), 61.01 (CH3), 56.30 (CH2), 56.27 (CH3), 54.91 (CH2), 52.64 (CH2), 45.90 (CH3), 36.40 (CH2). MS (ESI): 475.3 [M+1]. m.p. (from ethanol/water): 130° C.
    • Example 130 Synthesis of 4,5-dimethoxy-2-(4-methoxybenzamido)-N-(2-(4-methyl piperazin-1-yl)ethyl)benzamide (61)
  • Figure US20190248756A1-20190815-C00295
  • Compound 61 was obtained as a white solid in 6% yield. 1H-NMR (500 MHz, CDCl3): δ 12.49 (s, 1H, ArNHCO), 8.65 (s, 1H, CONHCH2), 8.03 (d, J=8.9, 2H), 7.12 (s, 1H), 7.02 (s, 1H), 7.00 (d, J=1.55, 2H), 4.02 (s, 3H, OCH3), 3.94 (s, 3H, OCH3), 3.88 (s, 3H, OCH3), 3.55 (q, J=5.25, 2H, NHCH 2CH2), 2.68 (t, J=6.15, NHCH2CH 2), 2.66-2.35 (m, 8H), 2.32 (s, 3H, N—CH 3). 13C-NMR (126 MHz, CDCl3): δ 168.87 (ArC═O), 165.18 (ArC═O), 162.43 (ArC), 152.43 (ArC), 143.95 (ArC), 136.39 (ArC), 129.20 (ArCH), 127.27 (ArC), 113.98 (ArCH), 11.14 (ArC), 109.37 (ArCH), 104.61 (ArCH), 56.42 (CH3), 56.13 (CH3), 55.78 (CH2), 55.43 (CH2), 55.22 (CH3), 52.56 (CH2), 46.01 (CH3), 35.98 (CH2). MS (ESI): 457.3 [M+1]. m.p. (from ethanol/water): 70° C.
    • Example 131 Synthesis of 2,3,4-trimethoxy-6-(4-methoxybenzamido)-N-(2-(4-methylpiperazin-1-yl)ethyl)benzamide (62)
  • Figure US20190248756A1-20190815-C00296
  • Compound 62 was obtained as a white solid in 38% yield. 1H-NMR (500 MHz, CDCl3): δ 8.65 (s, 1H, ArNHCO), 7.95 (d, J=8.5, 2H), 7.03-7.00 (1H, CONHCH2), 6.98 (d, J=8.5), 2H), 6.91 (s, 1H), 3.93 (s, 3H, C4′OCH3), 3.91 (s, 3H, OCH3), 3.9 (s, 3H, OCH3), 3.89 (s, 3H, OCH3), 3.43 (q, J=5.3, 2H, NHCH 2CH2), 2.47 (t, J=5.7, 2H, NHCH2CH 2), 2.44-2.31 (m, 8H), 2.27 (s, 3H, N—CH3). 13C-NMR (126 MHz, CDCl3): δ 167.83 (ArC═O), 166.67 (ArC═O), 162.72 (ArC), 151.87 (ArC), 149.18 (ArC), 144.50 (ArC), 129.49 (ArCH), 127.65 (ArC), 126.22 (ArC), 122.68 (ArC), 113.95 (ArCH), 106.43 (ArCH), 61.07 (CH3), 61.00 (CH3), 56.32 (CH3), 56.23 (CH2), 55.51 (CH2), 54.77 (CH3), 52.38 (CH2), 45.71 (CH3), 36.32 (CH2). MS (ESI): 487.3 [M+1]. m.p. (from ethanol/water): 115° C.
    • Example 132 Synthesis of N-(2-((2-(4-methylpiperazin-1-yl)ethyl)carbamoyl)phenyl) nicotinamide (63)
  • Figure US20190248756A1-20190815-C00297
  • Compound 63 was obtained as a white solid in 27% yield. 1H-NMR (500 MHz, CDCl3): δ 12.56 (s, 1H, ArNHCO), 9.31 (d, J=1.95, 1H, CONHCH2), 8.83 (d, J=8.1, 1H), 8.78 (dd, J=4.9, 1.55, 1H), 8.32 (dt, J=8.05, 1.95, 1H), 7.59-7.52 (m, 2H), 7.45 (dd, J=7.8, 5, 1H), 7.17 (td, J=7.45, 0.95, 1H), 7.14 (s, 1H), 3.55 (q, J=5.5, 2H, NHCH 2CH2), 2.65 (t, J=5.7, 2H, NHCH2CH 2), 2.63-2.24 (m, 8H), 2.32 (s, 3H, CH3). 13C-NMR (126 MHz, CDCl3): δ 168.98 (ArC═O), 163.73 (ArC═O), 152.43 (ArCH), 149.20 (ArCH), 139.92 (ArC), 134.83 (ArCH), 132.81 (ArCH), 130.50 (ArC), 126.56 (ArCH), 123.44 (ArCH), 123.25 (ArCH), 121.58 (ArCH), 120.15 (ArC), 55.83 (CH2), 55.17 (CH2), 52.74 (CH2), 45.99 (CH3), 29.68 (CH2). MS (ESI): 368.2 [M+1]. m.p. (from ethanol/water): 99° C. Acc. Mass (CI, M+1) C20H26N5O2, calc.: 368, 2081; found: 368.2083.
    • Example 133 Synthesis of N-(4,5-dimethoxy-2-((2-(4-methylpiperazin-1-yl)ethyl)carbamoyl) phenyl)nicotinamide (64)
  • Figure US20190248756A1-20190815-C00298
  • Compound 64 was obtained as a white solid in 46.84% yield. 1H-NMR (500 MHz, CDCl3): δ 12.86 (s, 1H, ArNHCO), 9.28 (d, J=2.05, 1H, CONHCH2), 8.75 (dd, J=4.9, 1.6, 1H), 8.59 (s, 1H), 8.30 (dt, J=8.15, 1.8, 1H), 7.44 (dd, J=7.9, 4.85, 1H), 7.27 (s, 1H), 7.03 (s, 1H), 3.99 (s, 3H, OCH3), 3.91 (s, 3H, OCH3), 3.53 (q, J=5.3, 2H, NHCH 2CH2), 2.65 (t, J=6.1, 2H, NHCH2CH 2), 2.62-2.30 (m, 8H), 2.28 (s, 3H, N—CH 3). 13C-NMR (126 MHz, CDCl3): δ 168.73 (ArC═O), 163.59 (ArC═O), 152.39 (ArC), 152.32 (ArCH), 149.10 (ArCH), 144.38 (ArC), 135.75 (ArC), 134.73 (ArCH), 130.53 (ArC), 123.49 (ArCH), 111.18 (ArC), 109.27 (ArCH), 104.56 (ArCH), 56.31 (CH3), 56.15 (CH3), 55.87 (CH2), 55.25 (CH2), 55.62 (CH2), 46.04 (CH3), 36.03 (CH2). MS (ESI): 428.2 [M+1]. m.p. (from ethanol/water): 126° C.
    • Example 134 Synthesis of N-(3,4,5-trimethoxy-2-((2-(4-methylpiperazin-1-yl)ethyl) carbamoyl)phenyl)nicotinamide (65)
  • Figure US20190248756A1-20190815-C00299
  • Compound 65 was obtained as a white solid in 7% yield. 1H-NMR (500 MHz, CDCl3): δ 9.22 (d, J=2.1, 1H, ArNHCO), 9.2 (s, 1H, CONHCH2), 8.8 (dd, J=5.1, 1.5, 1H), 8.28 (td, J=8.1, 1.8, 1H), 7.45 (dd, J=7.8, 4.8, 1H), 7.02 (s, 1H), 6.9 (s, 1H), 3.95 (s, 3H, OCH3), 3.94 (s, 3H, OCH3), 3.93 (s, 3H, OCH3), 3.47 (q, J=5.7, 2H, NHCH 2CH2), 2.58 (t, J=6, NHCH2CH 2), 2.55-2.34 (m, 8H), 2.32 (s, 3H, N—CH 3). 13C-NMR (126 MHz, CDCl3): δ 167.89 (ArC═O), 164.90 (ArC═O), 152.66 (ArCH), 151.98 (ArC), 149.30 (ArC), 148.94 (ArCH), 144.77 (ArC), 135.37 (ArCH), 129.84 (ArC), 126.40 (ArC), 123.53 (ArCH), 122.68 (ArC), 106.06 (ArCH), 61.04 (CH3), 61.01 (CH3), 56.39 (CH3), 56.17 (CH2), 54.65 (CH2), 52.38 (CH2), 45.70 (CH3), 36.15 (CH2). MS (ESI): 458.3 [M+1]. m.p. (from ethanol/water): 143° C.
    • Example 135 Synthesis of 2-(3-methoxybenzamido)-N-(2-(4-methylpiperazin-1-yl)ethyl)benzamide (101)
  • Figure US20190248756A1-20190815-C00300
  • Compound 101 was obtained as a white solid in 76% yield. 1H-NMR (500 MHz, CDCl3):δ 2.30 (s, 3H), 2.61-2.34 (m, 8H), 2.63 (t, J=6 Hz, 2H), 3.54 (q, J=5.1 Hz, 2H), 3.90 (s, 3H), 7.0 (d, J=9 Hz, 2H), 7.09 (t, J=6, 1H), 7.15 (s, 1H), 7.48-7.54 (m, 2H), 8.1 (d, J=8.45 Hz, 2H), 8.80 (d, J=10 Hz, 1H), 12.18 (s, 1H) ppm. 13C-NMR (126 MHz, CDCl3): δ 36.33 (CH2, C-aliphatic), 45.92 (CH3, C-aliphatic), 52.70 (CH2, C-aliphatic), 55.08 (CH2, C-aliphatic), 55.42 (CH3, C-aliphatic), 56.00 (CH2, C-aliphatic), 113.96 (CH, C-aromatic), 120.27 (C, C-aromatic), 121.46 (CH, C-aromatic), 122.56 (CH, C-aromatic), 126.63 (CH, C-aromatic), 127.25 (C, C-aromatic), 129.30 (CH, C-aromatic), 132.58 (CH, C-aromatic), 140.30 (C, C-aromatic), 162.49 (C, C-aromatic), 165.18 (C, C-aromatic), 169.21 (C, C-aromatic) ppm. MS (ESI)+: 397.2 [M+H]+. m.p. (from ethanol/water): 113-115° C.
    • Example 136 Synthesis of 2-(4-fluorobenzamido)-N-(2-(4-methylpiperazin-1-yl)ethyl)benzamide (107)
  • Figure US20190248756A1-20190815-C00301
  • Compound 107 was obtained as a yellow powder in 44% yield. 1H-NMR (500 MHz, CDCl3): δ 2.24 (d, J=9.6 Hz, 3H), 2.50 (s, 7H), 2.54-2.61 (m, 3H), 3.47 (dd, J=5.6, 10.9 Hz, 2H), 7.00 (s, 1H), 7.08-7.16 (m, 3H), 7.39-7.51 (m, 2H), 8.03-7.93 (m, 2H), 8.79-8.68 (m, 1H), 12.26 (s, 1H) ppm. 13C-NMR (126 MHz, CDCl3): δ 36.24 (CH2, C-aliphatic), 45.96 (CH3, C-aliphatic), 52.67 (CH2, C-aliphatic), 55.13 (CH2, C-aliphatic), 55.80 (CH2, C-aliphatic), 115.80 (CH, C-aromatic), 120.16 (C, C-aromatic), 121.53 (CH, C-aromatic), 122.93 (CH, C-aromatic), 126.56 (CH, C-aromatic), 129.79 (CH, C-aromatic), 129.87 (CH, C-aromatic), 132.81 (C, C-aromatic), 140.17 (C, C-aromatic), 163.70 (C, C-aromatic), 164.46 (C, C-aromatic), 166.10 (C, C-aromatic), 169.12 (C, C-aromatic) ppm. 19F-NMR (CDCl3): δ −107.64 ppm. MS (ESI)+: 385.2 [M+H]+. m.p. (from diethyl ether/n-hexane): 89-91° C.
    • Example 137: Synthesis of N-(2-(4-methylpiperazin-1-yl)ethyl)-2-(4-trifluoromethyl)benzamido) benzamide (108)
  • Figure US20190248756A1-20190815-C00302
  • Compound 108 was obtained as a yellow powder in 23% yield. 1H-NMR (500 MHz, CDCl3): δ 2.26 (s, 3H), 2.49 (d, J=41.4 Hz, 7H), 2.57-2.62 (m, 2H), 3.45-3.50 (m, 2H), 7.04-7.13 (m, 2H), 7.46-7.53 (m, 2H), 7.70 (d, J=8.2 Hz, 2H), 8.09 (d, J=8.1 Hz, 2H), 8.76 (d, J=7.8 Hz, 1H), 12.46 (s, 1H) ppm. 13C-NMR (126 MHz, CDCl3): δ 36.23 (CH2, C-aliphatic), 45.82 (CH3, C-aliphatic), 52.56 (CH2, C-aliphatic), 54.97 (CH2, C-aliphatic), 55.89 (CH2, C-aliphatic), 120.12 (C, C-aromatic), 121.57 (CH, C-aromatic), 123.26 (CH, C-aromatic), 125.76 (CH, C-aromatic), 125.82 (CH, C-aromatic), 126.61 (CH, C-aromatic), 127.87 (CH, C-aromatic), 132.89 (C, C-aromatic), 133.26 (C, C-aromatic), 138.26 (C, C-aromatic), 139.99 (C, C-aromatic), 164.17 (C, C-aromatic), 169.06 (C, C-aromatic) ppm. 19F-NMR (CDCl3): δ −63.1 ppm. MS (ESI)+: 435.2 [M+H]+. m.p. (from diethyl ether/n-hexane): 68-71° C.
    • Example 138 Synthesis of 2-fluoro-6-(4-methoxybenzamido)-N-(2-(4-methylpiperazin-1-yl)ethyl)benzamide (109)
  • Figure US20190248756A1-20190815-C00303
  • Compound 109 was obtained as a white powder in 45% yield. 1H-NMR (500 MHz, CDCl3): δ 2.36 (s, 3H), 2.48-2.81 (m, 10H), 3.41-3.60 (m, 2H), 3.81 (s, 3H), 6.79 (dd, J=8.3, 11.6 Hz, 1H), 6.93 (d, J=8.8 Hz, 2H), 7.40 (dt, J=10.2, 15.0 Hz, 2H), 7.94 (d, J=8.9 Hz, 2H), 8.58 (d, J=8.5 Hz, 1H), 12.40 (s, 1H) ppm. 13C-NMR (126 MHz, CDCl3): δ 36.48 (CH2, C-aliphatic), 45.16 (CH3, C-aliphatic), 51.46 (CH2, C-aliphatic), 54.68 (CH2, C-aliphatic), 55.38 (CH2, C-aliphatic), 55.48 (CH3, C-aliphatic), 108.49 (C, C-aromatic), 109.89 (CH, C-aromatic), 114.01 (CH, C-aromatic), 117.44 (CH, C-aromatic), 128.88 (CH, C-aromatic), 132.96 (C, C-aromatic), 142.18 (CH, C-aromatic), 142.22 (C, C-aromatic), 159.95 (C, C-aromatic), 161.91 (C, C-aromatic), 162.63 (C, C-aromatic), 165.50 (C, C-aromatic) ppm. 19F-NMR (CDCl3): δ −111.87 ppm. MS (ESI)+: 415.2 [M+H]+. m.p. (from diethyl ether/n-hexane): 81-83° C.
    • Example 139 Synthesis of 2-fluoro-6-(3-methoxybenzamido)-N-(2-(4-methylpiperazin-1-yl)ethyl)benzamide (110)
  • Figure US20190248756A1-20190815-C00304
  • Compound 110 was obtained as a white powder in 18% yield. 1H-NMR (500 MHz, CDCl3): δ 2.30 (s, 3H), 2.41-2.73 (m, 10H), 2.80 (s, 3H), 3.48-3.55 (m, 2H), 6.79 (dd, J=8.3, 11.6 Hz, 1H), 6.93 (d, J=8.8 Hz, 2H), 7.40 (dt, J=10.2, 15.0 Hz, 2H), 7.94 (d, J=8.9 Hz, 2H), 8.58 (d, J=8.5 Hz, 1H), 12.20 (s, 1H) ppm. 13C-NMR (126 MHz, CDCl3): δ 36.43 (CH2, C-aliphatic), 51.76 (CH2, C-aliphatic), 55.39 (CH2, C-aliphatic), 55.47 (CH3, C-aliphatic), 55.62 (CH2, C-aliphatic), 112.56 (CH, C-aromatic), 119.23 (CH, C-aromatic), 121.06 (CH, C-aromatic), 123.14 (CH, C-aromatic), 123.18 (CH, C-aromatic), 129.88 (CH, C-aromatic), 131.04 (C, C-aromatic), 137.28 (CH, C-aromatic), 137.36 (C, C-aromatic), 142.22 (C, C-aromatic) 148.74 (C, C-aromatic), 159.90 (C, C-aromatic), 160.86 (C, C-aromatic), 162.99 (C, C-aromatic) ppm. 19F-NMR (CDCl3): δ −106.45 ppm. MS (ESI)+: 415.2 [M+H]+. m.p. (from diethyl ether/n-hexane): 108-110° C.
    • Example 140A Synthesis of N-(2-(4-methylpiperazin-1-yl)ethyl)-2-(3-(trifluoromethyl)benzamido) benzamide (114)
  • Figure US20190248756A1-20190815-C00305
  • Compound 114 was obtained as a white powder in 40.28% yield. 1H-NMR (500 MHz, CDCl3): δ 2.27 (s, 3H), 2.64-2.39 (m, 10H), 3.49 (dd, J=5.3, 11.2 Hz, 2H), 7.10 (dd, J=4.1, 11.0 Hz, 2H), 7.46-7.52 (m, 2H), 7.58 (t, J=7.8 Hz, 1H), 7.73 (d, J=7.8 Hz, 1H), 8.13 (d, J=7.8 Hz, 1H), 8.29 (s, 1H), 8.74 (d, J=8.3 Hz, 1H), 12.46 (s, 1H) ppm. 13C-NMR (126 MHz, CDCl3): δ 36.19 (CH2, C-aliphatic), 45.82 (CH3, C-aliphatic), 52.53 (CH2, C-aliphatic), 54.93 (CH2, C-aliphatic), 5.89 (CH2, C-aliphatic), 120.14 (CH, C-aromatic), 121.59 (CH, C-aromatic), 123.26 (CH, C-aromatic), 125.10 (CH, C-aromatic), 126.63 (CH, C-aromatic), 128.34 (CH, C-aromatic), 129.37 (CH, C-aromatic), 130.07 (C, C-aromatic), 132.90 (CH, C-aromatic), 135.82 (C, C-aromatic), 139.93 (C, C-aromatic), 164.06 (C, C-aromatic), 169.07 (C, C-aromatic), 171.98 (C, C-aromatic) ppm. 19F-NMR (CDCl3): δ −62.69 ppm. MS (ESI)+: 435.2 [M+H]+: m.p.: 101-103° C.
    • Example 140B Synthesis of 2-fluoro-N-(2-((2-(4-methylpiperazin-1-yl)ethyl)carbamoyl)phenyl)-4-(trifluoromethoxy)benzamide (115)
  • Figure US20190248756A1-20190815-C00306
  • Compound 115 was obtained as a white powder in 34% yield. 1H-NMR (500 MHz, CDCl3): δ 2.23 (s, 3H), 2.35-2.56 (m, 8H), 2.54 (t, J=5.9 Hz, 2H), 3.45 (dd, J=5.4, 10.7 Hz, 2H), 6.85 (s, 1H), 7.00 (d, J=11.1 Hz, 1H), 7.05-7.13 (m, 2H), 7.41-7.49 (m, 2H), 8.04 (t, J=8.5 Hz, 1H), 8.67 (d, J=8.4 Hz, 1H), 11.89 (d, J=5.5 Hz, 1H) ppm. 13C-NMR (126 MHz, CDCl3): δ 36.23 (CH2, C-aliphatic), 45.95 (CH3, C-aliphatic), 52.69 (CH2, C-aliphatic), 55.12 (CH2, C-aliphatic), 55.90 (CH2, C-aliphatic), 109.33 (CH, C-aromatic), 116.56 (CH, C-aromatic), 121.41 (C, C-aromatic), 122.43 (CH, C-aromatic), 123.59 (CH, C-aromatic), 126.61 (CH, C-aromatic), 132.44 (CH, C-aromatic), 133.01 (CH, C-aromatic), 139.07 (C, C-aromatic), 151.86 (C,C-aromatic), 159.33 (C, C-aromatic), 160.83 (C, C-aromatic), 161.81 (C, C-aromatic), 168.28 (C, C-aromatic) ppm. 19F-NMR (CDCl3): δ −57.86, −108.13 ppm. MS (ESI)+: 469.2 [M+H]+. m.p. (from diethyl ether/n-hexane): 69-71° C.
    • Example 141 Synthesis of 4-(4-methoxybenzamido)-N-(2-(4-methylpiperazin-1-yl)ethyl)nicotinamide (116)
  • Figure US20190248756A1-20190815-C00307
  • Compound 116 was obtained as a white powder in 15% yield. 1H-NMR (500 MHz, CDCl3): δ 2.25 (s, 3H), 2.35-2.56 (m, 7H), 2.56-2.61 (m, 3H), 3.49 (dd, J=5.6, 10.8 Hz, 2H), 3.81 (s, 3H), 6.91-6.96 (m, 2H), 7.12 (s, 1H), 7.89-8.00 (m, 2H), 8.53 (d, J=5.8 Hz, 1H), 8.68 (s, 1H), 8.70 (d, J=5.8 Hz, 1H), 12.41 (s, 1H) ppm. 13C-NMR (126 MHz, CDCl3): δ 36.16 (CH2, C-aliphatic), 45.91 (CH3, C-aliphatic), 52.63 (CH2, C-aliphatic), 55.09 (CH2, C-aliphatic), 55.48 (CH3, C-aliphatic), 55.56 (CH2, C-aliphatic), 114.16 (CH, C-aromatic), 114.43 (CH, C-aromatic), 114.95 (C, C-aromatic), 126.23 (C, C-aromatic), 129.60 (CH, C-aromatic), 147.25 (C, C-aromatic), 147.99 (CH, C-aromatic), 153.37 (CH, C-aromatic), 163.04 (C, C-aromatic), 165.22 (C, C-aromatic), 167.68 (C, C-aromatic) ppm. MS (ESI)+: 398.2 [M+H]+. m.p. (from dichloromethane/n-hexane): 83-85° C.
    • Example 142 Synthesis of N-(2-(piperazin-1-yl)ethyl)-2-(4-(trifluoromethyl)benzamido) benzamide (117)
  • Figure US20190248756A1-20190815-C00308
  • Compound 117 was obtained as a white powder in 38% yield. 1H-NMR (500 MHz, CDCl3): δ 2.24 (s, 3H), 2.35-2.47 (m, 7H), 2.51 (dd, J=8.3, 14.2 Hz, 3H), 3.39 (dd, J=5.6, 11.0 Hz, 2H), 6.91 (s, 1H), 7.11 (td, J=1.1, 7.8 Hz, 1H), 7.42 (dd, J=1.3, 7.9 Hz, 1H), 7.46-7.52 (m, 2H), 7.56 (t, J=7.3 Hz, 1H), 7.61 (d, J=7.4 Hz, 1H), 7.67 (d, J=7.8 Hz, 1H), 8.71 (d, J=8.3 Hz, 1H), 11.55 (s, 1H) ppm. 13C-NMR (126 MHz, CDCl3): δ 36.17 (CH2, C-aliphatic), 46.00 (CH3, C-aliphatic), 52.73 (CH2, C-aliphatic), 55.18 (CH2, C-aliphatic), 55.80 (CH2, C-aliphatic), 113.80 (C, C-aromatic), 120.68 (C, C-aromatic), 121.76 (CH, C-aromatic), 123.43 (CH, C-aromatic), 126.46 (CH, C-aromatic), 126.74 (CH, C-aromatic), 126.77 (C, C-aromatic), 128.14 (CH, C-aromatic), 129.99 (CH, C-aromatic), 132.17 (CH, C-aromatic), 132.72 (CH, C-aromatic), 139.50 (C, C-aromatic), 166.14 (C, C-aromatic), 168.65 (C, C-aromatic) ppm. 19F-NMR (CDCl3): δ −58.93 ppm. MS (ESI)+: 435.2 [M+H]+. m.p. (from ethanol/water): 124-126° C.
    • General Procedure 6:
  • The compounds of the application with the general formula shown below can be prepared according to the synthetic scheme shown in Scheme 6.
  • Figure US20190248756A1-20190815-C00309
  • To a solution of compound (II) or (II′) (1 equivalent) in N,N-dimethyl-formamide (DMF) is added 2 equivalents of N,N-diisopropylethylamine (DIPEA) and 2.2 equivalent of 2-phenethylamine (VIIa). The reaction mixture is stirred at about 15° C. to about 28° C. for about 12 hours to about 24 hours. The reaction mixture is diluted with water, washed with ethyl acetate, washed with brine, dried over Mg2SO4, filtered and evaporated to give a crude compound which is then purified by silica gel column using a mixture of Chloroform:Methanol (9:1) as eluent. The product is collected under reduced pressure to provide the compound with the general formula shown in Scheme 6.
  • Compounds 70-94, 100, 119, 122 were prepared according to General Procedure 6 substituting (II) or (II′) with the appropriate substituted compound.
    • Example 143 Synthesis of 2-nitro-N-(2-(phenethylcarbamoyl)phenyl)benzamide (70)
  • Figure US20190248756A1-20190815-C00310
  • Compound 70 was obtained as a white powder in 45% yield. 1H-NMR (CDCl3): δ 2.94 (t, J=6.8 Hz, 2H), 3.69 (dd, J=6.8, 12.8 Hz, 2H), 6.30 (s, 1H), 7.24-7.28 (m, 3H), 7.36 (t, J=7.4 Hz, 3H), 7.56 (t, J=7.3 Hz, 1H), 7.58-7.67 (m, 1H), 7.7-7.79 (m, 3H), 8.07-8.12 (m, 1H), 8.72 (d, J=8.3 Hz, 1H), 11.67 (s, 1H) ppm. 13C-NMR (CDCl3): δ 35.43 (CH2, C-aliphatic), 41.09 (CH2, C-aliphatic), 120.63 (C, C-aromatic), 121.98 (CH, C-aromatic), 123.65 (CH, C-aromatic), 124.74 (CH, C-aromatic), 126.28 (CH, C-aromatic), 126.81 (CH, C-aromatic), 128.49 (CH, C-aromatic), 128.80 (CH, C-aromatic), 128.85 (CH, C-aromatic), 130.78 (CH, C-aromatic), 132.88 (CH, C-aromatic), 133.06 (CH, C-aromatic), 133.77 (C, C-aromatic), 138.45 (CH, C-aromatic), 139.23 (C, C-aromatic), 147.02 (C, C-aromatic), 164.36 (C, C-aromatic), 168.81 (C, C-aromatic) ppm. MS(ESI)+: 390.2 [M+H]+. m.p.: (from ethanol/water) 101-105° C.
    • Example 144 Synthesis of 2-(3-nitrobenzamido)-N-phenethylbenzamide (71)
  • Figure US20190248756A1-20190815-C00311
  • Compound 71 was obtained as a white powder in 14% yield. 1H-NMR (CDCl3): δ 2.94 (t, J=6.8 Hz, 2H), 3.70 (dd, J=6.7, 12.8 Hz, 2H), 6.27 (s, 1H), 7.12 (dd, J=4.2, 11.0 Hz, 1H), 7.25 (t, J=8.4 Hz, 2H), 7.35 (t, J=7.3 Hz, 3H), 7.38-7.44 (m, 2H), 7.49 (dd, J=1.2, 7.9 Hz, 1H), 7.52-7.57 (m, 1H), 7.68 (dd, J=1.8, 7.4 Hz, 1H), 8.79 (d, J=8.4 Hz, 1H), 11.50 (s, 1H) ppm. 13C-NMR (CDCl3): δ 35.50 (CH2, C-aliphatic), 41.16 (CH2, C-aliphatic), 120.14 (C, C-aromatic), 121.59 (CH, C-aromatic), 123.06 (CH, C-aromatic), 123.47 (CH, C-aromatic), 126.26 (CH, C-aromatic), 126.34 (CH, C-aromatic), 126.86 (CH, C-aromatic), 128.80 (CH, C-aromatic), 128.86 (CH, C-aromatic), 129.96 (CH, C-aromatic), 132.76 (CH, C-aromatic), 133.02 (CH, C-aromatic), 136.79 (C, C-aromatic), 138.42 (C, C-aromatic), 139.66 (C, C-aromatic), 148.64 (C, C-aromatic), 163.06 (C, C-aromatic), 169.08 (C, C-aromatic) ppm. MS(ESI)+: 379.1 [M+H]+. m.p.: (from ethanol) 102-104° C.
    • Example 145 Synthesis of 2-(4-nitrobenzamido)-N-phenethylbenzamide (72)
  • Figure US20190248756A1-20190815-C00312
  • Compound 72 was obtained as a white powder in 34% yield. 1H-NMR (CDCl3): δ2.99 (t, J=6.8 Hz, 4H), 3.78 (dd, J=6.7, 12.8 Hz, 4H), 6.36 (s, 2H), 7.15 (td, J=7.8, 1.1 Hz, 2H), 7.27 (d, J=4.8 Hz, 3H), 7.43-7.33 (m, 6H), 7.64-7.54 (m, 2H), 8.26-8.15 (m, 4H), 8.45-8.35 (m, 4H), 8.82 (dd, J=0.8, 8.4 Hz, 2H), 12.54 (s, 2H) ppm. 13C-NMR (CDCl3): δ 35.51 (CH2, C-aliphatic), 41.14 (CH2, C-aliphatic), 120.17 (C, C-aromatic), 121.55 (CH, C-aromatic), 123.54 (CH, C-aromatic), 124.01 (CH, C-aromatic), 126.35 (CH, C-aromatic), 126.90 (CH, C-aromatic), 128.62 (CH, C-aromatic), 128.79 (CH, C-aromatic), 128.88 (CH, C-aromatic), 133.06 (CH, C-aromatic), 138.36 (C, C-aromatic), 139.65 (C, C-aromatic), 140.39 (C, C-aromatic), 150.01 (C, C-aromatic), 162.99 (C, C-aromatic), 168.95 (C, C-aromatic) ppm. MS(ESI)+: 390.2 [M+H]+. m.p.: (from ethanol/H2O) 133-137° C.
    • Example 146 Synthesis of 2-fluoro-N-(2-(phenethylcarbamoyl)phenyl)benzamide (73)
  • Figure US20190248756A1-20190815-C00313
  • Compound 73 was obtained as a white powder in 40% yield. 1H-NMR (CDCl3): δ 2.95 (t, J=6.8 Hz, 2H), 3.75 (dd, J=6.7, 12.8 Hz, 2H), 6.22 (s, 1H), 7.10 (t, J=7.7 Hz, 1H), 7.21-7.25 (m, 3H), 7.28-7.37 (m, 5H), 7.51-7.55 (m, 2H), 7.95-8.09 (m, 1H), 8.76 (d, J=8.4 Hz, 1H), 11.67 (d, J=7.1 Hz, 1H) ppm. 13C-NMR (CDCl3): δ 35.52 (CH2, C-aliphatic), 41.03 (CH2, C-aliphatic), 116.56 (C, C-aromatic), 122.18 (C, C-aromatic), 122.48 (CH, C-aromatic), 123.39 (CH, C-aromatic), 124.63 (CH, C-aromatic), 124.65 (CH, C-aromatic), 126.39 (CH, C-aromatic), 126.74 (CH, C-aromatic), 128.80 (CH, C-aromatic), 131.58 (CH, C-aromatic), 132.34 (CH, C-aromatic), 133.37 (CH, C-aromatic), 133.44 (CH, C-aromatic), 138.58 (C, C-aromatic), 138.87 (C, C-aromatic), 168.69 (C, C-aromatic) ppm. 19F-NMR: δ −112.39 ppm. MS(ESI)+: 385.1 [M+Na]+. m.p.: (from ethanol/water) 95-97° C.
    • Example 147 Synthesis of 2-chloro-N-(2-(phenethylcarbamoyl)phenyl)benzamide (74)
  • Figure US20190248756A1-20190815-C00314
  • Compound 74 was obtained as a white powder in 37% yield. 1H-NMR (CDCl3): δ 2.94 (t, J=6.8 Hz, 4H), 3.70 (dd, J=6.7, 12.9 Hz, 4H), 6.27 (s, 2H), 7.11 (t, J=7.6 Hz, 2H), 7.25 (t, J=8.3 Hz, 5H), 7.32-7.44 (m, 10H), 7.49 (dd, J=1.3, 7.8 Hz, 2H), 7.55 (t, J=7.9 Hz, 2H), 7.68 (dd, J=1.8, 7.4 Hz, 2H), 8.79 (d, J=8.4 Hz, 2H), 11.50 (s, 2H) ppm. 13C-NMR (CDCl3): δ 35.48 (CH2, C-aliphatic), 41.04 (CH2, C-aliphatic), 121.80 (C, C-aromatic), 123.37 (CH, C-aromatic), 126.34 (CH, C-aromatic), 126.80 (CH, C-aromatic), 127.14 (CH, C-aromatic), 128.78 (CH, C-aromatic), 128.82 (CH, C-aromatic), 129.32 (CH, C-aromatic), 130.62 (C, C-aromatic), 131.34 (CH, C-aromatic), 132.67 (CH, C-aromatic), 136.16 (C, C-aromatic), 138.49 (C, C-aromatic), 139.18 (C, C-aromatic), 165.41 (C, C-aromatic), 168.76 (C, C-aromatic). MS(ESI)+: 379.1, 380.1 [M+H]+. m.p.: (from ethanol) 101-103° C.
    • Example 148 Synthesis of 2-(3-chlorobenzamido)-N-phenethylbenzamide (75)
  • Figure US20190248756A1-20190815-C00315
  • Compound 75 was obtained as a white powder in 63% yield. 1H-NMR (CDCl3): δ 2.98 (t, J=6.8 Hz, 2H), 3.78 (dd, J=6.7, 12.8 Hz, 2H), 6.31 (s, 1H), 7.07-7.13 (m, 1H), 7.23-7.30 (m, 3H), 7.33-7.38 (m, 3H), 7.48 (t, J=7.8 Hz, 1H), 7.52-7.58 (m, 2H), 7.91 (d, J=7.7 Hz, 1H), 8.07 (t, J=1.8 Hz, 1H), 8.79 (d, J=8.4 Hz, 1H), 12.19 (s, 1H) ppm. 13C-NMR (CDCl3): δ 35.53 (CH2, C-aliphatic), 41.09 (CH2, C-aliphatic), 120.42 (C, C-aromatic), 121.66 (CH, C-aromatic), 123.13 (CH, C-aromatic), 125.10 (CH, C-aromatic), 126.30 (CH, C-aromatic), 126.84 (CH, C-aromatic), 128.15 (CH, C-aromatic), 128.80 (CH, C-aromatic), 128.85 (CH, C-aromatic), 130.05 (CH, C-aromatic), 131.87 (CH, C-aromatic), 132.84 (CH, C-aromatic), 135.04 (C, C-aromatic), 136.72 (C, C-aromatic), 138.45 (C, C-aromatic), 139.75 (C, C-aromatic), 164.19 (C, C-aromatic), 169.07 (C, C-aromatic). MS(ESI)+: 379.1, 380.1 [M+H]+. m.p.: (from ethanol) 103-105° C.
    • Example 149 Synthesis of 2-(4-chlorobenzamido)-N-phenethylbenzamide (76)
  • Figure US20190248756A1-20190815-C00316
  • Compound 76 was obtained as a white powder in 61% yield. 1H-NMR (CDCl3): δ 2.98 (t, J=6.8 Hz, 2H), 3.76 (dd, J=6.7, 12.8 Hz, 2H), 6.37 (s, 1H), 7.04-7.12 (m, 1H), 7.24-7.29 (m, 3H), 7.34-7.40 (m, 3H), 7.53 (ddd, J=8.6, 7.6, 1.5 Hz, 3H), 7.97-8.02 (m, 2H), 8.79 (d, J=8.4 Hz, 1H), 12.20 (s, 1H) ppm. 13C-NMR (CDCl3): δ 40.70 (CH2, C-aliphatic), 42.03 (CH2, C-aliphatic), 120.30 (CH, C-aromatic), 120.44, 122.99 (CH, C-aromatic), 126.10 (CH, C-aromatic), 128.08 (CH, C-aromatic), 128.25 (CH, C-aromatic), 128.36 (CH, C-aromatic), 128.62 (CH, C-aromatic), 128.82 (CH, C-aromatic), 129.07 (CH, C-aromatic), 132.18 (CH, C-aromatic), 133.27 (C, C-aromatic), 136.89 (C, C-aromatic), 139.05 (C, C-aromatic), 139.11 (C, C-aromatic), 139.26 (C, C-aromatic), 163.27 (C═O), 168.6 (C═O). MS(ESI)+: 379.1, 380.1 [M+H]+. m.p.: 104-106° C.
    • Example 150 Synthesis of N-phenethyl-2-(3-(trifluoromethyl)benzamido)benzamide (77)
  • Figure US20190248756A1-20190815-C00317
  • Compound 77 was obtained as a white powder in 51% yield. 1H-NMR (CDCl3): δ 2.98 (t, J=6.8 Hz, 2H), 3.78 (dd, J=6.7, 12.8 Hz, 2H), 6.32 (s, 1H), 7.12 (t, J=7.6 Hz, 1H), 7.26 (d, J=7.4 Hz, 3H), 7.34-7.39 (m, 3H), 7.59-7.53 (m, 1H), 7.69 (t, J=7.8 Hz, 1H), 7.83 (d, J=7.7 Hz, 1H), 8.21 (d, J=7.8 Hz, 1H), 8.38 (s, 1H), 8.81 (d, J=8.4 Hz, 1H), 12.35 (s, 1H) ppm. 13C NMR (126 MHz, CDCl3): 34.85 (CH2, C-aromatic), 41.04 (CH2, C-aromatic), 120.17 (C, C-aromatic), 121.14 (CH, C-aromatic), 123.00 (CH, C-aromatic), 125.10 (CH, C-aromatic), 126.06 (CH, C-aromatic), 126.74 (CH, C-aromatic), 128.38 (CH, C-aromatic), 128.90 (CH, C-aromatic), 130.39 (CH, C-aromatic), 132.63 (CH, C-aromatic), 132.90 (C, C-aromatic), 135.70 (C, C-aromatic), 137.85 (C, C-aromatic), 139.71 (C, C-aromatic), 163.66 (C, C-aromatic), 168.95 (C, C-aromatic) ppm. 19F-NMR: δ −62.72 ppm. MS(ESI)+: 422.2 [M+H]+. m.p.: (from ethanol/water) 103-105° C.
    • Example 151 Synthesis of N-phenethyl-2-(4-(trifluoromethyl)benzamido)benzamide (78)
  • Figure US20190248756A1-20190815-C00318
  • Compound 78 was obtained as a white powder in 53% yield. 1H-NMR (CDCl3): δ 3.06-2.90 (m, 2H), 3.78 (dd, J=6.8, 12.7 Hz, 2H), 6.31 (s, 1H), 6.95-7.12 (m, 1H), 7.19-7.26 (m, 3H), 7.40-7.31 (m, 4H), 7.59-7.54 (m, 1H), 7.81 (d, J=8.2 Hz, 2H), 8.18 (d, J=8.1 Hz, 2H), 8.83 (dd, J=0.9, 8.4 Hz, 1H), 12.36 (s, 1H) ppm. 13C NMR (126 MHz, CDCl3): δ 34.84 (CH2, C-aliphatic), 40.75 (CH2, C-aliphatic), 119.87 (C, C-aromatic), 121.14 (CH, C-aromatic), 123.01 (CH, C-aromatic), 125.47 (CH, C-aromatic), 126.06 (CH, C-aromatic), 126.74 (CH, C-aromatic), 127.92 (CH, C-aromatic), 128.66 (CH, C-aromatic), 128.90 (CH, C-aromatic), 132.93 (CH, C-aromatic), 138.52 (C, C-aromatic), 140.02 (C, C-aromatic), 148.16 (C, C-aromatic), 157.09 (C, C-aromatic), 163.97 (C, C-aromatic), 188.19 (C, C-aromatic) ppm. 19F-NMR: δ −63.09 ppm. MS(ESI)+: 435.1 [M+H]+. m.p.: (from ethanol/water) 96-98° C.
    • Example 152 Synthesis of 2-(4-methoxybenzamido)-N-phenethylbenzamide (79)
  • Figure US20190248756A1-20190815-C00319
  • Compound 79 was obtained as a white powder in 62% yield. 1H-NMR (CDCl3): δ 2.98-3.11 (m, 2H), 3.79-3.71 (m, 2H), 3.91 (S, 3H), 6.32 (s, 1H), 7.00-7.08 (m, 3H), 7.20-7.29 (m, 5H), 7.34 (dq, J=7.3, 14.4 Hz, 4H), 7.42-7.53 (m, 1H), 7.91-8.10 (m, 2H), 8.79 (d, J=8.4 Hz, 1H), 12.01 (s, 1H) ppm. 13C-NMR (CDCl3): δ 35.53 (CH2, C-aliphatic), 41.08 (CH2, C-aliphatic), 55.46 (CH3, C-aliphatic), 113.98 (CH, C-aromatic), 120.38 (C, C-aromatic), 121.55 (CH, C-aromatic), 122.58 (CH, C-aromatic), 126.31 (CH, C-aromatic), 126.81 (CH, C-aromatic), 127.20 (CH, C-aromatic), 128.82 (CH, C-aromatic), 129.33 (CH, C-aromatic), 132.71 (CH, C-aromatic), 138.52 (C, C-aromatic), 140.15 (C, C-aromatic), 162.51 (C, C-aromatic), 165.71 (C, C-aromatic), 169.26 (C, C-aromatic) ppm. MS(ESI)+: 375.2 [M+H]+. m.p.: (from ethanol) 124-126° C.
    • Example 153 Synthesis of 2-fluoro-4-methoxy-N-(2-(phenethylcarbamoyl) phenyl)benzamide (80)
  • Figure US20190248756A1-20190815-C00320
  • Compound 80 was obtained as an orange powder in 21% yield. 1H-NMR (CDCl3): δ 2.97 (t, J=6.8 Hz, 2H), 3.75 (dd, J=6.7, 12.9 Hz, 2H), 3.89 (d, J=4.9 Hz, 3H), 6.17 (s, 1H), 6.73 (dd, J=2.4, 13.3 Hz, 1H), 6.84 (dd, J=2.4, 8.8 Hz, 1H), 7.09 (dd, J=4.2, 10.9 Hz, 1H), 7.26 (d, J=6.1 Hz, 3H), 7.31-7.37 (m, 3H), 7.51 (dd, J=4.3, 11.5 Hz, 1H), 8.06 (t, J=8.9 Hz, 1H), 8.71 (d, J=8.4 Hz, 1H), 11.55 (d, J=8.8 Hz, 1H) ppm. 13C-NMR (CDCl3): δ 35.53 (CH2, C-aliphatic), 41.02 (CH2, C-aliphatic), 55.84 (CH3, C-aliphatic), 101.76 (CH, C-aromatic), 101.98 (CH, C-aromatic), 110.72 (CH, C-aromatic), 117.4 (C, C-aromatic), 122.32 (C, C-aromatic), 122.59 (CH, C-aromatic), 123.16 (CH, C-aromatic), 125.10 (C, C-aromatic), 126.37 (CH, C-aromatic), 126.73 (CH, C-aromatic), 128.79 (CH, C-aromatic), 132.25 (CH, C-aromatic), 132.91 (CH, C-aromatic), 138.62 (C, C-aromatic), 138.97 (C, C-aromatic), 158.9 (C, C-aromatic), 163.2 (C, C-aromatic), 168.74 (C, C-aromatic) ppm. 19F-NMR (CDCl3): δ −109.11 ppm. MS(ESI)+: 415.2 [M+Na]+. m.p.: (from ethanol/water) 139-141° C.
    • Example 154 Synthesis of 2-fluoro-6-(2-fluorobenzamido)-N-phenethylbenzamide (81)
  • Figure US20190248756A1-20190815-C00321
  • Compound 81 was obtained as a white powder in 48% yield. 1H-NMR (CDCl3): δ 2.96 (t, J=6.9 Hz, 2H), 3.74-3.81 (m, 2H), 6.68 (s, 1H), 6.88 (m, 1H), 7.20-7.27 (m, 4H), 7.29-7.35 (m, 3H), 7.38-7.49 (m, 1H), 7.51-7.58 (m, 1H), 7.92-8.05 (m, 1H), 8.59 (d, J=8.5 Hz, 1H), 11.96 (d, J=6.3 Hz, 1H) ppm. 13C-NMR (CDCl3): δ 35.42 (CH2, C-aliphatic), 41.22 (CH2, C-aliphatic), 110.70 (C, C-aromatic), 116.61 (CH, C-aromatic), 118.33 (CH, C-aromatic), 122.68 (CH, C-aromatic), 124.67 (CH, C-aromatic), 126.69 (CH, C-aromatic), 128.75 (CH, C-aromatic), 131.54 (CH, C-aromatic), 132.65 (CH, C-aromatic), 133.53 (CH, C-aromatic), 138.47 (C, C-aromatic), 140.80 (C, C-aromatic), 159.37 (C, C-aromatic), 161.35 (C, C-aromatic), 162.44 (C, C-aromatic), 164.70 (C, C-aromatic) ppm. F-NMR (CDCl3): δ −111.60, −112.88 ppm. MS(ESI)+: 381.1 [M+H]+. m.p.: 96-98° C.
    • Example 155 Synthesis of 4-fluoro-2-(2-fluorobenzamido)-N-phenethylbenzamide (82)
  • Figure US20190248756A1-20190815-C00322
  • Compound 82 was obtained as a white powder in 44% yield. 1H-NMR (CDCl3): δ 2.96 (t, J=6.8 Hz, 2H), 3.75 (dd, J=6.7, 12.8 Hz, 2H), 6.13 (s, 1H), 6.76-6.79 (m, 1H), 7.23-7.27 (m, 4H), 7.30-7.38 (m, 4H), 7.47-7.61 (m, 1H), 7.91-8.07 (m, 1H), 8.63 (dd, J=2.6, 11.8 Hz, 1H), 11.95 (d, J=6.8 Hz, 1H) ppm. 13C-NMR (126 MHz, CDCl3): δ 35.47 (CH2, C-aromatic), 41.06 (CH2, C-aromatic), 109.49 (CH, C-aromatic), 110.15 (CH, C-aromatic), 116.52 (CH, C-aromatic), 122.02 (CH, C-aromatic), 124.74 (C, C-aromatic), 126.80 (CH, C-aromatic), 128.11 (CH, C-aromatic), 128.19 (CH, C-aromatic), 128.80 (CH, C-aromatic), 128.83 (CH, C-aromatic), 131.62 (C, C-aromatic), 133.65 (CH, C-aromatic), 133.72 (C, C-aromatic), 161.12 (C, C-aromatic), 162.98 (C, C-aromatic), 165.22 (C, C-aromatic), 167.69 (C, C-aromatic), 170.3 (C, C-aromatic) ppm. 19F-NMR: δ −103.79, −113.02 ppm. MS(ESI)+: 403.1 [M+Na]+. m.p.: (from ethanol/water) 104-106° C.
    • Example 156 Synthesis of 2-(2-fluorobenzamido)-4-methoxy-N-phenethylbenzamide (83)
  • Figure US20190248756A1-20190815-C00323
  • Compound 83 was obtained as a white powder in 51% yield. 1H-NMR (CDCl3): δ 0.2.95 (t, J 6.71 Hz, 2H), 3.61 (q, J 6.71 Hz, 2H), 3.90 (s, 3H), 6.13 (s, 1H), 6.64 (dd, J=2.43, 5.80, 1 Hz), 7.23 (t, J=8.42, 5H), 7.32 (q, J=8.42, 3H), 7.56-7.52 (m, 1H), 8.00-8.10 (m, 1H), 8.51 (d, J=2.50 Hz, 1H), 12.17 (d, J=5.9 Hz, 1H) ppm. 13C-NMR (CDCl3): δ 35.58 (CH2, C-aliphatic), 40.93 (CH2, C-aliphatic), 55.55 (CH3, C-aliphatic), 106.16 (CH, C-aromatic), 110.23 (CH, C-aromatic), 113.62 (C, C-aromatic), 116.63 (d, JC-F=23.9 Hz, C, C-aromatic), 124.61 (CH, C-aromatic), 124.64 (CH, C-aromatic), 126.70 (CH, C-aromatic), 127.70 (CH, C-aromatic), 128.78 (CH, C-aromatic), 128.82 (CH, C-aromatic), 131.31 (CH, C-aromatic), 133.36 (CH, C-aromatic), 138.72 (C, C-aromatic), 141.41 (C, C-aromatic), 162.68 (C, C-aromatic) ppm. 19F-NMR: δ −112.49 ppm. MS(ESI)+: 415.1 [M+Na]+. m.p.: (from ethanol/water) 108-110° C.
    • Example 157 Synthesis of 2-(2-fluorobenzamido)-3-methoxy-N-phenethylbenzamide (84)
  • Figure US20190248756A1-20190815-C00324
  • Compound 84 was obtained as a white powder in 66% yield. 1H-NMR (CDCl3): δ 2.87 (t, J=7.12 Hz, 2H), 3.65 (dd, J=5.96, 7.10 Hz, 2H), 3.89 (s, 3H), 6.38-6.40 (m, 1H), 7.07 (m, 2H), 7.18-7.23 (m, 4H), 7.26-7.32 (m, 4H), 7.52-7.56 (m, 1H), 8.12-8.15 (m, 1H), 8.83-8.86 (m, 1H) ppm. 13C-NMR (CDCl3): 35.53 (CH2, C-aliphatic), 41.02 (CH2, C-aliphatic), 56.16 (CH3, C-aliphatic), 113.21 (CH, C-aromatic), 116.32 (CH, C-aromatic), 119.59 (CH, C-aromatic), 123.36 (C, C-aromatic), 124.75 (CH, C-aromatic), 126.42 (CH, C-aromatic), 127.41 (CH, C-aromatic), 128.56 (CH, C-aromatic), 128.73 (CH, C-aromatic), 132.25 (CH, C-aromatic), 133.74 (CH, C-aromatic), 134.06 (C, C-aromatic), 138.91 (C, C-aromatic), 153.95 (C, C-aromatic), 159.92 (C, C-aromatic), 161.90 (C, C-aromatic), 168.10 (C, C-aromatic) ppm. 19F-NMR (CDCl3): −112.645 ppm. MS(ESI)+: 393.2 [M+H]+. m.p.: 130-132° C.
    • Example 158 Synthesis of 2-(3-fluorobenzamido)-3-methoxy-N-phenethylbenzamide (85)
  • Figure US20190248756A1-20190815-C00325
  • Compound 85 was obtained as a white powder in 42% yield. 1H-NMR (CDCl3): δ 2.875 (t, J=7.10 Hz, 2H), 3.62-3.66 (m, 2H), 3.89-3.89 (m, 6H), 6.38-6.39 (m, 1H), 7.02-7.07 (m, 2H), 7.10-7.12 (m, 1H), 7.20-7.26 (m, 4H), 7.28-7.31 (m, 2H), 7.40 (t, J=8.15 Hz, 1H), 7.52-7.53 (m, 2H), 8.81 (s, 1H) ppm. 13C-NMR (CDCl3): δ 35.50 (CH, C-aliphatic), 41.04 (CH, C-aliphatic), 55.47 (CH3 C-aliphatic), 56.16 (CH3, C-aliphatic), 112.75 (CH, C-aromatic), 113.69 (CH, C-aromatic), 118.33 (CH, C-aromatic), 119.24 (CH, C-aromatic), 119.61 (CH, C-aromatic), 124.54 (C, C-aromatic), 126.50 (CH, C-aromatic), 126.99 (CH, C-aromatic), 128.61 (CH, C-aromatic), 128.74 (CH, C-aromatic), 129.70 (CH, C-aromatic), 132.77 (C, C-aromatic), 135.68 (C, C-aromatic), 138.78 (C, C-aromatic), 154.20 (C, C-aromatic), 159.89 (C, C-aromatic), 166.32 (C, C-aromatic), 168.31 (C, C-aromatic) ppm. 19F-NMR (CDCl3): −111.82 ppm. MS(ESI)+: 393.2 [M+H]+. m.p.: 99-101° C.
    • Example 159 Synthesis of 2-(4-fluorobenzamido)-3-methoxy-N-phenethylbenzamide (86)
  • Figure US20190248756A1-20190815-C00326
  • Compound 86 was obtained as a white powder in 36% yield. 1H-NMR (CDCl3): δ 2.47-2.38 (m, 4H), 2.60-2.49 (m, 2H), 3.47 (dd, J=5.6, 11.4 Hz, 2H), 3.71-3.63 (m, 4H), 3.91 (s, 3H), 6.79 (s, 1H), 7.19-7.09 (m, 4H), 7.32-7.26 (m, 2H), 8.07-7.94 (m, 2H), 9.11 (s, 1H) ppm. 13C-NMR (CDCl3): δ 35.89 (CH2, C-aromatic), 40.58 (CH2, C-aromatic), 56.33 (CH3, C-aromatic), 113.99 (CH, C-aromatic), 119.30 (CH, C-aromatic), 124.88 (C, C-aromatic), 125.48 (CH, C-aromatic), 126.07 (CH, C-aromatic), 127.04 (CH, C-aromatic), 127.92 (CH, C-aromatic), 129.80 (CH, C-aromatic), 130.39 (C, C-aromatic), 131.66 (CH, C-aromatic), 138.89 (C, C-aromatic), 154.26 (C, C-aromatic), 163.95 (C, C-aromatic), 165.21 (C, C-aromatic), 166.41 (C, C-aromatic), 167.98 (C, C-aromatic) ppm. 19F-NMR (CDCl3): −111.86 ppm. MS(ESI)+: 415.1[M+Na]+. m.p.: 140-142° C.
    • Example 160 Synthesis of 2-fluoro-6-(4-methoxybenzamido)-N-phenethylbenzamide (87)
  • Figure US20190248756A1-20190815-C00327
  • Compound 87 was obtained as a white powder in 45% yield. 1H-NMR (CDCl3): δ 2.98 (t, J=6.9 Hz, 2H), 3.74-3.84 (m, 2H), 3.91 (s, 3H), 6.79-6.92 (m, 2H), 7.01-7.06 (m, 2H), 7.23-7.28 (m, 3H), 7.35 (t, J=7.5 Hz, 2H), 7.32-7.45 (m, 1H), 8.01-8.05 (m, 2H), 8.68 (d, J=8.5 Hz, 1H), 12.47 (s, 1H) ppm. 13C-NMR (CDCl3): δ 35.41 (CH2, C-aliphatic), 41.26 (CH2, C-aliphatic), 55.47 (CH3, C-aliphatic), 109.81 (CH, C-aromatic), 110.01 (CH, C-aromatic), 114.01 (CH, C-aromatic), 117.41 (CH, C-aromatic), 126.76 (CH, C-aromatic), 127.06 (CH, C-aromatic), 128.76 (C, C-aromatic), 129.42 (CH, C-aromatic), 132.99 (CH, C-aromatic), 133.08 (CH, C-aromatic), 138.43 (C, C-aromatic), 159.86 (C, C-aromatic), 161.81 (C, C-aromatic), 162.61 (C, C-aromatic), 165.26 (C, C-aromatic) ppm. 19F-NMR: δ −111.18 ppm. MS(ESI)+: 393 [M+H]+. m.p.: (from ethanol/water) 103-105° C.
    • Example 161 Synthesis of 4-fluoro-2-(4-methoxybenzamido)-N-phenethylbenzamide (88)
  • Figure US20190248756A1-20190815-C00328
  • Compound 88 was obtained as a white powder in 72% yield. 1H-NMR (CDCl3): δ2.97 (d, J=6.8 Hz, 1H), 3.76 (dd, J=6.8, 12.7 Hz, 2H), 3.91 (s, 3H), 6.28 (s, 1H), 6.63-6.73 (m, 1H), 7.02-7.06 (m, 2H), 7.24-7.40 (m, 7H), 7.94-8.05 (m, 2H), 8.65 (dd, J=2.6, 11.9 Hz, 1H), 12.26 (s, 1H) ppm. 13C-NMR (126 MHz, CDCl3): δ 35.49 (CH2, C-aromatic), 41.09 (CH2, C-aromatic), 55.46 (CH3, C-aromatic), 108.47 (CH, C-aromatic), 108.69 (CH, C-aromatic), 109.40 (CH, C-aromatic), 109.58 (C, C-aromatic), 114.06 (CH, C-aromatic), 126.84 (CH, C-aromatic), 128.16 (CH, C-aromatic), 128.77 (CH, C-aromatic), 129.39 (CH, C-aromatic), 138.47 (C, C-aromatic), 142.47 (C, C-aromatic), 162.73 (C, C-aromatic), 164.47 (C, C-aromatic), 165.29 (C, C-aromatic), 165.99 (C, C-aromatic), 168.60 (C, C-aromatic) ppm. 19F-NMR (CDCl3): −104.11 ppm. MS(ESI)+: 415.1 [M+Na]+. m.p.: (from ethanol/water) 12-129° C.
    • Example 162 Synthesis of 4-methoxy-2-(4-methoxybenzamido)-N-phenethylbenzamide (89)
  • Figure US20190248756A1-20190815-C00329
  • Compound 89 was obtained as a white powder in 14% yield. 1H-NMR (CDCl3): δ 2.97 (t, J=6.8 Hz, 2H), 3.75 (dd, J=6.7, 12.8 Hz, 2H), 3.89 (s, 6H), 6.13 (d, J=61.2 Hz, 1H), 6.58 (dd, J=2.5, 8.7 Hz, 1H), 7.04 (d, J=8.8 Hz, 2H), 7.27 (d, J=8.3 Hz, 3H), 7.36 (t, J=7.6 Hz, 3H), 8.05 (d, J=8.8 Hz, 2H), 8.57 (d, J=2.5 Hz, 1H), 12.51 (s, 1H) ppm. 13C-NMR (CDCl3): δ 35.61 (CH2, C-aliphatic), 40.98 (CH2, C-aliphatic), 55.46 (CH3, C-aliphatic), 55.55 (CH3, C-aliphatic), 104.90 (CH, C-aromatic), 109.86 (CH, C-aromatic), 112.07 (C, C-aromatic), 114.01 (CH, C-aromatic), 126.77 (CH, C-aromatic), 127.22 (C, C-aromatic), 127.62 (CH, C-aromatic), 128.81 (CH, C-aromatic), 129.34 (CH, C-aromatic), 138.66 (C, C-aromatic), 142.68 (C, C-aromatic), 162.53 (C, C-aromatic), 162.97 (C, C-aromatic), 165.45 (C, C-aromatic), 169.10 (C, C-aromatic) ppm. MS(ESI)+: 405 [M+H]+. m.p.: (from ethanol/water) 138-140° C.
    • Example 163 Synthesis of 3-methoxy-2-(2-methoxybenzamido)-N-phenethylbenzamide (90)
  • Figure US20190248756A1-20190815-C00330
  • Compound 90 was obtained as a white powder in 43% yield. 1H-NMR (CDCl3): δ 2.83 (t, J=7.3 Hz, 2H), 3.65-3.59 (m, 2H), 3.88 (s, 3H), 4.06 (s, 3H), 6.65 (s, 1H), 7.04 (dd, J=8.3, 14.5 Hz, 2H), 7.13 (d, J=7.7 Hz, 3H), 7.19 (d, J=7.4 Hz, 3H), 7.27-7.22 (m, 2H), 7.55-7.50 (m, 1H), 8.25 (t, J=9.1 Hz, 1H), 9.78-9.70 (m, 1H). 13C-NMR (CDCl3): δ 39.14 (CH2, C-aliphatic), 40.73 (CH2, C-aliphatic), 56.24 (CH3, C-aliphatic), 56.26 (CH3, C-aliphatic), 111.15 (CH, C-aromatic), 113.01 (CH, C-aromatic), 120.16 (CH, C-aromatic), 121.14 (CH, C-aromatic), 122.99 (C, C-aromatic), 123.30 (C, C-aromatic), 126.36 (CH, C-aromatic), 127.03 (CH, C-aromatic), 128.90 (CH, C-aromatic), 132.26 (CH, C-aromatic), 133.52 (CH, C-aromatic), 135.40 (CH, C-aromatic), 138.82 (C, C-aromatic), 153.73 (C, C-aromatic), 157.76 (C, C-aromatic), 164.55 (C, C-aromatic), 167.98 (C, C-aromatic) ppm. MS(ESI)+: 405.2 [M+H]+. m.p.: (from methanol/water) 133-136° C.
    • Example 164 Synthesis of 3-methoxy-2-(3-methoxybenzamido)-N-phenethylbenzamide (91)
  • Figure US20190248756A1-20190815-C00331
  • Compound 91 was obtained as a white powder in 42% yield. 1H-NMR (CDCl3): δ 2.87 (t, J=7.10 Hz, 2H), 3.62-3.66 (m, 2H), 3.89-3.89 (m, 6H), 6.38-6.39 (m, 1H), 7.02-7.07 (m, 2H), 7.10-7.12 (m, 1H), 7.20-7.26 (m, 4H), 7.28-7.31 (m, 2H), 7.40 (t, J=8.15 Hz, 1H), 7.51-7.53 (m, 2H), 8.81 (s, 1H) ppm. 13C-NMR (CDCl3): δ 35.50 (CH, C-aliphatic), 41.04 (CH, C-aliphatic), 55.47 (CH3 C-aliphatic), 56.16 (CH3, C-aliphatic), 112.75 (CH, C-aromatic), 113.69 (CH, C-aromatic), 118.33 (CH, C-aromatic), 119.24 (CH, C-aromatic), 119.61 (CH, C-aromatic), 124.54 (C, C-aromatic), 126.50 (CH, C-aromatic), 126.99 (CH, C-aromatic), 128.61 (CH, C-aromatic), 128.74 (CH, C-aromatic), 129.70 (CH, C-aromatic), 132.77 (C, C-aromatic), 135.68 (C, C-aromatic), 138.78 (C, C-aromatic), 154.20 (C, C-aromatic), 159.89 (C, C-aromatic), 166.32 (C, C-aromatic), 168.31 (C, C-aromatic) ppm. MS(ESI)+: 405.2 [M+H]+. m.p.: 100-102° C.
    • Example 165 Synthesis of 3-methoxy-2-(4-methoxybenzamido)-N-phenethylbenzamide (92)
  • Figure US20190248756A1-20190815-C00332
  • Compound 92 was obtained as a white powder in 74% yield. 1H-NMR (CDCl3): δ 2.80 (t, J=7.0 Hz, 2H), 3.61 (dd, J=7.1, 13.2 Hz, 2H), 3.88 (s, 3H), 3.89 (s, 3H), 6.56 (t, J=5.6 Hz, 1H), 6.97-7.01 (m, 3H), 7.04 (dd, J=2.9, 8.0 Hz, 2H), 7.19-7.34 (m, 5H), 7.91-7.99 (m, 2H), 8.82 (s, 1H) ppm. 13C-NMR (126 MHz, CDCl3): δ 35.49 (CH2, C-aromatic), 41.05 (CH2, C-aromatic), 55.48 (CH3, C-aromatic), 56.17 (CH3, C-aromatic), 113.62 (CH, C-aromatic), 113.88 (CH, C-aromatic), 119.28 (CH, C-aromatic), 124.74 (CH, C-aromatic), 126.37 (C, C-aromatic), 126.50 (C, C-aromatic), 126.87 (CH, C-aromatic), 128.62 (CH, C-aromatic), 128.76 (CH, C-aromatic), 129.59 (CH, C-aromatic), 132.75 (C, C-aromatic), 138.81 (C, C-aromatic), 154.18 (C, C-aromatic), 162.61 (C, C-aromatic), 166.12 (C, C-aromatic), 168.42 (C, C-aromatic) ppm. MS(ESI)+: 405 [M+H]+. m.p.: (from ethanol/water) 136-138° C.
    • Example 166 Synthesis of 2-(2,4-dimethoxybenzamido)-3-methoxy-N-phenethylbenzamide (93)
  • Figure US20190248756A1-20190815-C00333
  • Compound 93 was obtained as a white powder in 68% yield. 1H-NMR (CDCl3): δ 2.81 (t, J=7.33 Hz, 2H), 3.59-3.63 (m, 2H), 3.87 (s, 3H), 3.900 (s, 3H), 4.02 (s, 3H), 6.56 (d, J=2.32 Hz, 1H), 6.64 (dd, J=2.33, 8.80 Hz, 1H), 6.75 (s, 1H), 7.01 (dd, J=1.28, 8.28 Hz, 1H), 7.14-7.20 (m, 4H), 7.24-7.27 (m, 3H), 8.228 (d, J=8.76 Hz, 1H), 9.608 (s, 1H) ppm. 13C-NMR (CDCl3): δ 35.56 (CH2, C-aliphatic), 41.03 (CH2, C-aliphatic), 55.58 (CH3, C-aliphatic), 56.13 (CH3, C-aliphatic), 56.15 (CH3, C-aliphatic), 98.75 (CH, C-aromatic), 105.55 (CH, C-aromatic), 112.71 (CH, C-aromatic), 114.27 (C, C-aromatic), 120.13 (CH, C-aromatic), 123.51 (C, C-aromatic), 126.25 (CH, C-aromatic), 127.25 (CH, C-aromatic), 128.45 (CH, C-aromatic), 128.70 (CH, C-aromatic), 128.82 (CH, C-aromatic), 134.38 (CH, C-aromatic), 135.64 (C, C-aromatic), 139.11 (C, C-aromatic), 154.04 (C, C-aromatic), 159.32 (C, C-aromatic), 163.96 (C, C-aromatic), 165.10 (C, C-aromatic), 168.33 (C, C-aromatic) ppm. MS(ESI)+: 435.2 [M+H]+. m.p.: 132-134° C.
    • Example 167 Synthesis of N-(2-(phenethylcarbamoyl)phenyl)nicotinamide (94)
  • Figure US20190248756A1-20190815-C00334
  • Compound 94 was obtained as a white solid in 99% yield. 1H-NMR (500 MHz, CDCl3): δ 12.40 (s, 1H, ArNHCO), 9.30 (s, 1H, CONHCH2), 8.79-8.76 (m, 2H), 8.31 (dt, J=10.2, 1H), 7.52 (t, J=4.95, 1H), 7.48 (dd, J=9.92, 4.98, 1H), 7.40 (dd, J=9.96, 0.05, 1H), 7.34 (t, 9.90, 2H), 7.26 (q, J=10.02, 3H), 7.08 (t, J=9.97, 1H), 6.62 (s, 1H), 3.76 (q, J=10.0, 2H, NHCH2CH2), 2.97 (t, J=10, 2H, NHCH2CH2). 13C-NMR (126 MHz, CDCl3): δ 169.12 (ArC═O), 163.64 (ArC═O), 152.30 (ArCH), 149.01 (ArCH), 139.60 (ArC), 138.50 (ArC), 135.03 (ArCH), 132.80 (ArCH), 130.51 (ArC), 128.81 (ArCH), 126.79 (ArCH), 126.51 (ArCH), 123.59 (ArCH), 123.29 (ArCH), 121.54 (ArCH), 120.32 (ArC), 41.17 (CH2), 35.52 (CH2). MS (ESI): 346.2 [M+1]. m.p. (from ethanol/water): 94° C.
    • Example 168 Synthesis of 3-(4-methoxybenzamido)-N-phenethylisonicotinamide (100)
  • Figure US20190248756A1-20190815-C00335
  • Compound 100 was obtained as a white powder in 34% yield. 1H-NMR (CDCl3): δ 2.99 (t, J=6.8 Hz, 2H), 3.78 (dd, J=6.8, 12.8 Hz, 2H), 3.91 (s, 3H), 6.73 (s, 1H), 7.03-7.06 (m, 2H), 7.14 (d, J=5.0 Hz, 1H), 7.21-7.27 (m, 2H), 7.25-7.34 (m, 3H), 7.99-8.02 (m, 2H), 8.32 (d, J=5.1 Hz, 1H), 10.04 (s, 1H), 11.63 (s, 1H) ppm. 13C-NMR (126 MHz, CDCl3): δ35.34 (CH2, C-aromatic), 41.21 (CH2, C-aromatic), 55.51 (CH3, C-aromatic), 114.11 (CH, C-aromatic), 119.23 (CH, C-aromatic), 126.04 (C, C-aromatic), 126.23 (C, C-aromatic), 126.94 (CH, C-aromatic), 128.49 (CH, C-aromatic), 128.78 (CH, C-aromatic), 128.89 (CH, C-aromatic), 129.50 (CH, C-aromatic), 135.37 (C, C-aromatic), 138.23 (C, C-aromatic), 143.80 (CH, C-aromatic), 144.46 (CH, C-aromatic), 162.85 (C, C-aromatic), 164.99 (C, C-aromatic), 167.35 (C, C-aromatic) ppm. MS(ESI)+: 376 [M+H]+. m.p.: (from ethanol/water) 120-122° C.
    • Example 169 Synthesis of N-(2-methoxy-6-(phenethylcarbamoyl)phenyl)-2-naphthamide (119)
  • Figure US20190248756A1-20190815-C00336
  • Compound 119 was obtained as a white powder in 50% yield. 1H-NMR (CDCl3): δ 2.86-2.89 (2H, m), 3.62-3.66 (2H, m), 3.899 (3H, s), 6.40-6.43 (1H, m, N), 7.04-7.06 (1H, m), 7.08-7.10 (1H, m), 7.195 (3H, t), 7.25-7.28 (3H, m), 7.57-7.63 (2H, m), 7.92-8.04 (4H, m), 8.511 (1H, d), 9.03 (1H, s, N) ppm. 13C-NMR (CDCl3): δ 35.46 (CH2, C-aliphatic), 41.005 (CH2, C-aliphatic), 56.20 (—CH3, C-aliphatic), 113.72 (CH, C-aromatic), 119.23 (CH, C-aromatic), 124.07 (CH, C-aromatic), 124.49 (C, C-aromatic), 126.51 (CH, C-aromatic), 126.78 (CH, C-aromatic), 127.07 (CH, C-aromatic), 127.79 (CH, C-aromatic), 127.89 (CH, C-aromatic), 128.42 (CH, C-aromatic), 128.59 (CH, C-aromatic) 128.62 (CH, C-aromatic), 128.76 (CH, C-aromatic), 129.21 (CH, C-aromatic), 131.34 (C, C-aromatic), 132.67 (C, C-aromatic), 135.07 (C, C-aromatic), 138.74 (C, C-aromatic), 154.18 (C, C-aromatic), 165.66 (C, C-aromatic), 166.57 (C, C-aromatic) ppm. MS(ESI)+: 425.2 [M+H]+. m.p.: 188-190° C.
    • Example 170 Synthesis of N-(5-methoxy-2-(phenethylcarbamoyl)phenyl)-2-naphthamide (122)
  • Figure US20190248756A1-20190815-C00337
  • Compound 122 was obtained as a white powder in 29% yield. 1H-NMR (CDCl3): δ 2.99 (t, J=6.8 Hz, 2H), 3.78 (dd, J=1.7, 6.8 Hz, 2H), 6.18 (s, 1H), 3.95 (s, 3H), 6.63 (dd, J=2.6, 8.8 Hz, 1H), 7.25-7.32 (m, 7H), 7.34-7.41 (m, 2H), 7.56-7.66 (m, 2H), 7.93 (d, J=7.7 Hz, 1H), 8.01 (d, J=8.6 Hz, 1H), 8.07 (d, J=7.7 Hz, 1H), 8.14 (dd, J=1.8, 8.6 Hz, 1H), 8.58-8.70 (m, 2H), 12.77 (s, 1H) ppm. 13C-NMR (CDCl3): δ 35.65 (CH2, C-aliphatic), 40.99 (CH2, C-aliphatic), 55.58 (CH3, C-aliphatic), 105.22 (CH, C-aromatic), 110.10 (CH, C-aromatic), 112.34 (C, C-aromatic), 123.66 (CH, C-aromatic), 126.64 (CH, C-aromatic), 126.77 (CH, C-aromatic), 127.62 (CH, C-aromatic), 127.72 (CH, C-aromatic), 127.83 (CH, C-aromatic), 127.85 (CH, C-aromatic), 128.52 (CH, C-aromatic), 128.66 (CH, C-aromatic), 128.82 (CH, C-aromatic) 129.47 (CH, C-aromatic), 132.13 (C, C-aromatic), 132.82 (C, C-aromatic), 135.01 (C, C-aromatic), 138.66 (C, C-aromatic), 142.54 (C, C-aromatic), 163.02 (C, C-aromatic), 135.92 (C, C-aromatic), 169.05 (C, C-aromatic) ppm. MS(ESI)+: 448.2 [M+H]+. m.p. (from ethanol/water): 119-121° C.
    • General Procedure 7:
  • The compounds of the application with the general formula shown below can be prepared according to the synthetic scheme shown in Scheme 7.
  • Figure US20190248756A1-20190815-C00338
  • To a solution of compound (II) or (II′) (1 equivalent) in N,N-dimethyl-formamide (DMF) is added 2 equivalents of N,N-diisopropylethylamine (DIPEA) and 2.2 equivalent of 3-phenyl-1-propylamine (VIIIa). The reaction mixture is stirred at about 15° C. to about 28° C. for about 6 hours to about 24 hours. The reaction mixture is diluted with water, washed with ethyl acetate, washed with brine, dried over Mg2SO4, filtered and evaporated to give a crude compound which is then purified by silica gel column using a mixture of Chloroform:Methanol (9:1) as eluent. The product is collected under reduced pressure to provide the compound with the general formula shown in Scheme 7.
  • Compounds 95-98, 120, 124, 125, 129, 136, and 140 were prepared according to General Procedure 7 substituting (II) or (II′) with the appropriate substituted compound.
    • Example 171 Synthesis of 2-fluoro-N-(2-((3-phenylpropyl)carbamoyl)phenyl)benzamide (95)
  • Figure US20190248756A1-20190815-C00339
  • Compound 95 was obtained as a white powder in 63% yield. 1H-NMR (500 MHz, CDCl3): 2.01 (2H, q, J=7.0 Hz), 2.77 (2H, q, J=7.20 Hz), 3.53 (2H, q, J=6.40 Hz), 6.14 (1H, s), 7.09-7.12 (1H, m), 7.30-7.33 (8H, m), 7.49-7.54 (2H, m), 8.06-8.08 (1H, m), 8.74 (1H, dd, J=1, 4.40 Hz), 11.7 (1H, d, J=6.11 Hz) ppm. 13C-NMR (126 MHz, CDCl3): δ 33.19 (CH2, C-aliphatic), 39.82 (CH2, C-aliphatic), 41.54 (CH2, C-aliphatic), 116.44 (CH, C-aromatic), 116.63 (CH, C-aromatic), 122.17 (C, C-aromatic), 122.49 (CH, C-aromatic), 123.30 (CH, C-aromatic), 124.61 (CH, C-aromatic), 125.83 (CH, C-aromatic), 126.17 (CH, C-aromatic), 126.39 (CH, C-aromatic), 128.37 (CH, C-aromatic), 128.64 (CH, C-aromatic), 131.54 (CH, C-aromatic), 132.27 (CH, C-aromatic), 133.30 (CH, C-aromatic), 138.87 (C, C-aromatic), 141.30 (C, C-aromatic), 141.90 (C, C-aromatic), 168.64 (C, C═O) ppm. 19F-NMR (CDCl3): δ −112.40 ppm. MS (ESI)+: 399.1 [M+Na]+. m.p. (from DCM/n-hexane): 61-63° C.
    • Example 172 Synthesis of 2-(4-methoxybenzamido)-N-(3-phenylpropyl)benzamide (96)
  • Figure US20190248756A1-20190815-C00340
  • Compound 96 was obtained as a white powder in 62% yield. MS (ESI)+: 411.2 [M+Na]+. m.p. (from DCM/n-hexane): 93-94° C.
    • Example 173 Synthesis of N-(2-((3-phenylpropyl)carbamoyl)phenyl)-1-naphthamide (97)
  • Figure US20190248756A1-20190815-C00341
  • Compound 97 was obtained as a white powder in 59% yield. 1H-NMR (500 MHz, CDCl3): δ 1.97 (2H, q, J=7.22 Hz), 2.74 (2H, t, J=7.40 Hz), 3.46 (2H, m), 6.16 (1H, s), 7.13 (1H, dd, J=1.16, 7.43 Hz), 7.19-7.25 (4H, m), 7.30 (2H, dd, J=4.4, 12.3 Hz), 7.57 (4H, m), 7.90 (2H, m), 7.99 (1H, d, J=8.29 Hz), 8.56 (1H, m), 8.91 (1H, dd, J=0.90, 8.45 Hz), 11.71 (1H, s) ppm. 13C-NMR (126 MHz, CDCl3): δ 30.80 (CH2, C-aliphatic), 33.54 (CH2, C-aliphatic), 39.80 (CH2, C-aliphatic), 120.96 (C, C-aromatic), 121.71 (CH, C-aromatic), 123.04 (CH, C-aromatic), 124.99 (CH, C-aromatic), 125.56 (CH, C-aromatic), 125.63 (CH, C-aromatic), 126.18 (CH, C-aromatic), 126.38 (CH, C-aromatic), 126.43 (CH, C-aromatic), 127.13 (CH, C-aromatic), 128.36 (CH, C-aromatic), 128.65 (CH, C-aromatic), 130.46 (C, C-aromatic), 131.22 (CH, C-aromatic), 132.57 (CH, C-aromatic), 133.94 (C, C-aromatic), 134.40 (C, C-aromatic), 139.72 (C, C-aromatic), 141.22 (C, C-aromatic), 167.93 (C, C═O), 168.82 (C, C═O) ppm. MS (ESI)+: 431.2 [M+Na]+. m.p. (from Ethanol/Water): 98-100° C.
    • Example 174 Synthesis of N-(2-((3-phenylpropyl)carbamoyl)phenyl)-2-naphthamide (98)
  • Figure US20190248756A1-20190815-C00342
  • Compound 98 was obtained as a white powder in 57% yield. 1H-NMR (500 MHz, CDCl3): δ 2.01-2.08 (2H, m), 2.67-2.71 (2H, m), 3.56 (2H, dd, J=6.9, 12.8 Hz), 6.32 (1H, s), 7.09 (1H, m), 7.22 (3H, t, J=6.5 Hz), 7.30-7.34 (3H, m), 7.53-7.64 (3H, m), 7.93 (1H, d, J=7.93 Hz), 7.99 (1H, d, J=8.6 Hz), 8.05 (1H, d, J=7.8 Hz), 8.11 (1H, dd, J=1.8, 8.6 Hz), 8.60 (1H, s), 8.78-8.89 (1H, m), 12.29 (1H, s) ppm. 13C-NMR (126 MHz, CDCl3): δ 30.84 (CH2, C-aliphatic), 33.60 (CH2, C-aliphatic), 39.90 (CH2, C-aliphatic), 120.67 (C, C-aromatic), 121.72 (CH, C-aromatic), 122.79 (CH, C-aromatic), 123.69 (CH, C-aromatic), 125.83 (CH, C-aromatic), 126.21 (CH, C-aromatic), 126.38 (CH, C-aromatic), 126.63 (CH, C-aromatic), 127.71 (CH, C-aromatic), 127.79 (CH, C-aromatic), 128.39 (CH, C-aromatic), 128.41 (CH, C-aromatic), 126.66 (CH, C-aromatic), 129.41 (CH, C-aromatic), 132.14 (C, C-aromatic), 132.63 (CH, C-aromatic), 132.81 (C, C-aromatic), 134.98 (C, C-aromatic), 139.96 (C, C-aromatic), 141.25 (C, C-aromatic), 165.68 (C, C═O), 169.16 (C, C═O) ppm. MS (ESI)+: 431.2 [M+Na]+. m.p.: 99-101° C.
    • Example 175 Synthesis of N-(2-methoxy-6-((3-phenylpropyl)carbamoyl)phenyl)-2-naphthamide (120)
  • Figure US20190248756A1-20190815-C00343
  • Compound 120 was obtained as a white powder in 45% yield. 1H-NMR (500 MHz, CDCl3): δ 1.81-1.93 (m, 2H), 2.60-2.66 (m, 2H), 3.40 (dd, J=6.8, 13.1 Hz, 2H), 3.90 (s, 3H), 6.55 (s, 1H), 7.07 (t, J=7.0 Hz, 4H), 7.16 (dq, J=7.0, 14.2 Hz, 2H), 7.26-7.32 (m, 2H), 7.60 (ddd, J=6.8, 13.7, 14.9 Hz, 2H), 7.89-7.99 (m, 3H), 8.00 (dd, J=11.9, 13.5 Hz, 1H), 8.52 (s, 1H), 8.91 (s, 1H) ppm. 13C-NMR (126 MHz, CDCl3): δ 30.97 (CH2, C-aliphatic), 32.26 (CH2, C-aliphatic), 39.56 (CH2, C-aliphatic), 56.18 (CH3, C-aliphatic), 113.49 (CH, C-aromatic), 119.44 (CH, C-aromatic), 124.01 (CH, C-aromatic), 125.89 (CH, C-aromatic), 126.80 (CH, C-aromatic), 127.40 (CH, C-aromatic), 127.78 (CH, C-aromatic), 127.92 (CH, C-aromatic), 128.31 (CH, C-aromatic), 128.37 (CH, C-aromatic), 128.48 (CH, C-aromatic) 128.62 (CH, C-aromatic), 129.22 (CH, C-aromatic), 131.20 (C, C-aromatic), 132.67 (C, C-aromatic), 133.64 (C, C-aromatic), 135.07 (C, C-aromatic), 141.34 (C, C-aromatic), 154.32 (C, C-aromatic), 167.08 (C, C-aromatic), 168.34 (C, C-aromatic) ppm. MS (ESI)+: 439.2 [M+H]+. m.p. (from methanol/water): 152-154° C.
    • Example 176 Synthesis of 2-(2-fluorobenzamido)-3,4,5-trimethoxy-N-(3-phenylpropyl)benzamide (124)
  • Figure US20190248756A1-20190815-C00344
  • Compound 124 was obtained as a white powder in 78% yield. 1H-NMR (500 MHz, CDCl3): δ 1.73 (dt, J=7.5, 14.8 Hz, 2H), 2.60-2.44 (m, 2H), 3.31 (dd, J=7.0, 13.0 Hz, 2H), 3.82 (s, 3H), 3.83 (s, 3H), 3.84 (s, 3H), 6.56 (s, 1H), 6.84 (s, 1H), 7.03-6.97 (m, 2H), 7.05-7.13 (m, 2H), 7.11-7.18 (m, 3H), 7.39-7.48 (m, 1H), 8.02 (td, J=1.8, 7.8 Hz, 1H), 8.37 (d, J=13.7 Hz, 1H) ppm. 13C-NMR (126 MHz, CDCl3): δ 31.06 (CH2, C-aliphatic), 33.14 (CH2, C-aliphatic), 39.54 (CH2, C-aliphatic), 56.29 (CH3, C-aliphatic), 61.03 (CH3, C-aliphatic), 61.23 (CH3, C-aliphatic), 106.76 (CH, C-aromatic), 116.27 (CH, C-aromatic), 116.47 (CH, C-aromatic), 120.59 (C, C-aromatic), 124.95 (CH, C-aromatic), 125.87 (CH, C-aromatic), 128.30 (CH, C-aromatic), 128.35 (CH, C-aromatic), 130.25 (C, C-aromatic), 132.24 (CH, C-aromatic), 134.03 (CH, C-aromatic) 134.10 (CH, C-aromatic), 141.37 (C, C-aromatic), 144.07 (C, C-aromatic), 149.13 (C, C-aromatic), 152.73 (C, C-aromatic), 159.87 (C, C-aromatic), 161.85 (C, C-aromatic), 166.92 (C, C-aromatic), 167.53 (C, C-aromatic) ppm. 19F-NMR (CDCl3) δ −112.27 ppm. MS (ESI)+: 489.2 [M+H]+. m.p.: 145-147° C.
    • Example 177 Synthesis of N-(2-methoxy-6-((3-phenylpropyl)carbamoyl)phenyl)-1-naphthamide (125)
  • Figure US20190248756A1-20190815-C00345
  • Compound 125 was obtained as a white powder in 69% yield. 1H-NMR (500 MHz, CDCl3): δ 1.82-2.00 (m, 2H), 2.59-2.81 (m, 2H), 3.47 (dd, J=7.0, 13.1 Hz, 2H), 3.93 (s, 3H), 6.48 (s, 1H), 7.04-7.12 (m, 2H), 7.17 (dd, J=7.1, 18.8 Hz, 3H), 7.24 (t, J=7.2 Hz, 2H), 7.31 (t, J=8.1 Hz, 1H), 7.47-7.53 (m, 1H), 7.55-7.59 (m, 2H), 7.87 (d, J=6.9 Hz, 1H), 7.90-7.96 (m, 1H), 7.99 (d, J=8.2 Hz, 1H), 8.21 (s, 1H), 8.55 (dd, J=3.6, 6.1 Hz, 1H) ppm. 13C-NMR (126 MHz, CDCl3): δ 31.13 (CH2, C-aliphatic), 33.35 (CH2, C-aliphatic), 39.73 (CH2, C-aliphatic), 56.13 (CH3, C-aliphatic), 113.28 (CH, C-aromatic), 119.51 (CH, C-aromatic), 123.54 (C, C-aromatic), 124.83 (CH, C-aromatic), 125.64 (CH, C-aromatic), 125.91 (CH, C-aromatic), 125.97 (CH, C-aromatic), 126.44 (CH, C-aromatic), 127.25 (CH, C-aromatic), 127.52 (CH, C-aromatic), 128.31 (CH, C-aromatic) 128.40 (CH, C-aromatic), 128.42 (CH, C-aromatic), 130.45 (C, C-aromatic), 131.21 (CH, C-aromatic), 133.73 (C, C-aromatic), 133.79 (C, C-aromatic), 134.30 (C, C-aromatic), 141.42 (C, C-aromatic), 154.23 (C, C-aromatic), 168.34 (C, C-atomatic), 168.96 (C, C-aromatic) ppm. MS (ESI)+: 461.2 [M+Na]+. m.p. (from ethyl acetate/n-hexane): 150-152° C.
    • Example 178 Synthesis of N-(2-((3-phenylpropyl)carbamoyl)phenyl)nicotinamide (129)
  • Figure US20190248756A1-20190815-C00346
  • Compound 129 was obtained as a white powder in 65% yield. 1H-NMR (500 MHz, CDCl3): δ 1.80-2.00 (m, 2H), 2.59-2.77 (m, 2H), 3.45 (dd, J=6.9, 12.7 Hz, 2H), 6.18 (s, 1H), 7.00 (tt, J=4.2, 8.4 Hz, 1H), 7.13-7.17 (m, 4H), 7.22-7.25 (m, 3H), 7.34-7.40 (m, 1H), 7.43-7.48 (m, 1H), 8.14-8.31 (m, 1H), 8.43-8.83 (m, 2H), 9.22 (s, 1H), 12.33 (s, 1H) ppm. 13C-NMR (126 MHz, CDCl3): δ 30.77 (CH2, C-aliphatic), 33.64 (CH2, C-aliphatic), 39.95 (CH2, C-aliphatic), 120.19 (CH, C-aromatic), 121.61 (CH, C-aromatic), 123.16 (C, C-aromatic), 123.48 (CH, C-aromatic), 126.34 (CH, C-aromatic), 128.40 (CH, C-aromatic), 128.73 (CH, C-aromatic), 130.11 (C,C-aromatic), 130.47 (CH, C-aromatic), 132.85 (CH, C-aromatic), 134.86 (CH, C-aromatic), 139.73 (C, C-aromatic), 141.21 (C, C-aromatic), 149.20 (CH, C-aromatic), 152.48 (CH, C-aromatic), 163.75 (C, C-aromatic), 169.01 (C, C-aromatic) ppm. m.p. (from ethanol/water): 74-76° C.
    • Example 179 Synthesis of N-(3-fluoro-2-((3-phenylpropyl)carbamoyl)phenyl)nicotinamide (136)
  • Figure US20190248756A1-20190815-C00347
  • Compound 136 was obtained as a white powder in 67% yield. 1H-NMR (500 MHz, CDCl3): δ 1.91-2.09 (m, 2H), 2.71-2.80 (m, 2H), 3.55 (td, J=1.4, 7.2 Hz, 2H), 6.93 (ddd, J=1.0, 8.3, 12.6 Hz, 2H), 7.20-7.27 (m, 1H), 7.27-7.35 (m, 4H), 7.43-7.53 (m, 2H), 8.27-8.39 (m, 1H), 8.71 (d, J=8.5 Hz, 1H), 8.82 (s, 1H), 9.33 (s, 1H), 12.93 (s, 1H) ppm. 13C-NMR (126 MHz, CDCl3): δ 30.72 (CH2, C-aliphatic), 33.21 (CH2, C-aliphatic), 39.63 (CH2, C-aliphatic), 110.60 (CH, C-aromatic), 110.80 (CH, C-aromatic), 117.58 (CH, C-aromatic), 123.51 (CH, C-aromatic), 126.17 (CH, C-aromatic), 128.36 (CH, C-aromatic), 128.56 (CH, C-aromatic), 133.21 (CH, C-aromatic), 133.31 (CH, C-aromatic), 134.93 (CH, C-aromatic), 140.97 (C, C-aromatic), 141.83 (C, C-aromatic), 149.24 (CH, C-aromatic), 152.61 (CH, C-aromatic), 159.96 (C, C-aromatic), 161.91 (C, C-aromatic), 163.90 (C, C-aromatic), 165.62 (C, C-aromatic), 210.12 (C, C-aromatic) ppm. 19F-NMR (CDCl3): δ −110.84 ppm. m.p. (from ethanol/water): 79-81° C.
    • Example 180 Synthesis of 2-(4-methoxybenzamido)-N-(3-phenylpropyl)benzamide (140)
  • Figure US20190248756A1-20190815-C00348
  • Compound 140 was obtained as a white powder in 52% yield. 1H-NMR (500 MHz, CDCl3): δ 1.99-2.09 (m, 2H), 2.79 (t, J=7.4 Hz, 2H), 3.54 (dd, J=6.9, 12.8 Hz, 2H), 3.90 (s, 3H), 6.24 (s, 1H), 6.98-7.10 (m, 3H), 7.20-7.30 (m, 4H), 7.33-7.42 (m, 2H), 7.39-7.57 (m, 1H), 7.88-8.06 (m, 2H), 8.80 (d, J=7.7 Hz, 1H), 12.03 (s, 1H) ppm. 13C-NMR (126 MHz, CDCl3): δ 30.83 (CH2, C-aliphatic), 33.60 (CH2, C-aliphatic), 39.88 (CH2, C-aliphatic), 55.45 (CH3, C-aliphatic), 113.98 (CH, C-aromatic), 120.37 (C, C-aromatic), 121.55 (CH, C-aromatic), 122.49 (CH, C-aromatic), 126.23 (CH, C-aromatic), 126.32 (C, C-aromatic), 127.23 (CH, C-aromatic), 128.40 (CH, C-aromatic), 128.70 (CH, C-aromatic), 129.32 (CH, C-aromatic), 132.64 (CH, C-aromatic), 140.14 (C, C-aromatic), 141.25 (C, C-aromatic), 162.50 (C, C-aromatic), 165.23 (C, C-aromatic), 169.21 (C, C-aromatic) ppm. m.p. (from ethyl acetate/n-hexane): 103-105° C.
    • General Procedure 8:
  • The compounds of the application with the general formula shown below can be prepared according to the synthetic scheme shown in Scheme 8.
  • Figure US20190248756A1-20190815-C00349
  • To a solution of compound (II) or (II′) (1 equivalent) in N,N-dimethyl-formamide (DMF) is added 2 equivalents of N,N-diisopropylethylamine (DIPEA) and 2.2 equivalent of 2-(4-methylpiperazin-1-yl)ethanamine (XIIa). The reaction mixture is stirred at about 15° C. to about 28° C. for about 6 hours to about 24 hours. The reaction mixture is diluted with water, washed with ethyl acetate, washed with brine, dried over Mg2SO4, filtered and evaporated to give a crude compound which is then purified by silica gel column using a mixture of Chloroform:Methanol (9:1) as eluent. The product is collected under reduced pressure to provide the compound with the general formula shown in Scheme 8.
  • Compounds 66-69, 123, 135, and 137 were prepared according to General Procedure 8 substituting (II) or (II′) with the appropriate substituted compound.
    • Example 181 Synthesis of 2-fluoro-N-(2-((3-(4-methylpiperazin-1-yl)propyl)carbamoyl) phenyl)benzamide (66)
  • Figure US20190248756A1-20190815-C00350
  • Compound 66 was obtained as a white powder in 69% yield. 1H-NMR (500 MHz, CDCl3): δ 1.68 (2H, m), 2.23 (3H, s), 2.31-2.49 (8H, m), 2.51 (2H, d, J=5.59 Hz), 3.43 (2H, m), 7.07 (1H, m), 7.51 (5H, m), 7.81 (2H, ddd, J=7.61, 3.12, 1.17 Hz), 7.88 (1H, d, J=0.31 Hz), 8.50 (1H, m), 8.84 (2H, m), 12.02 (1H, t, J=0.37 Hz) ppm. 13C-NMR (126 MHz, CDCl3): δ 23.43 (CH2, C-aliphatic), 41.37 (CH2, C-aliphatic), 46.10 (CH3, C-aliphatic), 53.38 (CH2, C-aliphatic), 55.10 (CH2, C-aliphatic), 58.75 (CH2, C-aliphatic), 120.75 (C, C-aromatic), 121.51 (CH, C-aromatic), 122.71 (CH, C-aromatic), 125.02 (CH, C-aromatic), 125.58 (CH, C-aromatic), 125.72 (CH, C-aromatic), 126.32 (CH, C-aromatic), 127.05 (CH, C-aromatic), 127.39 (CH, C-aromatic), 128.31 (CH, C-aromatic), 130.53 (C, C-aromatic), 131.12 (CH, C-aromatic), 132.49 (CH, C-aromatic), 133.96 (C, C-aromatic), 134.54 (C, C-aromatic), 140.13 (C, C-aromatic), 167.94 (C, C═O), 168.82 (C, C═O) ppm. MS (ESI)+: 431.2 [M+H]+. m. p.: 98-100° C.
    • Example 182 Synthesis of 2-(4-methoxybenzamido)-N-(3-(4-methylpiperazin-1-yl)propyl)benzamide (67)
  • Figure US20190248756A1-20190815-C00351
  • Compound 67 was obtained as a white powder in 69% yield. m. p.: (from Acetone/n-hexane): 79-80° C.
    • Example 183 Synthesis of N-(2-((3-(4-methylpiperazin-1-yl)propyl)carbamoyl)phenyl)-1-naphthamide (68)
  • Figure US20190248756A1-20190815-C00352
  • Compound 68 was obtained as a white powder in 69% yield. 1H-NMR (500 MHz, CDCl3): δ 1.68 (2H, m), 2.23 (3H, s), 2.31-2.49 (8H, m), 2.51 (2H, d, J=5.59 Hz), 3.43 (2H, m), 7.07 (1H, m), 7.51 (5H, m), 7.81 (2H, ddd, J=7.61, 3.12, 1.17 Hz), 7.88 (1H, d, J=0.31 Hz), 8.50 (1H, m), 8.84 (2H, m), 12.02 (1H, t, J=0.37 Hz) ppm. 13C-NMR (126 MHz, CDCl3): δ 23.43 (CH2, C-aliphatic), 41.37 (CH2, C-aliphatic), 46.10 (CH3, C-aliphatic), 53.38 (CH2, C-aliphatic), 55.10 (CH2, C-aliphatic), 58.75 (CH2, C-aliphatic), 120.75 (C, C-aromatic), 121.51 (CH, C-aromatic), 122.71 (CH, C-aromatic), 125.02 (CH, C-aromatic), 125.58 (CH, C-aromatic), 125.72 (CH, C-aromatic), 126.32 (CH, C-aromatic), 127.05 (CH, C-aromatic), 127.39 (CH, C-aromatic), 128.31 (CH, C-aromatic), 130.53 (C, C-aromatic), 131.12 (CH, C-aromatic), 132.49 (CH, C-aromatic), 133.96 (C, C-aromatic), 134.54 (C, C-aromatic), 140.13 (C, C-aromatic), 167.94 (C, C═O), 168.82 (C, C═O) ppm. MS (ESI)+: 431.2 [M+H]+. m. p.: 98-100° C.
    • Example 184 Synthesis of N-(2-((3-(4-methylpiperazin-1-yl)propyl)carbamoyl)phenyl)-2-naphthamide (69)
  • Figure US20190248756A1-20190815-C00353
  • Compound 69 was obtained as a white powder in 99% yield. 1H-NMR (500 MHz, CDCl3): δ 1.30 (3H, m), 1.84 (2H, m), 2.33 (3H, s), 2.38-2.57 (5H, m), 2.65 (2H, d, J=5.47 Hz), 3.36 (2H, m), 7.16 (1H, td, J=0.95, 7.59 Hz), 7.29 (1H, s), 7.60 (3H, dd, J=6.42 Hz), 7.69 (1H, dd, J=1.30, 7.87 Hz), 7.93 (1H, d, J=0.39 Hz), 7.99 (1H, s), 8.06 (1H, m), 8.14 (1H, d, J=6.74 Hz), 8.63 (1H, t, J=0.62 Hz), 8.95 (2H, m), 12.67 (1H, d, J=0.19 Hz) ppm. 13C-NMR (126 MHz, CDCl3): δ 23.50 (CH2, C-aliphatic), 41.32 (CH2, C-aliphatic), 46.02 (CH3, C-aliphatic), 53.29 (CH2, C-aliphatic), 54.98 (CH2, C-aliphatic), 58.62 (CH2, C-aliphatic), 120.56 (C, C-aromatic), 121.58 (CH, C-aromatic), 122.55 (CH, C-aromatic), 123.75 (CH, C-aromatic), 126.58 (CH, C-aromatic), 127.37 (CH, C-aromatic), 127.70 (CH, C-aromatic), 127.73 (CH, C-aromatic), 128.44 (CH C-aromatic), 128.59 (CH, C-aromatic), 129.42 (CH, C-aromatic), 132.26 (C, C-aromatic), 132.55 (CH, C-aromatic), 132.82 (C, C-aromatic), 134.96 (C, C-aromatic), 140.26 (C, C-aromatic), 165.00 (C, C═O), 169.18 (C, C═O) ppm. MS (ESI)+: 431.2 [M+H]+. m. p.: 71-72° C.
    • Example 185 Synthesis of N-(2-methoxy-6-((3-(4-methylpiperazin-1-yl)propyl)carbamoyl)phenyl)-2-naphthamide (123)
  • Figure US20190248756A1-20190815-C00354
  • Compound 123 was obtained as a white powder in 29% yield. 1H-NMR (500 MHz, CDCl3): δ 1.73 (dt, J=6.0, 12.0 Hz, 3H), 2.27 (s, 3H), 2.35 (bs, 6H), 2.51-2.56 (m, 3H), 3.47 (dd, J=5.8, 11.2 Hz, 2H), 3.95 (s, 3H), 7.15 (d, J=8.3 Hz, 1H), 7.20 (dd, J=1.2, 7.8 Hz, 1H), 7.24-7.34 (m, 1H), 7.54-7.63 (m, 2H), 7.91 (d, J=7.9 Hz, 1H), 7.95 (d, J=8.6 Hz, 1H), 8.00 (d, J=7.9 Hz, 1H), 8.06 (dd, J=1.8, 8.6 Hz, 1H), 8.26 (s, 1H), 8.55 (s, 1H), 9.77 (s, 1H) ppm. 13C-NMR (126 MHz, CDCl3): δ 24.31 (CH2, C-aliphatic), 40.44 (CH2, C-aliphatic), 45.93 (CH3, C-aliphatic), 53.07 (CH2, C-aliphatic), 54.94 (CH2, C-aliphatic), 56.28 (CH3, C-aliphatic), 57.79 (CH2, C-aliphatic), 114.25 (CH, C-aromatic), 119.38 (CH, C-aromatic), 124.25 (CH, C-aromatic), 125.99 (C, C-aromatic), 126.29 (CH, C-aromatic), 126.65 (CH, C-aromatic), 127.74 (CH, C-aromatic), 128.47 (CH, C-aromatic), 128.47 (CH, C-aromatic), 128.50 (CH, C-aromatic), 129.23 (CH, C-aromatic), 131.21 (C, C-aromatic), 131.68 (C, C-aromatic), 132.73 (C, C-aromatic), 135.01 (C, C-aromatic), 154.46 (C, C-aromatic), 165.94 (C, C-aromatic), 168.42 (C, C-aromatic) ppm. MS (ESI)+: 448.2 [M+H]+. m. p. (from methanol/water): 119-121° C.
    • Example 186 Synthesis of N-(3-fluoro-2-((3-(4-methylpiperazin-1-yl)propyl)carbamoyl)phenyl)nicotinamide (135)
  • Figure US20190248756A1-20190815-C00355
  • Compound 135 was obtained as a white powder in 24% yield. 1H-NMR (500 MHz, CDCl3): δ 1.60-1.68 (m, 2H), 1.72-1.83 (m, 2H), 2.19 (s, 5H), 2.32 (s, 3H), 2.43-2.55 (m, 3H), 3.53 (dd, J=5.0, 11.0 Hz, 2H), 6.83 (ddd, J=1.0, 8.3, 11.6 Hz, 1H), 7.32-7.42 (m, 2H), 8.23 (ddd, J=1.7, 2.3, 8.0 Hz, 1H), 8.43 (s, 1H), 8.52 (t, J=23.0 Hz, 1H), 8.71 (dd, J=1.6, 4.8 Hz, 1H), 9.22 (d, J=1.7 Hz, 1H), 12.54 (s, 1H) ppm. 13C-NMR (126 MHz, CDCl3): δ 24.28 (CH2, C-aliphatic), 40.47 (CH2, C-aliphatic), 46.01 (CH3, C-aliphatic), 53.27 (CH2, C-aliphatic), 54.87 (CH2, C-aliphatic), 57.68 (CH2, C-aliphatic), 110.75 (CH, C-aromatic), 117.42 (CH, C-aromatic), 123.48 (CH, C-aromatic), 130.29 (C, C-aromatic), 132.86 (CH, C-aromatic), 134.89 (CH, C-aromatic), 141.22 (C, C-aromatic), 149.26 (CH, C-aromatic), 152.60 (CH, C-aromatic), 159.40 (C, C-aromatic), 161.36 (C, C-aromatic), 163.80 (C, C-aromatic), 164.91 (C, C-aromatic) ppm. 19F-NMR (CDCl3): δ −110.05 ppm. m. p.: 72-74° C.
    • Example 187 Synthesis of 3,4,5-trimethoxy-2-(4-methoxybenzamido)-N-(3-(4-methylpiperazin-1-yl)propyl)benzamide (137)
  • Figure US20190248756A1-20190815-C00356
  • Compound 137 was obtained as a white powder in 30% yield. 1H-NMR (500 MHz, CDCl3): δ 1.48-1.73 (m, 2H), 2.18 (s, 4H), 2.35 (t, J=6.5 Hz, 9H), 3.34 (dd, J=6.2, 11.9 Hz, 2H), 3.80 (s, 3H), 3.82 (s, 3H), 3.85 (s, 3H), 3.85 (s, 3H), 6.79 (s, 1H), 6.85-6.96 (m, 2H), 7.54 (s, 1H), 7.83-7.92 (m, 2H), 8.63 (s, 1H) ppm. 13C-NMR (126 MHz, CDCl3): δ 25.22 (CH2, C-aliphatic), 39.24 (CH2, C-aliphatic), 45.70 (CH3, C-aliphatic), 52.71 (CH2, C-aliphatic), 54.65 (CH2, C-aliphatic), 55.49 (CH3, C-aliphatic), 56.62 (CH2, C-aliphatic), 56.70 (CH3, C-aliphatic), 61.01 (CH3, C-aliphatic), 61.03 (CH3, C-aliphatic), 106.79 (CH, C-aromatic), 113.95 (CH, C-aromatic), 123.01 (C, C-aromatic), 126.35 (C, C-aromatic), 127.81 (C, C-aromatic), 129.51 (CH, C-aromatic), 144.73 (C, C-aromatic), 149.41 (C, C-aromatic), 151.82 (C, C-aromatic), 162.68 (C, C-aromatic), 166.67 (C, C-aromatic), 168.05 (C, C-aromatic) ppm. m. p.: 94-96° C.
    • Example 188 Synthesis of 2-fluoro-4-methoxybenzoylchloride (207)
  • Figure US20190248756A1-20190815-C00357
  • To a stirred solution of 2-fluoro-4-methoxybenzoic acid (0.0059 moles, 1.00 g) in SOCl2 (0.3835 moles, 30 mL, 1.635 g/mL) was added 4 drops of N, N-Dimethylformamide (DMF). The reaction mixture was heated under reflux for 8 hours. The excess reagent was then removed under reduced pressure to give the crude compound 207 in 98.2% yield.
    • Example 189 Synthesis of 2-(4-methyl-piperazin-1-yl)ethanamide. (208)
  • Figure US20190248756A1-20190815-C00358
  • Step 1: A solution of N-methyl-piperazine (0.018 moles, 1.99 mL), 1.4 mL of chloroacetonitrile (0.022 moles, 1.193 g/mL) and potassium carbonate (K2CO3) (0.086 moles, 12 g) in acetonitrile (CAN) (18 mL) is stirred for 96 hours at room temperature. The reaction was filtered under a vacuum and the filtrate was evaporated. Desired product was obtained in 5.18% yield.
  • Step 2: 4 g of the product obtained in step 1 (0.028 moles) was dissolved in a 1:1 mixture of Tetrahydrofuran:Diethylether and was added drop wise to a suspension of lithium aluminium hydride (3.2 g) in diethylether (20 mL) at 0° C.
  • The reaction was stirred at room temperature for 24 hours, cooled to 0° C. and 10 mL of NaOH 6N was added and mixture stirred for 20 minutes. The solid was removed by filtration and filtrate was evaporated to give the title compound (208) in 4.74% yield.
    • General Procedure 9:
  • The compounds of general formula (XIV) can be prepared according to the synthetic scheme shown in Scheme 9.
  • Figure US20190248756A1-20190815-C00359
  • A solution of methanol (2 mL), the starting nitro-compound 0.100 g; 0.00026 mol) and Pd—C (0.010 g) was stirred under H2 flow for 24 hours at room temperature. The solution was filtered on a celite bed and the filtrate was evaporated to give a solid which as purified by silica gel column chromatography using Chloroform:Ethanol (9:1) as eluent. The final compound was re-crystallized in ethanol and water to furnish the final compound (XIV).
    • General Procedure 10: The Preparation of Salts of Compound 12 Example 190 Synthesis of 4-(2-(2-(2-fluoro-4-methoxybenzamido)benzamido)ethyl)morpholin-4-ium chloride
  • Procedure: A solution of 12 (1 equivalent) is diluted in dichloromethane and HCl 12 M (1 equivalent) is added. The solvent is removed and the crude product is collected under reduced pressure The product was obtained as colorless oil in 90% yield. 1H-NMR (500 MHz, CDCl3): δ 2.85 (t, J=18.7 Hz, 2H), 3.23 (s, 2H), 3.60 (t, J=17.2 Hz, 2H), 3.79 (s, 3H), 3.99-3.83 (m, 4H), 4.17 (t, J=12.1 Hz, 2H), 6.60 (dd, J=2.4, 13.3 Hz, 1H), 6.73 (dd, J=2.4, 8.8 Hz, 1H), 7.04 (dd, J=14.9, 22.0 Hz, 1H), 7.38 (dd, J=8.9, 16.3 Hz, 1H), 7.96 (t, J=8.9 Hz, 1H), 8.34 (t, J=7.7 Hz, 1H), 8.60 (s, 1H), 8.98 (s, 1H), 11.75 (d, J=8.1 Hz, 1H), 12.20 (s, 1H) ppm. 13C-NMR (126 MHz, CDCl3): δ 33.99 (CH2, C-aliphatic), 53.18 (CH2, C-aliphatic), 55.83 (CH3, C-aliphatic), 58.90 (CH2, C-aliphatic), 63.54 (CH2, C-aliphatic), 110.56 (CH, C-aromatic), 114.79 (CH, C-aromatic), 120.10 (CH, C-aromatic), 122.14 (C, C-aromatic), 123.53 (CH, C-aromatic), 126.87 (CH, C-aromatic), 132.82 (CH, C-aromatic), 133.09 (CH, C-aromatic), 139.63 (C, C-aromatic), 161.93 (C, C-aromatic), 162.41 (C, C-aromatic), 163.55 (C, C-aromatic), 163.72 (C, C-aromatic), 169.46 (C, C-aromatic) ppm. 19F-NMR (CDCl3): δ −109.20 ppm. MS (ESI)+: 402.2 [M+H]+.
    • Example 191 Synthesis of 4-(2-(2-(2-fluoro-4-methoxybenzamido)benzamido)ethyl)morpholin-4-ium methanesulfonate
  • Procedure: A solution of 12 (1 equivalent) is diluted in acetone and methane sulfonic acid (1 equivalent) is added. The solvent is removed and the crude product is collected under reduced pressure. The product was obtained as colorless oil in 90% yield. 1H-NMR (500 MHz, CDCl3): δ 2.37 (s, 3H), 2.51 (dd, J=3.6, 1.8 Hz, 6H), 3.88 (s, 3H), 3.95 (s, 6H), 6.77-7.07 (m, 2H), 7.14-7.25 (m, 1H), 7.61-7.68 (m, 1H), 7.91 (t, J=8.9 Hz, 2H), 8.00-8.06 (m, 1H), 8.72 (d, J=7.8 Hz, 1H), 11.89 (d, J=6.6 Hz, 1H), 13.06-13.32 (bs, 1H) ppm. 13C-NMR (126 MHz, CDCl3): δ 39.50 (CH2, C-aliphatic), 40.00 (CH2, C-aliphatic), 52.22 (CH2, C-aliphatic), 56.81 (CH3, C-aliphatic), 58.65 (CH3, C-aromatic), 110.52 (CH, C-aromatic), 111.90 (CH, C-aromatic), 117.24 (CH, C-aromatic), 120.98 (C, C-aromatic), 123.54 (CH, C-aromatic), 131.69 (CH, C-aromatic), 132.76 (CH, C-aromatic), 134.60 (CH, C-aromatic), 141.19 (C, C-aromatic), 160.75 (C, C-aromatic), 161.86 (C, C-aromatic), 162.16 (C, C-aromatic), 163.82 (C, C-aromatic), 169.25 (C, C-aromatic) ppm. 19F-NMR (CDCl3): δ −109.78 ppm.
    • Example 192 Synthesis of 4-(2-(2-(2-fluoro-4-methoxybenzamido)benzamido)ethyl)morpholin-4-ium 2-carboxyacetate
  • Procedure:
  • A solution of 12 (1 equivalent) is diluted in dichloromethane and malonic acid (1 equivalent) is added. The solvent is removed and the crude product is collected under reduced pressure. The product was obtained as yellow oil in 90% yield. 1H-NMR (500 MHz, DMSO-d6): δ 2.37 (s, 3H), 2.59-2.72 (m, 4H), 3.01-3.16 (m, 3H), 3.56-3.65 (m, 4H), 3.80-3.93 (m, 3H), 6.96 (dd, J=2.4, 8.8 Hz, 1H), 7.02 (dd, J=13.5, 2.4 Hz, 1H), 7.18-7.26 (m, 1H), 7.52-7.59 (m, 1H), 7.75 (dt, J=5.8, 11.7 Hz, 1H), 7.87 (t, J=8.9 Hz, 1H), 8.56 (d, J=7.7 Hz, 1H), 8.78 (t, J=5.1 Hz, 1H), 11.86 (d, J=6.4 Hz, 1H) ppm. 13C-NMR (126 MHz, DMSO-d6): δ 39.83 (CH2, C-aliphatic), 41.72 (CH2, C-aliphatic), 53.21 (CH2, C-aliphatic), 56.58 (CH3, C-aliphatic), 57.09 (CH2, C-aliphatic), 65.93 (CH2, C-aliphatic), 102.35 (CH, C-aromatic), 111.79 (CH, C-aromatic), 114.97 (C, C-aromatic), 115.07 (CH, C-aromatic), 121.63 (C, C-aromatic), 122.13 (CH, C-aromatic), 123.54 (C, C-aromatic), 128.54 (CH, C-aromatic), 132.35 (CH, C-aromatic), 132.60 (CH, C-aromatic), 139.04 (C, C-aromatic), 160.22 (C, C-aromatic), 161.59 (C, C-aromatic), 162.20 (C, C-aromatic), 168.77 (C, C-aromatic), 169.59 (C, C-aromatic) ppm. 19F-NMR (CDCl3): δ −109.78 ppm.
    • Additional Compounds Example 193 Synthesis of 2-(2-fluoro-N-methylbenzamido)benzoic acid (104)
  • Procedure:
  • To a solution of N-methyl anthranilic acid (0.755 g; 0.0050 mol) in 30 mL of pyridine, 2-fluorobenzoyl chloride (0.011 mol; 1.30 mL; 1.342 g/mL) is added dropwise over a period of 30 minutes under an argon atmosphere at 0° C. The reaction mixture are stirred for 10 hours at room temperature and then poured into ice water (200 mL) and acidified with HCl 37% (25 mL). The precipitate was filtered off and the filtrate was extracted with diethyl ether. The combined organic phases are dried with Na2SO4 and evaporated to dryness to afford viscous product.
  • Figure US20190248756A1-20190815-C00360
  • Compound 104 was obtained as a white powder in 17% yield. 1H-NMR (500 MHz, CDCl3): δ 3.51 (s, 3H), 6.20 (s, 1H), 6.81 (t, J=9.0 Hz, 1H), 6.96 (t, J=7.2 Hz, 1H), 7.17 (td, J=1.7, 7.3 Hz, 1H), 7.29-7.33 (m, 2H), 7.37 (d, J=8.0 Hz, 1H), 7.50 (td, J=1.5, 7.8 Hz, 1H), 7.92 (dd, J=1.4, 7.8 Hz, 1H) ppm. 13C-NMR (126 MHz, CDCl3): δ 36.91 (CH3, C-aliphatic), 115.24 (CH, C-aromatic), 123.86 (CH, C-aromatic), 128.05 (CH, C-aromatic), 128.67 (CH, C-aromatic), 128.88 (C, C-aromatic), 129.94 (CH, C-aromatic), 131.00 (CH, C-aromatic), 131.14 (CH, C-aromatic), 132.88 (CH, C-aromatic), 142.58 (C, C-aromatic), 156.00 (C, C-aromatic), 158.16 (C, C-aromatic), 164.79 (C, C-aromatic), 166.27 (C, C-aromatic) ppm. 19F-NMR (CDCl3): δ −112.50 ppm. m. p.: (from diethyl ether/n-hexane) 128-130° C.
    • Example 194 2-(2-fluorobenzamido)nicotinic acid (105)
  • Figure US20190248756A1-20190815-C00361
  • Compound 105 was obtained as a white powder in 17% yield. 1H-NMR (500 MHz, CDCl3): δ 7.05 (dd, J=5.0, 7.3 Hz, 1H), 7.28-7.36 (m, 2H), 7.57 (ddd, J=1.7, 5.2, 15.1 Hz, 1H), 7.73 (td, J=1.8, 7.6 Hz, 1H), 8.18-8.31 (m, 2H), 14.85 (s, 1H) ppm. 13C-NMR (126 MHz, CDCl3): δ 118.31 (CH, C-aromatic), 124.54 (CH, C-aromatic), 129.78 (CH, C-aromatic), 132.53 (CH, C-aromatic), 139.30 (CH, C-aromatic), 140.03 (CH, C-aromatic), 145.46 (C, C-aromatic), 148.13 (CH, C-aromatic), 152.26 (C, C-aromatic), 165.02 (C, C-aromatic) ppm. 19F-NMR (CDCl3): δ −109.57 ppm. MS (ESI)+: 261.1 [M+H]+. m. p.: >90° C.
    • Biological Assays Example 195: Cell Toxicity Titer Blue Assay
  • A cell toxicity titer blue assay is run to determine the cell toxicity of the compounds of Formula (I) or Formula (Ia).
  • Compounds are dissolved in DMSO in order to store them in a 10 mM concentration. In order to use them in the cell toxicity blue assay, two different concentrations of each compound are prepared: 10 nM and 100 nM. Hence, to prepare the 10 nM concentrations 1 μl of the stored solution of each compound is diluted in 999 μl of culture media. To prepare the 100 nM concentration, 10 μl of the previous concentration is diluted in 990 μl of media.
  • Cells are kept in a 96 well plate, at low confluency, in 100 μl of complete growth media containing the compounds. The cells are in triplicates: each compound at each concentration is put in three wells, hence data are obtained in triplicate for each compound and for each concentration. They had been incubated for 24 hours at 37° C. and 5% CO2.
  • In each well containing 100 μl of media with the specific compound, 20 μl Cell Titre Blue reagent is added. The 96 well plate is incubated for one hour at 37° C. and 5% CO2.
  • Fluorescence is measured using Fluorostar Optima plate reader and using an excitation/emission of 560/590 nm. The results are analyzed using Microsoft Excel.
  • Results are shown in FIGS. 1a-1h . Ref. A refers to Reference Compound A.
    • Example 196: Scratch Assay
  • A Scratch assay is run to determine the migration of cells in the presence of a compound of Formula (I) or Formula (Ia).
  • It is necessary to prepare the solution of the compounds at 1 micromolar. In six well plates, the complete growth media of the seeded cells (density 11*10E−6 in 20 mL) is removed and replaced by 3 mL of a fresh media containing compounds of Formula (I) or Formula (Ia) (20 mL and 2 μl of compounds). Media is used as a negative compound.
  • After a 24 h incubation period at 5% CO2 and 37° C., the media is removed and a scratch is performed in each well. 1 mL of fresh complete growth media is used to wash the wells. After its removal, 3 mL of a solution containing a compound of Formula (I) or Formula (Ia) is added in each well in triplicate. Pictures of these wells are then taken. After 24 h, pictures of the wells are again taken. The comparison between the two images provides a measure of the migration of the cells.
    • Example 196a: Anti-Migration Activity of Compounds Tested During the Scratch Assay (FIG. 2)
  • The cell migration assay used was the transwell (Boyden chamber) assay of cell migration in human breast cancer cell line MDA-MB-436. After a scratch was performed in each well the cells were incubated with a 10 micromolar solution of compound for 24 hours prior to passage into transwell chambers where they were maintained in the presence of compound for a further 24 hours before assessment of migration (measured by total fluorescence on opposing surface of transwell membrane following staining). Reduced fluorescence directly correlates with number of cells migrated. The data show that 7 of the compounds that were tested significantly reduce cell migration compared to DMSO and that 2 of the compounds tested reduce migration significantly better than compound 12. Additionally, compound 31 was more effective at reducing cell migration than the known potent cell migration inhibitor MEKi, used here as a positive control. These ‘hits’ were confirmed in a second breast cancer cell line (MDA-MB-231).
    • Example 197: Determination of NF-kB Activity in Cells
  • For NF-κB luciferase assays, cells were seeded into clear bottom black 96-well plates (Corning Inc., Lowell, US) in antibiotic free culture media in appropriate density. After 24 hrs, cells were transfected with 10 ng of 3×KB luciferase plasmid and 10 ng of pcDNA3.1-Lacl plasmid per well. Empty pcDNA3.1 plasmid was also included to normalize the total weight of DNA transfected to 100 ng. For positive and negative controls respectively, 10 ng of pGL3control or pGL3 basic were transfected in place of 3×KB luciferase plasmid. Transfection was carried out using Lipofectamine LTX reagents (Invitrogen, Paisley, UK).
  • After 48 hrs post-transfection with luciferase reporter plasmid, the media was aspirated and cells were lyzed using 50 μl/well of Glo-lysis buffer (Promega, Southampton, UK). The plate was left on a rocker for 20 min to facilitate complete cell lysis. Then, 20 μl of lysate from each well was removed and transferred into a new clear bottom black well plate for measuring LacZ activity as a transfection efficiency control and followed by addition of 20 ul/well of Beta-Glo substrate (Promega, Southampton, UK) and cultivation at room temperature for at least 20 min. Subsequently, 30 μl/well of Bright-Glo luciferase substrate (Promega, Southampton, UK) was added to the original plate and asses immediately for luminescence activity. The luminescence produced from either reaction was read using a Flurostar Optima plate reader (BMG tabtech, Bucks, UK). The resulting luciferase activity was then normalized against lacZ activity obtained from Beta-glo measurement and is displayed as relative light units (R.t.U).
    • Example 197a: NF-kB Activity of Compound 12
  • The effect of Compound 12 and reference compound A (depicted below) on NF-KB activity was determined by NF-KB luciferase assay in MDA-MB-231 cells. This assay was performed in MDA-MB-231 human breast cancer cells stably expressing an NF-kB promoter Luciferase reporter.
  • MDA-MB-231 cells were stored in a small flask with complete growth media (5 mL) in incubator at 37° C. and 5% CO2. Every 72-96 hours, the cells are split. Trypsin (1 mL) is added and the flask is stirred and stored in the incubator for 5 minutes. Once the cells are floating, complete growth media is added and all the solution is moved in a 25 mL falcon. 500 μl of this solution is kept in the flask and 6 mL of complete growth media is added in order to keep the cell growing. The flask is incubated at and 5% CO2 and 37° C.
  • MDA-MB-231 breast cancer cells stably expressing an NF-kB promoter luciferase reporter were incubated for 20 hours with 1 micromolar compound 12, Reference compound A, or vehicle control prior to treatment with 100 ng/ml epithelial growth factor (EGF) for 3 hours and analysed for NF-κB activity. Luciferase expression was then measured by Clariostar plate reader. Data represents mean of 6 replicates, error bars=standard error of mean. Results for compound 12 are shown in FIG. 3.
  • At 1 micromolar, compound 12 showed complete suppression (100%) of EGF induced NF-kB activity in human breast cancer cells in vitro. Compound 12 demonstrated 25% greater of suppression NF-kB activity as compared to reference compound A.
    • Example 198: In Vivo Metastasis Mouse Model
  • Nude mice were injected i.v. with 200,000 highly metastatic human breast cancer cells expressing luciferase (MDA-MB-231-Luc) then given 3.5 mg/Kg of compound 12, reference compound A, or Reference compound B once daily for 10 days and monitored for tumours by total body scan using Xenogen-IVIS. Mice with a luciferase signal above background in repeated scans in any part of their torso were scored as having metastatic disease. Total light emission in abdominal region was quantified at time points up to 49 days post surgery and plotted as mean total light yield. Control n=12, Reference compound A n=10, Reference compound B n=4; compound 12 n=4. Results are shown in FIG. 4.
  • The results in the in vivo mouse models of metastatic breast cancer show the following disease free survival: 33% survival in untreated controls; 70% survival in animal treated with Reference compound A; 50% Reference compound B treated animals (n=4); 100% survival in animals treated with compound 12 (n=4).
  • Figure US20190248756A1-20190815-C00362
    • Example 199: In Vivo Metastasis Mouse Model 1
  • Model 1 tested the effect of Bcl3i compounds to inhibit the seeding and early colonization of circulating tumour cells at distal sites, most commonly in the lungs and liver. Human tumour cell lines were injected into the bloodstream of recipient mice, followed by single daily intraperitoneal injections of Bcl3 inhibitor (3.5 mg/kg in 1% DMSO) for 10 consecutive days. Tumour burden was monitored longitudinally for up to 8 weeks in vivo by live luminescence imaging, and subsequently histology performed on affected organs at the end of the experiment.
  • FIG. 5 shows the comparative effect of compounds of the application (each at 3.5 mg/Kg) on Model 1 (seeding and subsequent growth of human breast cancer MDA-MB-231 xenograft). The X axis represents the number of days after xenograft and the Y axis is the relative luminescence of the thoracic region by Xenon IVIS scanning of mice following injection of d-luciferin for 10 minutes. Consistent with in vitro data, compounds 31 and 49 exhibited more potent effects than compound 28. Compounds 31 and 49 exhibited equivalent inhibition of metastasis in vivo to compound 12. Compound 28 exhibited a significant reduction in tumour burden compared to controls but reduced effect compared to compound 12. n=5 for each treatment arm, except compound 12 and DMSO where n=20.
    • Example 200: Comparative Tumour Growth Kinetics in Mouse Model 4
  • Model 4 tested the effect of compounds of the application to inhibit the growth of tumour cells at the transplantation site. Human tumour cell lines were injected subcutaneously into recipient mice, followed 2 days later by single daily intraperitoneal injections of Bcl3 inhibitor (3.5 mg/kg in 1% DMSO) for the entire course of the experiment. Tumour burden was monitored longitudinally for up to 12 weeks in vivo by palpation and caliper measurements of tumour volume, and subsequently histology performed on tumours at the end of the experiment.
  • FIGS. 6 and 7 show the comparative effect of compound 12 (3.5 mg/kg intraperitoneal injection) on Model 4 in human breast cancer (MDA-MB-231) and human colorectal cell lines (SW480), respectively. The data show significant reductions in average tumour growth for both cell lines. The inserted waterfall plots demonstrate the extent of the biological variability between individual xenograft tumours, and they highlight the distribution of tumour sizes between treated (light grey) and untreated (dark grey) tumours.
    • Example 201: Effect of Compound 12 in Metastatic Breast Cancer
  • Method: MDA-MB-231 human breast cancer cells were used in each of the three xenograft models of metastatic breast cancer. Each of FIGS. 8, 9, 10 shows the effect of Compound 12 (3.5 mg/kg) administered intraperitoneally daily on tumour growth, dissemination or seeding. The most profound effect is seen in FIG. 8, tumour cell seeding at distal sites, but significant effects are also observed in subsequent growth and spread of the secondary tumours (FIG. 9) and on the growth of tumour at the xenograft site (FIG. 10).
    • Example 202: Effect of Compound 12 in Triple Negative Breast Invasive Ductal Carcinoma
  • Model 4 tested the effect of compounds of the application to inhibit the growth of tumour cells at the transplantation site. MDA-MB-436 cells were injected subcutaneously into recipient mice, followed 2 days later by single daily intraperitoneal injections of compound 12 (3.5 mg/kg in 1% DMSO) for the entire course of the experiment. Tumour burden was monitored longitudinally for up to 12 weeks in vivo by palpation and caliper measurements of tumour volume, and subsequently histology performed on tumours at the end of the experiment. FIG. 11 shows the effect of compound 12 in triple negative breast invasive ductal carcinoma. The data show significant reductions in average tumour growth for both cell lines. The inserted waterfall plot demonstrates the extent of the biological variability between individual xenograft tumours, and they highlight the distribution of tumour sizes between treated (light grey) and untreated (dark grey) tumours.
    • EQUIVALENTS
  • Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments and methods described herein. Such equivalents are intended to be encompassed by the scope of the present application.
    • INCORPORATION BY REFERENCE
  • All patents, patent applications, and literature references cited herein are hereby expressly incorporated by reference for all purposes.

Claims (20)

What is claimed:
1. A compound of Formula (Ia),
Figure US20190248756A1-20190815-C00363
or a pharmaceutically acceptable salt thereof, wherein:
A is CR3 or N;
X1 is CR8 or N;
X2 is CR9 or N;
X3 is CR10 or N;
wherein zero or one of X1, X2, or X3 is N;
R2, R3, R4, R5 and R6 are each, independently, hydrogen, halogen, C1-C6 haloalkyl, NO2, NRaRb, OH, O(C1-C6 alkyl), S(C1-C6 alkyl), O(C1-C6 haloalkyl), or S(C1-C6 haloalkyl);
or R2 and R3 together with the carbon atoms to which they attach form a C6 aryl ring, or R5 and R6 together with the carbon atoms to which they attach form a C6 aryl ring, or R3 and R4 together with the carbon atoms to which they attach form a C6 aryl ring, or R4 and R5 together with the carbon atoms to which they attach form a C6 aryl ring;
Ra and Rb are each, independently, hydrogen or C1-C6 alkyl;
R8, R9, R10, and Z are each, independently, hydrogen, halogen, OH, or O(C1-C6 alkyl);
R11 is OH, O(C1-C6 alkyl), or —NH—(CH2)q—Rq, wherein:
q is 2 or 3;
Rq is 1-piperazinyl, 1-(4-N—(RN))piperazinyl, N-morpholino or phenyl; and
RN is C1-C5 alkyl; and
R12 is hydrogen or C1-C6 alkyl;
wherein,
a) when A is CR3 and R2 is fluorine or chlorine, then Rq is phenyl or 1-(4-N—(RN))piperazinyl;
or
b) when A is CR3, R2 is fluorine or chlorine, q is 2 and Rq is N-morpholino, then at least one of R8, R9, R10, and Z is not hydrogen and R8 is not OCH3;
or
c) when A is CR3, R2 is fluorine or chlorine, q is 2 and Rq is N-morpholino, then at least one of R3, R4, R5 and R6 is not hydrogen or halogen; and at least three of R2, R3, R4, R5 and R6 are hydrogen.
2. The compound of claim 1, being of Formula (Ib),
Figure US20190248756A1-20190815-C00364
or a pharmaceutically acceptable salt thereof, wherein:
A is CR3 or N;
X1 is CR8 or N;
X2 is CR9 or N;
X3 is CR10 or N;
wherein zero or one of X1, X2, or X3 is N;
R2, R3, R4, R5 and R6 are each, independently, hydrogen, halogen, C1-C6 haloalkyl, NO2, NRaRb, OH, O(C1-C6 alkyl), or O(C1-C6 haloalkyl);
Ra and Rb are each, independently, hydrogen or C1-C6 alkyl;
R8, R9, R10, and Z are each, independently, hydrogen, fluorine, OH, or O(C1-C6 alkyl);
q is 2 or 3;
RN is C1-C5 alkyl; and
R12 is hydrogen or C1-C6 alkyl.
3. The compound of claim 1 being of Formula (Ic),
Figure US20190248756A1-20190815-C00365
or a pharmaceutically acceptable salt thereof, wherein:
X1 is CR8 or N;
X2 is CR9 or N;
X3 is CR10 or N;
wherein zero or one of X1, X2, or X3 is N;
R2 and R3 together with the carbon atoms to which they attach form a C6 aryl ring, or R5 and R6 together with the carbon atoms to which they attach form a C6 aryl ring, and
the remaining of R2, R3, R4, R5 and R6 are each, independently, hydrogen, halogen, C1-C6 haloalkyl, NO2, NRaRb, OH, O(C1-C6 alkyl), or O(C1-C6 haloalkyl);
Ra and Rb are each, independently, hydrogen or C1-C6 alkyl;
R8, R9, R10, and Z are each, independently, hydrogen, halogen, OH, or O(C1-C6 alkyl);
q is 2 or 3;
Rq is 1-piperazinyl, 1-(4-N—(RN))piperazinyl, N-morpholino or phenyl;
RN is C1-C5 alkyl;
R12 is hydrogen or C1-C6 alkyl; and
wherein,
a) when A is CR3 and R2 is fluorine or chlorine, then Rq is phenyl or 1-(4-N—(RN))piperazinyl,
or
b) when A is CR3, R2 is fluorine or chlorine, q is 2 and Rq is N-morpholino, then at least one of R8, R9, R10, and Z is not hydrogen and R8 is not OCH3.
4. The compound of claim 1, being of Formula (Ic),
Figure US20190248756A1-20190815-C00366
or a pharmaceutically acceptable salt thereof, wherein:
X1 is CR8 or N;
X2 is CR9 or N;
X3 is CR10 or N;
wherein zero or one of X1, X2, or X3 are N;
R3 and R4 together with the carbon atoms to which they attach form a C6 aryl ring, or R4 and R5 together with the carbon atoms to which they attach form a C6 aryl ring, and
R2, R6 and the remaining of R3 and R5 are each, independently, hydrogen, halogen, C1-C6 haloalkyl, NO2, NRaRb, OH, O(C1-C6 alkyl), or O(C1-C6 haloalkyl);
Ra and Rb are each, independently, hydrogen or C1-C6 alkyl;
R8, R9, R10, and Z are each, independently, hydrogen, halogen, OH, or O(C1-C6 alkyl);
q is 2 or 3;
Rq is 1-piperazinyl, 1-(4-N—(RN))piperazinyl, N-morpholino or phenyl;
RN is C1-C5 alkyl; and
R12 is hydrogen or C1-C6 alkyl;
wherein,
a) when A is CR3 and R2 is fluorine or chlorine, then Rq is phenyl or 1-(4-N—(RN))piperazinyl,
or
b) when A is CR3, R2 is fluorine or chlorine, q is 2 and Rq is N-morpholino, then at least one of R8, R9, R10, and Z is not hydrogen and R8 is not OCH3.
5. The compound of claim 1, being of Formula (Id),
Figure US20190248756A1-20190815-C00367
or a pharmaceutically acceptable salt thereof, wherein:
A is CR3 or N;
R2, R3, R4, R5 and R6 are each, independently, hydrogen, halogen, C1-C6 haloalkyl, NO2, NRaRb, OH, O(C1-C6 alkyl), or O(C1-C6 haloalkyl);
Ra and Rb are each, independently, hydrogen or C1-C6 alkyl;
R8, R10, and Z are each, independently, hydrogen, fluorine, OH, or O(C1-C6 alkyl);
R11 is OH, O(C1-C6 alkyl), or —NH—(CH2)q— Rq, wherein:
q is 2 or 3;
Rq is 1-piperazinyl, 1-(4-N—(RN))piperazinyl, N-morpholino or phenyl; and
RN is C1-C5 alkyl; and
R12 is hydrogen or C1-C6 alkyl;
wherein,
a) when A is CR3 and R2 is fluorine or chlorine, then Rq is phenyl or 1-(4-N—(RN))piperazinyl,
or
b) when A is CR3, R2 is fluorine or chlorine, q is 2 and Rq is N-morpholino, then at least one of R8, R10, and Z is not hydrogen and R8 is not OCH3;
or
c) when A is CR3, R2 is fluorine or chlorine, q is 2 and Rq is N-morpholino at least one of R3, R4, R5 and R6 is not hydrogen or halogen; and at least three of R2, R3, R4, R5 and R6 are hydrogen.
6. The compound of claim 1, being of Formula (Ie),
Figure US20190248756A1-20190815-C00368
or a pharmaceutically acceptable salt thereof, wherein:
A is CR3 or N;
R2, R3, R4, R5 and R6 are each, independently, hydrogen, halogen, C1-C6 haloalkyl, NO2, NRaRb, OH, O(C1-C6 alkyl), or O(C1-C6 haloalkyl);
Ra and Rb are each, independently, hydrogen or C1-C6 alkyl;
R8, R9, and Z are each, independently, hydrogen, fluorine, OH, or O(C1-C6 alkyl);
R11 is OH, O(C1-C6 alkyl), or —NH—(CH2)q—Rq, wherein:
q is 2 or 3;
Rq is 1-piperazinyl, 1-(4-N—(RN))piperazinyl, N-morpholino or phenyl; and
RN is C1-C5 alkyl; and
R12 is hydrogen or C1-C6 alkyl;
wherein,
a) when A is CR3 and R2 is fluorine or chlorine, then Rq is phenyl or 1-(4-N—(RN))piperazinyl,
or
b) when A is CR3, R2 is fluorine or chlorine, q is 2 and Rq is N-morpholino, then at least one of R8, R9, and Z is not hydrogen and R8 is not OCH3;
or
c) when A is CR3, R2 is fluorine or chlorine, q is 2 and Rq is N-morpholino at least one of R3, R4, R5 and R6 is not hydrogen or halogen; and at least three of R2, R3, R4, R5 and R6 are hydrogen.
7. The compound of claim 1, being of Formula (If),
Figure US20190248756A1-20190815-C00369
or a pharmaceutically acceptable salt thereof, wherein:
A is CR3 or N;
R2, R3, R4, R5 and R6 are each, independently, hydrogen, halogen, C1-C6 haloalkyl, NO2, NRaRb, OH, O(C1-C6 alkyl), or O(C1-C6 haloalkyl);
Ra and Rb are each, independently, hydrogen or C1-C6 alkyl;
R9, R10, and Z are each, independently, hydrogen, fluorine, OH, or O(C1-C6 alkyl);
R11 is OH, O(C1-C6 alkyl), or —NH—(CH2)q—Rq, wherein:
q is 2 or 3;
Rq is 1-piperazinyl, 1-(4-N—(RN))piperazinyl, N-morpholino or phenyl; and
RN is C1-C5 alkyl; and
R12 is hydrogen or C1-C6 alkyl;
wherein,
a) when A is CR3 and R2 is fluorine or chlorine, then Rq is phenyl or 1-(4-N—(RN))piperazinyl,
or
b) when A is CR3, R2 is fluorine or chlorine, q is 2 and Rq is N-morpholino, then at least one of R9, R10, and Z is not hydrogen and R8 is not OCH3;
or
c) when A is CR3, R2 is fluorine or chlorine, q is 2 and Rq is N-morpholino at least one of R3, R4, R5 and R6 is not hydrogen or halogen; and at least three of R2, R3, R4, R5 and R6 are hydrogen.
8. The compound of claim 1, selected from
Figure US20190248756A1-20190815-C00370
Figure US20190248756A1-20190815-C00371
Figure US20190248756A1-20190815-C00372
Figure US20190248756A1-20190815-C00373
Figure US20190248756A1-20190815-C00374
Figure US20190248756A1-20190815-C00375
Figure US20190248756A1-20190815-C00376
Figure US20190248756A1-20190815-C00377
Figure US20190248756A1-20190815-C00378
Figure US20190248756A1-20190815-C00379
Figure US20190248756A1-20190815-C00380
Figure US20190248756A1-20190815-C00381
Figure US20190248756A1-20190815-C00382
Figure US20190248756A1-20190815-C00383
Figure US20190248756A1-20190815-C00384
Figure US20190248756A1-20190815-C00385
Figure US20190248756A1-20190815-C00386
Figure US20190248756A1-20190815-C00387
Figure US20190248756A1-20190815-C00388
Figure US20190248756A1-20190815-C00389
Figure US20190248756A1-20190815-C00390
Figure US20190248756A1-20190815-C00391
Figure US20190248756A1-20190815-C00392
Figure US20190248756A1-20190815-C00393
Figure US20190248756A1-20190815-C00394
Figure US20190248756A1-20190815-C00395
Figure US20190248756A1-20190815-C00396
Figure US20190248756A1-20190815-C00397
Figure US20190248756A1-20190815-C00398
Figure US20190248756A1-20190815-C00399
Figure US20190248756A1-20190815-C00400
Figure US20190248756A1-20190815-C00401
or a pharmaceutically acceptable salt thereof.
9. The compound according to claim 8, wherein the compound is selected from
Figure US20190248756A1-20190815-C00402
or a pharmaceutically acceptable salt thereof.
10. A method for the treatment of cancer, the method comprising administering to a subject in need of such treatment an effective amount of a compound according to claim 1.
11. The method of claim 10, wherein the cancer is leukaemia or lymphoma.
12. The method of claim 11, wherein the cancer is anaplastic large cell lymphoma (ALCL), Classic Hodgkin lymphoma (cHL), non-Hodgkin's lymphoma; or a solid tumour cancer.
13. The method of claim 12, wherein the solid tumour cancer is breast cancer, melanoma, lung cancer, pancreatic cancer, oesophageal cancer, colorectal cancer, nasopharyngeal carcinoma, or hepatocarcinoma.
14. A method according to claim 10, wherein the treatment comprises the treatment or prevention of metastasis in cancer.
15. A method according to claim 10 wherein the cancer is breast cancer.
16. A method according to claim 10 wherein the cancer is triple negative breast cancer or HER2 enriched breast cancer.
17. A method according to claim 10 wherein the compound is to be used in combination with one or more additional active agents which are useful in the treatment of cancer.
18. A method according to claim 17, wherein the one or more additional active agents are selected from:
anti-HER2 agents;
standard adjuvant therapy regimens; and
anti-angiogenic/antimetastatic agents.
19. A pharmaceutical composition comprising a compound according to claim 1 and a pharmaceutically or veterinarily acceptable excipient or carrier.
20. A process for the preparation of a pharmaceutical composition according to claim 87, the process comprising bringing the compound according to claim 1 into association with a pharmaceutically or veterinarily acceptable excipient or carrier.
US16/397,245 2014-07-31 2019-04-29 Bcl-3 inhibitors Abandoned US20190248756A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US16/397,245 US20190248756A1 (en) 2014-07-31 2019-04-29 Bcl-3 inhibitors

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201462031774P 2014-07-31 2014-07-31
PCT/IB2015/001807 WO2016016728A2 (en) 2014-07-31 2015-07-31 Bcl-3 inhibitors
US201715500016A 2017-01-27 2017-01-27
US16/397,245 US20190248756A1 (en) 2014-07-31 2019-04-29 Bcl-3 inhibitors

Related Parent Applications (2)

Application Number Title Priority Date Filing Date
PCT/IB2015/001807 Continuation WO2016016728A2 (en) 2014-07-31 2015-07-31 Bcl-3 inhibitors
US15/500,016 Continuation US10273218B2 (en) 2014-07-31 2015-07-31 BCL-3 inhibitors

Publications (1)

Publication Number Publication Date
US20190248756A1 true US20190248756A1 (en) 2019-08-15

Family

ID=55025270

Family Applications (2)

Application Number Title Priority Date Filing Date
US15/500,016 Active US10273218B2 (en) 2014-07-31 2015-07-31 BCL-3 inhibitors
US16/397,245 Abandoned US20190248756A1 (en) 2014-07-31 2019-04-29 Bcl-3 inhibitors

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US15/500,016 Active US10273218B2 (en) 2014-07-31 2015-07-31 BCL-3 inhibitors

Country Status (3)

Country Link
US (2) US10273218B2 (en)
EP (2) EP3174602A2 (en)
WO (1) WO2016016728A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201313664D0 (en) * 2013-07-31 2013-09-11 Univ Cardiff Bcl-3 inhibitors
TWI771410B (en) 2017-04-27 2022-07-21 日商石原產業股份有限公司 N-(4-pyridyl)nicotinamide compound or salt thereof
CN108911965A (en) * 2018-08-03 2018-11-30 上海华堇生物技术有限责任公司 The preparation method of 2- methoxy benzoyl chloride
EP4017592A1 (en) * 2019-08-21 2022-06-29 The Scripps Research Institute Monocyclic agonists of stimulator of interferon genes sting

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US693255A (en) * 1901-05-25 1902-02-11 Stiles Fry Washing-machine.
FR7409M (en) * 1968-06-28 1969-11-03
DE2417216A1 (en) 1974-04-09 1975-11-06 Basf Ag FUNGICIDES
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
CA2057324A1 (en) * 1990-12-18 1992-06-19 Lora Louise Fitch Benzamide and sulfonamide hypoglycemic agents
JP2003520854A (en) 2000-01-27 2003-07-08 サイトビア インコーポレイテッド Substituted nicotinamides and analogs and their use as activators of caspases and inducers of apoptosis
US20050113450A1 (en) 2002-08-23 2005-05-26 Atli Thorarensen Antibacterial agents
WO2004022525A1 (en) * 2002-09-05 2004-03-18 Neurosearch A/S Amide derivatives and their use as chloride channel blockers
US6819898B2 (en) * 2002-11-22 2004-11-16 Kabushiki Kaisha Toshiba Image forming apparatus including stopping member and backstop member to stop rotation of revolver type developing unit
SE0401342D0 (en) * 2004-05-25 2004-05-25 Astrazeneca Ab Therapeutic compounds
US8916550B2 (en) 2005-05-09 2014-12-23 Hydra Biosciences, Inc. Compounds for modulating TRPV3 function
WO2008124838A1 (en) 2007-04-10 2008-10-16 University Of Maryland, Baltimore Compounds that inhibit human dna ligases and methods of treating cancer
WO2009026241A1 (en) 2007-08-23 2009-02-26 Kalypsys, Inc. Heterocyclic modulators of tgr5
EP2844345B1 (en) 2012-05-04 2022-08-03 The United States of America, as Represented by The Secretary, Department of Health and Human Services Modulators of the relaxin receptor 1
WO2014077784A1 (en) * 2012-11-19 2014-05-22 Agency For Science, Technology And Research Method of treating cancer
GB201313664D0 (en) * 2013-07-31 2013-09-11 Univ Cardiff Bcl-3 inhibitors

Also Published As

Publication number Publication date
EP3628374B1 (en) 2023-08-30
US20170267653A1 (en) 2017-09-21
WO2016016728A2 (en) 2016-02-04
WO2016016728A3 (en) 2016-08-11
EP3628374A2 (en) 2020-04-01
EP3628374C0 (en) 2023-08-30
EP3174602A2 (en) 2017-06-07
US10273218B2 (en) 2019-04-30
EP3628374A3 (en) 2020-07-29

Similar Documents

Publication Publication Date Title
US20240180919A1 (en) Ezh2 inhibitors for treating cancer
US11202781B2 (en) EZH2 inhibitors for treating lymphoma
US20220235065A1 (en) Amine-substituted heterocyclic compounds as ehmt2 inhibitors and methods of use thereof
KR101478933B1 (en) Compositions and methods of treating cell proliferation disorders
US20190248756A1 (en) Bcl-3 inhibitors
TWI280127B (en) Remedies for neurodegenerative diseases
JP2020114831A (en) Biguanide compound and use thereof
WO2015038778A1 (en) SUBSTITUTED UREA EIF2α KINASE ACTIVATORS
WO2012016133A2 (en) Ros1 kinase inhibitors for the treatment of glioblastoma and other p53-deficient cancers
US20200317642A1 (en) Amine-substituted heterocyclic compounds as ehmt2 inhibitors and derivatives thereof
WO2015056663A1 (en) 4-aminomethylbenzoic acid derivative
JP2023036991A (en) Amine-Substituted Heterocyclic Compounds as EHMT2 Inhibitors, Their Salts, and Their Synthetic Methods
US20190337921A1 (en) Tetrasubstituted alkene compounds and their use
CN113831338A (en) Histone deacetylase inhibitor and preparation method and application thereof
TWI762634B (en) Amino-aryl-benzamide compounds and methods of use thereof
CN107235906A (en) One group of pyrazole amide analog derivative and its application
JP6758374B2 (en) Antitumor compounds targeting IDH2 mutations and how to use them
HUP0303760A2 (en) Substituted benzoic acid derivatives exhibiting nf-kb inhibiting activity and pharmaceutical compositions containing them
KR102114389B1 (en) Novel sodium channel inhibitor compound, preparation method thereof, and pharmaceutical composition for prevention or treatment of sodium channel related diseases containing the same as an active ingredient
CN113735788B (en) Ibuprofen triazole thiol derivatives and their applications in the preparation of novel coronavirus inhibitors
WO2010060277A1 (en) Substituted acetyl hydrazide derivatives, their preparation and uses thereof
WO1998014430A1 (en) Pyrimidine derivatives
HK40098892A (en) Amine-substituted heterocyclic compounds as ehmt2 inhibitors and methods of use thereof
OA19666A (en) Amine-substituted heterocyclic compounds as Ehmt2 inhibitors and methods of use thereof.

Legal Events

Date Code Title Description
STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION